data_1lab_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1lab _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -120.53 159.47 25.13 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 100.893 -3.743 . . . . 0.0 100.893 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 -160.97 0.8 Allowed 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.03 -21.95 3.88 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-N 113.531 -1.668 . . . . 0.0 110.297 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.47 ' CG ' HG21 ' A' ' 68' ' ' VAL . 48.2 mmtt -132.5 145.18 50.96 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 105.479 -2.045 . . . . 0.0 105.479 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.43 173.33 6.08 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 104.071 -2.566 . . . . 0.0 104.071 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -42.48 80.93 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.379 2.053 . . . . 0.0 115.013 158.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -121.7 -72.64 0.68 Allowed 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 103.584 -2.747 . . . . 0.0 103.584 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.426 ' H ' HG12 ' A' ' 68' ' ' VAL . 35.5 pt 37.41 40.58 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 124.302 1.001 . . . . 0.0 112.863 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.68 -14.34 0.07 OUTLIER Glycine 0 C--N 1.305 -1.188 0 CA-C-O 117.194 -1.892 . . . . 0.0 115.614 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -101.21 -177.93 3.59 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 120.439 2.119 . . . . 0.0 114.733 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -4.47 -66.74 0.0 OUTLIER Glycine 0 N--CA 1.494 2.509 0 CA-C-N 110.178 -3.192 . . . . 0.0 116.182 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.0 mm -127.28 76.42 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -81.97 4.34 23.06 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 112.725 -2.034 . . . . 0.0 111.787 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.506 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 4.5 pt-20 -132.4 -176.7 4.17 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.252 0.549 . . . . 0.0 110.864 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.81 116.29 0.84 Allowed Glycine 0 N--CA 1.494 2.517 0 CA-C-O 118.079 -1.401 . . . . 0.0 111.679 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -102.97 109.87 21.57 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 99.966 -4.087 . . . . 0.0 99.966 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' HA ' ' A' ' 62' ' ' GLU . 2.7 mt -99.17 126.66 52.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.8 t -93.85 -61.76 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 124.666 1.229 . . . . 0.0 109.971 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.58 ' NZ ' ' CE1' ' A' ' 22' ' ' PHE . 25.1 tttm -130.43 151.04 51.35 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.574 -179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.481 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 8.6 m95 -119.63 173.47 6.99 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 179.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.58 ' CE1' ' NZ ' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -133.34 -1.25 3.21 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 -179.783 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.562 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 4.2 m -98.62 170.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 115.318 1.599 . . . . 0.0 115.318 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -139.2 48.03 1.56 Allowed Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 125.574 1.796 . . . . 0.0 111.829 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.497 ' C ' ' H ' ' A' ' 27' ' ' ASP . 67.2 Cg_exo -8.61 174.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 N-CA-C 118.865 2.602 . . . . 0.0 118.865 -70.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.562 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.11 28.41 8.83 Favored Glycine 0 N--CA 1.505 3.275 0 N-CA-C 107.84 -2.104 . . . . 0.0 107.84 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.516 ' CG ' ' HZ3' ' A' ' 54' ' ' LYS . 19.2 t70 8.79 -85.24 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 110.985 -2.608 . . . . 0.0 111.474 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.54 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS . 2.6 mt-10 -104.22 115.53 30.56 Favored 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 105.606 -1.998 . . . . 0.0 105.606 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 p -108.65 161.57 7.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 124.819 2.247 . . . . 0.0 110.562 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.415 ' OD1' ' HB2' ' A' ' 33' ' ' ASP . 29.3 p30 -98.15 -164.16 1.11 Allowed 'General case' 0 C--N 1.284 -2.248 0 CA-C-N 109.965 -3.288 . . . . 0.0 108.883 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.532 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.274 0.3 OUTLIER -122.35 69.71 0.97 Allowed 'General case' 0 C--N 1.292 -1.896 1 N-CA-C 99.497 -4.26 . . . . 0.0 99.497 -179.323 . . . . . . . . 5 4 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.493 ' C ' ' OG ' ' A' ' 49' ' ' SER . 3.5 p30 -177.34 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.489 0 C-N-CA 125.705 1.602 . . . . 0.0 111.735 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.6 ' CB ' ' HG ' ' A' ' 49' ' ' SER . 8.9 t70 18.13 -137.74 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.264 0 N-CA-C 119.661 3.208 . . . . 0.0 119.661 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.542 HG13 ' CG ' ' A' ' 22' ' ' PHE . 1.2 t -114.87 167.4 7.53 Favored 'Isoleucine or valine' 0 CA--C 1.445 -3.095 0 CA-C-O 124.3 2.0 . . . . 0.0 114.29 -179.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.53 ' HA ' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -108.57 120.23 41.85 Favored 'General case' 0 N--CA 1.412 -2.363 3 CA-C-N 106.151 -5.022 . . . . 0.0 99.251 179.877 . . . . . . . . 4 4 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.481 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 27.7 m -73.57 151.8 40.8 Favored 'General case' 0 C--N 1.263 -3.193 2 N-CA-C 97.986 -4.82 . . . . 0.0 97.986 179.873 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -104.52 102.89 12.51 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-N 112.371 -2.195 . . . . 0.0 107.806 -179.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.6 146.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 N-CA-C 104.682 -2.34 . . . . 0.0 104.682 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -115.15 152.43 32.61 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.46 HD22 ' HB1' ' A' ' 43' ' ' ALA . 6.7 p-10 -141.13 -178.13 5.44 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.421 ' CG ' HD21 ' A' ' 40' ' ' ASN . 0.3 OUTLIER -7.58 -72.43 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 116.952 2.205 . . . . 0.0 116.952 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -136.82 -11.61 1.76 Allowed 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 114.318 -1.31 . . . . 0.0 109.255 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HB1' HD22 ' A' ' 40' ' ' ASN . . . -111.58 178.7 4.24 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 120.91 0.386 . . . . 0.0 111.886 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.5 t -130.86 147.55 33.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.465 -2.42 . . . . 0.0 104.465 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -120.37 161.78 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 122.655 1.217 . . . . 0.0 111.242 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.458 ' C ' HD13 ' A' ' 47' ' ' ILE . 12.1 pt-20 -122.24 122.75 39.87 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 110.489 -3.05 . . . . 0.0 108.186 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.53 ' C ' ' HA ' ' A' ' 35' ' ' LEU . 1.9 mp -115.02 83.16 9.31 Favored Pre-proline 0 CA--C 1.572 1.798 0 CA-C-O 115.946 -1.978 . . . . 0.0 108.729 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.444 ' HA ' ' O ' ' A' ' 34' ' ' VAL . 75.9 Cg_endo -62.93 -167.09 0.06 OUTLIER 'Trans proline' 0 N--CA 1.52 3.036 0 C-N-CA 123.952 3.102 . . . . 0.0 105.716 176.675 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.6 ' HG ' ' CB ' ' A' ' 33' ' ' ASP . 19.2 p -108.73 86.48 3.71 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -32.22 -49.21 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 121.887 1.725 . . . . 0.0 115.308 163.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.532 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -132.49 164.84 33.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-O 121.817 0.817 . . . . 0.0 110.328 179.646 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.501 ' NZ ' ' OE2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -102.54 173.32 6.4 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 128.827 3.829 . . . . 0.0 110.11 179.724 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.24 -136.87 5.98 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 104.995 -3.242 . . . . 0.0 104.995 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.54 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 41.0 tptt -112.73 173.26 6.46 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 -179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.412 ' HB ' ' C ' ' A' ' 26' ' ' GLY . 50.5 t -127.35 70.05 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.975 1 N-CA-C 97.342 -5.058 . . . . 0.0 97.342 179.665 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 75.4 mt -38.06 -79.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 111.623 -2.535 . . . . 0.0 114.227 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -143.04 167.48 21.97 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.759 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.1 mp -131.11 141.21 46.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 1 N-CA-C 98.004 -4.813 . . . . 0.0 98.004 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.404 HD13 ' N ' ' A' ' 59' ' ' LEU . 5.6 mp -103.7 -58.85 1.81 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 123.772 0.67 . . . . 0.0 110.555 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.425 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 24.1 t -113.62 75.92 2.77 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -49.76 -83.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.851 2.367 . . . . 0.0 115.2 -167.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.412 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -134.86 -179.91 5.9 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 76.81 -38.57 1.51 Allowed Glycine 0 N--CA 1.49 2.266 0 CA-C-N 114.14 -1.391 . . . . 0.0 114.335 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.425 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 2.0 m -103.25 177.14 4.92 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 43.9 t -117.74 148.99 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.8 166.67 14.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.506 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 8.8 t -117.87 -155.45 0.6 Allowed 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 104.783 -2.303 . . . . 0.0 104.783 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.47 HG21 ' CG ' ' A' ' 5' ' ' LYS . 84.4 t -120.44 151.51 23.24 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 1 N-CA-C 97.25 -5.093 . . . . 0.0 97.25 179.106 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 104.58 -38.74 3.12 Favored Glycine 0 N--CA 1.494 2.565 1 N-CA-C 99.768 -5.333 . . . . 0.0 99.768 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.465 ' H ' ' C ' ' A' ' 68' ' ' VAL . 35.2 tt0 -100.09 164.49 11.96 Favored 'General case' 0 C--N 1.304 -1.373 1 N-CA-C 99.929 -4.101 . . . . 0.0 99.929 179.501 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.98 -175.52 2.8 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 33.1 tp -135.23 -67.19 0.55 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 103.652 -2.721 . . . . 0.0 103.652 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.2 tt -135.03 165.04 32.13 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 102.988 -2.967 . . . . 0.0 102.988 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.8 t -137.25 161.38 36.37 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.45 -2.796 . . . . 0.0 103.45 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.83 152.33 48.99 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 112.456 -2.156 . . . . 0.0 106.385 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.86 131.57 56.92 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 100.48 -3.896 . . . . 0.0 100.48 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.46 60.19 13.54 Favored Pre-proline 0 C--N 1.295 -1.78 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -53.09 68.34 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.618 0 C-N-CA 124.777 3.651 . . . . 0.0 115.855 -176.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 132.7 68.75 0.08 OUTLIER Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.505 1 N-CA-C 100.096 -4.039 . . . . 0.0 100.096 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.461 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 101.771 -3.418 . . . . 0.0 101.771 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -100.67 85.94 3.02 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 105.622 -1.992 . . . . 0.0 105.622 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.461 ' OE1' ' N ' ' A' ' 1' ' ' ALA . 1.5 mp0 -77.96 -178.33 5.45 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -99.91 -29.57 12.5 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 117.903 2.557 . . . . 0.0 117.903 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.453 ' CG ' HG21 ' A' ' 68' ' ' VAL . 30.5 mmtp -127.57 173.64 9.7 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 102.411 -3.181 . . . . 0.0 102.411 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 88.6 mt -101.14 176.18 2.01 Favored Pre-proline 0 C--N 1.299 -1.618 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -66.12 82.04 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 N-CA-C 104.098 -3.078 . . . . 0.0 104.098 158.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -123.87 -80.68 0.63 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 124.583 1.177 . . . . 0.0 109.628 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.9 pt 41.96 26.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.515 0 O-C-N 123.38 0.425 . . . . 0.0 110.454 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.24 -69.67 0.18 Allowed Glycine 0 N--CA 1.483 1.776 0 C-N-CA 120.683 -0.77 . . . . 0.0 114.064 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.406 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -61.27 171.17 1.44 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 124.537 2.113 . . . . 0.0 116.358 -179.435 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -6.84 -53.1 0.0 OUTLIER Glycine 0 N--CA 1.493 2.469 0 CA-C-N 109.956 -3.293 . . . . 0.0 119.953 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.2 mm -118.96 116.99 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.47 ' O ' HG22 ' A' ' 68' ' ' VAL . 9.5 p80 -96.26 -45.62 6.76 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 114.68 -1.145 . . . . 0.0 112.232 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.54 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 33.8 mt-10 -107.83 -173.2 2.22 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 123.043 1.401 . . . . 0.0 113.059 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.05 122.33 1.98 Allowed Glycine 0 C--N 1.286 -2.205 0 CA-C-N 111.722 -2.49 . . . . 0.0 106.881 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 78.7 tt0 -102.23 96.15 6.79 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 103.399 -2.815 . . . . 0.0 103.399 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.8 mt -86.17 120.62 36.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 -56.09 5.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.969 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.052 -179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.523 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -136.15 150.68 49.17 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 124.206 0.941 . . . . 0.0 112.12 -179.432 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.757 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 10.1 m95 -114.38 174.62 5.86 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 124.821 1.325 . . . . 0.0 108.112 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.497 ' CD2' HG23 ' A' ' 34' ' ' VAL . 6.6 m-85 -128.03 -13.76 5.07 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 112.382 -2.19 . . . . 0.0 112.885 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.569 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 14.7 m -98.89 -172.96 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.653 -0.654 . . . . 0.0 111.761 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.624 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.3 mptp? -123.08 -30.11 0.05 OUTLIER Pre-proline 0 N--CA 1.503 2.208 0 N-CA-C 119.266 3.061 . . . . 0.0 119.266 179.077 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.624 ' C ' ' H ' ' A' ' 24' ' ' LYS . 11.3 Cg_endo -39.17 162.82 0.23 Allowed 'Cis proline' 0 N--CA 1.498 1.764 1 N-CA-C 122.747 4.095 . . . . 0.0 122.747 13.208 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.569 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -95.5 32.42 6.27 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 -179.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.9 t70 11.79 -100.94 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.248 0 O-C-N 129.749 3.852 . . . . 0.0 109.606 179.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -103.33 130.38 50.59 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 179.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.402 ' CG2' ' H ' ' A' ' 30' ' ' ASN . 7.6 p -120.48 177.91 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 122.348 1.07 . . . . 0.0 112.918 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.488 ' C ' ' OD1' ' A' ' 30' ' ' ASN . 45.0 p30 -95.42 -166.47 1.46 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.961 -1.927 . . . . 0.0 107.422 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.445 ' HB2' ' HB3' ' A' ' 52' ' ' LYS 0.25 2.4 tt0 -124.86 50.75 1.71 Allowed 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 100.467 -3.901 . . . . 0.0 100.467 -179.498 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -175.93 28.32 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.043 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 30' ' ' ASN . 0.5 OUTLIER -96.32 -176.25 3.59 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.945 0.878 . . . . 0.0 111.335 -179.308 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.497 HG23 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -74.77 -172.53 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.482 -1.648 0 CA-C-O 127.654 3.597 . . . . 0.0 117.582 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.514 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.13 -160.21 0.74 Allowed 'General case' 0 C--N 1.276 -2.624 2 CA-C-N 102.377 -6.738 . . . . 0.0 106.959 -179.214 . . . . . . . . 4 4 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.757 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 9.2 m -120.09 156.51 30.86 Favored 'General case' 0 C--N 1.273 -2.748 2 N-CA-C 94.215 -6.217 . . . . 0.0 94.215 179.212 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.46 ' OE1' ' NZ ' ' A' ' 20' ' ' LYS . 5.3 tt0 -107.94 109.83 21.42 Favored 'General case' 0 C--N 1.285 -2.236 1 N-CA-C 98.676 -4.564 . . . . 0.0 98.676 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 56.1 t -121.43 154.9 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.412 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 tt0 -114.82 147.2 40.15 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 16.4 p-10 -136.43 -176.0 4.19 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.412 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 3.0 p-10 -6.73 -67.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.176 0 O-C-N 126.175 2.172 . . . . 0.0 115.838 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.412 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 40.0 mtmt -138.19 -22.18 1.05 Allowed 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 123.011 0.525 . . . . 0.0 109.957 179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.75 -168.57 1.54 Allowed 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 29.8 t -123.69 133.7 68.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 N-CA-C 103.309 -2.849 . . . . 0.0 103.309 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.94 153.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 122.515 1.15 . . . . 0.0 109.012 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.447 ' C ' HD13 ' A' ' 47' ' ' ILE . 10.0 pt-20 -119.58 127.79 53.3 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 110.86 -2.882 . . . . 0.0 108.526 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.514 ' H ' ' HB2' ' A' ' 35' ' ' LEU . 1.7 mp -117.2 79.54 11.19 Favored Pre-proline 0 C--N 1.299 -1.588 0 N-CA-C 101.573 -3.491 . . . . 0.0 101.573 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.415 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 86.3 Cg_endo -62.29 -166.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.513 2.639 0 C-N-CA 123.569 2.846 . . . . 0.0 107.854 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 45.9 p -98.78 106.66 38.67 Favored Pre-proline 0 C--N 1.286 -2.153 0 CA-C-N 113.483 -1.69 . . . . 0.0 111.879 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 89.2 Cg_exo -55.32 -44.46 48.66 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.012 1.808 . . . . 0.0 114.979 166.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.509 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -132.13 171.58 17.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 123.837 0.711 . . . . 0.0 109.858 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.527 ' NZ ' ' O ' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -105.01 167.85 9.44 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 127.347 2.905 . . . . 0.0 107.614 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 76' ' ' ASP . . . 144.1 -121.77 1.69 Allowed Glycine 0 C--N 1.285 -2.282 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.596 ' NZ ' ' HB2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -117.41 166.41 12.35 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 23.9 t -129.91 59.29 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 1 N-CA-C 99.459 -4.274 . . . . 0.0 99.459 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 21.9 mt -29.1 -76.88 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 111.143 -2.753 . . . . 0.0 115.02 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -143.79 167.16 22.95 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.284 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.419 HD13 ' HA ' ' A' ' 25' ' ' PRO . 4.1 mp -135.55 139.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 1 N-CA-C 98.527 -4.619 . . . . 0.0 98.527 179.601 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.417 HD13 ' N ' ' A' ' 59' ' ' LEU . 5.7 mp -101.56 -56.91 2.18 Favored 'General case' 0 C--N 1.296 -1.756 0 O-C-N 124.003 0.814 . . . . 0.0 110.604 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 t -117.93 67.96 6.34 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -41.93 -78.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 122.709 2.273 . . . . 0.0 117.989 -167.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -142.97 174.58 10.55 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.66 -52.97 0.91 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.868 -1.158 . . . . 0.0 111.462 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.5 m -102.42 -177.5 3.42 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.2 t -109.95 145.49 16.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 103.733 -2.692 . . . . 0.0 103.733 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -120.55 147.83 44.66 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.287 14.7 t -99.84 -151.7 0.4 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.478 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.529 ' C ' ' H ' ' A' ' 70' ' ' GLN . 61.8 t -118.62 160.75 18.18 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 178.877 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 97.61 -47.28 1.57 Allowed Glycine 0 N--CA 1.499 2.852 1 N-CA-C 98.408 -5.877 . . . . 0.0 98.408 -179.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.529 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -89.58 153.61 20.63 Favored 'General case' 0 C--N 1.304 -1.393 1 N-CA-C 99.953 -4.091 . . . . 0.0 99.953 179.325 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.56 -175.94 3.0 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 103.104 -2.924 . . . . 0.0 103.104 179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.7 tp -139.9 -70.44 0.4 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.9 tt -139.05 166.33 22.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 104.203 -2.517 . . . . 0.0 104.203 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.2 t -138.92 160.08 40.59 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 102.439 -3.171 . . . . 0.0 102.439 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -129.98 148.53 51.85 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.022 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.432 ' OD2' ' NZ ' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -113.09 150.26 32.35 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 102.227 -3.249 . . . . 0.0 102.227 179.135 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.527 ' O ' ' NZ ' ' A' ' 52' ' ' LYS . . . -114.36 -40.94 0.08 OUTLIER Pre-proline 0 C--N 1.295 -1.774 0 O-C-N 124.883 1.365 . . . . 0.0 107.696 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.511 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 10.2 Cg_endo -94.72 176.84 11.42 Favored 'Cis proline' 0 C--N 1.312 -1.375 0 CA-C-N 121.628 1.617 . . . . 0.0 111.328 -22.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.81 -36.72 4.19 Favored Glycine 0 N--CA 1.498 2.8 1 N-CA-C 99.058 -5.617 . . . . 0.0 99.058 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.479 ' H ' ' C ' ' A' ' 78' ' ' PRO . 52.1 t80 . . . . . 0 CA--C 1.573 1.831 1 N-CA-C 98.597 -4.594 . . . . 0.0 98.597 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.474 1 N-CA-C 98.138 -4.764 . . . . 0.0 98.138 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -137.13 90.76 2.56 Favored 'General case' 0 C--N 1.288 -2.078 1 N-CA-C 88.977 -8.157 . . . . 0.0 88.977 178.473 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 3' ' ' GLU . 1.3 pm0 -87.57 -168.1 2.11 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 122.638 1.208 . . . . 0.0 113.843 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.483 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 22.5 t80 -88.22 -46.99 8.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 117.853 2.538 . . . . 0.0 117.853 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.483 ' HE2' ' CZ ' ' A' ' 4' ' ' PHE . 0.3 OUTLIER -131.57 174.68 9.86 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 179.63 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.13 172.96 3.69 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 104.187 -2.523 . . . . 0.0 104.187 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -56.31 89.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 121.43 1.42 . . . . 0.0 111.374 164.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.434 ' HB3' HG13 ' A' ' 68' ' ' VAL . 9.5 t0 -122.45 -82.05 0.65 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 102.968 -2.975 . . . . 0.0 102.968 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.5 pt 36.8 37.0 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 CA-C-O 121.601 0.715 . . . . 0.0 109.821 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.7 -154.58 11.94 Favored Glycine 0 N--CA 1.48 1.575 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.32 138.53 37.75 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.44 -74.1 0.33 Allowed Glycine 0 N--CA 1.486 1.968 0 N-CA-C 106.907 -2.477 . . . . 0.0 106.907 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.2 mm -133.46 141.4 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-N 118.363 1.081 . . . . 0.0 108.297 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -131.9 -51.88 0.98 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.54 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -116.59 172.11 7.43 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.463 -1.244 . . . . 0.0 111.995 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.82 155.51 26.17 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 106.542 -2.623 . . . . 0.0 106.542 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -122.54 136.74 54.96 Favored 'General case' 0 C--N 1.303 -1.445 1 N-CA-C 98.968 -4.456 . . . . 0.0 98.968 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . 0.285 2.6 mt -103.95 113.67 41.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.278 0 N-CA-C 102.734 -3.062 . . . . 0.0 102.734 -179.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.9 t -76.5 -55.07 12.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.459 ' HE3' ' CE2' ' A' ' 22' ' ' PHE . 22.4 tttp -141.41 158.32 44.02 Favored 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 118.981 -1.088 . . . . 0.0 113.579 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.509 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 36.9 m95 -113.86 170.89 7.93 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 178.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.471 ' N ' ' CD1' ' A' ' 22' ' ' PHE . 9.5 m-85 -128.28 -46.43 1.35 Allowed 'General case' 0 C--N 1.3 -1.584 0 CA-C-N 114.126 -1.397 . . . . 0.0 109.735 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 m -97.39 175.68 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.445 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -128.04 165.98 26.91 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 105.593 -2.003 . . . . 0.0 105.593 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -76.52 122.71 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 121.915 1.744 . . . . 0.0 110.776 -172.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.13 -7.27 19.02 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.226 -2.349 . . . . 0.0 107.226 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.445 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -79.52 173.23 12.79 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 124.177 1.941 . . . . 0.0 111.041 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.667 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.2 OUTLIER -118.55 146.26 44.72 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 100.584 -3.858 . . . . 0.0 100.584 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . 0.25 0.9 OUTLIER -122.19 171.2 11.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 -179.776 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.434 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 53.7 t30 -119.42 -29.51 5.11 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 125.03 2.348 . . . . 0.0 115.135 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.45 ' HG2' ' HB2' ' A' ' 49' ' ' SER 0.366 11.9 tp10 47.26 78.74 0.07 Allowed 'General case' 0 C--N 1.267 -2.995 5 N-CA-C 131.644 7.646 . . . . 0.0 131.644 -179.213 . . . . . . . . 4 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -155.43 31.5 0.38 Allowed 'General case' 0 C--N 1.28 -2.434 4 CA-C-N 94.066 -10.515 . . . . 0.0 93.984 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -117.22 -168.7 1.52 Allowed 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 126.927 2.091 . . . . 0.0 107.82 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HB ' ' CG ' ' A' ' 22' ' ' PHE . 3.6 t -134.47 161.85 39.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 N-CA-C 100.597 -3.853 . . . . 0.0 100.597 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.509 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 3.4 mm? -125.54 -84.85 0.63 Allowed 'General case' 0 C--N 1.272 -2.77 0 CA-C-N 109.874 -3.33 . . . . 0.0 102.389 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.403 ' SG ' ' OE1' ' A' ' 46' ' ' GLU . 11.2 p -123.97 172.77 8.69 Favored 'General case' 0 N--CA 1.495 1.777 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.582 -178.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.405 ' HA ' ' N ' ' A' ' 46' ' ' GLU 0.367 18.5 tt0 -134.34 138.25 44.77 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 -179.287 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.473 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 25.5 t -139.77 145.57 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 35.6 tt0 -107.29 107.65 18.68 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 6.4 p-10 -136.77 174.57 10.47 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 2.8 p-10 -3.78 -59.49 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 118.234 2.679 . . . . 0.0 118.234 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 28.3 mttm -131.15 -4.05 3.91 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 123.687 0.617 . . . . 0.0 110.029 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -106.09 164.43 11.99 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.75 -43.11 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 111.392 -2.64 . . . . 0.0 109.178 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.3 t -111.83 167.35 5.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.473 ' CG ' ' HB ' ' A' ' 38' ' ' VAL . 4.0 mt-10 -120.5 -73.32 0.65 Allowed 'General case' 0 C--N 1.294 -1.846 0 O-C-N 128.016 3.323 . . . . 0.0 116.556 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.479 HG22 ' C ' ' A' ' 48' ' ' PRO . 1.2 mp -84.37 142.54 40.65 Favored Pre-proline 0 C--N 1.274 -2.68 0 CA-C-N 108.487 -3.961 . . . . 0.0 110.225 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.479 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -96.64 177.59 0.59 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 N-CA-C 105.248 -2.635 . . . . 0.0 105.248 82.646 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.45 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 1.6 m -124.36 -177.61 0.57 Allowed Pre-proline 0 C--N 1.278 -2.512 0 CA-C-N 114.462 -1.244 . . . . 0.0 109.243 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -87.51 -31.43 0.22 Allowed 'Trans proline' 0 C--N 1.314 -1.285 0 N-CA-C 117.236 1.975 . . . . 0.0 117.236 164.6 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.525 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.6 p -138.34 167.97 20.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 120.246 3.425 . . . . 0.0 120.246 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.525 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 2.2 ptmm? -97.06 177.26 5.66 Favored 'General case' 0 C--N 1.292 -1.9 1 CA-C-N 106.212 -4.995 . . . . 0.0 110.266 -179.395 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.02 -141.71 9.21 Favored Glycine 0 C--N 1.286 -2.237 0 N-CA-C 103.331 -3.908 . . . . 0.0 103.331 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.667 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 12.3 tppt? -110.97 173.23 6.43 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 103.915 -2.624 . . . . 0.0 103.915 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 39.3 t -125.72 68.84 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.166 1 N-CA-C 97.963 -4.829 . . . . 0.0 97.963 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 38.3 mt -30.48 -76.02 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 126.135 2.147 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -142.04 161.58 37.64 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 77.8 mt -132.99 114.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 1 N-CA-C 93.882 -6.34 . . . . 0.0 93.882 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.5 mt -90.9 -40.4 11.75 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 114.759 1.392 . . . . 0.0 114.759 -179.456 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.71 79.97 23.61 Favored Pre-proline 0 N--CA 1.496 1.864 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.817 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_exo -34.8 -107.66 0.0 OUTLIER 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 124.426 3.417 . . . . 0.0 120.532 -175.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -132.73 173.8 10.98 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 56.92 30.94 60.73 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.7 m -138.24 160.28 39.87 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 102.014 -3.328 . . . . 0.0 102.014 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -97.56 135.6 31.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -127.06 144.98 50.89 Favored 'General case' 0 C--N 1.294 -1.834 1 N-CA-C 99.764 -4.162 . . . . 0.0 99.764 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.259 66.8 p -116.87 -144.78 0.38 Allowed 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 124.296 1.998 . . . . 0.0 107.413 -179.855 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.439 ' C ' ' H ' ' A' ' 70' ' ' GLN . 74.8 t -121.65 155.07 25.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 1 N-CA-C 93.247 -6.575 . . . . 0.0 93.247 179.056 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 93.27 -47.04 2.39 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 103.148 -3.981 . . . . 0.0 103.148 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.439 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.2 tt0 -94.0 155.0 17.36 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 102.426 -3.176 . . . . 0.0 102.426 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.55 -174.61 2.6 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 102.769 -3.048 . . . . 0.0 102.769 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.6 tp -145.99 -66.84 0.29 Allowed 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 113.349 -1.751 . . . . 0.0 106.874 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 11.8 tt -133.21 166.58 28.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 110.852 -2.886 . . . . 0.0 105.609 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 t -140.19 159.8 41.38 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 102.152 -3.277 . . . . 0.0 102.152 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.62 154.92 50.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.36 145.89 48.39 Favored 'General case' 0 C--N 1.295 -1.798 1 N-CA-C 99.536 -4.246 . . . . 0.0 99.536 179.282 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -140.79 -49.95 0.02 OUTLIER Pre-proline 0 C--N 1.295 -1.765 0 O-C-N 123.746 0.653 . . . . 0.0 111.581 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -84.4 -45.85 0.3 Allowed 'Cis proline' 0 C--N 1.315 -1.224 0 CA-C-N 119.722 0.936 . . . . 0.0 109.98 -22.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -141.89 124.84 2.55 Favored Glycine 0 C--N 1.293 -1.818 1 N-CA-C 98.749 -5.74 . . . . 0.0 98.749 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 36.6 p90 . . . . . 0 C--N 1.283 -2.317 0 O-C-N 127.109 2.299 . . . . 0.0 106.007 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.51 2.531 0 N-CA-C 102.668 -3.086 . . . . 0.0 102.668 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.1 t80 16.37 102.96 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 127.051 2.72 . . . . 0.0 112.813 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.654 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 2.6 pm0 -82.53 -171.0 3.24 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-N 110.482 -3.054 . . . . 0.0 112.917 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.459 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.2 t80 -93.86 -49.94 5.58 Favored 'General case' 0 N--CA 1.494 1.725 0 CA-C-N 113.684 -1.598 . . . . 0.0 114.063 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.467 ' CB ' HG23 ' A' ' 68' ' ' VAL . 11.8 mmmm -126.1 165.93 17.95 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 101.633 -3.469 . . . . 0.0 101.633 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 61.0 mt -105.48 -178.03 0.57 Allowed Pre-proline 0 C--N 1.3 -1.564 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.45 96.43 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.356 0 C-N-CA 121.685 1.59 . . . . 0.0 110.855 170.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.549 ' HB3' HG13 ' A' ' 68' ' ' VAL . 24.2 t0 -122.34 -99.3 0.43 Allowed 'General case' 0 C--N 1.302 -1.478 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 179.795 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.471 HG22 ' CG1' ' A' ' 68' ' ' VAL . 32.4 pt 34.74 42.05 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 O-C-N 124.572 1.17 . . . . 0.0 108.239 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.79 -137.27 4.77 Favored Glycine 0 N--CA 1.482 1.725 0 CA-C-N 114.45 -1.25 . . . . 0.0 113.895 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.63 146.64 28.64 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 104.695 -2.335 . . . . 0.0 104.695 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.31 -76.24 0.22 Allowed Glycine 0 N--CA 1.486 1.969 0 N-CA-C 103.249 -3.94 . . . . 0.0 103.249 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 42.1 mm -131.21 173.5 14.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 N-CA-C 103.427 -2.805 . . . . 0.0 103.427 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -155.0 -33.09 0.1 Allowed 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.159 1.457 . . . . 0.0 107.701 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.415 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.3 OUTLIER -117.07 -165.54 1.08 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 113.975 -1.466 . . . . 0.0 113.355 179.908 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.89 128.18 2.81 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 103.735 -3.746 . . . . 0.0 103.735 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.422 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 30.4 tt0 -104.64 91.49 3.88 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 101.146 -3.65 . . . . 0.0 101.146 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.5 mt -81.86 110.62 17.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 103.969 -2.604 . . . . 0.0 103.969 -179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -88.81 -45.28 15.58 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 113.563 -1.653 . . . . 0.0 106.62 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.571 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 2.4 ttmp? -130.9 161.46 31.82 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.117 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.489 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 11.3 m95 -124.28 168.74 12.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 101.457 -3.534 . . . . 0.0 101.457 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.407 ' N ' ' CD1' ' A' ' 22' ' ' PHE . 6.9 m-85 -123.0 -47.41 2.04 Favored 'General case' 0 C--N 1.295 -1.782 0 O-C-N 124.542 1.151 . . . . 0.0 108.245 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -99.58 178.13 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.331 1.062 . . . . 0.0 110.775 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 ptmt -115.17 172.63 3.48 Favored Pre-proline 0 C--N 1.295 -1.79 0 CA-C-N 112.104 -2.316 . . . . 0.0 105.025 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -93.78 143.45 1.86 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.228 1.952 . . . . 0.0 110.384 166.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.64 -10.33 38.37 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.231 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -108.53 -175.9 2.9 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.81 ' CG ' ' HZ1' ' A' ' 54' ' ' LYS . 0.6 OUTLIER -118.82 163.99 16.07 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.226 -179.724 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.527 HG23 ' CB ' ' A' ' 31' ' ' GLU . 3.1 p -133.01 174.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.481 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 19.8 t-20 -116.21 -35.85 4.23 Favored 'General case' 0 N--CA 1.523 3.203 0 CA-C-O 126.903 3.24 . . . . 0.0 115.649 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.527 ' CB ' HG23 ' A' ' 29' ' ' VAL 0.395 33.0 tt0 20.18 123.08 0.0 OUTLIER 'General case' 0 C--N 1.273 -2.759 5 N-CA-C 151.831 15.123 . . . . 0.0 151.831 -179.537 . . . . . . . . 4 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' CG ' ' N ' ' A' ' 33' ' ' ASP . 11.2 p-10 -123.01 -48.23 2.01 Favored 'General case' 0 C--N 1.287 -2.117 4 CA-C-N 93.237 -10.892 . . . . 0.0 97.625 178.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' CG ' ' A' ' 32' ' ' ASP . 3.7 t0 -22.55 176.6 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.617 0 C-N-CA 131.427 3.891 . . . . 0.0 116.186 179.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.489 ' HA ' HG21 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -107.39 167.52 3.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 127.366 3.46 . . . . 0.0 114.292 -179.597 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.489 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.1 mp -130.9 -87.34 0.49 Allowed 'General case' 0 C--N 1.283 -2.289 1 CA-C-N 106.562 -4.836 . . . . 0.0 103.688 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.89 169.63 13.73 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.514 ' HG3' HG23 ' A' ' 45' ' ' VAL . 1.2 tm-20 -135.09 156.88 48.26 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 126.341 2.276 . . . . 0.0 104.946 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.477 ' CG1' ' N ' ' A' ' 39' ' ' GLN . 54.0 t -139.5 179.58 2.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 125.481 1.738 . . . . 0.0 111.439 -179.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.477 ' N ' ' CG1' ' A' ' 38' ' ' VAL . 25.0 tt0 -137.8 102.72 4.8 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 113.313 -1.767 . . . . 0.0 108.234 178.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.413 HD21 ' CG ' ' A' ' 41' ' ' ASP . 9.9 p-10 -147.41 175.8 10.53 Favored 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.916 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.413 ' CG ' HD21 ' A' ' 40' ' ' ASN . 1.0 OUTLIER -15.7 -68.66 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 119.139 3.014 . . . . 0.0 119.139 -179.601 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.579 ' CB ' ' HZ1' ' A' ' 42' ' ' LYS . 0.3 OUTLIER -126.14 -8.85 6.49 Favored 'General case' 0 C--N 1.289 -2.023 0 CA-C-N 114.794 -1.093 . . . . 0.0 110.958 -179.407 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -111.39 156.03 22.23 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.874 -1.13 . . . . 0.0 109.734 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.47 -88.98 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 114.135 -1.393 . . . . 0.0 108.742 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.514 HG23 ' HG3' ' A' ' 37' ' ' GLU . 61.5 t -68.27 162.86 3.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 104.566 -2.383 . . . . 0.0 104.566 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.43 ' CB ' HD13 ' A' ' 47' ' ' ILE . 2.4 mt-10 -108.3 -60.65 1.7 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 126.806 2.566 . . . . 0.0 115.479 -179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.489 HG21 ' HA ' ' A' ' 34' ' ' VAL . 1.6 mp -96.1 143.21 25.73 Favored Pre-proline 0 C--N 1.273 -2.745 1 CA-C-N 108.033 -4.167 . . . . 0.0 108.904 -179.507 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.468 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.03 177.11 0.46 Allowed 'Trans proline' 0 C--N 1.305 -1.731 1 C-N-CA 126.281 4.654 . . . . 0.0 106.509 90.036 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.455 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 16.1 m -128.45 171.15 9.04 Favored Pre-proline 0 C--N 1.28 -2.434 0 O-C-N 125.144 1.528 . . . . 0.0 114.285 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -105.35 -17.13 0.05 OUTLIER 'Trans proline' 0 CA--C 1.555 1.549 0 C-N-CA 124.575 3.517 . . . . 0.0 119.653 173.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.577 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.2 p -135.24 170.35 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.705 0 CA-C-O 122.896 1.331 . . . . 0.0 111.789 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.577 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -125.07 178.3 5.61 Favored 'General case' 0 C--N 1.286 -2.195 1 CA-C-N 108.239 -4.073 . . . . 0.0 111.266 -179.555 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.61 -134.93 4.35 Favored Glycine 0 C--N 1.287 -2.177 1 N-CA-C 100.3 -5.12 . . . . 0.0 100.3 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.81 ' HZ1' ' CG ' ' A' ' 28' ' ' GLU . 15.1 tppt? -112.93 176.55 4.97 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 104.497 -2.409 . . . . 0.0 104.497 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.419 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 24.0 t -123.75 100.84 8.25 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 1 N-CA-C 93.148 -6.612 . . . . 0.0 93.148 179.68 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.5 mt -74.61 -83.08 0.06 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 117.582 -1.647 . . . . 0.0 106.946 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.2 160.99 30.37 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.001 . . . . 0.0 112.668 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -132.75 118.36 33.79 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 1 N-CA-C 92.761 -6.755 . . . . 0.0 92.761 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -92.69 -41.18 10.3 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 123.727 0.642 . . . . 0.0 111.787 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -111.32 124.59 32.33 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 101.632 -3.47 . . . . 0.0 101.632 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -57.07 -124.16 0.0 OUTLIER 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 123.921 3.081 . . . . 0.0 116.453 176.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.509 ' C ' ' H ' ' A' ' 64' ' ' THR . 0.0 OUTLIER -127.49 -170.34 2.21 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 100.885 -3.746 . . . . 0.0 100.885 179.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.07 -19.95 0.12 Allowed Glycine 0 N--CA 1.491 2.347 0 CA-C-N 113.277 -1.783 . . . . 0.0 113.711 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.509 ' H ' ' C ' ' A' ' 62' ' ' GLU . 2.2 m -101.97 170.03 8.39 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 104.394 -2.447 . . . . 0.0 104.394 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.407 HG21 ' HG3' ' A' ' 17' ' ' GLU . 45.0 t -105.77 148.8 9.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 103.816 -2.661 . . . . 0.0 103.816 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -119.5 156.66 29.82 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.415 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -101.06 -160.86 0.82 Allowed 'General case' 0 C--N 1.283 -2.289 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.549 HG13 ' HB3' ' A' ' 8' ' ' ASP . 52.2 t -126.69 153.17 35.23 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.39 1 N-CA-C 94.353 -6.166 . . . . 0.0 94.353 178.386 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . 0.469 ' N ' HG11 ' A' ' 68' ' ' VAL . . . 94.44 -36.16 3.89 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 103.588 -3.805 . . . . 0.0 103.588 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.484 ' H ' ' C ' ' A' ' 68' ' ' VAL . 31.6 tt0 -92.93 163.75 13.57 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 101.817 -3.401 . . . . 0.0 101.817 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.3 m -108.84 -179.02 3.74 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 101.724 -3.435 . . . . 0.0 101.724 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.06 -65.64 0.23 Allowed 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 7.8 tt -130.19 163.56 35.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.2 t -140.42 158.32 44.18 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 103.142 -2.91 . . . . 0.0 103.142 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -132.39 149.54 52.33 Favored 'General case' 0 C--N 1.287 -2.11 0 CA-C-N 111.83 -2.441 . . . . 0.0 104.855 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.26 123.17 48.12 Favored 'General case' 0 C--N 1.292 -1.913 1 N-CA-C 96.511 -5.366 . . . . 0.0 96.511 179.716 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -139.77 58.72 12.09 Favored Pre-proline 0 N--CA 1.491 1.607 1 N-CA-C 99.786 -4.153 . . . . 0.0 99.786 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -78.1 67.77 8.03 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 121.778 1.652 . . . . 0.0 112.066 -153.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.3 59.06 0.05 OUTLIER Glycine 0 N--CA 1.501 2.972 0 C-N-CA 119.72 -1.228 . . . . 0.0 112.806 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 116.338 -1.791 . . . . 0.0 107.554 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 2.097 0 N-CA-C 103.73 -2.692 . . . . 0.0 103.73 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.78 128.27 51.54 Favored 'General case' 0 C--N 1.29 -2.015 1 N-CA-C 99.962 -4.088 . . . . 0.0 99.962 -179.635 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -102.23 -173.29 2.3 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -101.14 -43.16 6.09 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.609 0.719 . . . . 0.0 112.509 -179.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.458 ' CB ' HG21 ' A' ' 68' ' ' VAL . 0.1 OUTLIER -128.49 160.27 32.84 Favored 'General case' 0 C--N 1.297 -1.685 1 N-CA-C 99.338 -4.319 . . . . 0.0 99.338 179.79 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 25.5 mt -103.31 -169.37 0.18 Allowed Pre-proline 0 C--N 1.296 -1.745 0 N-CA-C 105.319 -2.104 . . . . 0.0 105.319 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -55.48 85.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.12 1.88 . . . . 0.0 107.577 148.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.482 ' HB3' HG13 ' A' ' 68' ' ' VAL . 3.2 t0 -123.15 -88.65 0.61 Allowed 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.521 ' H ' HG13 ' A' ' 68' ' ' VAL . 1.3 pt 37.77 43.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.321 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.33 -176.1 50.51 Favored Glycine 0 N--CA 1.493 2.453 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.551 -179.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -80.72 144.73 31.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.86 -77.89 0.26 Allowed Glycine 0 C--N 1.294 -1.786 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.2 mt -137.93 103.79 2.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 102.736 -3.061 . . . . 0.0 102.736 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.67 20.71 18.61 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-N 122.178 2.263 . . . . 0.0 108.35 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.498 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 1.4 pm0 -121.95 -174.26 2.84 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 123.725 1.726 . . . . 0.0 114.09 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.4 101.65 0.27 Allowed Glycine 0 N--CA 1.492 2.43 0 CA-C-N 112.483 -2.144 . . . . 0.0 109.7 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -92.94 89.2 6.45 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.9 mt -84.18 103.89 11.9 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 100.851 -3.759 . . . . 0.0 100.851 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.7 t -84.33 -46.17 17.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.331 -179.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 25.8 tttt -142.24 159.77 41.57 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 114.983 -1.008 . . . . 0.0 111.1 -179.543 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.506 ' CE3' HG21 ' A' ' 23' ' ' VAL . 17.7 m95 -122.16 162.52 21.18 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 179.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -120.68 -20.74 6.94 Favored 'General case' 0 C--N 1.292 -1.895 0 O-C-N 124.984 1.428 . . . . 0.0 108.76 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.506 HG21 ' CE3' ' A' ' 21' ' ' TRP . 5.1 m -99.89 179.31 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-O 123.753 1.74 . . . . 0.0 112.147 -179.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.536 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -130.42 140.13 37.73 Favored Pre-proline 0 C--N 1.288 -2.095 1 N-CA-C 97.743 -4.91 . . . . 0.0 97.743 -179.71 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -54.69 162.56 4.73 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.42 1.413 . . . . 0.0 114.945 -175.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.52 26.55 0.08 OUTLIER Glycine 0 C--N 1.294 -1.764 0 CA-C-N 110.785 -2.916 . . . . 0.0 117.662 179.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.508 ' C ' ' NZ ' ' A' ' 54' ' ' LYS . 23.0 t0 -87.0 -168.48 2.26 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 113.498 -3.281 . . . . 0.0 107.115 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.482 ' H ' ' CG ' ' A' ' 27' ' ' ASP . 5.5 mm-40 -102.92 127.55 50.08 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 100.391 -3.929 . . . . 0.0 100.391 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.9 p -109.55 160.74 8.33 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -96.72 -164.17 1.12 Allowed 'General case' 0 C--N 1.292 -1.901 0 CA-C-N 113.472 -1.695 . . . . 0.0 109.137 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . 0.284 9.9 tt0 -117.87 56.21 0.86 Allowed 'General case' 0 C--N 1.289 -2.048 1 N-CA-C 98.332 -4.692 . . . . 0.0 98.332 -178.88 . . . . . . . . 3 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -178.04 1.39 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.84 0 CA-C-N 112.049 -2.341 . . . . 0.0 116.442 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.433 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 42.3 t0 -90.31 -172.14 3.35 Favored 'General case' 0 N--CA 1.508 2.463 0 CA-C-N 118.789 0.722 . . . . 0.0 111.371 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.492 HG13 ' H ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -112.51 176.34 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 126.375 2.988 . . . . 0.0 102.956 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.492 ' H ' HG13 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -140.08 -83.29 0.25 Allowed 'General case' 0 C--N 1.274 -2.697 1 CA-C-N 107.485 -4.416 . . . . 0.0 100.504 179.317 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.456 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -126.08 172.34 10.07 Favored 'General case' 0 N--CA 1.51 2.568 0 CA-C-N 122.179 2.263 . . . . 0.0 115.153 -179.287 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.459 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 2.1 tt0 -119.77 101.33 7.82 Favored 'General case' 0 N--CA 1.493 1.707 1 N-CA-C 92.966 -6.679 . . . . 0.0 92.966 179.443 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 t -108.18 150.43 10.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 26.7 tt0 -121.23 164.53 16.81 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 104.116 -2.55 . . . . 0.0 104.116 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.2 p-10 -152.98 -178.75 7.11 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 102.623 -3.102 . . . . 0.0 102.623 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD2' ' NZ ' ' A' ' 42' ' ' LYS . 0.8 OUTLIER -5.79 -57.62 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 118.231 2.678 . . . . 0.0 118.231 -179.613 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.5 ' NZ ' ' OD2' ' A' ' 41' ' ' ASP . 2.2 mttp -146.36 -34.3 0.29 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.31 149.88 38.63 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.86 -1.064 . . . . 0.0 113.2 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 21.9 t -122.6 110.99 28.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 1 N-CA-C 95.696 -5.668 . . . . 0.0 95.696 179.582 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t -114.71 162.61 12.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 CA-C-O 124.709 2.195 . . . . 0.0 108.455 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -118.35 153.12 34.55 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 109.044 -3.707 . . . . 0.0 106.766 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 mp -121.43 126.25 26.57 Favored Pre-proline 0 C--N 1.302 -1.47 1 N-CA-C 94.132 -6.247 . . . . 0.0 94.132 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -90.77 -176.69 1.02 Allowed 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.537 2.158 . . . . 0.0 107.934 167.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -91.85 112.8 56.51 Favored Pre-proline 0 C--N 1.288 -2.079 0 CA-C-N 113.207 -1.815 . . . . 0.0 108.228 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -69.7 -34.59 14.49 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 121.497 1.465 . . . . 0.0 108.363 168.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.482 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.52 168.79 21.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 125.458 1.723 . . . . 0.0 111.94 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.482 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -102.82 162.18 13.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 127.32 2.888 . . . . 0.0 105.307 179.19 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 163.12 -141.84 7.44 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.508 ' NZ ' ' C ' ' A' ' 27' ' ' ASP . 0.5 OUTLIER -117.96 175.28 5.75 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 104.405 -2.442 . . . . 0.0 104.405 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' LEU . 21.7 t -128.52 57.19 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.048 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.402 ' C ' ' O ' ' A' ' 55' ' ' VAL . 85.0 mt -26.9 -76.77 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 CA-C-N 112.729 -2.032 . . . . 0.0 113.632 -179.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -130.59 153.5 48.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 124.77 1.294 . . . . 0.0 110.161 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -131.25 119.62 44.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 1 N-CA-C 93.425 -6.509 . . . . 0.0 93.425 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.421 HD13 ' N ' ' A' ' 59' ' ' LEU . 6.0 mp -90.9 -44.86 9.12 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.9 t -119.42 140.65 29.47 Favored Pre-proline 0 C--N 1.296 -1.757 1 N-CA-C 97.802 -4.888 . . . . 0.0 97.802 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -91.51 -101.34 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.033 1.155 . . . . 0.0 110.214 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.18 -168.71 1.97 Allowed 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 102.071 -3.307 . . . . 0.0 102.071 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 79.67 -45.87 2.98 Favored Glycine 0 C--N 1.287 -2.186 0 CA-C-N 113.404 -1.725 . . . . 0.0 112.101 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.6 m -98.83 172.51 7.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.4 t -108.03 150.63 10.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 104.614 -2.365 . . . . 0.0 104.614 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.97 168.11 13.25 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 103.661 -2.718 . . . . 0.0 103.661 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 12.2 t -129.02 -151.32 0.47 Allowed 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.524 ' C ' ' H ' ' A' ' 70' ' ' GLN . 97.4 t -121.98 159.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.322 0 N-CA-C 101.028 -3.693 . . . . 0.0 101.028 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.32 -43.86 1.7 Allowed Glycine 0 CA--C 1.549 2.211 1 N-CA-C 97.142 -6.383 . . . . 0.0 97.142 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.524 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.1 tt0 -88.81 162.56 16.13 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 102.289 -3.226 . . . . 0.0 102.289 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.7 m -109.6 -176.93 3.14 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 101.965 -3.346 . . . . 0.0 101.965 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.3 tp -146.91 -65.49 0.28 Allowed 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 1.4 tt -133.25 166.13 30.23 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-N 112.125 -2.307 . . . . 0.0 105.174 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -138.49 156.71 47.29 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 101.42 -3.548 . . . . 0.0 101.42 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -136.11 147.57 47.85 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.51 142.34 42.43 Favored 'General case' 0 C--N 1.299 -1.63 1 N-CA-C 97.946 -4.835 . . . . 0.0 97.946 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.13 36.6 0.25 Allowed Pre-proline 0 C--N 1.293 -1.853 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.386 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -37.21 61.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 124.921 3.747 . . . . 0.0 119.406 -143.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 153.5 42.3 0.02 OUTLIER Glycine 0 N--CA 1.495 2.59 0 N-CA-C 106.472 -2.651 . . . . 0.0 106.472 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.304 -1.398 0 N-CA-C 100.634 -3.839 . . . . 0.0 100.634 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.069 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -126.07 127.84 46.46 Favored 'General case' 0 N--CA 1.503 2.224 0 N-CA-C 102.569 -3.123 . . . . 0.0 102.569 -179.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.12 -151.25 0.47 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 125.319 1.637 . . . . 0.0 111.818 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.54 ' CE2' ' HE2' ' A' ' 5' ' ' LYS . 8.2 t80 -113.3 -49.68 2.9 Favored 'General case' 0 N--CA 1.502 2.162 0 CA-C-N 113.375 -1.738 . . . . 0.0 114.655 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.54 ' HE2' ' CE2' ' A' ' 4' ' ' PHE . 28.4 mmtt -131.45 155.11 47.92 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 66.0 mt -84.05 173.66 7.0 Favored Pre-proline 0 C--N 1.296 -1.724 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.818 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -54.18 85.91 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.585 2.19 . . . . 0.0 109.791 162.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.438 ' HB3' HG12 ' A' ' 68' ' ' VAL . 10.4 t0 -122.9 -80.22 0.62 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.3 pt 37.07 39.03 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.575 0 CA-C-O 121.896 0.855 . . . . 0.0 109.447 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.12 -150.56 11.33 Favored Glycine 0 N--CA 1.48 1.629 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.594 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -95.01 139.19 31.71 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 103.309 -2.848 . . . . 0.0 103.309 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.97 -79.27 0.33 Allowed Glycine 0 N--CA 1.487 2.081 0 N-CA-C 103.774 -3.731 . . . . 0.0 103.774 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.3 mm -130.73 133.25 63.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 22.1 t-80 -130.34 -19.23 3.14 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.503 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 0.5 OUTLIER -131.32 178.1 6.97 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 122.975 1.369 . . . . 0.0 110.55 -179.524 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.83 125.44 4.12 Favored Glycine 0 C--N 1.29 -2.019 0 N-CA-C 104.8 -3.32 . . . . 0.0 104.8 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.427 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 37.5 tt0 -100.31 96.31 7.36 Favored 'General case' 0 C--N 1.307 -1.272 1 N-CA-C 97.28 -5.081 . . . . 0.0 97.28 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mt -81.96 125.12 39.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 N-CA-C 103.573 -2.751 . . . . 0.0 103.573 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.6 t -86.38 -64.0 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 103.26 -2.867 . . . . 0.0 103.26 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.413 ' HE3' ' O ' ' A' ' 21' ' ' TRP . 1.3 tmtp? -142.99 167.75 21.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 124.018 0.824 . . . . 0.0 113.22 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.512 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 30.3 m95 -113.73 173.06 6.61 Favored 'General case' 0 N--CA 1.502 2.131 0 C-N-CA 123.92 0.888 . . . . 0.0 109.004 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -126.92 -48.51 1.49 Allowed 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.541 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 m -100.23 178.69 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.172 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.02 161.77 26.34 Favored Pre-proline 0 C--N 1.295 -1.785 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.814 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -78.16 122.56 5.76 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.249 1.966 . . . . 0.0 110.857 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.16 -15.99 22.78 Favored Glycine 0 N--CA 1.483 1.816 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.23 174.37 7.32 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 123.018 1.389 . . . . 0.0 111.74 -178.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.521 ' CG ' ' HZ1' ' A' ' 54' ' ' LYS . 45.6 mt-10 -119.93 117.41 28.01 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 111.166 -2.743 . . . . 0.0 104.242 -179.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 p -108.58 176.59 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.719 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.42 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -104.65 -26.3 12.37 Favored 'General case' 0 N--CA 1.522 3.166 0 CA-C-O 126.698 3.142 . . . . 0.0 112.94 -179.697 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.403 ' CG ' ' O ' ' A' ' 51' ' ' VAL 0.377 10.8 tp10 35.46 78.71 0.03 OUTLIER 'General case' 0 C--N 1.272 -2.796 5 N-CA-C 138.398 10.147 . . . . 0.0 138.398 -179.389 . . . . . . . . 4 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -141.67 27.21 1.87 Allowed 'General case' 0 C--N 1.287 -2.127 4 CA-C-N 94.721 -10.218 . . . . 0.0 96.273 179.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -108.94 -165.59 1.04 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 126.105 1.762 . . . . 0.0 107.343 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.434 HG13 ' H ' ' A' ' 35' ' ' LEU . 1.6 t -120.3 163.02 18.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 CA-C-O 125.554 2.597 . . . . 0.0 108.893 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.512 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.6 mp -126.45 -84.0 0.62 Allowed 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 108.726 -3.852 . . . . 0.0 103.033 179.15 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.561 ' SG ' HG21 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -123.66 172.69 8.62 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 -178.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.417 ' N ' ' SG ' ' A' ' 36' ' ' CYS 0.369 18.5 tt0 -134.04 140.31 46.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 127.064 2.728 . . . . 0.0 103.646 -179.244 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.561 HG21 ' SG ' ' A' ' 36' ' ' CYS . 25.0 t -139.39 151.34 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 CA-C-N 119.145 0.884 . . . . 0.0 109.7 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 43.4 tp60 -106.5 128.25 53.95 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -156.01 -173.09 4.36 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -11.69 -73.63 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.608 0 O-C-N 126.479 2.362 . . . . 0.0 116.608 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -128.38 -7.27 5.27 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.408 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.81 159.2 15.08 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.276 -0.97 . . . . 0.0 113.15 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.9 t -124.65 -35.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 126.678 2.486 . . . . 0.0 112.942 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.407 HG21 ' HG3' ' A' ' 37' ' ' GLU . 10.9 t -113.1 169.51 4.78 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 125.239 1.415 . . . . 0.0 108.282 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.425 ' CD ' ' HZ3' ' A' ' 5' ' ' LYS . 3.6 mt-10 -120.45 -67.8 0.95 Allowed 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 121.422 3.86 . . . . 0.0 121.422 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.4 HG22 ' C ' ' A' ' 48' ' ' PRO . 1.6 mp -92.85 149.49 37.84 Favored Pre-proline 0 C--N 1.273 -2.73 0 CA-C-N 108.746 -3.843 . . . . 0.0 108.672 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.4 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -103.18 -178.31 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.708 1.373 . . . . 0.0 109.152 83.395 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.4 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 0.7 OUTLIER -130.96 179.53 1.32 Allowed Pre-proline 0 C--N 1.286 -2.164 0 CA-C-N 113.481 -1.69 . . . . 0.0 108.428 -179.798 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -102.32 -26.53 0.03 OUTLIER 'Trans proline' 0 CA--C 1.548 1.179 0 N-CA-C 120.016 3.045 . . . . 0.0 120.016 171.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.517 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.9 OUTLIER -127.89 160.6 37.32 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.454 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.517 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -106.75 167.61 9.75 Favored 'General case' 0 C--N 1.294 -1.825 1 CA-C-N 107.451 -4.431 . . . . 0.0 111.148 -179.625 . . . . . . . . 4 4 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.28 -141.37 6.75 Favored Glycine 0 C--N 1.292 -1.909 1 N-CA-C 100.024 -5.23 . . . . 0.0 100.024 -179.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.521 ' HZ1' ' CG ' ' A' ' 28' ' ' GLU . 14.4 tppt? -105.79 175.1 5.61 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 102.151 -3.277 . . . . 0.0 102.151 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.436 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 47.4 t -126.1 60.69 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.216 1 N-CA-C 96.549 -5.352 . . . . 0.0 96.549 179.39 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.406 ' C ' ' O ' ' A' ' 55' ' ' VAL . 91.2 mt -22.55 -80.34 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.163 0 CA-C-N 112.816 -1.993 . . . . 0.0 112.999 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -139.76 164.18 30.64 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 125.049 1.468 . . . . 0.0 107.817 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.9 mt -132.47 130.99 60.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 1 N-CA-C 95.67 -5.678 . . . . 0.0 95.67 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.403 HD13 ' N ' ' A' ' 59' ' ' LEU . 5.9 mp -87.74 -52.61 5.21 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 123.8 0.688 . . . . 0.0 109.689 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.5 t -116.67 140.54 26.89 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 101.135 -3.654 . . . . 0.0 101.135 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -87.5 -106.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.694 1.596 . . . . 0.0 111.004 178.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -129.56 159.57 35.95 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 102.567 -3.123 . . . . 0.0 102.567 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 107.17 -33.09 6.63 Favored Glycine 0 N--CA 1.498 2.782 0 C-N-CA 119.278 -1.439 . . . . 0.0 114.61 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.2 m -109.28 -175.9 2.88 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.2 t -112.43 150.93 14.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.88 163.73 18.73 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -107.57 -160.77 0.75 Allowed 'General case' 0 C--N 1.285 -2.224 0 N-CA-C 104.234 -2.506 . . . . 0.0 104.234 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.438 HG12 ' HB3' ' A' ' 8' ' ' ASP 0.265 44.6 t -124.0 153.86 30.38 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 1 N-CA-C 92.643 -6.799 . . . . 0.0 92.643 178.226 . . . . . . . . 4 3 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.6 -45.8 1.99 Allowed Glycine 0 N--CA 1.498 2.77 0 N-CA-C 103.294 -3.922 . . . . 0.0 103.294 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.424 ' H ' ' C ' ' A' ' 68' ' ' VAL . 37.3 tt0 -85.84 160.21 19.51 Favored 'General case' 0 C--N 1.303 -1.452 1 N-CA-C 99.777 -4.157 . . . . 0.0 99.777 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.4 m -106.54 -178.43 3.65 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 102.122 -3.288 . . . . 0.0 102.122 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.469 HD23 ' CE2' ' A' ' 4' ' ' PHE . 47.9 tp -143.33 -60.07 0.42 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 14.2 tt -132.96 161.97 40.76 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 104.573 -2.38 . . . . 0.0 104.573 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 t -140.09 164.73 29.25 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -134.01 144.21 48.58 Favored 'General case' 0 N--CA 1.505 2.275 0 CA-C-N 113.873 -1.512 . . . . 0.0 109.587 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -110.07 55.19 0.65 Allowed 'General case' 0 N--CA 1.504 2.249 0 CA-C-O 125.05 2.357 . . . . 0.0 112.32 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -91.37 132.26 34.23 Favored Pre-proline 0 C--N 1.293 -1.848 0 CA-C-N 112.456 -2.156 . . . . 0.0 107.652 -179.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -91.43 171.61 2.94 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 124.012 3.141 . . . . 0.0 106.949 150.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.95 -34.04 4.91 Favored Glycine 0 N--CA 1.493 2.487 1 N-CA-C 102.037 -4.425 . . . . 0.0 102.037 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 7.1 m-85 . . . . . 0 C--N 1.302 -1.482 0 N-CA-C 103.078 -2.934 . . . . 0.0 103.078 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -119.22 139.39 51.95 Favored 'General case' 0 N--CA 1.512 2.668 0 N-CA-C 100.732 -3.803 . . . . 0.0 100.732 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.406 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 0.0 OUTLIER -114.99 -161.03 0.76 Allowed 'General case' 0 N--CA 1.502 2.17 0 CA-C-N 120.798 1.635 . . . . 0.0 109.401 -179.67 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -126.99 -29.1 2.83 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 116.828 2.158 . . . . 0.0 116.828 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.449 ' CB ' HG21 ' A' ' 68' ' ' VAL . 17.9 mmmt -128.26 169.38 14.25 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-N 122.21 2.277 . . . . 0.0 105.279 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 64.6 mt -91.45 177.34 2.26 Favored Pre-proline 0 N--CA 1.493 1.705 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.741 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -61.14 80.05 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.649 0 N-CA-C 106.954 -1.979 . . . . 0.0 106.954 148.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.405 ' HB3' HG13 ' A' ' 68' ' ' VAL . 9.9 t70 -123.09 -80.05 0.62 Allowed 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.475 ' H ' HG13 ' A' ' 68' ' ' VAL . 45.5 pt 38.4 34.78 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.51 0 CA-C-N 119.794 1.179 . . . . 0.0 110.168 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.08 -115.03 2.89 Favored Glycine 0 N--CA 1.48 1.587 0 C-N-CA 120.84 -0.695 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -103.46 133.45 48.49 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.278 0.561 . . . . 0.0 110.873 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 116.92 -78.43 0.29 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 106.613 -2.595 . . . . 0.0 106.613 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.5 mm -133.45 134.1 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.089 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -119.22 -41.96 2.71 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 102.013 -3.328 . . . . 0.0 102.013 179.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.535 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.7 OUTLIER -130.65 167.47 18.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 124.005 0.816 . . . . 0.0 110.098 179.601 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.95 149.27 19.12 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -99.05 97.62 8.74 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 104.11 -2.552 . . . . 0.0 104.11 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.7 mm -83.85 115.04 25.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 t -97.02 -48.32 12.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 O-C-N 125.061 1.475 . . . . 0.0 111.12 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.553 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -137.79 144.66 41.67 Favored 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.488 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 24.1 m95 -114.25 170.14 8.51 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.553 ' CZ ' ' HE2' ' A' ' 20' ' ' LYS . 2.6 m-85 -121.47 -51.17 2.08 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 113.87 -1.514 . . . . 0.0 111.161 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 m -100.49 175.01 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.145 -1.022 . . . . 0.0 110.311 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.492 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -116.0 156.87 46.21 Favored Pre-proline 0 C--N 1.299 -1.63 0 N-CA-C 104.323 -2.473 . . . . 0.0 104.323 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -64.67 145.16 86.29 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 120.865 1.044 . . . . 0.0 111.22 171.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.56 19.73 28.94 Favored Glycine 0 N--CA 1.488 2.149 0 CA-C-O 118.733 -1.037 . . . . 0.0 111.864 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -106.33 170.05 8.15 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.63 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.449 ' CD ' ' HE2' ' A' ' 54' ' ' LYS . 21.0 mt-10 -129.25 88.4 2.7 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 p -74.36 178.38 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-N 110.718 -2.946 . . . . 0.0 108.892 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.452 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 42.6 t30 -107.39 -29.71 9.1 Favored 'General case' 0 N--CA 1.517 2.892 0 CA-C-O 124.693 2.187 . . . . 0.0 112.097 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.387 11.1 tp10 44.63 75.22 0.11 Allowed 'General case' 0 C--N 1.279 -2.474 5 N-CA-C 135.413 9.042 . . . . 0.0 135.413 -179.742 . . . . . . . . 4 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 32' ' ' ASP . 11.8 p-10 -144.31 27.36 1.41 Allowed 'General case' 0 C--N 1.284 -2.248 4 CA-C-N 94.649 -10.251 . . . . 0.0 94.709 178.69 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -112.19 -169.56 1.49 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 127.652 2.381 . . . . 0.0 110.833 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.475 ' HA ' HG21 ' A' ' 47' ' ' ILE . 1.5 t -119.94 162.17 18.64 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 CA-C-O 124.302 2.001 . . . . 0.0 107.994 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.488 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 7.1 mp -126.22 -85.35 0.62 Allowed 'General case' 0 C--N 1.282 -2.356 1 CA-C-N 108.162 -4.108 . . . . 0.0 102.485 179.075 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.502 ' SG ' HD11 ' A' ' 47' ' ' ILE . 14.6 p -123.81 174.99 7.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -178.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.528 ' CG ' ' HA ' ' A' ' 45' ' ' VAL . 1.9 tt0 -133.27 140.07 47.27 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 126.925 2.641 . . . . 0.0 105.887 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.418 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 29.1 t -137.73 153.56 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-N 119.705 1.139 . . . . 0.0 108.32 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -112.15 122.65 48.33 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -159.63 170.78 20.87 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 179.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.492 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 6.0 p-10 -3.88 -67.57 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 117.537 2.421 . . . . 0.0 117.537 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.492 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 84.9 mttt -126.19 -0.88 7.07 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 124.42 1.075 . . . . 0.0 111.459 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -104.01 154.45 19.66 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 114.41 1.263 . . . . 0.0 114.41 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.7 t -129.95 -47.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 CA-C-N 111.109 -2.769 . . . . 0.0 109.0 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.528 ' HA ' ' CG ' ' A' ' 37' ' ' GLU . 21.8 t -105.8 160.98 5.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 CA-C-N 112.68 -2.054 . . . . 0.0 106.878 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HB3' HD13 ' A' ' 47' ' ' ILE . 4.8 mt-10 -119.36 -67.14 1.01 Allowed 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 120.619 3.563 . . . . 0.0 120.619 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.502 HD11 ' SG ' ' A' ' 36' ' ' CYS . 1.1 mp -90.81 147.38 35.91 Favored Pre-proline 0 C--N 1.272 -2.768 0 CA-C-N 109.781 -3.372 . . . . 0.0 109.587 -179.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.48 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -100.71 178.57 0.23 Allowed 'Trans proline' 0 C--N 1.314 -1.283 0 N-CA-C 107.378 -1.816 . . . . 0.0 107.378 84.303 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.461 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 14.5 m -128.78 -176.55 0.54 Allowed Pre-proline 0 C--N 1.285 -2.232 0 CA-C-N 113.609 -1.632 . . . . 0.0 107.41 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -100.64 -30.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 123.121 2.547 . . . . 0.0 118.093 178.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -138.18 162.41 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.33 0 CA-C-O 123.559 1.647 . . . . 0.0 114.381 -179.348 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.532 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -112.52 169.81 8.62 Favored 'General case' 0 C--N 1.296 -1.723 1 CA-C-N 107.796 -4.275 . . . . 0.0 110.213 -179.645 . . . . . . . . 4 4 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 167.23 -141.25 6.76 Favored Glycine 0 C--N 1.288 -2.113 1 N-CA-C 96.799 -6.52 . . . . 0.0 96.799 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.449 ' HE2' ' CD ' ' A' ' 28' ' ' GLU . 0.6 OUTLIER -93.6 -179.31 4.98 Favored 'General case' 0 C--N 1.288 -2.066 1 N-CA-C 99.785 -4.154 . . . . 0.0 99.785 179.99 . . . . . . . . 4 4 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 48.1 t -127.9 98.39 4.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.451 1 N-CA-C 91.689 -7.152 . . . . 0.0 91.689 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 55.1 mt -58.81 -88.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 124.787 1.304 . . . . 0.0 109.874 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -139.43 166.16 25.31 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -126.57 134.7 65.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 1 N-CA-C 94.43 -6.137 . . . . 0.0 94.43 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.8 mp -94.6 -57.25 2.53 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.276 -0.97 . . . . 0.0 112.238 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.429 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 22.8 t -113.05 94.22 29.02 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 101.061 -3.681 . . . . 0.0 101.061 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -71.93 -81.31 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 CA-C-N 120.09 1.068 . . . . 0.0 109.558 -171.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -137.11 164.2 28.99 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.53 -49.46 1.2 Allowed Glycine 0 N--CA 1.499 2.881 0 C-N-CA 119.962 -1.113 . . . . 0.0 113.133 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.429 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 0.6 OUTLIER -95.78 -172.27 2.56 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 105.511 -2.033 . . . . 0.0 105.511 -179.88 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.1 t -114.92 144.82 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.39 147.84 49.7 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 7.8 p -106.54 -160.04 0.72 Allowed 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.658 1.694 . . . . 0.0 108.367 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.475 HG13 ' H ' ' A' ' 9' ' ' ILE . 44.8 t -115.07 155.85 16.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.309 1 N-CA-C 91.751 -7.129 . . . . 0.0 91.751 178.477 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.19 -36.79 3.77 Favored Glycine 0 N--CA 1.49 2.264 1 N-CA-C 102.464 -4.254 . . . . 0.0 102.464 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.447 ' H ' ' C ' ' A' ' 68' ' ' VAL . 33.0 tt0 -104.2 164.19 11.89 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 102.316 -3.216 . . . . 0.0 102.316 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -98.69 -178.15 3.89 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 103.658 -2.719 . . . . 0.0 103.658 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 36.4 tp -138.66 -72.03 0.41 Allowed 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.001 -2.222 . . . . 0.0 105.001 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 10.9 tt -132.7 159.79 42.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.6 t -137.99 163.92 30.33 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 125.869 1.98 . . . . 0.0 106.496 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.9 155.58 49.58 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 125.636 1.835 . . . . 0.0 110.984 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -120.06 144.8 47.38 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 104.265 -2.494 . . . . 0.0 104.265 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -143.68 84.07 10.16 Favored Pre-proline 0 N--CA 1.492 1.636 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -61.73 53.68 0.11 Allowed 'Trans proline' 0 N--CA 1.507 2.292 0 C-N-CA 124.792 3.662 . . . . 0.0 118.723 -168.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.21 63.5 0.19 Allowed Glycine 0 N--CA 1.489 2.169 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.8 t80 . . . . . 0 N--CA 1.497 1.883 0 N-CA-C 102.821 -3.029 . . . . 0.0 102.821 179.657 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.4 ' N ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.494 1.731 1 N-CA-C 97.812 -4.884 . . . . 0.0 97.812 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . 0.4 ' HB3' ' CB ' ' A' ' 75' ' ' LEU . 18.8 t80 -117.2 93.15 4.07 Favored 'General case' 0 C--N 1.297 -1.689 1 N-CA-C 95.009 -5.923 . . . . 0.0 95.009 178.849 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.4 ' OE2' ' N ' ' A' ' 1' ' ' ALA . 7.1 mp0 -68.41 -177.45 0.92 Allowed 'General case' 0 C--N 1.302 -1.493 0 O-C-N 125.6 1.813 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -110.31 -30.15 7.83 Favored 'General case' 0 N--CA 1.51 2.553 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -179.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.559 ' CG ' HG23 ' A' ' 68' ' ' VAL . 36.5 mmtt -127.06 166.59 17.32 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 103.074 -2.935 . . . . 0.0 103.074 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 74.2 mt -108.79 -173.65 0.27 Allowed Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -54.29 85.36 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.856 1.704 . . . . 0.0 109.031 158.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.431 ' HB3' HG13 ' A' ' 68' ' ' VAL . 3.7 t70 -121.88 -74.73 0.61 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 101.761 -3.422 . . . . 0.0 101.761 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.494 ' H ' HG13 ' A' ' 68' ' ' VAL . 40.2 pt 30.47 38.62 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.975 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.53 -46.83 1.01 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 119.439 -1.362 . . . . 0.0 112.706 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.02 80.9 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 124.355 2.026 . . . . 0.0 113.987 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.68 -68.18 0.26 Allowed Glycine 0 C--N 1.277 -2.746 0 CA-C-N 111.877 -2.42 . . . . 0.0 107.637 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.457 ' CG2' ' H ' ' A' ' 14' ' ' HIS . 40.4 mm -127.2 -172.96 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.457 ' H ' ' CG2' ' A' ' 13' ' ' ILE . 2.1 p80 -144.02 -50.97 0.31 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.583 0.706 . . . . 0.0 111.276 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.523 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.7 pt-20 -103.24 -168.81 1.56 Allowed 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 116.381 1.993 . . . . 0.0 116.381 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.09 112.15 0.59 Allowed Glycine 0 C--N 1.286 -2.227 0 CA-C-N 112.795 -2.002 . . . . 0.0 108.202 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -98.95 92.02 5.32 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 101.567 -3.494 . . . . 0.0 101.567 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.7 mt -85.01 104.2 12.89 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.9 t -86.82 -47.49 16.05 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.476 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.441 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 41.1 tttt -126.22 146.31 50.04 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-N 114.431 -1.258 . . . . 0.0 113.394 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.474 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 4.8 m95 -121.6 176.76 5.54 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 103.846 -2.65 . . . . 0.0 103.846 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.46 ' CD2' HG23 ' A' ' 34' ' ' VAL . 13.8 m-85 -123.76 -34.91 2.96 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 126.257 2.223 . . . . 0.0 112.189 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.478 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 10.3 m -103.74 176.54 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.977 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -140.9 61.31 14.58 Favored Pre-proline 0 N--CA 1.492 1.627 0 N-CA-C 117.933 2.568 . . . . 0.0 117.933 -179.438 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' C ' ' H ' ' A' ' 27' ' ' ASP . 5.8 Cg_exo -21.54 -179.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 N-CA-C 119.699 2.923 . . . . 0.0 119.699 -60.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.478 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.33 28.61 8.69 Favored Glycine 0 N--CA 1.497 2.713 0 CA-C-N 111.597 -2.547 . . . . 0.0 108.198 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.457 ' O ' ' HA ' ' A' ' 54' ' ' LYS . 5.2 t0 7.86 -95.6 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.16 0 O-C-N 128.527 3.133 . . . . 0.0 110.905 179.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.428 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 3.1 mm-40 -98.44 119.7 37.59 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 100.818 -3.771 . . . . 0.0 100.818 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -120.23 168.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 122.296 1.046 . . . . 0.0 109.208 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.7 m-20 -99.85 -168.13 1.56 Allowed 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 112.535 -2.12 . . . . 0.0 107.729 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.524 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.263 4.6 tt0 -120.62 52.36 1.17 Allowed 'General case' 0 N--CA 1.494 1.753 1 N-CA-C 97.838 -4.875 . . . . 0.0 97.838 -179.727 . . . . . . . . 4 3 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -171.37 36.89 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 111.403 -2.635 . . . . 0.0 111.711 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.439 ' CG ' ' N ' ' A' ' 34' ' ' VAL . 19.1 t70 -112.96 -178.38 3.37 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.455 -0.778 . . . . 0.0 109.116 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.46 HG23 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -84.77 -166.06 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 127.314 3.435 . . . . 0.0 117.664 179.75 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.562 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -115.27 -150.68 0.47 Allowed 'General case' 0 C--N 1.281 -2.404 2 CA-C-N 103.319 -6.31 . . . . 0.0 108.645 -179.553 . . . . . . . . 4 4 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.474 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 1.8 m -127.19 159.38 34.47 Favored 'General case' 0 C--N 1.284 -2.282 2 N-CA-C 97.025 -5.176 . . . . 0.0 97.025 179.193 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -114.64 108.6 17.02 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 100.492 -3.892 . . . . 0.0 100.492 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 49.1 t -112.96 147.61 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -113.09 155.53 24.76 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.088 -1.045 . . . . 0.0 108.886 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -140.49 -168.97 2.68 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 104.683 -2.339 . . . . 0.0 104.683 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.457 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.9 OUTLIER -11.13 -64.0 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 126.427 2.33 . . . . 0.0 115.301 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.457 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 17.2 mttp -144.82 -21.87 0.51 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 124.065 0.853 . . . . 0.0 110.439 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.44 -176.33 3.08 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.628 1.204 . . . . 0.0 112.431 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.3 t -125.94 137.58 57.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 103.398 -2.816 . . . . 0.0 103.398 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.5 t -112.05 157.8 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.496 ' C ' HD13 ' A' ' 47' ' ' ILE . 5.7 pt-20 -119.8 141.26 49.66 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 111.572 -2.558 . . . . 0.0 109.952 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.562 ' H ' ' HB2' ' A' ' 35' ' ' LEU . 1.9 mp -125.92 75.22 71.47 Favored Pre-proline 0 CA--C 1.574 1.87 0 N-CA-C 101.556 -3.498 . . . . 0.0 101.556 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_endo -62.07 -172.42 0.11 Allowed 'Trans proline' 0 N--CA 1.512 2.574 0 C-N-CA 122.894 2.396 . . . . 0.0 108.173 -177.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.7 p -105.07 85.22 1.2 Allowed Pre-proline 0 C--N 1.286 -2.19 0 CA-C-N 112.934 -1.939 . . . . 0.0 111.567 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -46.31 -31.98 10.08 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.588 1.525 . . . . 0.0 112.926 176.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.524 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -131.09 167.61 25.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.504 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -102.76 165.15 11.22 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 127.141 2.776 . . . . 0.0 108.097 179.408 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 148.23 -139.85 7.95 Favored Glycine 0 C--N 1.293 -1.808 0 N-CA-C 106.237 -2.745 . . . . 0.0 106.237 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -111.91 169.03 9.12 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 -179.503 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.4 t -128.38 61.55 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 100.856 -3.757 . . . . 0.0 100.856 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 40.8 mt -31.37 -74.11 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 110.845 -2.889 . . . . 0.0 114.227 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -138.75 163.76 31.34 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 114.127 1.158 . . . . 0.0 114.127 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.407 HD13 ' HD3' ' A' ' 25' ' ' PRO . 56.1 mt -136.36 136.94 48.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 1 N-CA-C 100.062 -4.051 . . . . 0.0 100.062 179.762 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.3 mt -94.25 -63.56 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.727 0.775 . . . . 0.0 110.453 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.492 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 15.8 t -115.94 73.8 4.91 Favored Pre-proline 0 N--CA 1.491 1.622 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 -179.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -45.88 -77.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.067 1.845 . . . . 0.0 113.335 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.2 -177.14 4.7 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.45 -49.96 4.32 Favored Glycine 0 N--CA 1.492 2.4 0 CA-C-N 113.929 -1.487 . . . . 0.0 113.007 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.492 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 5.3 m -103.51 -176.22 3.02 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.4 150.05 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.87 160.8 26.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 9.5 t -115.25 -161.29 0.77 Allowed 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.559 HG23 ' CG ' ' A' ' 5' ' ' LYS . 73.3 t -120.25 153.78 23.28 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 95.036 -5.913 . . . . 0.0 95.036 178.618 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.58 -37.99 3.42 Favored Glycine 0 N--CA 1.492 2.427 1 N-CA-C 101.513 -4.635 . . . . 0.0 101.513 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -97.53 159.43 14.93 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 100.71 -3.811 . . . . 0.0 100.71 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.5 179.25 5.07 Favored 'General case' 0 C--N 1.288 -2.082 0 N-CA-C 100.222 -3.992 . . . . 0.0 100.222 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 52.4 tp -138.81 -67.22 0.46 Allowed 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.78 161.94 37.65 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 103.107 -2.924 . . . . 0.0 103.107 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.8 t -137.42 157.45 46.55 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 126.327 2.267 . . . . 0.0 105.714 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.4 ' CB ' ' HB3' ' A' ' 2' ' ' PHE . 0.6 OUTLIER -137.43 150.92 47.99 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -114.26 151.35 32.98 Favored 'General case' 0 C--N 1.296 -1.72 1 N-CA-C 98.865 -4.494 . . . . 0.0 98.865 179.388 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -117.76 -36.68 0.07 OUTLIER Pre-proline 0 N--CA 1.501 2.078 0 C-N-CA 119.465 -0.894 . . . . 0.0 112.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -64.02 -178.87 0.65 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 125.701 2.421 . . . . 0.0 107.647 -62.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.44 -39.23 2.1 Favored Glycine 0 N--CA 1.5 2.926 1 N-CA-C 101.933 -4.467 . . . . 0.0 101.933 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.581 0 N-CA-C 101.476 -3.527 . . . . 0.0 101.476 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 80' ' ' TYR . . . . . . . . 0 N--CA 1.508 2.462 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -141.38 159.21 42.69 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.59 -142.42 0.27 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.636 ' CZ ' ' HD3' ' A' ' 5' ' ' LYS . 14.1 t80 -126.37 -60.75 1.24 Allowed 'General case' 0 N--CA 1.504 2.228 0 O-C-N 124.422 1.076 . . . . 0.0 113.34 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.636 ' HD3' ' CZ ' ' A' ' 4' ' ' PHE . 20.9 mmmt -132.1 143.61 50.14 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 67.9 mt -90.27 173.46 5.69 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 125.053 1.471 . . . . 0.0 107.963 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -40.88 81.59 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.294 0 N-CA-C 118.414 2.429 . . . . 0.0 118.414 168.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -122.68 -76.82 0.59 Allowed 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 103.604 -2.739 . . . . 0.0 103.604 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 27.4 pt 37.4 44.45 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.251 0 CA-C-O 122.683 1.23 . . . . 0.0 108.865 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.62 -161.95 37.84 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -109.59 160.83 15.93 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 118.551 1.176 . . . . 0.0 108.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.28 -72.49 0.38 Allowed Glycine 0 N--CA 1.485 1.934 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.5 mm -132.4 82.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 124.933 1.02 . . . . 0.0 110.248 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.489 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -105.57 16.13 25.92 Favored 'General case' 0 N--CA 1.507 2.38 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.092 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.432 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 7.8 pt-20 -140.09 166.92 23.35 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 113.923 -1.49 . . . . 0.0 108.01 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.03 125.3 4.65 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 107.417 -2.273 . . . . 0.0 107.417 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.9 100.45 11.97 Favored 'General case' 0 C--N 1.302 -1.471 1 N-CA-C 99.04 -4.43 . . . . 0.0 99.04 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.0 mm -82.4 124.57 39.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 1 N-CA-C 99.599 -4.223 . . . . 0.0 99.599 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.0 t -105.24 -39.79 5.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.736 ' HE3' ' CZ ' ' A' ' 22' ' ' PHE . 20.5 tttp -136.7 155.25 50.12 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.169 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.472 ' O ' ' NZ ' ' A' ' 20' ' ' LYS . 14.8 m95 -122.77 178.81 4.86 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 125.495 1.747 . . . . 0.0 106.489 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.736 ' CZ ' ' HE3' ' A' ' 20' ' ' LYS . 28.3 m-85 -132.94 -52.58 0.91 Allowed 'General case' 0 N--CA 1.504 2.259 0 O-C-N 124.373 1.045 . . . . 0.0 112.638 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 m -99.16 175.86 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 124.062 0.851 . . . . 0.0 109.596 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -117.35 161.99 30.5 Favored Pre-proline 0 C--N 1.295 -1.788 0 O-C-N 125.724 1.89 . . . . 0.0 108.443 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -56.07 112.77 1.17 Allowed 'Trans proline' 0 C--N 1.316 -1.153 0 C-N-CA 121.703 1.602 . . . . 0.0 113.013 174.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.51 16.81 14.89 Favored Glycine 0 N--CA 1.484 1.887 0 CA-C-O 117.167 -1.907 . . . . 0.0 113.501 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -86.76 161.12 18.56 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 116.652 -2.019 . . . . 0.0 108.008 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.483 ' OE1' ' NZ ' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -109.71 92.16 3.94 Favored 'General case' 0 C--N 1.294 -1.816 1 N-CA-C 99.813 -4.143 . . . . 0.0 99.813 -179.574 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.1 p -91.64 176.16 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 C-N-CA 117.308 -1.757 . . . . 0.0 106.368 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.585 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 26.9 t30 -105.72 -21.72 13.12 Favored 'General case' 0 N--CA 1.529 3.498 0 CA-C-O 123.701 1.715 . . . . 0.0 112.243 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.411 ' HB3' ' HB3' ' A' ' 52' ' ' LYS 0.404 3.8 tp10 36.41 67.9 0.29 Allowed 'General case' 0 C--N 1.281 -2.389 5 N-CA-C 135.059 8.911 . . . . 0.0 135.059 179.566 . . . . . . . . 4 3 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.9 p-10 -137.4 22.66 2.96 Favored 'General case' 0 C--N 1.288 -2.108 4 CA-C-N 95.715 -9.766 . . . . 0.0 96.572 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.48 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 28.5 t70 -115.23 -148.94 0.44 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 127.15 2.18 . . . . 0.0 105.54 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.48 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 1.9 t -120.08 163.32 17.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 126.531 3.062 . . . . 0.0 109.054 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.558 ' N ' HG23 ' A' ' 47' ' ' ILE . 13.4 tp -123.27 -81.95 0.64 Allowed 'General case' 0 C--N 1.283 -2.319 2 CA-C-N 107.451 -4.432 . . . . 0.0 99.368 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' HD11 ' A' ' 47' ' ' ILE . 16.9 p -132.44 172.46 12.45 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.473 ' CG ' HG23 ' A' ' 45' ' ' VAL . 3.7 tt0 -130.42 138.51 50.37 Favored 'General case' 0 N--CA 1.5 2.067 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 25.2 t -135.26 145.53 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.335 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.46 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 4.7 tt0 -109.12 138.81 44.9 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -164.31 -161.17 0.58 Allowed 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 105.805 -1.924 . . . . 0.0 105.805 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.587 ' OD2' ' NZ ' ' A' ' 42' ' ' LYS . 5.6 p-10 -29.03 -58.31 0.14 Allowed 'General case' 0 C--N 1.297 -1.713 0 O-C-N 126.562 2.414 . . . . 0.0 114.475 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.587 ' NZ ' ' OD2' ' A' ' 41' ' ' ASP . 2.9 mttt -137.9 -8.85 1.59 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.678 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -93.73 158.26 15.76 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 114.609 1.337 . . . . 0.0 114.609 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.88 -44.28 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 126.335 2.272 . . . . 0.0 109.451 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.473 HG23 ' CG ' ' A' ' 37' ' ' GLU . 23.4 t -103.53 155.86 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 C-N-CA 125.574 1.55 . . . . 0.0 108.749 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.481 ' HB3' HD13 ' A' ' 47' ' ' ILE . 7.9 mt-10 -114.27 -63.42 1.45 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 126.683 2.489 . . . . 0.0 114.608 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.582 HG22 ' C ' ' A' ' 48' ' ' PRO . 1.2 mp -92.88 149.64 38.07 Favored Pre-proline 0 C--N 1.281 -2.374 0 CA-C-N 108.821 -3.809 . . . . 0.0 115.094 -178.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.582 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.25 177.59 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.112 0 N-CA-C 107.569 -1.743 . . . . 0.0 107.569 87.582 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.7 m -119.13 177.33 1.37 Allowed Pre-proline 0 C--N 1.284 -2.257 0 CA-C-N 112.838 -1.983 . . . . 0.0 113.315 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -95.94 -44.79 0.02 OUTLIER 'Trans proline' 0 CA--C 1.555 1.572 0 N-CA-C 118.57 2.488 . . . . 0.0 118.57 169.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.645 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.8 OUTLIER -130.76 166.24 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 123.191 1.472 . . . . 0.0 114.947 -179.375 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.645 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -121.1 170.57 9.41 Favored 'General case' 0 C--N 1.3 -1.561 1 CA-C-N 107.835 -4.257 . . . . 0.0 112.314 179.971 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.22 -124.64 1.21 Allowed Glycine 0 N--CA 1.49 2.281 1 N-CA-C 96.897 -6.481 . . . . 0.0 96.897 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 16.8 tttp -107.35 -174.92 2.65 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.3 t -130.93 65.75 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.279 1 N-CA-C 97.292 -5.077 . . . . 0.0 97.292 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.1 mt -29.53 -78.09 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 112.242 -2.253 . . . . 0.0 110.956 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -145.68 165.88 27.46 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 33.3 mt -132.78 139.93 48.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 1 N-CA-C 98.258 -4.719 . . . . 0.0 98.258 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -106.97 -31.34 8.36 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 123.819 0.7 . . . . 0.0 111.199 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.8 t -107.39 130.31 23.02 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -49.91 -150.38 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 124.254 3.302 . . . . 0.0 116.487 158.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 39.93 3.57 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 111.86 -2.427 . . . . 0.0 107.847 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -142.82 -6.2 0.71 Allowed Glycine 0 N--CA 1.497 2.734 0 CA-C-N 111.504 -2.589 . . . . 0.0 116.071 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.1 m -121.63 172.67 7.94 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 105.244 -2.132 . . . . 0.0 105.244 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.39 144.31 16.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 102.672 -3.084 . . . . 0.0 102.672 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -118.79 164.97 14.6 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.0 p -109.28 -163.2 0.85 Allowed 'General case' 0 C--N 1.283 -2.307 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.47 HG21 ' CB ' ' A' ' 5' ' ' LYS . 52.2 t -119.39 154.16 21.94 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 1 N-CA-C 92.681 -6.785 . . . . 0.0 92.681 178.748 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 101.06 -38.62 3.06 Favored Glycine 0 N--CA 1.49 2.291 1 N-CA-C 100.416 -5.073 . . . . 0.0 100.416 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.461 ' H ' ' C ' ' A' ' 68' ' ' VAL . 25.4 tt0 -99.94 160.57 14.21 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 101.013 -3.699 . . . . 0.0 101.013 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -105.89 -175.6 2.84 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 101.687 -3.449 . . . . 0.0 101.687 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.575 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . 0.9 OUTLIER -145.15 -57.46 0.33 Allowed 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 16.0 tt -137.13 163.48 32.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 t -135.86 159.21 42.36 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 103.114 -2.921 . . . . 0.0 103.114 179.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -138.58 147.16 42.68 Favored 'General case' 0 C--N 1.289 -2.062 0 O-C-N 125.392 1.682 . . . . 0.0 107.734 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.509 ' CG ' ' H ' ' A' ' 54' ' ' LYS . 2.1 p30 -115.64 158.19 23.09 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 104.154 -2.536 . . . . 0.0 104.154 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.535 ' CB ' ' HB2' ' A' ' 80' ' ' TYR . . . -139.38 139.02 21.46 Favored Pre-proline 0 C--N 1.29 -1.994 0 N-CA-C 102.627 -3.101 . . . . 0.0 102.627 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -70.53 -37.35 7.42 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 121.974 1.783 . . . . 0.0 110.466 173.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.541 ' O ' ' CD1' ' A' ' 80' ' ' TYR . . . -121.97 27.11 6.27 Favored Glycine 0 N--CA 1.493 2.494 0 CA-C-O 115.992 -2.56 . . . . 0.0 113.086 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.541 ' CD1' ' O ' ' A' ' 79' ' ' GLY . 21.7 m-85 . . . . . 0 N--CA 1.503 2.215 0 CA-C-O 115.509 -2.186 . . . . 0.0 108.283 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.047 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -115.34 147.11 40.87 Favored 'General case' 0 N--CA 1.498 1.946 1 N-CA-C 99.897 -4.112 . . . . 0.0 99.897 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -113.65 -168.79 1.39 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 118.878 0.763 . . . . 0.0 112.639 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -105.69 -22.94 12.85 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.465 ' CB ' HG23 ' A' ' 68' ' ' VAL . 11.0 mmtm -127.55 177.64 6.64 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 102.638 -3.097 . . . . 0.0 102.638 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 83.5 mt -105.62 176.22 1.8 Allowed Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -54.44 82.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.676 1.584 . . . . 0.0 110.111 153.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.41 ' HB3' HG13 ' A' ' 68' ' ' VAL . 7.6 t70 -122.06 -82.65 0.65 Allowed 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.485 -2.043 . . . . 0.0 105.485 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 24.0 pt 39.16 27.71 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 124.055 0.847 . . . . 0.0 111.647 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.18 -70.99 0.05 OUTLIER Glycine 0 N--CA 1.477 1.423 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.825 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.407 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 1.1 mp0 -51.06 153.08 2.01 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 124.415 2.055 . . . . 0.0 116.312 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -22.16 -41.01 0.01 OUTLIER Glycine 0 N--CA 1.498 2.824 0 CA-C-N 110.908 -2.86 . . . . 0.0 118.439 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.401 HD13 ' N ' ' A' ' 13' ' ' ILE . 3.2 mp -115.94 64.0 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.216 1.008 . . . . 0.0 108.81 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -85.72 7.61 22.92 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-N 114.72 -1.127 . . . . 0.0 112.493 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.1 pt-20 -129.68 -165.89 1.59 Allowed 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.992 0.901 . . . . 0.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.14 112.51 0.55 Allowed Glycine 0 N--CA 1.503 3.106 0 CA-C-O 117.484 -1.731 . . . . 0.0 112.808 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -104.17 85.95 2.47 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 103.223 -2.881 . . . . 0.0 103.223 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.441 HD13 HD13 ' A' ' 72' ' ' LEU . 1.9 mp -87.48 124.63 40.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.9 t -101.8 -46.85 11.32 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 O-C-N 124.53 1.144 . . . . 0.0 109.252 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.446 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 12.1 ttmt -131.69 145.18 51.5 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 124.564 1.165 . . . . 0.0 112.123 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -115.98 -178.64 3.45 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 178.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -126.56 -27.15 3.17 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 111.248 -2.706 . . . . 0.0 111.169 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.525 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 7.4 m -101.49 -177.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.172 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -100.19 -41.23 0.22 Allowed Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.502 ' C ' ' H ' ' A' ' 27' ' ' ASP . 43.1 Cg_endo -49.56 170.84 1.38 Allowed 'Cis proline' 0 N--CA 1.498 1.762 1 N-CA-C 124.991 4.958 . . . . 0.0 124.991 29.714 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.525 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -94.22 37.39 3.42 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 105.846 -2.902 . . . . 0.0 105.846 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.502 ' H ' ' C ' ' A' ' 25' ' ' PRO . 14.9 t70 3.1 -90.46 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.175 0 O-C-N 127.796 2.703 . . . . 0.0 110.131 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.475 ' HG2' ' CE ' ' A' ' 54' ' ' LYS . 6.7 mt-10 -99.53 111.58 23.91 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 101.972 -3.344 . . . . 0.0 101.972 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 163.98 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 CA-C-O 124.49 2.091 . . . . 0.0 114.704 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.608 HD21 ' CG ' ' A' ' 32' ' ' ASP . 10.2 p-10 -98.22 -171.27 2.11 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 110.075 -3.239 . . . . 0.0 112.17 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.444 ' OE2' ' NZ ' ' A' ' 52' ' ' LYS . 4.7 tt0 -121.88 68.11 0.92 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.608 ' CG ' HD21 ' A' ' 30' ' ' ASN . 3.5 p30 -179.7 -27.61 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 112.965 -1.925 . . . . 0.0 110.808 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -28.77 154.04 0.0 OUTLIER 'General case' 0 N--CA 1.514 2.768 0 CA-C-O 122.992 1.377 . . . . 0.0 114.279 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.526 HG13 ' H ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -56.17 -176.73 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 124.188 4.885 . . . . 0.0 124.188 -179.251 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.526 ' H ' HG13 ' A' ' 34' ' ' VAL . 1.1 mm? -86.69 174.25 8.97 Favored 'General case' 0 N--CA 1.411 -2.393 2 CA-C-N 101.792 -7.004 . . . . 0.0 101.488 -179.38 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.0 m -127.97 155.08 44.83 Favored 'General case' 0 C--N 1.265 -3.082 2 N-CA-C 97.587 -4.968 . . . . 0.0 97.587 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.446 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 12.9 mt-10 -118.26 103.53 9.91 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.59 155.68 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 CA-C-N 113.429 -1.714 . . . . 0.0 107.158 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -118.37 162.07 18.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -155.23 -172.31 4.13 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.446 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 4.3 p-10 -17.57 -62.44 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 126.409 2.318 . . . . 0.0 115.2 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.446 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 53.3 mttp -140.45 -13.91 0.99 Allowed 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.185 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -109.71 175.21 5.53 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 116.598 2.073 . . . . 0.0 116.598 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.4 t -122.59 136.48 59.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 1 N-CA-C 99.611 -4.218 . . . . 0.0 99.611 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.7 t -117.47 161.27 16.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.448 1.118 . . . . 0.0 109.589 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.485 ' C ' HD13 ' A' ' 47' ' ' ILE . 11.9 pt-20 -123.67 129.13 50.64 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 110.227 -3.17 . . . . 0.0 106.758 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 3.7 mp -125.07 96.71 39.3 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 115.806 -2.045 . . . . 0.0 106.266 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.472 ' N ' HD12 ' A' ' 35' ' ' LEU . 60.7 Cg_endo -68.62 -164.85 0.12 Allowed 'Trans proline' 0 N--CA 1.515 2.742 0 C-N-CA 124.446 3.431 . . . . 0.0 106.917 -174.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 14.4 t -104.02 103.25 36.74 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 111.875 -2.42 . . . . 0.0 108.962 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.411 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 85.3 Cg_exo -49.31 -55.24 4.33 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.659 2.906 . . . . 0.0 119.01 161.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.402 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.59 168.43 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-O 121.933 0.873 . . . . 0.0 112.748 -179.613 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.444 ' NZ ' ' OE2' ' A' ' 31' ' ' GLU . 4.1 pttt -96.33 167.89 10.9 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 111.409 -2.632 . . . . 0.0 106.719 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.08 -135.87 5.87 Favored Glycine 0 C--N 1.289 -2.071 0 N-CA-C 105.955 -2.858 . . . . 0.0 105.955 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.475 ' CE ' ' HG2' ' A' ' 28' ' ' GLU . 4.3 tptt -116.82 164.92 13.93 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 104.966 -2.235 . . . . 0.0 104.966 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 22.1 t -126.43 58.11 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.809 1 N-CA-C 100.164 -4.013 . . . . 0.0 100.164 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 18.0 mt -29.51 -73.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 CA-C-N 110.29 -3.141 . . . . 0.0 115.084 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -137.03 163.9 29.66 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.973 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 25' ' ' PRO . 58.5 mt -138.61 144.56 29.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 1 N-CA-C 98.87 -4.493 . . . . 0.0 98.87 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -111.33 -54.79 2.57 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.5 t -113.42 78.77 3.67 Favored Pre-proline 0 C--N 1.3 -1.571 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -55.18 -85.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 121.708 1.605 . . . . 0.0 113.455 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -139.7 170.63 15.54 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 78.41 -35.71 1.78 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.11 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.7 m -99.63 171.98 7.57 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 67.1 t -115.06 142.97 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.66 160.18 31.5 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.8 t -105.41 -156.91 0.59 Allowed 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.465 HG23 ' CB ' ' A' ' 5' ' ' LYS . 61.5 t -121.69 158.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 1 N-CA-C 94.886 -5.968 . . . . 0.0 94.886 178.408 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.43 -29.36 9.73 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 104.675 -3.37 . . . . 0.0 104.675 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.438 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -109.41 156.71 19.72 Favored 'General case' 0 C--N 1.302 -1.483 1 N-CA-C 99.119 -4.4 . . . . 0.0 99.119 179.793 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -87.2 -174.15 4.74 Favored 'General case' 0 C--N 1.288 -2.089 0 N-CA-C 100.93 -3.73 . . . . 0.0 100.93 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.441 HD13 HD13 ' A' ' 18' ' ' ILE . 3.9 tt -145.99 -62.97 0.32 Allowed 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 104.554 -2.387 . . . . 0.0 104.554 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 tt -138.42 162.17 30.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 102.092 -3.299 . . . . 0.0 102.092 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 t -136.92 159.73 41.0 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 103.96 -2.608 . . . . 0.0 103.96 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.4 146.05 36.1 Favored 'General case' 0 C--N 1.284 -2.255 0 CA-C-N 111.806 -2.452 . . . . 0.0 105.113 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.07 159.31 16.68 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 98.895 -4.483 . . . . 0.0 98.895 179.318 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.448 ' H ' ' HA ' ' A' ' 78' ' ' PRO . . . -138.13 -36.79 0.02 OUTLIER Pre-proline 0 C--N 1.289 -2.03 0 CA-C-N 114.274 -1.33 . . . . 0.0 111.093 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.448 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 18.6 Cg_endo -104.18 138.39 1.03 Allowed 'Cis proline' 0 C--N 1.316 -1.139 0 C-N-CA 129.235 0.931 . . . . 0.0 111.334 -24.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.85 41.79 0.76 Allowed Glycine 0 N--CA 1.498 2.825 0 N-CA-C 105.974 -2.851 . . . . 0.0 105.974 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.9 m-30 . . . . . 0 C--N 1.299 -1.591 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.133 0 N-CA-C 104.184 -2.524 . . . . 0.0 104.184 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -125.17 160.69 28.55 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 103.026 -2.953 . . . . 0.0 103.026 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.8 -158.53 0.87 Allowed 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -112.22 -45.14 3.31 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 125.582 1.801 . . . . 0.0 111.819 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.477 ' CG ' HG21 ' A' ' 68' ' ' VAL . 0.3 OUTLIER -124.24 -175.07 3.15 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 100.815 -3.772 . . . . 0.0 100.815 179.36 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -115.45 -176.39 0.37 Allowed Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 104.288 -2.486 . . . . 0.0 104.288 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.83 88.07 0.05 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 N-CA-C 103.094 -3.464 . . . . 0.0 103.094 145.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.405 ' CB ' HG13 ' A' ' 68' ' ' VAL 0.313 0.8 OUTLIER -121.6 -91.43 0.56 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 111.874 -2.421 . . . . 0.0 104.803 -179.616 . . . . . . . . 4 4 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.593 ' H ' HG13 ' A' ' 68' ' ' VAL . 38.8 pt 45.66 37.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -88.65 -171.31 46.03 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.712 -1.755 . . . . 0.0 108.712 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -89.46 163.62 15.18 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-O 122.983 1.373 . . . . 0.0 110.595 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -74.44 0.21 Allowed Glycine 0 C--N 1.293 -1.845 0 CA-C-N 112.346 -2.206 . . . . 0.0 108.824 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.7 mt -131.93 114.66 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 101.612 -3.477 . . . . 0.0 101.612 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -125.26 18.0 8.32 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 121.827 2.103 . . . . 0.0 107.712 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.5 OUTLIER -127.34 -177.93 4.26 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 123.116 1.436 . . . . 0.0 113.146 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.25 101.03 0.33 Allowed Glycine 0 N--CA 1.503 3.103 0 CA-C-N 112.664 -2.062 . . . . 0.0 110.827 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.408 ' OE1' ' NE2' ' A' ' 39' ' ' GLN . 17.0 tt0 -101.92 102.25 12.78 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 105.166 -2.161 . . . . 0.0 105.166 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 mt -89.24 131.92 35.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 105.639 -1.986 . . . . 0.0 105.639 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.78 -57.91 4.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -129.37 169.74 14.52 Favored 'General case' 0 N--CA 1.508 2.447 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.789 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.439 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 23.8 m95 -130.49 171.64 12.78 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 126.017 2.073 . . . . 0.0 106.763 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.469 ' N ' ' CD1' ' A' ' 22' ' ' PHE . 21.8 m-85 -124.94 -52.12 1.67 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 124.937 1.398 . . . . 0.0 109.102 -179.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.5 m -99.32 179.1 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.5 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -119.9 168.26 10.67 Favored Pre-proline 0 C--N 1.292 -1.904 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.404 ' HD3' HD11 ' A' ' 58' ' ' ILE . 83.9 Cg_endo -74.19 144.45 33.42 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 121.453 1.435 . . . . 0.0 108.888 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.95 -14.97 62.28 Favored Glycine 0 CA--C 1.476 -2.383 0 CA-C-O 116.654 -2.192 . . . . 0.0 110.166 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.5 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 4.3 m-20 -82.61 -173.07 4.41 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.735 ' CG ' ' HZ1' ' A' ' 54' ' ' LYS 0.25 6.5 mt-10 -122.42 158.35 29.91 Favored 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 101.593 -3.484 . . . . 0.0 101.593 179.92 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.4 p -121.93 157.57 26.0 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 CA-C-O 122.228 1.013 . . . . 0.0 110.261 -179.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.408 ' HB3' ' CG ' ' A' ' 32' ' ' ASP . 5.3 m-20 -98.58 -167.65 1.53 Allowed 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 111.066 -2.788 . . . . 0.0 113.283 -178.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.9 tt0 -122.98 52.5 1.35 Allowed 'General case' 0 C--N 1.298 -1.641 1 N-CA-C 96.789 -5.263 . . . . 0.0 96.789 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.408 ' CG ' ' HB3' ' A' ' 30' ' ' ASN . 0.6 OUTLIER -164.1 -59.21 0.04 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.902 -179.42 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.603 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 14.3 t70 -52.17 -168.91 0.0 OUTLIER 'General case' 0 N--CA 1.513 2.692 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.603 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -97.42 -168.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 129.135 2.974 . . . . 0.0 109.837 -179.357 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.524 ' H ' HG11 ' A' ' 34' ' ' VAL . 24.0 tp -141.23 -95.59 0.14 Allowed 'General case' 0 C--N 1.294 -1.836 1 CA-C-N 107.74 -4.3 . . . . 0.0 100.861 178.704 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.439 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -122.47 -179.08 4.08 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-N 118.634 0.652 . . . . 0.0 111.364 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -119.75 111.89 18.57 Favored 'General case' 0 N--CA 1.499 1.979 1 N-CA-C 97.524 -4.991 . . . . 0.0 97.524 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 46.3 t -120.13 151.67 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 119.501 1.046 . . . . 0.0 112.315 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.408 ' NE2' ' OE1' ' A' ' 17' ' ' GLU . 20.7 tt0 -117.81 151.72 36.77 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.728 -1.124 . . . . 0.0 108.302 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -146.24 -179.88 7.04 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 104.597 -2.371 . . . . 0.0 104.597 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -6.1 -69.67 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.031 0 N-CA-C 116.069 1.877 . . . . 0.0 116.069 -179.381 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.513 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 40.2 mttp -136.73 -20.25 1.33 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 123.319 0.647 . . . . 0.0 110.318 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -100.36 165.56 11.4 Favored 'General case' 0 N--CA 1.492 1.673 0 C-N-CA 118.453 -1.299 . . . . 0.0 111.399 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 t -132.45 130.57 60.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 N-CA-C 102.896 -3.002 . . . . 0.0 102.896 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.449 HG13 ' H ' ' A' ' 46' ' ' GLU . 1.5 t -127.79 173.56 12.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 CA-C-O 124.755 2.217 . . . . 0.0 105.406 179.277 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.52 ' C ' HD13 ' A' ' 47' ' ' ILE . 10.6 pt-20 -121.32 164.15 17.49 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 108.479 -3.964 . . . . 0.0 105.047 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.52 HD13 ' C ' ' A' ' 46' ' ' GLU . 2.7 mp -125.69 130.54 24.03 Favored Pre-proline 0 C--N 1.295 -1.773 0 N-CA-C 101.548 -3.501 . . . . 0.0 101.548 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -93.02 -171.98 0.33 Allowed 'Trans proline' 0 N--CA 1.497 1.725 1 C-N-CA 126.087 4.525 . . . . 0.0 108.796 173.457 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.33 98.53 12.42 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.45 -44.67 29.27 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.549 1.5 . . . . 0.0 110.671 157.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -133.15 166.11 30.35 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 122.463 1.125 . . . . 0.0 109.253 179.436 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.538 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -110.89 146.04 37.22 Favored 'General case' 0 C--N 1.297 -1.688 2 O-C-N 130.118 4.636 . . . . 0.0 104.483 179.784 . . . . . . . . 4 4 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.86 -151.06 13.22 Favored Glycine 0 N--CA 1.504 3.199 0 N-CA-C 105.206 -3.158 . . . . 0.0 105.206 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.735 ' HZ1' ' CG ' ' A' ' 28' ' ' GLU . 53.6 tptt -96.27 171.99 8.24 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 119.993 1.897 . . . . 0.0 106.835 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -125.47 84.09 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 1 N-CA-C 94.46 -6.126 . . . . 0.0 94.46 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.41 -82.03 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 113.516 -1.675 . . . . 0.0 109.438 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -137.94 165.66 25.98 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.504 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.404 HD11 ' HD3' ' A' ' 25' ' ' PRO . 60.0 mt -130.09 137.94 55.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 1 N-CA-C 97.61 -4.959 . . . . 0.0 97.61 179.705 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.17 -56.16 2.63 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 124.251 0.97 . . . . 0.0 108.592 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.4 t -112.68 126.44 28.31 Favored Pre-proline 0 C--N 1.295 -1.793 1 N-CA-C 96.939 -5.208 . . . . 0.0 96.939 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -79.81 -84.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 CA-C-N 121.461 1.557 . . . . 0.0 108.19 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.24 -151.8 0.47 Allowed 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 100.614 -3.846 . . . . 0.0 100.614 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.93 -42.97 0.16 Allowed Glycine 0 C--N 1.283 -2.377 0 CA-C-N 111.029 -2.805 . . . . 0.0 115.116 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.8 m -109.37 -176.43 3.02 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.6 t -111.16 156.07 12.42 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.32 171.25 11.11 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 3.8 t -128.12 -159.79 0.97 Allowed 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 102.846 -3.02 . . . . 0.0 102.846 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.593 HG13 ' H ' ' A' ' 9' ' ' ILE 0.256 57.8 t -117.68 155.38 19.46 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.268 1 N-CA-C 94.431 -6.137 . . . . 0.0 94.431 179.025 . . . . . . . . 4 3 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . 0.477 ' N ' HG11 ' A' ' 68' ' ' VAL . . . 98.27 -27.61 18.59 Favored Glycine 0 N--CA 1.485 1.932 1 N-CA-C 102.398 -4.281 . . . . 0.0 102.398 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLN . . . . . 0.445 ' H ' ' C ' ' A' ' 68' ' ' VAL . 38.9 tt0 -105.01 154.65 19.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 102.042 -3.318 . . . . 0.0 102.042 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -94.9 179.55 5.19 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 102.201 -3.259 . . . . 0.0 102.201 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 35.8 tp -138.26 -69.9 0.44 Allowed 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.6 tt -141.99 162.22 19.98 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 102.937 -2.986 . . . . 0.0 102.937 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.3 t -137.39 160.04 40.22 Favored 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.413 HD22 ' H ' ' A' ' 76' ' ' ASP . 1.2 tt -133.39 149.87 51.82 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 112.669 -2.06 . . . . 0.0 107.862 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.413 ' H ' HD22 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -109.2 150.68 27.55 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 101.97 -3.345 . . . . 0.0 101.97 179.562 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -141.83 94.72 7.18 Favored Pre-proline 0 C--N 1.289 -2.026 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -45.0 70.51 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 123.803 3.002 . . . . 0.0 116.486 174.524 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 126.89 9.63 4.2 Favored Glycine 0 N--CA 1.485 1.929 0 CA-C-O 116.495 -2.281 . . . . 0.0 113.157 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 14.3 m-30 . . . . . 0 N--CA 1.501 2.087 0 N-CA-C 105.524 -2.028 . . . . 0.0 105.524 179.51 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -120.53 159.47 25.13 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 100.893 -3.743 . . . . 0.0 100.893 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 -160.97 0.8 Allowed 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.03 -21.95 3.88 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-N 113.531 -1.668 . . . . 0.0 110.297 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.47 ' CG ' HG21 ' A' ' 68' ' ' VAL . 48.2 mmtt -132.5 145.18 50.96 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 105.479 -2.045 . . . . 0.0 105.479 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.43 173.33 6.08 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 104.071 -2.566 . . . . 0.0 104.071 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -42.48 80.93 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.379 2.053 . . . . 0.0 115.013 158.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -121.7 -72.64 0.68 Allowed 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 103.584 -2.747 . . . . 0.0 103.584 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.426 ' H ' HG12 ' A' ' 68' ' ' VAL . 35.5 pt 37.41 40.58 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 124.302 1.001 . . . . 0.0 112.863 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.68 -14.34 0.07 OUTLIER Glycine 0 C--N 1.305 -1.188 0 CA-C-O 117.194 -1.892 . . . . 0.0 115.614 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -101.21 -177.93 3.59 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 120.439 2.119 . . . . 0.0 114.733 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -4.47 -66.74 0.0 OUTLIER Glycine 0 N--CA 1.494 2.509 0 CA-C-N 110.178 -3.192 . . . . 0.0 116.182 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.0 mm -127.28 76.42 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -81.97 4.34 23.06 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 112.725 -2.034 . . . . 0.0 111.787 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.506 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 4.5 pt-20 -132.4 -176.7 4.17 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.252 0.549 . . . . 0.0 110.864 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.81 116.29 0.84 Allowed Glycine 0 N--CA 1.494 2.517 0 CA-C-O 118.079 -1.401 . . . . 0.0 111.679 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -102.97 109.87 21.57 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 99.966 -4.087 . . . . 0.0 99.966 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' HA ' ' A' ' 62' ' ' GLU . 2.7 mt -99.17 126.66 52.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.8 t -93.85 -61.76 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 124.666 1.229 . . . . 0.0 109.971 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.58 ' NZ ' ' CE1' ' A' ' 22' ' ' PHE . 25.1 tttm -130.43 151.04 51.35 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.574 -179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.481 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 8.6 m95 -119.63 173.47 6.99 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 179.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.58 ' CE1' ' NZ ' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -133.34 -1.25 3.21 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 -179.783 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.562 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 4.2 m -98.62 170.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 115.318 1.599 . . . . 0.0 115.318 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -139.2 48.03 1.56 Allowed Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 125.574 1.796 . . . . 0.0 111.829 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.497 ' C ' ' H ' ' A' ' 27' ' ' ASP . 67.2 Cg_exo -8.61 174.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 N-CA-C 118.865 2.602 . . . . 0.0 118.865 -70.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.562 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.11 28.41 8.83 Favored Glycine 0 N--CA 1.505 3.275 0 N-CA-C 107.84 -2.104 . . . . 0.0 107.84 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.516 ' CG ' ' HZ3' ' A' ' 54' ' ' LYS . 19.2 t70 8.79 -85.24 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 110.985 -2.608 . . . . 0.0 111.474 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.54 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS . 2.6 mt-10 -104.22 115.53 30.56 Favored 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 105.606 -1.998 . . . . 0.0 105.606 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 p -108.65 161.57 7.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 124.819 2.247 . . . . 0.0 110.562 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.415 ' OD1' ' HB2' ' A' ' 33' ' ' ASP . 29.3 p30 -98.15 -164.16 1.11 Allowed 'General case' 0 C--N 1.284 -2.248 0 CA-C-N 109.965 -3.288 . . . . 0.0 108.883 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.532 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.274 0.3 OUTLIER -122.35 69.71 0.97 Allowed 'General case' 0 C--N 1.292 -1.896 1 N-CA-C 99.497 -4.26 . . . . 0.0 99.497 -179.323 . . . . . . . . 5 4 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.493 ' C ' ' OG ' ' A' ' 49' ' ' SER . 3.5 p30 -177.34 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.489 0 C-N-CA 125.705 1.602 . . . . 0.0 111.735 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.6 ' CB ' ' HG ' ' A' ' 49' ' ' SER . 8.9 t70 18.13 -137.74 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.264 0 N-CA-C 119.661 3.208 . . . . 0.0 119.661 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.542 HG13 ' CG ' ' A' ' 22' ' ' PHE . 1.2 t -114.87 167.4 7.53 Favored 'Isoleucine or valine' 0 CA--C 1.445 -3.095 0 CA-C-O 124.3 2.0 . . . . 0.0 114.29 -179.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.53 ' HA ' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -108.57 120.23 41.85 Favored 'General case' 0 N--CA 1.412 -2.363 3 CA-C-N 106.151 -5.022 . . . . 0.0 99.251 179.877 . . . . . . . . 4 4 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.481 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 27.7 m -73.57 151.8 40.8 Favored 'General case' 0 C--N 1.263 -3.193 2 N-CA-C 97.986 -4.82 . . . . 0.0 97.986 179.873 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -104.52 102.89 12.51 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-N 112.371 -2.195 . . . . 0.0 107.806 -179.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.6 146.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 N-CA-C 104.682 -2.34 . . . . 0.0 104.682 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -115.15 152.43 32.61 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.46 HD22 ' HB1' ' A' ' 43' ' ' ALA . 6.7 p-10 -141.13 -178.13 5.44 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.421 ' CG ' HD21 ' A' ' 40' ' ' ASN . 0.3 OUTLIER -7.58 -72.43 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 116.952 2.205 . . . . 0.0 116.952 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -136.82 -11.61 1.76 Allowed 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 114.318 -1.31 . . . . 0.0 109.255 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HB1' HD22 ' A' ' 40' ' ' ASN . . . -111.58 178.7 4.24 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 120.91 0.386 . . . . 0.0 111.886 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.5 t -130.86 147.55 33.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.465 -2.42 . . . . 0.0 104.465 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -120.37 161.78 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 122.655 1.217 . . . . 0.0 111.242 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.458 ' C ' HD13 ' A' ' 47' ' ' ILE . 12.1 pt-20 -122.24 122.75 39.87 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 110.489 -3.05 . . . . 0.0 108.186 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.53 ' C ' ' HA ' ' A' ' 35' ' ' LEU . 1.9 mp -115.02 83.16 9.31 Favored Pre-proline 0 CA--C 1.572 1.798 0 CA-C-O 115.946 -1.978 . . . . 0.0 108.729 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.444 ' HA ' ' O ' ' A' ' 34' ' ' VAL . 75.9 Cg_endo -62.93 -167.09 0.06 OUTLIER 'Trans proline' 0 N--CA 1.52 3.036 0 C-N-CA 123.952 3.102 . . . . 0.0 105.716 176.675 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.6 ' HG ' ' CB ' ' A' ' 33' ' ' ASP . 19.2 p -108.73 86.48 3.71 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -32.22 -49.21 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 121.887 1.725 . . . . 0.0 115.308 163.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.532 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -132.49 164.84 33.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-O 121.817 0.817 . . . . 0.0 110.328 179.646 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.501 ' NZ ' ' OE2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -102.54 173.32 6.4 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 128.827 3.829 . . . . 0.0 110.11 179.724 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.24 -136.87 5.98 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 104.995 -3.242 . . . . 0.0 104.995 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.54 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 41.0 tptt -112.73 173.26 6.46 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 -179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.412 ' HB ' ' C ' ' A' ' 26' ' ' GLY . 50.5 t -127.35 70.05 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.975 1 N-CA-C 97.342 -5.058 . . . . 0.0 97.342 179.665 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 75.4 mt -38.06 -79.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 111.623 -2.535 . . . . 0.0 114.227 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -143.04 167.48 21.97 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.759 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.1 mp -131.11 141.21 46.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 1 N-CA-C 98.004 -4.813 . . . . 0.0 98.004 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.404 HD13 ' N ' ' A' ' 59' ' ' LEU . 5.6 mp -103.7 -58.85 1.81 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 123.772 0.67 . . . . 0.0 110.555 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.425 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 24.1 t -113.62 75.92 2.77 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -49.76 -83.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.851 2.367 . . . . 0.0 115.2 -167.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.412 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -134.86 -179.91 5.9 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 76.81 -38.57 1.51 Allowed Glycine 0 N--CA 1.49 2.266 0 CA-C-N 114.14 -1.391 . . . . 0.0 114.335 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.425 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 2.0 m -103.25 177.14 4.92 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 43.9 t -117.74 148.99 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.8 166.67 14.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.506 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 8.8 t -117.87 -155.45 0.6 Allowed 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 104.783 -2.303 . . . . 0.0 104.783 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.47 HG21 ' CG ' ' A' ' 5' ' ' LYS . 84.4 t -120.44 151.51 23.24 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 1 N-CA-C 97.25 -5.093 . . . . 0.0 97.25 179.106 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 104.58 -38.74 3.12 Favored Glycine 0 N--CA 1.494 2.565 1 N-CA-C 99.768 -5.333 . . . . 0.0 99.768 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.465 ' H ' ' C ' ' A' ' 68' ' ' VAL . 35.2 tt0 -100.09 164.49 11.96 Favored 'General case' 0 C--N 1.304 -1.373 1 N-CA-C 99.929 -4.101 . . . . 0.0 99.929 179.501 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.98 -175.52 2.8 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 33.1 tp -135.23 -67.19 0.55 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 103.652 -2.721 . . . . 0.0 103.652 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.2 tt -135.03 165.04 32.13 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 102.988 -2.967 . . . . 0.0 102.988 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.8 t -137.25 161.38 36.37 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.45 -2.796 . . . . 0.0 103.45 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.83 152.33 48.99 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 112.456 -2.156 . . . . 0.0 106.385 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.86 131.57 56.92 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 100.48 -3.896 . . . . 0.0 100.48 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.46 60.19 13.54 Favored Pre-proline 0 C--N 1.295 -1.78 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -53.09 68.34 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.618 0 C-N-CA 124.777 3.651 . . . . 0.0 115.855 -176.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 132.7 68.75 0.08 OUTLIER Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.505 1 N-CA-C 100.096 -4.039 . . . . 0.0 100.096 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.461 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 101.771 -3.418 . . . . 0.0 101.771 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -100.67 85.94 3.02 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 105.622 -1.992 . . . . 0.0 105.622 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.461 ' OE1' ' N ' ' A' ' 1' ' ' ALA . 1.5 mp0 -77.96 -178.33 5.45 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -99.91 -29.57 12.5 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 117.903 2.557 . . . . 0.0 117.903 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.453 ' CG ' HG21 ' A' ' 68' ' ' VAL . 30.5 mmtp -127.57 173.64 9.7 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 102.411 -3.181 . . . . 0.0 102.411 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 88.6 mt -101.14 176.18 2.01 Favored Pre-proline 0 C--N 1.299 -1.618 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -66.12 82.04 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 N-CA-C 104.098 -3.078 . . . . 0.0 104.098 158.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -123.87 -80.68 0.63 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 124.583 1.177 . . . . 0.0 109.628 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.9 pt 41.96 26.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.515 0 O-C-N 123.38 0.425 . . . . 0.0 110.454 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.24 -69.67 0.18 Allowed Glycine 0 N--CA 1.483 1.776 0 C-N-CA 120.683 -0.77 . . . . 0.0 114.064 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -61.27 171.17 1.44 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 124.537 2.113 . . . . 0.0 116.358 -179.435 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -6.84 -53.1 0.0 OUTLIER Glycine 0 N--CA 1.493 2.469 0 CA-C-N 109.956 -3.293 . . . . 0.0 119.953 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.2 mm -118.96 116.99 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.47 ' O ' HG22 ' A' ' 68' ' ' VAL . 9.5 p80 -96.26 -45.62 6.76 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 114.68 -1.145 . . . . 0.0 112.232 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.54 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 33.8 mt-10 -107.83 -173.2 2.22 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 123.043 1.401 . . . . 0.0 113.059 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.05 122.33 1.98 Allowed Glycine 0 C--N 1.286 -2.205 0 CA-C-N 111.722 -2.49 . . . . 0.0 106.881 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 78.7 tt0 -102.23 96.15 6.79 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 103.399 -2.815 . . . . 0.0 103.399 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.8 mt -86.17 120.62 36.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 -56.09 5.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.969 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.052 -179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.523 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -136.15 150.68 49.17 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 124.206 0.941 . . . . 0.0 112.12 -179.432 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.757 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 10.1 m95 -114.38 174.62 5.86 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 124.821 1.325 . . . . 0.0 108.112 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.497 ' CD2' HG23 ' A' ' 34' ' ' VAL . 6.6 m-85 -128.03 -13.76 5.07 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 112.382 -2.19 . . . . 0.0 112.885 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.569 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 14.7 m -98.89 -172.96 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.653 -0.654 . . . . 0.0 111.761 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.624 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.3 mptp? -123.08 -30.11 0.05 OUTLIER Pre-proline 0 N--CA 1.503 2.208 0 N-CA-C 119.266 3.061 . . . . 0.0 119.266 179.077 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.624 ' C ' ' H ' ' A' ' 24' ' ' LYS . 11.3 Cg_endo -39.17 162.82 0.23 Allowed 'Cis proline' 0 N--CA 1.498 1.764 1 N-CA-C 122.747 4.095 . . . . 0.0 122.747 13.208 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.569 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -95.5 32.42 6.27 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 -179.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.9 t70 11.79 -100.94 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.248 0 O-C-N 129.749 3.852 . . . . 0.0 109.606 179.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -103.33 130.38 50.59 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 179.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.402 ' CG2' ' H ' ' A' ' 30' ' ' ASN . 7.6 p -120.48 177.91 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 122.348 1.07 . . . . 0.0 112.918 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.488 ' C ' ' OD1' ' A' ' 30' ' ' ASN . 45.0 p30 -95.42 -166.47 1.46 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.961 -1.927 . . . . 0.0 107.422 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.445 ' HB2' ' HB3' ' A' ' 52' ' ' LYS 0.25 2.4 tt0 -124.86 50.75 1.71 Allowed 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 100.467 -3.901 . . . . 0.0 100.467 -179.498 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -175.93 28.32 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.043 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 30' ' ' ASN . 0.5 OUTLIER -96.32 -176.25 3.59 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.945 0.878 . . . . 0.0 111.335 -179.308 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.497 HG23 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -74.77 -172.53 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.482 -1.648 0 CA-C-O 127.654 3.597 . . . . 0.0 117.582 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.514 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.13 -160.21 0.74 Allowed 'General case' 0 C--N 1.276 -2.624 2 CA-C-N 102.377 -6.738 . . . . 0.0 106.959 -179.214 . . . . . . . . 4 4 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.757 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 9.2 m -120.09 156.51 30.86 Favored 'General case' 0 C--N 1.273 -2.748 2 N-CA-C 94.215 -6.217 . . . . 0.0 94.215 179.212 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.46 ' OE1' ' NZ ' ' A' ' 20' ' ' LYS . 5.3 tt0 -107.94 109.83 21.42 Favored 'General case' 0 C--N 1.285 -2.236 1 N-CA-C 98.676 -4.564 . . . . 0.0 98.676 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 56.1 t -121.43 154.9 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.412 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 tt0 -114.82 147.2 40.15 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 16.4 p-10 -136.43 -176.0 4.19 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.412 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 3.0 p-10 -6.73 -67.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.176 0 O-C-N 126.175 2.172 . . . . 0.0 115.838 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.412 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 40.0 mtmt -138.19 -22.18 1.05 Allowed 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 123.011 0.525 . . . . 0.0 109.957 179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.75 -168.57 1.54 Allowed 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 29.8 t -123.69 133.7 68.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 N-CA-C 103.309 -2.849 . . . . 0.0 103.309 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.94 153.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 122.515 1.15 . . . . 0.0 109.012 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.447 ' C ' HD13 ' A' ' 47' ' ' ILE . 10.0 pt-20 -119.58 127.79 53.3 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 110.86 -2.882 . . . . 0.0 108.526 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.514 ' H ' ' HB2' ' A' ' 35' ' ' LEU . 1.7 mp -117.2 79.54 11.19 Favored Pre-proline 0 C--N 1.299 -1.588 0 N-CA-C 101.573 -3.491 . . . . 0.0 101.573 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.415 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 86.3 Cg_endo -62.29 -166.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.513 2.639 0 C-N-CA 123.569 2.846 . . . . 0.0 107.854 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 45.9 p -98.78 106.66 38.67 Favored Pre-proline 0 C--N 1.286 -2.153 0 CA-C-N 113.483 -1.69 . . . . 0.0 111.879 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 89.2 Cg_exo -55.32 -44.46 48.66 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.012 1.808 . . . . 0.0 114.979 166.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.509 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -132.13 171.58 17.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 123.837 0.711 . . . . 0.0 109.858 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.527 ' NZ ' ' O ' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -105.01 167.85 9.44 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 127.347 2.905 . . . . 0.0 107.614 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 76' ' ' ASP . . . 144.1 -121.77 1.69 Allowed Glycine 0 C--N 1.285 -2.282 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.596 ' NZ ' ' HB2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -117.41 166.41 12.35 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 23.9 t -129.91 59.29 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 1 N-CA-C 99.459 -4.274 . . . . 0.0 99.459 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 21.9 mt -29.1 -76.88 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 111.143 -2.753 . . . . 0.0 115.02 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -143.79 167.16 22.95 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.284 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.419 HD13 ' HA ' ' A' ' 25' ' ' PRO . 4.1 mp -135.55 139.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 1 N-CA-C 98.527 -4.619 . . . . 0.0 98.527 179.601 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.417 HD13 ' N ' ' A' ' 59' ' ' LEU . 5.7 mp -101.56 -56.91 2.18 Favored 'General case' 0 C--N 1.296 -1.756 0 O-C-N 124.003 0.814 . . . . 0.0 110.604 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 t -117.93 67.96 6.34 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -41.93 -78.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 122.709 2.273 . . . . 0.0 117.989 -167.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -142.97 174.58 10.55 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.66 -52.97 0.91 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.868 -1.158 . . . . 0.0 111.462 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.5 m -102.42 -177.5 3.42 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.2 t -109.95 145.49 16.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 103.733 -2.692 . . . . 0.0 103.733 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -120.55 147.83 44.66 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.287 14.7 t -99.84 -151.7 0.4 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.478 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.529 ' C ' ' H ' ' A' ' 70' ' ' GLN . 61.8 t -118.62 160.75 18.18 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 178.877 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 97.61 -47.28 1.57 Allowed Glycine 0 N--CA 1.499 2.852 1 N-CA-C 98.408 -5.877 . . . . 0.0 98.408 -179.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.529 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -89.58 153.61 20.63 Favored 'General case' 0 C--N 1.304 -1.393 1 N-CA-C 99.953 -4.091 . . . . 0.0 99.953 179.325 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.56 -175.94 3.0 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 103.104 -2.924 . . . . 0.0 103.104 179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.7 tp -139.9 -70.44 0.4 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.9 tt -139.05 166.33 22.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 104.203 -2.517 . . . . 0.0 104.203 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.2 t -138.92 160.08 40.59 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 102.439 -3.171 . . . . 0.0 102.439 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -129.98 148.53 51.85 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.022 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.432 ' OD2' ' NZ ' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -113.09 150.26 32.35 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 102.227 -3.249 . . . . 0.0 102.227 179.135 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.527 ' O ' ' NZ ' ' A' ' 52' ' ' LYS . . . -114.36 -40.94 0.08 OUTLIER Pre-proline 0 C--N 1.295 -1.774 0 O-C-N 124.883 1.365 . . . . 0.0 107.696 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.511 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 10.2 Cg_endo -94.72 176.84 11.42 Favored 'Cis proline' 0 C--N 1.312 -1.375 0 CA-C-N 121.628 1.617 . . . . 0.0 111.328 -22.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.81 -36.72 4.19 Favored Glycine 0 N--CA 1.498 2.8 1 N-CA-C 99.058 -5.617 . . . . 0.0 99.058 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.479 ' H ' ' C ' ' A' ' 78' ' ' PRO . 52.1 t80 . . . . . 0 CA--C 1.573 1.831 1 N-CA-C 98.597 -4.594 . . . . 0.0 98.597 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.474 1 N-CA-C 98.138 -4.764 . . . . 0.0 98.138 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -137.13 90.76 2.56 Favored 'General case' 0 C--N 1.288 -2.078 1 N-CA-C 88.977 -8.157 . . . . 0.0 88.977 178.473 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 3' ' ' GLU . 1.3 pm0 -87.57 -168.1 2.11 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 122.638 1.208 . . . . 0.0 113.843 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.483 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 22.5 t80 -88.22 -46.99 8.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 117.853 2.538 . . . . 0.0 117.853 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.483 ' HE2' ' CZ ' ' A' ' 4' ' ' PHE . 0.3 OUTLIER -131.57 174.68 9.86 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 179.63 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.13 172.96 3.69 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 104.187 -2.523 . . . . 0.0 104.187 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -56.31 89.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 121.43 1.42 . . . . 0.0 111.374 164.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.434 ' HB3' HG13 ' A' ' 68' ' ' VAL . 9.5 t0 -122.45 -82.05 0.65 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 102.968 -2.975 . . . . 0.0 102.968 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.5 pt 36.8 37.0 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 CA-C-O 121.601 0.715 . . . . 0.0 109.821 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.7 -154.58 11.94 Favored Glycine 0 N--CA 1.48 1.575 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.32 138.53 37.75 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.44 -74.1 0.33 Allowed Glycine 0 N--CA 1.486 1.968 0 N-CA-C 106.907 -2.477 . . . . 0.0 106.907 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.2 mm -133.46 141.4 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-N 118.363 1.081 . . . . 0.0 108.297 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -131.9 -51.88 0.98 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.54 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -116.59 172.11 7.43 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.463 -1.244 . . . . 0.0 111.995 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.82 155.51 26.17 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 106.542 -2.623 . . . . 0.0 106.542 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -122.54 136.74 54.96 Favored 'General case' 0 C--N 1.303 -1.445 1 N-CA-C 98.968 -4.456 . . . . 0.0 98.968 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . 0.285 2.6 mt -103.95 113.67 41.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.278 0 N-CA-C 102.734 -3.062 . . . . 0.0 102.734 -179.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.9 t -76.5 -55.07 12.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.459 ' HE3' ' CE2' ' A' ' 22' ' ' PHE . 22.4 tttp -141.41 158.32 44.02 Favored 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 118.981 -1.088 . . . . 0.0 113.579 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.509 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 36.9 m95 -113.86 170.89 7.93 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 178.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.471 ' N ' ' CD1' ' A' ' 22' ' ' PHE . 9.5 m-85 -128.28 -46.43 1.35 Allowed 'General case' 0 C--N 1.3 -1.584 0 CA-C-N 114.126 -1.397 . . . . 0.0 109.735 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 m -97.39 175.68 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.445 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -128.04 165.98 26.91 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 105.593 -2.003 . . . . 0.0 105.593 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -76.52 122.71 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 121.915 1.744 . . . . 0.0 110.776 -172.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.13 -7.27 19.02 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.226 -2.349 . . . . 0.0 107.226 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.445 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -79.52 173.23 12.79 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 124.177 1.941 . . . . 0.0 111.041 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.667 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.2 OUTLIER -118.55 146.26 44.72 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 100.584 -3.858 . . . . 0.0 100.584 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . 0.25 0.9 OUTLIER -122.19 171.2 11.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 -179.776 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.434 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 53.7 t30 -119.42 -29.51 5.11 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 125.03 2.348 . . . . 0.0 115.135 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.45 ' HG2' ' HB2' ' A' ' 49' ' ' SER 0.366 11.9 tp10 47.26 78.74 0.07 Allowed 'General case' 0 C--N 1.267 -2.995 5 N-CA-C 131.644 7.646 . . . . 0.0 131.644 -179.213 . . . . . . . . 4 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -155.43 31.5 0.38 Allowed 'General case' 0 C--N 1.28 -2.434 4 CA-C-N 94.066 -10.515 . . . . 0.0 93.984 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -117.22 -168.7 1.52 Allowed 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 126.927 2.091 . . . . 0.0 107.82 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' HB ' ' CG ' ' A' ' 22' ' ' PHE . 3.6 t -134.47 161.85 39.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 N-CA-C 100.597 -3.853 . . . . 0.0 100.597 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.509 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 3.4 mm? -125.54 -84.85 0.63 Allowed 'General case' 0 C--N 1.272 -2.77 0 CA-C-N 109.874 -3.33 . . . . 0.0 102.389 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.403 ' SG ' ' OE1' ' A' ' 46' ' ' GLU . 11.2 p -123.97 172.77 8.69 Favored 'General case' 0 N--CA 1.495 1.777 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.582 -178.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.405 ' HA ' ' N ' ' A' ' 46' ' ' GLU 0.367 18.5 tt0 -134.34 138.25 44.77 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 -179.287 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.473 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 25.5 t -139.77 145.57 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 35.6 tt0 -107.29 107.65 18.68 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 6.4 p-10 -136.77 174.57 10.47 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 2.8 p-10 -3.78 -59.49 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 118.234 2.679 . . . . 0.0 118.234 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 28.3 mttm -131.15 -4.05 3.91 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 123.687 0.617 . . . . 0.0 110.029 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -106.09 164.43 11.99 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.75 -43.11 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 111.392 -2.64 . . . . 0.0 109.178 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.3 t -111.83 167.35 5.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.473 ' CG ' ' HB ' ' A' ' 38' ' ' VAL . 4.0 mt-10 -120.5 -73.32 0.65 Allowed 'General case' 0 C--N 1.294 -1.846 0 O-C-N 128.016 3.323 . . . . 0.0 116.556 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.479 HG22 ' C ' ' A' ' 48' ' ' PRO . 1.2 mp -84.37 142.54 40.65 Favored Pre-proline 0 C--N 1.274 -2.68 0 CA-C-N 108.487 -3.961 . . . . 0.0 110.225 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.479 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -96.64 177.59 0.59 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 N-CA-C 105.248 -2.635 . . . . 0.0 105.248 82.646 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.45 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 1.6 m -124.36 -177.61 0.57 Allowed Pre-proline 0 C--N 1.278 -2.512 0 CA-C-N 114.462 -1.244 . . . . 0.0 109.243 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -87.51 -31.43 0.22 Allowed 'Trans proline' 0 C--N 1.314 -1.285 0 N-CA-C 117.236 1.975 . . . . 0.0 117.236 164.6 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.525 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.6 p -138.34 167.97 20.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 120.246 3.425 . . . . 0.0 120.246 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.525 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 2.2 ptmm? -97.06 177.26 5.66 Favored 'General case' 0 C--N 1.292 -1.9 1 CA-C-N 106.212 -4.995 . . . . 0.0 110.266 -179.395 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.02 -141.71 9.21 Favored Glycine 0 C--N 1.286 -2.237 0 N-CA-C 103.331 -3.908 . . . . 0.0 103.331 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.667 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 12.3 tppt? -110.97 173.23 6.43 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 103.915 -2.624 . . . . 0.0 103.915 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 39.3 t -125.72 68.84 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.166 1 N-CA-C 97.963 -4.829 . . . . 0.0 97.963 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 38.3 mt -30.48 -76.02 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 126.135 2.147 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -142.04 161.58 37.64 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 77.8 mt -132.99 114.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 1 N-CA-C 93.882 -6.34 . . . . 0.0 93.882 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.5 mt -90.9 -40.4 11.75 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 114.759 1.392 . . . . 0.0 114.759 -179.456 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.71 79.97 23.61 Favored Pre-proline 0 N--CA 1.496 1.864 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.817 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_exo -34.8 -107.66 0.0 OUTLIER 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 124.426 3.417 . . . . 0.0 120.532 -175.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -132.73 173.8 10.98 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 56.92 30.94 60.73 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.7 m -138.24 160.28 39.87 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 102.014 -3.328 . . . . 0.0 102.014 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -97.56 135.6 31.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -127.06 144.98 50.89 Favored 'General case' 0 C--N 1.294 -1.834 1 N-CA-C 99.764 -4.162 . . . . 0.0 99.764 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.259 66.8 p -116.87 -144.78 0.38 Allowed 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 124.296 1.998 . . . . 0.0 107.413 -179.855 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.439 ' C ' ' H ' ' A' ' 70' ' ' GLN . 74.8 t -121.65 155.07 25.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 1 N-CA-C 93.247 -6.575 . . . . 0.0 93.247 179.056 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 93.27 -47.04 2.39 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 103.148 -3.981 . . . . 0.0 103.148 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.439 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.2 tt0 -94.0 155.0 17.36 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 102.426 -3.176 . . . . 0.0 102.426 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.55 -174.61 2.6 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 102.769 -3.048 . . . . 0.0 102.769 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.6 tp -145.99 -66.84 0.29 Allowed 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 113.349 -1.751 . . . . 0.0 106.874 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 11.8 tt -133.21 166.58 28.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 110.852 -2.886 . . . . 0.0 105.609 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 t -140.19 159.8 41.38 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 102.152 -3.277 . . . . 0.0 102.152 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.62 154.92 50.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.36 145.89 48.39 Favored 'General case' 0 C--N 1.295 -1.798 1 N-CA-C 99.536 -4.246 . . . . 0.0 99.536 179.282 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -140.79 -49.95 0.02 OUTLIER Pre-proline 0 C--N 1.295 -1.765 0 O-C-N 123.746 0.653 . . . . 0.0 111.581 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -84.4 -45.85 0.3 Allowed 'Cis proline' 0 C--N 1.315 -1.224 0 CA-C-N 119.722 0.936 . . . . 0.0 109.98 -22.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -141.89 124.84 2.55 Favored Glycine 0 C--N 1.293 -1.818 1 N-CA-C 98.749 -5.74 . . . . 0.0 98.749 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 36.6 p90 . . . . . 0 C--N 1.283 -2.317 0 O-C-N 127.109 2.299 . . . . 0.0 106.007 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.51 2.531 0 N-CA-C 102.668 -3.086 . . . . 0.0 102.668 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.1 t80 16.37 102.96 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 127.051 2.72 . . . . 0.0 112.813 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.654 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 2.6 pm0 -82.53 -171.0 3.24 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-N 110.482 -3.054 . . . . 0.0 112.917 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.459 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.2 t80 -93.86 -49.94 5.58 Favored 'General case' 0 N--CA 1.494 1.725 0 CA-C-N 113.684 -1.598 . . . . 0.0 114.063 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' CB ' HG23 ' A' ' 68' ' ' VAL . 11.8 mmmm -126.1 165.93 17.95 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 101.633 -3.469 . . . . 0.0 101.633 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 61.0 mt -105.48 -178.03 0.57 Allowed Pre-proline 0 C--N 1.3 -1.564 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.45 96.43 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.356 0 C-N-CA 121.685 1.59 . . . . 0.0 110.855 170.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.549 ' HB3' HG13 ' A' ' 68' ' ' VAL . 24.2 t0 -122.34 -99.3 0.43 Allowed 'General case' 0 C--N 1.302 -1.478 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 179.795 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.471 HG22 ' CG1' ' A' ' 68' ' ' VAL . 32.4 pt 34.74 42.05 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 O-C-N 124.572 1.17 . . . . 0.0 108.239 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.79 -137.27 4.77 Favored Glycine 0 N--CA 1.482 1.725 0 CA-C-N 114.45 -1.25 . . . . 0.0 113.895 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.63 146.64 28.64 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 104.695 -2.335 . . . . 0.0 104.695 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.31 -76.24 0.22 Allowed Glycine 0 N--CA 1.486 1.969 0 N-CA-C 103.249 -3.94 . . . . 0.0 103.249 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 42.1 mm -131.21 173.5 14.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 N-CA-C 103.427 -2.805 . . . . 0.0 103.427 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -155.0 -33.09 0.1 Allowed 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.159 1.457 . . . . 0.0 107.701 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.415 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.3 OUTLIER -117.07 -165.54 1.08 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 113.975 -1.466 . . . . 0.0 113.355 179.908 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.89 128.18 2.81 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 103.735 -3.746 . . . . 0.0 103.735 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.422 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 30.4 tt0 -104.64 91.49 3.88 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 101.146 -3.65 . . . . 0.0 101.146 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.5 mt -81.86 110.62 17.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 103.969 -2.604 . . . . 0.0 103.969 -179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -88.81 -45.28 15.58 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 113.563 -1.653 . . . . 0.0 106.62 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.571 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 2.4 ttmp? -130.9 161.46 31.82 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.117 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.489 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 11.3 m95 -124.28 168.74 12.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 101.457 -3.534 . . . . 0.0 101.457 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.407 ' N ' ' CD1' ' A' ' 22' ' ' PHE . 6.9 m-85 -123.0 -47.41 2.04 Favored 'General case' 0 C--N 1.295 -1.782 0 O-C-N 124.542 1.151 . . . . 0.0 108.245 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -99.58 178.13 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.331 1.062 . . . . 0.0 110.775 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 ptmt -115.17 172.63 3.48 Favored Pre-proline 0 C--N 1.295 -1.79 0 CA-C-N 112.104 -2.316 . . . . 0.0 105.025 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -93.78 143.45 1.86 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.228 1.952 . . . . 0.0 110.384 166.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.64 -10.33 38.37 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.231 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -108.53 -175.9 2.9 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.81 ' CG ' ' HZ1' ' A' ' 54' ' ' LYS . 0.6 OUTLIER -118.82 163.99 16.07 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.226 -179.724 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.527 HG23 ' CB ' ' A' ' 31' ' ' GLU . 3.1 p -133.01 174.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.481 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 19.8 t-20 -116.21 -35.85 4.23 Favored 'General case' 0 N--CA 1.523 3.203 0 CA-C-O 126.903 3.24 . . . . 0.0 115.649 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.527 ' CB ' HG23 ' A' ' 29' ' ' VAL 0.395 33.0 tt0 20.18 123.08 0.0 OUTLIER 'General case' 0 C--N 1.273 -2.759 5 N-CA-C 151.831 15.123 . . . . 0.0 151.831 -179.537 . . . . . . . . 4 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' CG ' ' N ' ' A' ' 33' ' ' ASP . 11.2 p-10 -123.01 -48.23 2.01 Favored 'General case' 0 C--N 1.287 -2.117 4 CA-C-N 93.237 -10.892 . . . . 0.0 97.625 178.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' CG ' ' A' ' 32' ' ' ASP . 3.7 t0 -22.55 176.6 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.617 0 C-N-CA 131.427 3.891 . . . . 0.0 116.186 179.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.489 ' HA ' HG21 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -107.39 167.52 3.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 127.366 3.46 . . . . 0.0 114.292 -179.597 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.489 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.1 mp -130.9 -87.34 0.49 Allowed 'General case' 0 C--N 1.283 -2.289 1 CA-C-N 106.562 -4.836 . . . . 0.0 103.688 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.89 169.63 13.73 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.514 ' HG3' HG23 ' A' ' 45' ' ' VAL . 1.2 tm-20 -135.09 156.88 48.26 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 126.341 2.276 . . . . 0.0 104.946 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.477 ' CG1' ' N ' ' A' ' 39' ' ' GLN . 54.0 t -139.5 179.58 2.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 125.481 1.738 . . . . 0.0 111.439 -179.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.477 ' N ' ' CG1' ' A' ' 38' ' ' VAL . 25.0 tt0 -137.8 102.72 4.8 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 113.313 -1.767 . . . . 0.0 108.234 178.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.413 HD21 ' CG ' ' A' ' 41' ' ' ASP . 9.9 p-10 -147.41 175.8 10.53 Favored 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.916 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.413 ' CG ' HD21 ' A' ' 40' ' ' ASN . 1.0 OUTLIER -15.7 -68.66 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 119.139 3.014 . . . . 0.0 119.139 -179.601 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.579 ' CB ' ' HZ1' ' A' ' 42' ' ' LYS . 0.3 OUTLIER -126.14 -8.85 6.49 Favored 'General case' 0 C--N 1.289 -2.023 0 CA-C-N 114.794 -1.093 . . . . 0.0 110.958 -179.407 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -111.39 156.03 22.23 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.874 -1.13 . . . . 0.0 109.734 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.47 -88.98 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 114.135 -1.393 . . . . 0.0 108.742 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.514 HG23 ' HG3' ' A' ' 37' ' ' GLU . 61.5 t -68.27 162.86 3.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 104.566 -2.383 . . . . 0.0 104.566 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.43 ' CB ' HD13 ' A' ' 47' ' ' ILE . 2.4 mt-10 -108.3 -60.65 1.7 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 126.806 2.566 . . . . 0.0 115.479 -179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.489 HG21 ' HA ' ' A' ' 34' ' ' VAL . 1.6 mp -96.1 143.21 25.73 Favored Pre-proline 0 C--N 1.273 -2.745 1 CA-C-N 108.033 -4.167 . . . . 0.0 108.904 -179.507 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.468 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.03 177.11 0.46 Allowed 'Trans proline' 0 C--N 1.305 -1.731 1 C-N-CA 126.281 4.654 . . . . 0.0 106.509 90.036 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.455 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 16.1 m -128.45 171.15 9.04 Favored Pre-proline 0 C--N 1.28 -2.434 0 O-C-N 125.144 1.528 . . . . 0.0 114.285 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -105.35 -17.13 0.05 OUTLIER 'Trans proline' 0 CA--C 1.555 1.549 0 C-N-CA 124.575 3.517 . . . . 0.0 119.653 173.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.577 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.2 p -135.24 170.35 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.705 0 CA-C-O 122.896 1.331 . . . . 0.0 111.789 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.577 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -125.07 178.3 5.61 Favored 'General case' 0 C--N 1.286 -2.195 1 CA-C-N 108.239 -4.073 . . . . 0.0 111.266 -179.555 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.61 -134.93 4.35 Favored Glycine 0 C--N 1.287 -2.177 1 N-CA-C 100.3 -5.12 . . . . 0.0 100.3 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.81 ' HZ1' ' CG ' ' A' ' 28' ' ' GLU . 15.1 tppt? -112.93 176.55 4.97 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 104.497 -2.409 . . . . 0.0 104.497 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.419 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 24.0 t -123.75 100.84 8.25 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 1 N-CA-C 93.148 -6.612 . . . . 0.0 93.148 179.68 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.5 mt -74.61 -83.08 0.06 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 117.582 -1.647 . . . . 0.0 106.946 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.2 160.99 30.37 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.001 . . . . 0.0 112.668 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -132.75 118.36 33.79 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 1 N-CA-C 92.761 -6.755 . . . . 0.0 92.761 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -92.69 -41.18 10.3 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 123.727 0.642 . . . . 0.0 111.787 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -111.32 124.59 32.33 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 101.632 -3.47 . . . . 0.0 101.632 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -57.07 -124.16 0.0 OUTLIER 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 123.921 3.081 . . . . 0.0 116.453 176.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.509 ' C ' ' H ' ' A' ' 64' ' ' THR . 0.0 OUTLIER -127.49 -170.34 2.21 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 100.885 -3.746 . . . . 0.0 100.885 179.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.07 -19.95 0.12 Allowed Glycine 0 N--CA 1.491 2.347 0 CA-C-N 113.277 -1.783 . . . . 0.0 113.711 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.509 ' H ' ' C ' ' A' ' 62' ' ' GLU . 2.2 m -101.97 170.03 8.39 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 104.394 -2.447 . . . . 0.0 104.394 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.407 HG21 ' HG3' ' A' ' 17' ' ' GLU . 45.0 t -105.77 148.8 9.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 103.816 -2.661 . . . . 0.0 103.816 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -119.5 156.66 29.82 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.415 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -101.06 -160.86 0.82 Allowed 'General case' 0 C--N 1.283 -2.289 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.549 HG13 ' HB3' ' A' ' 8' ' ' ASP . 52.2 t -126.69 153.17 35.23 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.39 1 N-CA-C 94.353 -6.166 . . . . 0.0 94.353 178.386 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . 0.469 ' N ' HG11 ' A' ' 68' ' ' VAL . . . 94.44 -36.16 3.89 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 103.588 -3.805 . . . . 0.0 103.588 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.484 ' H ' ' C ' ' A' ' 68' ' ' VAL . 31.6 tt0 -92.93 163.75 13.57 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 101.817 -3.401 . . . . 0.0 101.817 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.3 m -108.84 -179.02 3.74 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 101.724 -3.435 . . . . 0.0 101.724 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.06 -65.64 0.23 Allowed 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 7.8 tt -130.19 163.56 35.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.2 t -140.42 158.32 44.18 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 103.142 -2.91 . . . . 0.0 103.142 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -132.39 149.54 52.33 Favored 'General case' 0 C--N 1.287 -2.11 0 CA-C-N 111.83 -2.441 . . . . 0.0 104.855 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.26 123.17 48.12 Favored 'General case' 0 C--N 1.292 -1.913 1 N-CA-C 96.511 -5.366 . . . . 0.0 96.511 179.716 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -139.77 58.72 12.09 Favored Pre-proline 0 N--CA 1.491 1.607 1 N-CA-C 99.786 -4.153 . . . . 0.0 99.786 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -78.1 67.77 8.03 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 121.778 1.652 . . . . 0.0 112.066 -153.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.3 59.06 0.05 OUTLIER Glycine 0 N--CA 1.501 2.972 0 C-N-CA 119.72 -1.228 . . . . 0.0 112.806 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 116.338 -1.791 . . . . 0.0 107.554 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 2.097 0 N-CA-C 103.73 -2.692 . . . . 0.0 103.73 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.78 128.27 51.54 Favored 'General case' 0 C--N 1.29 -2.015 1 N-CA-C 99.962 -4.088 . . . . 0.0 99.962 -179.635 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -102.23 -173.29 2.3 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -101.14 -43.16 6.09 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.609 0.719 . . . . 0.0 112.509 -179.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.458 ' CB ' HG21 ' A' ' 68' ' ' VAL . 0.1 OUTLIER -128.49 160.27 32.84 Favored 'General case' 0 C--N 1.297 -1.685 1 N-CA-C 99.338 -4.319 . . . . 0.0 99.338 179.79 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 25.5 mt -103.31 -169.37 0.18 Allowed Pre-proline 0 C--N 1.296 -1.745 0 N-CA-C 105.319 -2.104 . . . . 0.0 105.319 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -55.48 85.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.12 1.88 . . . . 0.0 107.577 148.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.482 ' HB3' HG13 ' A' ' 68' ' ' VAL . 3.2 t0 -123.15 -88.65 0.61 Allowed 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.521 ' H ' HG13 ' A' ' 68' ' ' VAL . 1.3 pt 37.77 43.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.321 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.33 -176.1 50.51 Favored Glycine 0 N--CA 1.493 2.453 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.551 -179.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -80.72 144.73 31.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.86 -77.89 0.26 Allowed Glycine 0 C--N 1.294 -1.786 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.2 mt -137.93 103.79 2.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 102.736 -3.061 . . . . 0.0 102.736 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.67 20.71 18.61 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-N 122.178 2.263 . . . . 0.0 108.35 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.498 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 1.4 pm0 -121.95 -174.26 2.84 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 123.725 1.726 . . . . 0.0 114.09 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.4 101.65 0.27 Allowed Glycine 0 N--CA 1.492 2.43 0 CA-C-N 112.483 -2.144 . . . . 0.0 109.7 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -92.94 89.2 6.45 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.9 mt -84.18 103.89 11.9 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 100.851 -3.759 . . . . 0.0 100.851 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.7 t -84.33 -46.17 17.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.331 -179.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 25.8 tttt -142.24 159.77 41.57 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 114.983 -1.008 . . . . 0.0 111.1 -179.543 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.506 ' CE3' HG21 ' A' ' 23' ' ' VAL . 17.7 m95 -122.16 162.52 21.18 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 179.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -120.68 -20.74 6.94 Favored 'General case' 0 C--N 1.292 -1.895 0 O-C-N 124.984 1.428 . . . . 0.0 108.76 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.506 HG21 ' CE3' ' A' ' 21' ' ' TRP . 5.1 m -99.89 179.31 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-O 123.753 1.74 . . . . 0.0 112.147 -179.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.536 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -130.42 140.13 37.73 Favored Pre-proline 0 C--N 1.288 -2.095 1 N-CA-C 97.743 -4.91 . . . . 0.0 97.743 -179.71 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -54.69 162.56 4.73 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.42 1.413 . . . . 0.0 114.945 -175.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.52 26.55 0.08 OUTLIER Glycine 0 C--N 1.294 -1.764 0 CA-C-N 110.785 -2.916 . . . . 0.0 117.662 179.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.508 ' C ' ' NZ ' ' A' ' 54' ' ' LYS . 23.0 t0 -87.0 -168.48 2.26 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 113.498 -3.281 . . . . 0.0 107.115 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.482 ' H ' ' CG ' ' A' ' 27' ' ' ASP . 5.5 mm-40 -102.92 127.55 50.08 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 100.391 -3.929 . . . . 0.0 100.391 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.9 p -109.55 160.74 8.33 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -96.72 -164.17 1.12 Allowed 'General case' 0 C--N 1.292 -1.901 0 CA-C-N 113.472 -1.695 . . . . 0.0 109.137 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . 0.284 9.9 tt0 -117.87 56.21 0.86 Allowed 'General case' 0 C--N 1.289 -2.048 1 N-CA-C 98.332 -4.692 . . . . 0.0 98.332 -178.88 . . . . . . . . 3 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -178.04 1.39 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.84 0 CA-C-N 112.049 -2.341 . . . . 0.0 116.442 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.433 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 42.3 t0 -90.31 -172.14 3.35 Favored 'General case' 0 N--CA 1.508 2.463 0 CA-C-N 118.789 0.722 . . . . 0.0 111.371 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.492 HG13 ' H ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -112.51 176.34 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 126.375 2.988 . . . . 0.0 102.956 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.492 ' H ' HG13 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -140.08 -83.29 0.25 Allowed 'General case' 0 C--N 1.274 -2.697 1 CA-C-N 107.485 -4.416 . . . . 0.0 100.504 179.317 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.456 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -126.08 172.34 10.07 Favored 'General case' 0 N--CA 1.51 2.568 0 CA-C-N 122.179 2.263 . . . . 0.0 115.153 -179.287 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.459 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 2.1 tt0 -119.77 101.33 7.82 Favored 'General case' 0 N--CA 1.493 1.707 1 N-CA-C 92.966 -6.679 . . . . 0.0 92.966 179.443 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 t -108.18 150.43 10.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 26.7 tt0 -121.23 164.53 16.81 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 104.116 -2.55 . . . . 0.0 104.116 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.2 p-10 -152.98 -178.75 7.11 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 102.623 -3.102 . . . . 0.0 102.623 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD2' ' NZ ' ' A' ' 42' ' ' LYS . 0.8 OUTLIER -5.79 -57.62 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 118.231 2.678 . . . . 0.0 118.231 -179.613 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.5 ' NZ ' ' OD2' ' A' ' 41' ' ' ASP . 2.2 mttp -146.36 -34.3 0.29 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.31 149.88 38.63 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.86 -1.064 . . . . 0.0 113.2 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 21.9 t -122.6 110.99 28.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 1 N-CA-C 95.696 -5.668 . . . . 0.0 95.696 179.582 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t -114.71 162.61 12.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 CA-C-O 124.709 2.195 . . . . 0.0 108.455 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -118.35 153.12 34.55 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 109.044 -3.707 . . . . 0.0 106.766 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 mp -121.43 126.25 26.57 Favored Pre-proline 0 C--N 1.302 -1.47 1 N-CA-C 94.132 -6.247 . . . . 0.0 94.132 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -90.77 -176.69 1.02 Allowed 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.537 2.158 . . . . 0.0 107.934 167.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -91.85 112.8 56.51 Favored Pre-proline 0 C--N 1.288 -2.079 0 CA-C-N 113.207 -1.815 . . . . 0.0 108.228 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -69.7 -34.59 14.49 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 121.497 1.465 . . . . 0.0 108.363 168.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.482 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.52 168.79 21.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 125.458 1.723 . . . . 0.0 111.94 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.482 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -102.82 162.18 13.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 127.32 2.888 . . . . 0.0 105.307 179.19 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 163.12 -141.84 7.44 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.508 ' NZ ' ' C ' ' A' ' 27' ' ' ASP . 0.5 OUTLIER -117.96 175.28 5.75 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 104.405 -2.442 . . . . 0.0 104.405 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' LEU . 21.7 t -128.52 57.19 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.048 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.402 ' C ' ' O ' ' A' ' 55' ' ' VAL . 85.0 mt -26.9 -76.77 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 CA-C-N 112.729 -2.032 . . . . 0.0 113.632 -179.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -130.59 153.5 48.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 124.77 1.294 . . . . 0.0 110.161 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -131.25 119.62 44.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 1 N-CA-C 93.425 -6.509 . . . . 0.0 93.425 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.421 HD13 ' N ' ' A' ' 59' ' ' LEU . 6.0 mp -90.9 -44.86 9.12 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.9 t -119.42 140.65 29.47 Favored Pre-proline 0 C--N 1.296 -1.757 1 N-CA-C 97.802 -4.888 . . . . 0.0 97.802 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -91.51 -101.34 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.033 1.155 . . . . 0.0 110.214 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.18 -168.71 1.97 Allowed 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 102.071 -3.307 . . . . 0.0 102.071 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 79.67 -45.87 2.98 Favored Glycine 0 C--N 1.287 -2.186 0 CA-C-N 113.404 -1.725 . . . . 0.0 112.101 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.6 m -98.83 172.51 7.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.4 t -108.03 150.63 10.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 104.614 -2.365 . . . . 0.0 104.614 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.97 168.11 13.25 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 103.661 -2.718 . . . . 0.0 103.661 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 12.2 t -129.02 -151.32 0.47 Allowed 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.524 ' C ' ' H ' ' A' ' 70' ' ' GLN . 97.4 t -121.98 159.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.322 0 N-CA-C 101.028 -3.693 . . . . 0.0 101.028 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.32 -43.86 1.7 Allowed Glycine 0 CA--C 1.549 2.211 1 N-CA-C 97.142 -6.383 . . . . 0.0 97.142 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.524 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.1 tt0 -88.81 162.56 16.13 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 102.289 -3.226 . . . . 0.0 102.289 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.7 m -109.6 -176.93 3.14 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 101.965 -3.346 . . . . 0.0 101.965 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.3 tp -146.91 -65.49 0.28 Allowed 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 1.4 tt -133.25 166.13 30.23 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-N 112.125 -2.307 . . . . 0.0 105.174 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -138.49 156.71 47.29 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 101.42 -3.548 . . . . 0.0 101.42 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -136.11 147.57 47.85 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.51 142.34 42.43 Favored 'General case' 0 C--N 1.299 -1.63 1 N-CA-C 97.946 -4.835 . . . . 0.0 97.946 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.13 36.6 0.25 Allowed Pre-proline 0 C--N 1.293 -1.853 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.386 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -37.21 61.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 124.921 3.747 . . . . 0.0 119.406 -143.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 153.5 42.3 0.02 OUTLIER Glycine 0 N--CA 1.495 2.59 0 N-CA-C 106.472 -2.651 . . . . 0.0 106.472 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.304 -1.398 0 N-CA-C 100.634 -3.839 . . . . 0.0 100.634 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.069 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -126.07 127.84 46.46 Favored 'General case' 0 N--CA 1.503 2.224 0 N-CA-C 102.569 -3.123 . . . . 0.0 102.569 -179.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.12 -151.25 0.47 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 125.319 1.637 . . . . 0.0 111.818 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.54 ' CE2' ' HE2' ' A' ' 5' ' ' LYS . 8.2 t80 -113.3 -49.68 2.9 Favored 'General case' 0 N--CA 1.502 2.162 0 CA-C-N 113.375 -1.738 . . . . 0.0 114.655 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.54 ' HE2' ' CE2' ' A' ' 4' ' ' PHE . 28.4 mmtt -131.45 155.11 47.92 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 66.0 mt -84.05 173.66 7.0 Favored Pre-proline 0 C--N 1.296 -1.724 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.818 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -54.18 85.91 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.585 2.19 . . . . 0.0 109.791 162.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.438 ' HB3' HG12 ' A' ' 68' ' ' VAL . 10.4 t0 -122.9 -80.22 0.62 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.3 pt 37.07 39.03 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.575 0 CA-C-O 121.896 0.855 . . . . 0.0 109.447 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.12 -150.56 11.33 Favored Glycine 0 N--CA 1.48 1.629 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.594 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -95.01 139.19 31.71 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 103.309 -2.848 . . . . 0.0 103.309 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.97 -79.27 0.33 Allowed Glycine 0 N--CA 1.487 2.081 0 N-CA-C 103.774 -3.731 . . . . 0.0 103.774 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.3 mm -130.73 133.25 63.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 22.1 t-80 -130.34 -19.23 3.14 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.503 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 0.5 OUTLIER -131.32 178.1 6.97 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 122.975 1.369 . . . . 0.0 110.55 -179.524 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.83 125.44 4.12 Favored Glycine 0 C--N 1.29 -2.019 0 N-CA-C 104.8 -3.32 . . . . 0.0 104.8 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.427 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 37.5 tt0 -100.31 96.31 7.36 Favored 'General case' 0 C--N 1.307 -1.272 1 N-CA-C 97.28 -5.081 . . . . 0.0 97.28 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mt -81.96 125.12 39.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 N-CA-C 103.573 -2.751 . . . . 0.0 103.573 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.6 t -86.38 -64.0 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 103.26 -2.867 . . . . 0.0 103.26 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.413 ' HE3' ' O ' ' A' ' 21' ' ' TRP . 1.3 tmtp? -142.99 167.75 21.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 124.018 0.824 . . . . 0.0 113.22 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.512 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 30.3 m95 -113.73 173.06 6.61 Favored 'General case' 0 N--CA 1.502 2.131 0 C-N-CA 123.92 0.888 . . . . 0.0 109.004 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -126.92 -48.51 1.49 Allowed 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.541 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 m -100.23 178.69 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.172 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.02 161.77 26.34 Favored Pre-proline 0 C--N 1.295 -1.785 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.814 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -78.16 122.56 5.76 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.249 1.966 . . . . 0.0 110.857 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.16 -15.99 22.78 Favored Glycine 0 N--CA 1.483 1.816 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.23 174.37 7.32 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 123.018 1.389 . . . . 0.0 111.74 -178.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.521 ' CG ' ' HZ1' ' A' ' 54' ' ' LYS . 45.6 mt-10 -119.93 117.41 28.01 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 111.166 -2.743 . . . . 0.0 104.242 -179.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 p -108.58 176.59 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.719 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.42 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -104.65 -26.3 12.37 Favored 'General case' 0 N--CA 1.522 3.166 0 CA-C-O 126.698 3.142 . . . . 0.0 112.94 -179.697 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.403 ' CG ' ' O ' ' A' ' 51' ' ' VAL 0.377 10.8 tp10 35.46 78.71 0.03 OUTLIER 'General case' 0 C--N 1.272 -2.796 5 N-CA-C 138.398 10.147 . . . . 0.0 138.398 -179.389 . . . . . . . . 4 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -141.67 27.21 1.87 Allowed 'General case' 0 C--N 1.287 -2.127 4 CA-C-N 94.721 -10.218 . . . . 0.0 96.273 179.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -108.94 -165.59 1.04 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 126.105 1.762 . . . . 0.0 107.343 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.434 HG13 ' H ' ' A' ' 35' ' ' LEU . 1.6 t -120.3 163.02 18.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 CA-C-O 125.554 2.597 . . . . 0.0 108.893 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.512 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.6 mp -126.45 -84.0 0.62 Allowed 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 108.726 -3.852 . . . . 0.0 103.033 179.15 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.561 ' SG ' HG21 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -123.66 172.69 8.62 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 -178.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.417 ' N ' ' SG ' ' A' ' 36' ' ' CYS 0.369 18.5 tt0 -134.04 140.31 46.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 127.064 2.728 . . . . 0.0 103.646 -179.244 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.561 HG21 ' SG ' ' A' ' 36' ' ' CYS . 25.0 t -139.39 151.34 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 CA-C-N 119.145 0.884 . . . . 0.0 109.7 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 43.4 tp60 -106.5 128.25 53.95 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -156.01 -173.09 4.36 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -11.69 -73.63 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.608 0 O-C-N 126.479 2.362 . . . . 0.0 116.608 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -128.38 -7.27 5.27 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.408 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.81 159.2 15.08 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.276 -0.97 . . . . 0.0 113.15 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.9 t -124.65 -35.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 126.678 2.486 . . . . 0.0 112.942 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.407 HG21 ' HG3' ' A' ' 37' ' ' GLU . 10.9 t -113.1 169.51 4.78 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 125.239 1.415 . . . . 0.0 108.282 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.425 ' CD ' ' HZ3' ' A' ' 5' ' ' LYS . 3.6 mt-10 -120.45 -67.8 0.95 Allowed 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 121.422 3.86 . . . . 0.0 121.422 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.4 HG22 ' C ' ' A' ' 48' ' ' PRO . 1.6 mp -92.85 149.49 37.84 Favored Pre-proline 0 C--N 1.273 -2.73 0 CA-C-N 108.746 -3.843 . . . . 0.0 108.672 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.4 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -103.18 -178.31 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.708 1.373 . . . . 0.0 109.152 83.395 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.4 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 0.7 OUTLIER -130.96 179.53 1.32 Allowed Pre-proline 0 C--N 1.286 -2.164 0 CA-C-N 113.481 -1.69 . . . . 0.0 108.428 -179.798 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -102.32 -26.53 0.03 OUTLIER 'Trans proline' 0 CA--C 1.548 1.179 0 N-CA-C 120.016 3.045 . . . . 0.0 120.016 171.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.517 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.9 OUTLIER -127.89 160.6 37.32 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.454 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.517 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -106.75 167.61 9.75 Favored 'General case' 0 C--N 1.294 -1.825 1 CA-C-N 107.451 -4.431 . . . . 0.0 111.148 -179.625 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.28 -141.37 6.75 Favored Glycine 0 C--N 1.292 -1.909 1 N-CA-C 100.024 -5.23 . . . . 0.0 100.024 -179.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.521 ' HZ1' ' CG ' ' A' ' 28' ' ' GLU . 14.4 tppt? -105.79 175.1 5.61 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 102.151 -3.277 . . . . 0.0 102.151 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.436 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 47.4 t -126.1 60.69 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.216 1 N-CA-C 96.549 -5.352 . . . . 0.0 96.549 179.39 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.406 ' C ' ' O ' ' A' ' 55' ' ' VAL . 91.2 mt -22.55 -80.34 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.163 0 CA-C-N 112.816 -1.993 . . . . 0.0 112.999 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -139.76 164.18 30.64 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 125.049 1.468 . . . . 0.0 107.817 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.9 mt -132.47 130.99 60.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 1 N-CA-C 95.67 -5.678 . . . . 0.0 95.67 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.403 HD13 ' N ' ' A' ' 59' ' ' LEU . 5.9 mp -87.74 -52.61 5.21 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 123.8 0.688 . . . . 0.0 109.689 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.5 t -116.67 140.54 26.89 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 101.135 -3.654 . . . . 0.0 101.135 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -87.5 -106.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.694 1.596 . . . . 0.0 111.004 178.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -129.56 159.57 35.95 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 102.567 -3.123 . . . . 0.0 102.567 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 107.17 -33.09 6.63 Favored Glycine 0 N--CA 1.498 2.782 0 C-N-CA 119.278 -1.439 . . . . 0.0 114.61 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.2 m -109.28 -175.9 2.88 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.2 t -112.43 150.93 14.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.88 163.73 18.73 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -107.57 -160.77 0.75 Allowed 'General case' 0 C--N 1.285 -2.224 0 N-CA-C 104.234 -2.506 . . . . 0.0 104.234 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.438 HG12 ' HB3' ' A' ' 8' ' ' ASP 0.265 44.6 t -124.0 153.86 30.38 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 1 N-CA-C 92.643 -6.799 . . . . 0.0 92.643 178.226 . . . . . . . . 4 3 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.6 -45.8 1.99 Allowed Glycine 0 N--CA 1.498 2.77 0 N-CA-C 103.294 -3.922 . . . . 0.0 103.294 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.424 ' H ' ' C ' ' A' ' 68' ' ' VAL . 37.3 tt0 -85.84 160.21 19.51 Favored 'General case' 0 C--N 1.303 -1.452 1 N-CA-C 99.777 -4.157 . . . . 0.0 99.777 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.4 m -106.54 -178.43 3.65 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 102.122 -3.288 . . . . 0.0 102.122 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.469 HD23 ' CE2' ' A' ' 4' ' ' PHE . 47.9 tp -143.33 -60.07 0.42 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 14.2 tt -132.96 161.97 40.76 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 104.573 -2.38 . . . . 0.0 104.573 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 t -140.09 164.73 29.25 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -134.01 144.21 48.58 Favored 'General case' 0 N--CA 1.505 2.275 0 CA-C-N 113.873 -1.512 . . . . 0.0 109.587 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -110.07 55.19 0.65 Allowed 'General case' 0 N--CA 1.504 2.249 0 CA-C-O 125.05 2.357 . . . . 0.0 112.32 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -91.37 132.26 34.23 Favored Pre-proline 0 C--N 1.293 -1.848 0 CA-C-N 112.456 -2.156 . . . . 0.0 107.652 -179.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -91.43 171.61 2.94 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 124.012 3.141 . . . . 0.0 106.949 150.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.95 -34.04 4.91 Favored Glycine 0 N--CA 1.493 2.487 1 N-CA-C 102.037 -4.425 . . . . 0.0 102.037 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 7.1 m-85 . . . . . 0 C--N 1.302 -1.482 0 N-CA-C 103.078 -2.934 . . . . 0.0 103.078 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -119.22 139.39 51.95 Favored 'General case' 0 N--CA 1.512 2.668 0 N-CA-C 100.732 -3.803 . . . . 0.0 100.732 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.406 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 0.0 OUTLIER -114.99 -161.03 0.76 Allowed 'General case' 0 N--CA 1.502 2.17 0 CA-C-N 120.798 1.635 . . . . 0.0 109.401 -179.67 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -126.99 -29.1 2.83 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 116.828 2.158 . . . . 0.0 116.828 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.449 ' CB ' HG21 ' A' ' 68' ' ' VAL . 17.9 mmmt -128.26 169.38 14.25 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-N 122.21 2.277 . . . . 0.0 105.279 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 64.6 mt -91.45 177.34 2.26 Favored Pre-proline 0 N--CA 1.493 1.705 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.741 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -61.14 80.05 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.649 0 N-CA-C 106.954 -1.979 . . . . 0.0 106.954 148.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.405 ' HB3' HG13 ' A' ' 68' ' ' VAL . 9.9 t70 -123.09 -80.05 0.62 Allowed 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.475 ' H ' HG13 ' A' ' 68' ' ' VAL . 45.5 pt 38.4 34.78 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.51 0 CA-C-N 119.794 1.179 . . . . 0.0 110.168 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.08 -115.03 2.89 Favored Glycine 0 N--CA 1.48 1.587 0 C-N-CA 120.84 -0.695 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -103.46 133.45 48.49 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.278 0.561 . . . . 0.0 110.873 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 116.92 -78.43 0.29 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 106.613 -2.595 . . . . 0.0 106.613 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.5 mm -133.45 134.1 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.089 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -119.22 -41.96 2.71 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 102.013 -3.328 . . . . 0.0 102.013 179.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.535 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.7 OUTLIER -130.65 167.47 18.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 124.005 0.816 . . . . 0.0 110.098 179.601 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.95 149.27 19.12 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -99.05 97.62 8.74 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 104.11 -2.552 . . . . 0.0 104.11 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.7 mm -83.85 115.04 25.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 t -97.02 -48.32 12.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 O-C-N 125.061 1.475 . . . . 0.0 111.12 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.553 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -137.79 144.66 41.67 Favored 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.488 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 24.1 m95 -114.25 170.14 8.51 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.553 ' CZ ' ' HE2' ' A' ' 20' ' ' LYS . 2.6 m-85 -121.47 -51.17 2.08 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 113.87 -1.514 . . . . 0.0 111.161 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 m -100.49 175.01 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.145 -1.022 . . . . 0.0 110.311 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.492 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -116.0 156.87 46.21 Favored Pre-proline 0 C--N 1.299 -1.63 0 N-CA-C 104.323 -2.473 . . . . 0.0 104.323 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -64.67 145.16 86.29 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 120.865 1.044 . . . . 0.0 111.22 171.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.56 19.73 28.94 Favored Glycine 0 N--CA 1.488 2.149 0 CA-C-O 118.733 -1.037 . . . . 0.0 111.864 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -106.33 170.05 8.15 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.63 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.449 ' CD ' ' HE2' ' A' ' 54' ' ' LYS . 21.0 mt-10 -129.25 88.4 2.7 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 p -74.36 178.38 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-N 110.718 -2.946 . . . . 0.0 108.892 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.452 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 42.6 t30 -107.39 -29.71 9.1 Favored 'General case' 0 N--CA 1.517 2.892 0 CA-C-O 124.693 2.187 . . . . 0.0 112.097 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.387 11.1 tp10 44.63 75.22 0.11 Allowed 'General case' 0 C--N 1.279 -2.474 5 N-CA-C 135.413 9.042 . . . . 0.0 135.413 -179.742 . . . . . . . . 4 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 32' ' ' ASP . 11.8 p-10 -144.31 27.36 1.41 Allowed 'General case' 0 C--N 1.284 -2.248 4 CA-C-N 94.649 -10.251 . . . . 0.0 94.709 178.69 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -112.19 -169.56 1.49 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 127.652 2.381 . . . . 0.0 110.833 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.475 ' HA ' HG21 ' A' ' 47' ' ' ILE . 1.5 t -119.94 162.17 18.64 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 CA-C-O 124.302 2.001 . . . . 0.0 107.994 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.488 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 7.1 mp -126.22 -85.35 0.62 Allowed 'General case' 0 C--N 1.282 -2.356 1 CA-C-N 108.162 -4.108 . . . . 0.0 102.485 179.075 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.502 ' SG ' HD11 ' A' ' 47' ' ' ILE . 14.6 p -123.81 174.99 7.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -178.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.528 ' CG ' ' HA ' ' A' ' 45' ' ' VAL . 1.9 tt0 -133.27 140.07 47.27 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 126.925 2.641 . . . . 0.0 105.887 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.418 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 29.1 t -137.73 153.56 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-N 119.705 1.139 . . . . 0.0 108.32 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -112.15 122.65 48.33 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -159.63 170.78 20.87 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 179.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.492 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 6.0 p-10 -3.88 -67.57 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 117.537 2.421 . . . . 0.0 117.537 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.492 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 84.9 mttt -126.19 -0.88 7.07 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 124.42 1.075 . . . . 0.0 111.459 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -104.01 154.45 19.66 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 114.41 1.263 . . . . 0.0 114.41 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.7 t -129.95 -47.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 CA-C-N 111.109 -2.769 . . . . 0.0 109.0 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.528 ' HA ' ' CG ' ' A' ' 37' ' ' GLU . 21.8 t -105.8 160.98 5.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 CA-C-N 112.68 -2.054 . . . . 0.0 106.878 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HB3' HD13 ' A' ' 47' ' ' ILE . 4.8 mt-10 -119.36 -67.14 1.01 Allowed 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 120.619 3.563 . . . . 0.0 120.619 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.502 HD11 ' SG ' ' A' ' 36' ' ' CYS . 1.1 mp -90.81 147.38 35.91 Favored Pre-proline 0 C--N 1.272 -2.768 0 CA-C-N 109.781 -3.372 . . . . 0.0 109.587 -179.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.48 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -100.71 178.57 0.23 Allowed 'Trans proline' 0 C--N 1.314 -1.283 0 N-CA-C 107.378 -1.816 . . . . 0.0 107.378 84.303 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.461 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 14.5 m -128.78 -176.55 0.54 Allowed Pre-proline 0 C--N 1.285 -2.232 0 CA-C-N 113.609 -1.632 . . . . 0.0 107.41 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -100.64 -30.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 123.121 2.547 . . . . 0.0 118.093 178.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -138.18 162.41 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.33 0 CA-C-O 123.559 1.647 . . . . 0.0 114.381 -179.348 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.532 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -112.52 169.81 8.62 Favored 'General case' 0 C--N 1.296 -1.723 1 CA-C-N 107.796 -4.275 . . . . 0.0 110.213 -179.645 . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 167.23 -141.25 6.76 Favored Glycine 0 C--N 1.288 -2.113 1 N-CA-C 96.799 -6.52 . . . . 0.0 96.799 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.449 ' HE2' ' CD ' ' A' ' 28' ' ' GLU . 0.6 OUTLIER -93.6 -179.31 4.98 Favored 'General case' 0 C--N 1.288 -2.066 1 N-CA-C 99.785 -4.154 . . . . 0.0 99.785 179.99 . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 48.1 t -127.9 98.39 4.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.451 1 N-CA-C 91.689 -7.152 . . . . 0.0 91.689 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 55.1 mt -58.81 -88.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 124.787 1.304 . . . . 0.0 109.874 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -139.43 166.16 25.31 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -126.57 134.7 65.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 1 N-CA-C 94.43 -6.137 . . . . 0.0 94.43 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.8 mp -94.6 -57.25 2.53 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.276 -0.97 . . . . 0.0 112.238 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.429 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 22.8 t -113.05 94.22 29.02 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 101.061 -3.681 . . . . 0.0 101.061 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -71.93 -81.31 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 CA-C-N 120.09 1.068 . . . . 0.0 109.558 -171.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -137.11 164.2 28.99 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.53 -49.46 1.2 Allowed Glycine 0 N--CA 1.499 2.881 0 C-N-CA 119.962 -1.113 . . . . 0.0 113.133 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.429 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 0.6 OUTLIER -95.78 -172.27 2.56 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 105.511 -2.033 . . . . 0.0 105.511 -179.88 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.1 t -114.92 144.82 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.39 147.84 49.7 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 7.8 p -106.54 -160.04 0.72 Allowed 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.658 1.694 . . . . 0.0 108.367 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.475 HG13 ' H ' ' A' ' 9' ' ' ILE . 44.8 t -115.07 155.85 16.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.309 1 N-CA-C 91.751 -7.129 . . . . 0.0 91.751 178.477 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.19 -36.79 3.77 Favored Glycine 0 N--CA 1.49 2.264 1 N-CA-C 102.464 -4.254 . . . . 0.0 102.464 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.447 ' H ' ' C ' ' A' ' 68' ' ' VAL . 33.0 tt0 -104.2 164.19 11.89 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 102.316 -3.216 . . . . 0.0 102.316 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -98.69 -178.15 3.89 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 103.658 -2.719 . . . . 0.0 103.658 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 36.4 tp -138.66 -72.03 0.41 Allowed 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.001 -2.222 . . . . 0.0 105.001 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 10.9 tt -132.7 159.79 42.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.6 t -137.99 163.92 30.33 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 125.869 1.98 . . . . 0.0 106.496 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.9 155.58 49.58 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 125.636 1.835 . . . . 0.0 110.984 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -120.06 144.8 47.38 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 104.265 -2.494 . . . . 0.0 104.265 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -143.68 84.07 10.16 Favored Pre-proline 0 N--CA 1.492 1.636 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -61.73 53.68 0.11 Allowed 'Trans proline' 0 N--CA 1.507 2.292 0 C-N-CA 124.792 3.662 . . . . 0.0 118.723 -168.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.21 63.5 0.19 Allowed Glycine 0 N--CA 1.489 2.169 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.8 t80 . . . . . 0 N--CA 1.497 1.883 0 N-CA-C 102.821 -3.029 . . . . 0.0 102.821 179.657 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.4 ' N ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.494 1.731 1 N-CA-C 97.812 -4.884 . . . . 0.0 97.812 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.4 ' HB3' ' CB ' ' A' ' 75' ' ' LEU . 18.8 t80 -117.2 93.15 4.07 Favored 'General case' 0 C--N 1.297 -1.689 1 N-CA-C 95.009 -5.923 . . . . 0.0 95.009 178.849 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.4 ' OE2' ' N ' ' A' ' 1' ' ' ALA . 7.1 mp0 -68.41 -177.45 0.92 Allowed 'General case' 0 C--N 1.302 -1.493 0 O-C-N 125.6 1.813 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -110.31 -30.15 7.83 Favored 'General case' 0 N--CA 1.51 2.553 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -179.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.559 ' CG ' HG23 ' A' ' 68' ' ' VAL . 36.5 mmtt -127.06 166.59 17.32 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 103.074 -2.935 . . . . 0.0 103.074 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 74.2 mt -108.79 -173.65 0.27 Allowed Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -54.29 85.36 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.856 1.704 . . . . 0.0 109.031 158.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.431 ' HB3' HG13 ' A' ' 68' ' ' VAL . 3.7 t70 -121.88 -74.73 0.61 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 101.761 -3.422 . . . . 0.0 101.761 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.494 ' H ' HG13 ' A' ' 68' ' ' VAL . 40.2 pt 30.47 38.62 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.975 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.53 -46.83 1.01 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 119.439 -1.362 . . . . 0.0 112.706 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.02 80.9 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 124.355 2.026 . . . . 0.0 113.987 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.68 -68.18 0.26 Allowed Glycine 0 C--N 1.277 -2.746 0 CA-C-N 111.877 -2.42 . . . . 0.0 107.637 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.457 ' CG2' ' H ' ' A' ' 14' ' ' HIS . 40.4 mm -127.2 -172.96 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.457 ' H ' ' CG2' ' A' ' 13' ' ' ILE . 2.1 p80 -144.02 -50.97 0.31 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.583 0.706 . . . . 0.0 111.276 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.523 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.7 pt-20 -103.24 -168.81 1.56 Allowed 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 116.381 1.993 . . . . 0.0 116.381 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.09 112.15 0.59 Allowed Glycine 0 C--N 1.286 -2.227 0 CA-C-N 112.795 -2.002 . . . . 0.0 108.202 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -98.95 92.02 5.32 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 101.567 -3.494 . . . . 0.0 101.567 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.7 mt -85.01 104.2 12.89 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.9 t -86.82 -47.49 16.05 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.476 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.441 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 41.1 tttt -126.22 146.31 50.04 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-N 114.431 -1.258 . . . . 0.0 113.394 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.474 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 4.8 m95 -121.6 176.76 5.54 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 103.846 -2.65 . . . . 0.0 103.846 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.46 ' CD2' HG23 ' A' ' 34' ' ' VAL . 13.8 m-85 -123.76 -34.91 2.96 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 126.257 2.223 . . . . 0.0 112.189 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.478 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 10.3 m -103.74 176.54 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.977 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -140.9 61.31 14.58 Favored Pre-proline 0 N--CA 1.492 1.627 0 N-CA-C 117.933 2.568 . . . . 0.0 117.933 -179.438 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' C ' ' H ' ' A' ' 27' ' ' ASP . 5.8 Cg_exo -21.54 -179.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 N-CA-C 119.699 2.923 . . . . 0.0 119.699 -60.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.478 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.33 28.61 8.69 Favored Glycine 0 N--CA 1.497 2.713 0 CA-C-N 111.597 -2.547 . . . . 0.0 108.198 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.457 ' O ' ' HA ' ' A' ' 54' ' ' LYS . 5.2 t0 7.86 -95.6 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.16 0 O-C-N 128.527 3.133 . . . . 0.0 110.905 179.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.428 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 3.1 mm-40 -98.44 119.7 37.59 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 100.818 -3.771 . . . . 0.0 100.818 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -120.23 168.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 122.296 1.046 . . . . 0.0 109.208 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.7 m-20 -99.85 -168.13 1.56 Allowed 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 112.535 -2.12 . . . . 0.0 107.729 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.524 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.263 4.6 tt0 -120.62 52.36 1.17 Allowed 'General case' 0 N--CA 1.494 1.753 1 N-CA-C 97.838 -4.875 . . . . 0.0 97.838 -179.727 . . . . . . . . 4 3 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -171.37 36.89 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 111.403 -2.635 . . . . 0.0 111.711 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.439 ' CG ' ' N ' ' A' ' 34' ' ' VAL . 19.1 t70 -112.96 -178.38 3.37 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.455 -0.778 . . . . 0.0 109.116 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.46 HG23 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -84.77 -166.06 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 127.314 3.435 . . . . 0.0 117.664 179.75 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.562 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -115.27 -150.68 0.47 Allowed 'General case' 0 C--N 1.281 -2.404 2 CA-C-N 103.319 -6.31 . . . . 0.0 108.645 -179.553 . . . . . . . . 4 4 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.474 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 1.8 m -127.19 159.38 34.47 Favored 'General case' 0 C--N 1.284 -2.282 2 N-CA-C 97.025 -5.176 . . . . 0.0 97.025 179.193 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -114.64 108.6 17.02 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 100.492 -3.892 . . . . 0.0 100.492 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 49.1 t -112.96 147.61 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -113.09 155.53 24.76 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.088 -1.045 . . . . 0.0 108.886 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -140.49 -168.97 2.68 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 104.683 -2.339 . . . . 0.0 104.683 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.457 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.9 OUTLIER -11.13 -64.0 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 126.427 2.33 . . . . 0.0 115.301 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.457 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 17.2 mttp -144.82 -21.87 0.51 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 124.065 0.853 . . . . 0.0 110.439 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.44 -176.33 3.08 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.628 1.204 . . . . 0.0 112.431 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.3 t -125.94 137.58 57.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 103.398 -2.816 . . . . 0.0 103.398 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.5 t -112.05 157.8 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.496 ' C ' HD13 ' A' ' 47' ' ' ILE . 5.7 pt-20 -119.8 141.26 49.66 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 111.572 -2.558 . . . . 0.0 109.952 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.562 ' H ' ' HB2' ' A' ' 35' ' ' LEU . 1.9 mp -125.92 75.22 71.47 Favored Pre-proline 0 CA--C 1.574 1.87 0 N-CA-C 101.556 -3.498 . . . . 0.0 101.556 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_endo -62.07 -172.42 0.11 Allowed 'Trans proline' 0 N--CA 1.512 2.574 0 C-N-CA 122.894 2.396 . . . . 0.0 108.173 -177.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.7 p -105.07 85.22 1.2 Allowed Pre-proline 0 C--N 1.286 -2.19 0 CA-C-N 112.934 -1.939 . . . . 0.0 111.567 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -46.31 -31.98 10.08 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.588 1.525 . . . . 0.0 112.926 176.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.524 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -131.09 167.61 25.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.504 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -102.76 165.15 11.22 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 127.141 2.776 . . . . 0.0 108.097 179.408 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 148.23 -139.85 7.95 Favored Glycine 0 C--N 1.293 -1.808 0 N-CA-C 106.237 -2.745 . . . . 0.0 106.237 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -111.91 169.03 9.12 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 -179.503 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.4 t -128.38 61.55 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 100.856 -3.757 . . . . 0.0 100.856 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 40.8 mt -31.37 -74.11 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 110.845 -2.889 . . . . 0.0 114.227 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -138.75 163.76 31.34 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 114.127 1.158 . . . . 0.0 114.127 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.407 HD13 ' HD3' ' A' ' 25' ' ' PRO . 56.1 mt -136.36 136.94 48.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 1 N-CA-C 100.062 -4.051 . . . . 0.0 100.062 179.762 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.3 mt -94.25 -63.56 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.727 0.775 . . . . 0.0 110.453 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.492 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 15.8 t -115.94 73.8 4.91 Favored Pre-proline 0 N--CA 1.491 1.622 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 -179.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -45.88 -77.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.067 1.845 . . . . 0.0 113.335 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.2 -177.14 4.7 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.45 -49.96 4.32 Favored Glycine 0 N--CA 1.492 2.4 0 CA-C-N 113.929 -1.487 . . . . 0.0 113.007 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.492 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 5.3 m -103.51 -176.22 3.02 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.4 150.05 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.87 160.8 26.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 9.5 t -115.25 -161.29 0.77 Allowed 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.559 HG23 ' CG ' ' A' ' 5' ' ' LYS . 73.3 t -120.25 153.78 23.28 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 95.036 -5.913 . . . . 0.0 95.036 178.618 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.58 -37.99 3.42 Favored Glycine 0 N--CA 1.492 2.427 1 N-CA-C 101.513 -4.635 . . . . 0.0 101.513 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -97.53 159.43 14.93 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 100.71 -3.811 . . . . 0.0 100.71 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.5 179.25 5.07 Favored 'General case' 0 C--N 1.288 -2.082 0 N-CA-C 100.222 -3.992 . . . . 0.0 100.222 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 52.4 tp -138.81 -67.22 0.46 Allowed 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.78 161.94 37.65 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 103.107 -2.924 . . . . 0.0 103.107 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.8 t -137.42 157.45 46.55 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 126.327 2.267 . . . . 0.0 105.714 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.4 ' CB ' ' HB3' ' A' ' 2' ' ' PHE . 0.6 OUTLIER -137.43 150.92 47.99 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -114.26 151.35 32.98 Favored 'General case' 0 C--N 1.296 -1.72 1 N-CA-C 98.865 -4.494 . . . . 0.0 98.865 179.388 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -117.76 -36.68 0.07 OUTLIER Pre-proline 0 N--CA 1.501 2.078 0 C-N-CA 119.465 -0.894 . . . . 0.0 112.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -64.02 -178.87 0.65 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 125.701 2.421 . . . . 0.0 107.647 -62.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.44 -39.23 2.1 Favored Glycine 0 N--CA 1.5 2.926 1 N-CA-C 101.933 -4.467 . . . . 0.0 101.933 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.581 0 N-CA-C 101.476 -3.527 . . . . 0.0 101.476 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 80' ' ' TYR . . . . . . . . 0 N--CA 1.508 2.462 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -141.38 159.21 42.69 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.59 -142.42 0.27 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.636 ' CZ ' ' HD3' ' A' ' 5' ' ' LYS . 14.1 t80 -126.37 -60.75 1.24 Allowed 'General case' 0 N--CA 1.504 2.228 0 O-C-N 124.422 1.076 . . . . 0.0 113.34 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.636 ' HD3' ' CZ ' ' A' ' 4' ' ' PHE . 20.9 mmmt -132.1 143.61 50.14 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 67.9 mt -90.27 173.46 5.69 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 125.053 1.471 . . . . 0.0 107.963 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -40.88 81.59 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.294 0 N-CA-C 118.414 2.429 . . . . 0.0 118.414 168.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -122.68 -76.82 0.59 Allowed 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 103.604 -2.739 . . . . 0.0 103.604 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 27.4 pt 37.4 44.45 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.251 0 CA-C-O 122.683 1.23 . . . . 0.0 108.865 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.62 -161.95 37.84 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -109.59 160.83 15.93 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 118.551 1.176 . . . . 0.0 108.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.28 -72.49 0.38 Allowed Glycine 0 N--CA 1.485 1.934 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.5 mm -132.4 82.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 124.933 1.02 . . . . 0.0 110.248 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.489 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -105.57 16.13 25.92 Favored 'General case' 0 N--CA 1.507 2.38 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.092 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.432 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 7.8 pt-20 -140.09 166.92 23.35 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 113.923 -1.49 . . . . 0.0 108.01 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.03 125.3 4.65 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 107.417 -2.273 . . . . 0.0 107.417 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.9 100.45 11.97 Favored 'General case' 0 C--N 1.302 -1.471 1 N-CA-C 99.04 -4.43 . . . . 0.0 99.04 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.0 mm -82.4 124.57 39.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 1 N-CA-C 99.599 -4.223 . . . . 0.0 99.599 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.0 t -105.24 -39.79 5.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.736 ' HE3' ' CZ ' ' A' ' 22' ' ' PHE . 20.5 tttp -136.7 155.25 50.12 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.169 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.472 ' O ' ' NZ ' ' A' ' 20' ' ' LYS . 14.8 m95 -122.77 178.81 4.86 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 125.495 1.747 . . . . 0.0 106.489 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.736 ' CZ ' ' HE3' ' A' ' 20' ' ' LYS . 28.3 m-85 -132.94 -52.58 0.91 Allowed 'General case' 0 N--CA 1.504 2.259 0 O-C-N 124.373 1.045 . . . . 0.0 112.638 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 m -99.16 175.86 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 124.062 0.851 . . . . 0.0 109.596 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -117.35 161.99 30.5 Favored Pre-proline 0 C--N 1.295 -1.788 0 O-C-N 125.724 1.89 . . . . 0.0 108.443 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -56.07 112.77 1.17 Allowed 'Trans proline' 0 C--N 1.316 -1.153 0 C-N-CA 121.703 1.602 . . . . 0.0 113.013 174.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.51 16.81 14.89 Favored Glycine 0 N--CA 1.484 1.887 0 CA-C-O 117.167 -1.907 . . . . 0.0 113.501 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -86.76 161.12 18.56 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 116.652 -2.019 . . . . 0.0 108.008 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.483 ' OE1' ' NZ ' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -109.71 92.16 3.94 Favored 'General case' 0 C--N 1.294 -1.816 1 N-CA-C 99.813 -4.143 . . . . 0.0 99.813 -179.574 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.1 p -91.64 176.16 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 C-N-CA 117.308 -1.757 . . . . 0.0 106.368 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.585 ' OD1' ' NZ ' ' A' ' 52' ' ' LYS . 26.9 t30 -105.72 -21.72 13.12 Favored 'General case' 0 N--CA 1.529 3.498 0 CA-C-O 123.701 1.715 . . . . 0.0 112.243 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.411 ' HB3' ' HB3' ' A' ' 52' ' ' LYS 0.404 3.8 tp10 36.41 67.9 0.29 Allowed 'General case' 0 C--N 1.281 -2.389 5 N-CA-C 135.059 8.911 . . . . 0.0 135.059 179.566 . . . . . . . . 4 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.9 p-10 -137.4 22.66 2.96 Favored 'General case' 0 C--N 1.288 -2.108 4 CA-C-N 95.715 -9.766 . . . . 0.0 96.572 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.48 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 28.5 t70 -115.23 -148.94 0.44 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 127.15 2.18 . . . . 0.0 105.54 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.48 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 1.9 t -120.08 163.32 17.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 126.531 3.062 . . . . 0.0 109.054 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.558 ' N ' HG23 ' A' ' 47' ' ' ILE . 13.4 tp -123.27 -81.95 0.64 Allowed 'General case' 0 C--N 1.283 -2.319 2 CA-C-N 107.451 -4.432 . . . . 0.0 99.368 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' HD11 ' A' ' 47' ' ' ILE . 16.9 p -132.44 172.46 12.45 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.473 ' CG ' HG23 ' A' ' 45' ' ' VAL . 3.7 tt0 -130.42 138.51 50.37 Favored 'General case' 0 N--CA 1.5 2.067 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 25.2 t -135.26 145.53 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.335 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.46 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 4.7 tt0 -109.12 138.81 44.9 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -164.31 -161.17 0.58 Allowed 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 105.805 -1.924 . . . . 0.0 105.805 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.587 ' OD2' ' NZ ' ' A' ' 42' ' ' LYS . 5.6 p-10 -29.03 -58.31 0.14 Allowed 'General case' 0 C--N 1.297 -1.713 0 O-C-N 126.562 2.414 . . . . 0.0 114.475 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.587 ' NZ ' ' OD2' ' A' ' 41' ' ' ASP . 2.9 mttt -137.9 -8.85 1.59 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.678 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -93.73 158.26 15.76 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 114.609 1.337 . . . . 0.0 114.609 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.88 -44.28 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 126.335 2.272 . . . . 0.0 109.451 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.473 HG23 ' CG ' ' A' ' 37' ' ' GLU . 23.4 t -103.53 155.86 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 C-N-CA 125.574 1.55 . . . . 0.0 108.749 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.481 ' HB3' HD13 ' A' ' 47' ' ' ILE . 7.9 mt-10 -114.27 -63.42 1.45 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 126.683 2.489 . . . . 0.0 114.608 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.582 HG22 ' C ' ' A' ' 48' ' ' PRO . 1.2 mp -92.88 149.64 38.07 Favored Pre-proline 0 C--N 1.281 -2.374 0 CA-C-N 108.821 -3.809 . . . . 0.0 115.094 -178.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.582 ' C ' HG22 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.25 177.59 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.112 0 N-CA-C 107.569 -1.743 . . . . 0.0 107.569 87.582 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.7 m -119.13 177.33 1.37 Allowed Pre-proline 0 C--N 1.284 -2.257 0 CA-C-N 112.838 -1.983 . . . . 0.0 113.315 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -95.94 -44.79 0.02 OUTLIER 'Trans proline' 0 CA--C 1.555 1.572 0 N-CA-C 118.57 2.488 . . . . 0.0 118.57 169.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.645 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.8 OUTLIER -130.76 166.24 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 123.191 1.472 . . . . 0.0 114.947 -179.375 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.645 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -121.1 170.57 9.41 Favored 'General case' 0 C--N 1.3 -1.561 1 CA-C-N 107.835 -4.257 . . . . 0.0 112.314 179.971 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.22 -124.64 1.21 Allowed Glycine 0 N--CA 1.49 2.281 1 N-CA-C 96.897 -6.481 . . . . 0.0 96.897 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 16.8 tttp -107.35 -174.92 2.65 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.3 t -130.93 65.75 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.279 1 N-CA-C 97.292 -5.077 . . . . 0.0 97.292 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.1 mt -29.53 -78.09 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 112.242 -2.253 . . . . 0.0 110.956 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -145.68 165.88 27.46 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 33.3 mt -132.78 139.93 48.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 1 N-CA-C 98.258 -4.719 . . . . 0.0 98.258 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -106.97 -31.34 8.36 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 123.819 0.7 . . . . 0.0 111.199 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.8 t -107.39 130.31 23.02 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -49.91 -150.38 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 124.254 3.302 . . . . 0.0 116.487 158.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 39.93 3.57 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 111.86 -2.427 . . . . 0.0 107.847 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -142.82 -6.2 0.71 Allowed Glycine 0 N--CA 1.497 2.734 0 CA-C-N 111.504 -2.589 . . . . 0.0 116.071 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.1 m -121.63 172.67 7.94 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 105.244 -2.132 . . . . 0.0 105.244 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.39 144.31 16.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 102.672 -3.084 . . . . 0.0 102.672 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -118.79 164.97 14.6 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.0 p -109.28 -163.2 0.85 Allowed 'General case' 0 C--N 1.283 -2.307 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.47 HG21 ' CB ' ' A' ' 5' ' ' LYS . 52.2 t -119.39 154.16 21.94 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 1 N-CA-C 92.681 -6.785 . . . . 0.0 92.681 178.748 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 101.06 -38.62 3.06 Favored Glycine 0 N--CA 1.49 2.291 1 N-CA-C 100.416 -5.073 . . . . 0.0 100.416 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.461 ' H ' ' C ' ' A' ' 68' ' ' VAL . 25.4 tt0 -99.94 160.57 14.21 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 101.013 -3.699 . . . . 0.0 101.013 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -105.89 -175.6 2.84 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 101.687 -3.449 . . . . 0.0 101.687 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.575 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . 0.9 OUTLIER -145.15 -57.46 0.33 Allowed 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 16.0 tt -137.13 163.48 32.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 t -135.86 159.21 42.36 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 103.114 -2.921 . . . . 0.0 103.114 179.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -138.58 147.16 42.68 Favored 'General case' 0 C--N 1.289 -2.062 0 O-C-N 125.392 1.682 . . . . 0.0 107.734 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.509 ' CG ' ' H ' ' A' ' 54' ' ' LYS . 2.1 p30 -115.64 158.19 23.09 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 104.154 -2.536 . . . . 0.0 104.154 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.535 ' CB ' ' HB2' ' A' ' 80' ' ' TYR . . . -139.38 139.02 21.46 Favored Pre-proline 0 C--N 1.29 -1.994 0 N-CA-C 102.627 -3.101 . . . . 0.0 102.627 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -70.53 -37.35 7.42 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 121.974 1.783 . . . . 0.0 110.466 173.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.541 ' O ' ' CD1' ' A' ' 80' ' ' TYR . . . -121.97 27.11 6.27 Favored Glycine 0 N--CA 1.493 2.494 0 CA-C-O 115.992 -2.56 . . . . 0.0 113.086 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.541 ' CD1' ' O ' ' A' ' 79' ' ' GLY . 21.7 m-85 . . . . . 0 N--CA 1.503 2.215 0 CA-C-O 115.509 -2.186 . . . . 0.0 108.283 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.047 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -115.34 147.11 40.87 Favored 'General case' 0 N--CA 1.498 1.946 1 N-CA-C 99.897 -4.112 . . . . 0.0 99.897 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -113.65 -168.79 1.39 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 118.878 0.763 . . . . 0.0 112.639 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -105.69 -22.94 12.85 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.465 ' CB ' HG23 ' A' ' 68' ' ' VAL . 11.0 mmtm -127.55 177.64 6.64 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 102.638 -3.097 . . . . 0.0 102.638 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 83.5 mt -105.62 176.22 1.8 Allowed Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -54.44 82.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.676 1.584 . . . . 0.0 110.111 153.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.41 ' HB3' HG13 ' A' ' 68' ' ' VAL . 7.6 t70 -122.06 -82.65 0.65 Allowed 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.485 -2.043 . . . . 0.0 105.485 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 24.0 pt 39.16 27.71 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 124.055 0.847 . . . . 0.0 111.647 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.18 -70.99 0.05 OUTLIER Glycine 0 N--CA 1.477 1.423 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.825 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.407 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 1.1 mp0 -51.06 153.08 2.01 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 124.415 2.055 . . . . 0.0 116.312 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -22.16 -41.01 0.01 OUTLIER Glycine 0 N--CA 1.498 2.824 0 CA-C-N 110.908 -2.86 . . . . 0.0 118.439 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.401 HD13 ' N ' ' A' ' 13' ' ' ILE . 3.2 mp -115.94 64.0 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.216 1.008 . . . . 0.0 108.81 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -85.72 7.61 22.92 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-N 114.72 -1.127 . . . . 0.0 112.493 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.1 pt-20 -129.68 -165.89 1.59 Allowed 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.992 0.901 . . . . 0.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.14 112.51 0.55 Allowed Glycine 0 N--CA 1.503 3.106 0 CA-C-O 117.484 -1.731 . . . . 0.0 112.808 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -104.17 85.95 2.47 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 103.223 -2.881 . . . . 0.0 103.223 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.441 HD13 HD13 ' A' ' 72' ' ' LEU . 1.9 mp -87.48 124.63 40.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.9 t -101.8 -46.85 11.32 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 O-C-N 124.53 1.144 . . . . 0.0 109.252 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.446 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 12.1 ttmt -131.69 145.18 51.5 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 124.564 1.165 . . . . 0.0 112.123 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -115.98 -178.64 3.45 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 178.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -126.56 -27.15 3.17 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 111.248 -2.706 . . . . 0.0 111.169 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.525 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 7.4 m -101.49 -177.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.172 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -100.19 -41.23 0.22 Allowed Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.502 ' C ' ' H ' ' A' ' 27' ' ' ASP . 43.1 Cg_endo -49.56 170.84 1.38 Allowed 'Cis proline' 0 N--CA 1.498 1.762 1 N-CA-C 124.991 4.958 . . . . 0.0 124.991 29.714 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.525 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -94.22 37.39 3.42 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 105.846 -2.902 . . . . 0.0 105.846 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.502 ' H ' ' C ' ' A' ' 25' ' ' PRO . 14.9 t70 3.1 -90.46 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.175 0 O-C-N 127.796 2.703 . . . . 0.0 110.131 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.475 ' HG2' ' CE ' ' A' ' 54' ' ' LYS . 6.7 mt-10 -99.53 111.58 23.91 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 101.972 -3.344 . . . . 0.0 101.972 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 163.98 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 CA-C-O 124.49 2.091 . . . . 0.0 114.704 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.608 HD21 ' CG ' ' A' ' 32' ' ' ASP . 10.2 p-10 -98.22 -171.27 2.11 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 110.075 -3.239 . . . . 0.0 112.17 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.444 ' OE2' ' NZ ' ' A' ' 52' ' ' LYS . 4.7 tt0 -121.88 68.11 0.92 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.608 ' CG ' HD21 ' A' ' 30' ' ' ASN . 3.5 p30 -179.7 -27.61 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 112.965 -1.925 . . . . 0.0 110.808 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -28.77 154.04 0.0 OUTLIER 'General case' 0 N--CA 1.514 2.768 0 CA-C-O 122.992 1.377 . . . . 0.0 114.279 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.526 HG13 ' H ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -56.17 -176.73 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 124.188 4.885 . . . . 0.0 124.188 -179.251 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.526 ' H ' HG13 ' A' ' 34' ' ' VAL . 1.1 mm? -86.69 174.25 8.97 Favored 'General case' 0 N--CA 1.411 -2.393 2 CA-C-N 101.792 -7.004 . . . . 0.0 101.488 -179.38 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.0 m -127.97 155.08 44.83 Favored 'General case' 0 C--N 1.265 -3.082 2 N-CA-C 97.587 -4.968 . . . . 0.0 97.587 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.446 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 12.9 mt-10 -118.26 103.53 9.91 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.59 155.68 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 CA-C-N 113.429 -1.714 . . . . 0.0 107.158 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -118.37 162.07 18.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -155.23 -172.31 4.13 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.446 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 4.3 p-10 -17.57 -62.44 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 126.409 2.318 . . . . 0.0 115.2 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.446 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 53.3 mttp -140.45 -13.91 0.99 Allowed 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.185 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -109.71 175.21 5.53 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 116.598 2.073 . . . . 0.0 116.598 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.4 t -122.59 136.48 59.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 1 N-CA-C 99.611 -4.218 . . . . 0.0 99.611 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.7 t -117.47 161.27 16.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.448 1.118 . . . . 0.0 109.589 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.485 ' C ' HD13 ' A' ' 47' ' ' ILE . 11.9 pt-20 -123.67 129.13 50.64 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 110.227 -3.17 . . . . 0.0 106.758 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 3.7 mp -125.07 96.71 39.3 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 115.806 -2.045 . . . . 0.0 106.266 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.472 ' N ' HD12 ' A' ' 35' ' ' LEU . 60.7 Cg_endo -68.62 -164.85 0.12 Allowed 'Trans proline' 0 N--CA 1.515 2.742 0 C-N-CA 124.446 3.431 . . . . 0.0 106.917 -174.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 14.4 t -104.02 103.25 36.74 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 111.875 -2.42 . . . . 0.0 108.962 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.411 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 85.3 Cg_exo -49.31 -55.24 4.33 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.659 2.906 . . . . 0.0 119.01 161.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.402 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.59 168.43 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-O 121.933 0.873 . . . . 0.0 112.748 -179.613 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.444 ' NZ ' ' OE2' ' A' ' 31' ' ' GLU . 4.1 pttt -96.33 167.89 10.9 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 111.409 -2.632 . . . . 0.0 106.719 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.08 -135.87 5.87 Favored Glycine 0 C--N 1.289 -2.071 0 N-CA-C 105.955 -2.858 . . . . 0.0 105.955 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.475 ' CE ' ' HG2' ' A' ' 28' ' ' GLU . 4.3 tptt -116.82 164.92 13.93 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 104.966 -2.235 . . . . 0.0 104.966 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 22.1 t -126.43 58.11 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.809 1 N-CA-C 100.164 -4.013 . . . . 0.0 100.164 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 18.0 mt -29.51 -73.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 CA-C-N 110.29 -3.141 . . . . 0.0 115.084 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -137.03 163.9 29.66 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.973 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 25' ' ' PRO . 58.5 mt -138.61 144.56 29.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 1 N-CA-C 98.87 -4.493 . . . . 0.0 98.87 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -111.33 -54.79 2.57 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.5 t -113.42 78.77 3.67 Favored Pre-proline 0 C--N 1.3 -1.571 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -55.18 -85.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 121.708 1.605 . . . . 0.0 113.455 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -139.7 170.63 15.54 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 78.41 -35.71 1.78 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.11 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.7 m -99.63 171.98 7.57 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 67.1 t -115.06 142.97 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.66 160.18 31.5 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.8 t -105.41 -156.91 0.59 Allowed 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.465 HG23 ' CB ' ' A' ' 5' ' ' LYS . 61.5 t -121.69 158.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 1 N-CA-C 94.886 -5.968 . . . . 0.0 94.886 178.408 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.43 -29.36 9.73 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 104.675 -3.37 . . . . 0.0 104.675 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.438 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -109.41 156.71 19.72 Favored 'General case' 0 C--N 1.302 -1.483 1 N-CA-C 99.119 -4.4 . . . . 0.0 99.119 179.793 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -87.2 -174.15 4.74 Favored 'General case' 0 C--N 1.288 -2.089 0 N-CA-C 100.93 -3.73 . . . . 0.0 100.93 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.441 HD13 HD13 ' A' ' 18' ' ' ILE . 3.9 tt -145.99 -62.97 0.32 Allowed 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 104.554 -2.387 . . . . 0.0 104.554 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 tt -138.42 162.17 30.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 102.092 -3.299 . . . . 0.0 102.092 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 t -136.92 159.73 41.0 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 103.96 -2.608 . . . . 0.0 103.96 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.4 146.05 36.1 Favored 'General case' 0 C--N 1.284 -2.255 0 CA-C-N 111.806 -2.452 . . . . 0.0 105.113 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.07 159.31 16.68 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 98.895 -4.483 . . . . 0.0 98.895 179.318 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.448 ' H ' ' HA ' ' A' ' 78' ' ' PRO . . . -138.13 -36.79 0.02 OUTLIER Pre-proline 0 C--N 1.289 -2.03 0 CA-C-N 114.274 -1.33 . . . . 0.0 111.093 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.448 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 18.6 Cg_endo -104.18 138.39 1.03 Allowed 'Cis proline' 0 C--N 1.316 -1.139 0 C-N-CA 129.235 0.931 . . . . 0.0 111.334 -24.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.85 41.79 0.76 Allowed Glycine 0 N--CA 1.498 2.825 0 N-CA-C 105.974 -2.851 . . . . 0.0 105.974 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.9 m-30 . . . . . 0 C--N 1.299 -1.591 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.133 0 N-CA-C 104.184 -2.524 . . . . 0.0 104.184 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -125.17 160.69 28.55 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 103.026 -2.953 . . . . 0.0 103.026 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.8 -158.53 0.87 Allowed 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -112.22 -45.14 3.31 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 125.582 1.801 . . . . 0.0 111.819 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.477 ' CG ' HG21 ' A' ' 68' ' ' VAL . 0.3 OUTLIER -124.24 -175.07 3.15 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 100.815 -3.772 . . . . 0.0 100.815 179.36 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -115.45 -176.39 0.37 Allowed Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 104.288 -2.486 . . . . 0.0 104.288 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.83 88.07 0.05 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 N-CA-C 103.094 -3.464 . . . . 0.0 103.094 145.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.405 ' CB ' HG13 ' A' ' 68' ' ' VAL 0.313 0.8 OUTLIER -121.6 -91.43 0.56 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 111.874 -2.421 . . . . 0.0 104.803 -179.616 . . . . . . . . 4 4 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.593 ' H ' HG13 ' A' ' 68' ' ' VAL . 38.8 pt 45.66 37.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -88.65 -171.31 46.03 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.712 -1.755 . . . . 0.0 108.712 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -89.46 163.62 15.18 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-O 122.983 1.373 . . . . 0.0 110.595 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -74.44 0.21 Allowed Glycine 0 C--N 1.293 -1.845 0 CA-C-N 112.346 -2.206 . . . . 0.0 108.824 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.7 mt -131.93 114.66 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 101.612 -3.477 . . . . 0.0 101.612 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -125.26 18.0 8.32 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 121.827 2.103 . . . . 0.0 107.712 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.5 OUTLIER -127.34 -177.93 4.26 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 123.116 1.436 . . . . 0.0 113.146 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.25 101.03 0.33 Allowed Glycine 0 N--CA 1.503 3.103 0 CA-C-N 112.664 -2.062 . . . . 0.0 110.827 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.408 ' OE1' ' NE2' ' A' ' 39' ' ' GLN . 17.0 tt0 -101.92 102.25 12.78 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 105.166 -2.161 . . . . 0.0 105.166 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 mt -89.24 131.92 35.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 105.639 -1.986 . . . . 0.0 105.639 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.78 -57.91 4.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -129.37 169.74 14.52 Favored 'General case' 0 N--CA 1.508 2.447 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.789 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.439 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 23.8 m95 -130.49 171.64 12.78 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 126.017 2.073 . . . . 0.0 106.763 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.469 ' N ' ' CD1' ' A' ' 22' ' ' PHE . 21.8 m-85 -124.94 -52.12 1.67 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 124.937 1.398 . . . . 0.0 109.102 -179.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.5 m -99.32 179.1 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.5 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -119.9 168.26 10.67 Favored Pre-proline 0 C--N 1.292 -1.904 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.404 ' HD3' HD11 ' A' ' 58' ' ' ILE . 83.9 Cg_endo -74.19 144.45 33.42 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 121.453 1.435 . . . . 0.0 108.888 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.95 -14.97 62.28 Favored Glycine 0 CA--C 1.476 -2.383 0 CA-C-O 116.654 -2.192 . . . . 0.0 110.166 179.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.5 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 4.3 m-20 -82.61 -173.07 4.41 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.735 ' CG ' ' HZ1' ' A' ' 54' ' ' LYS 0.25 6.5 mt-10 -122.42 158.35 29.91 Favored 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 101.593 -3.484 . . . . 0.0 101.593 179.92 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.4 p -121.93 157.57 26.0 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 CA-C-O 122.228 1.013 . . . . 0.0 110.261 -179.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.408 ' HB3' ' CG ' ' A' ' 32' ' ' ASP . 5.3 m-20 -98.58 -167.65 1.53 Allowed 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 111.066 -2.788 . . . . 0.0 113.283 -178.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.9 tt0 -122.98 52.5 1.35 Allowed 'General case' 0 C--N 1.298 -1.641 1 N-CA-C 96.789 -5.263 . . . . 0.0 96.789 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.408 ' CG ' ' HB3' ' A' ' 30' ' ' ASN . 0.6 OUTLIER -164.1 -59.21 0.04 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.902 -179.42 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.603 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 14.3 t70 -52.17 -168.91 0.0 OUTLIER 'General case' 0 N--CA 1.513 2.692 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.603 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -97.42 -168.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 129.135 2.974 . . . . 0.0 109.837 -179.357 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.524 ' H ' HG11 ' A' ' 34' ' ' VAL . 24.0 tp -141.23 -95.59 0.14 Allowed 'General case' 0 C--N 1.294 -1.836 1 CA-C-N 107.74 -4.3 . . . . 0.0 100.861 178.704 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.439 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -122.47 -179.08 4.08 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-N 118.634 0.652 . . . . 0.0 111.364 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -119.75 111.89 18.57 Favored 'General case' 0 N--CA 1.499 1.979 1 N-CA-C 97.524 -4.991 . . . . 0.0 97.524 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 46.3 t -120.13 151.67 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 119.501 1.046 . . . . 0.0 112.315 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.408 ' NE2' ' OE1' ' A' ' 17' ' ' GLU . 20.7 tt0 -117.81 151.72 36.77 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.728 -1.124 . . . . 0.0 108.302 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -146.24 -179.88 7.04 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 104.597 -2.371 . . . . 0.0 104.597 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -6.1 -69.67 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.031 0 N-CA-C 116.069 1.877 . . . . 0.0 116.069 -179.381 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.513 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 40.2 mttp -136.73 -20.25 1.33 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 123.319 0.647 . . . . 0.0 110.318 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -100.36 165.56 11.4 Favored 'General case' 0 N--CA 1.492 1.673 0 C-N-CA 118.453 -1.299 . . . . 0.0 111.399 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 t -132.45 130.57 60.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 N-CA-C 102.896 -3.002 . . . . 0.0 102.896 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.449 HG13 ' H ' ' A' ' 46' ' ' GLU . 1.5 t -127.79 173.56 12.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 CA-C-O 124.755 2.217 . . . . 0.0 105.406 179.277 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.52 ' C ' HD13 ' A' ' 47' ' ' ILE . 10.6 pt-20 -121.32 164.15 17.49 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 108.479 -3.964 . . . . 0.0 105.047 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.52 HD13 ' C ' ' A' ' 46' ' ' GLU . 2.7 mp -125.69 130.54 24.03 Favored Pre-proline 0 C--N 1.295 -1.773 0 N-CA-C 101.548 -3.501 . . . . 0.0 101.548 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -93.02 -171.98 0.33 Allowed 'Trans proline' 0 N--CA 1.497 1.725 1 C-N-CA 126.087 4.525 . . . . 0.0 108.796 173.457 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.33 98.53 12.42 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.45 -44.67 29.27 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.549 1.5 . . . . 0.0 110.671 157.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -133.15 166.11 30.35 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 122.463 1.125 . . . . 0.0 109.253 179.436 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.538 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -110.89 146.04 37.22 Favored 'General case' 0 C--N 1.297 -1.688 2 O-C-N 130.118 4.636 . . . . 0.0 104.483 179.784 . . . . . . . . 4 4 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.86 -151.06 13.22 Favored Glycine 0 N--CA 1.504 3.199 0 N-CA-C 105.206 -3.158 . . . . 0.0 105.206 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.735 ' HZ1' ' CG ' ' A' ' 28' ' ' GLU . 53.6 tptt -96.27 171.99 8.24 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 119.993 1.897 . . . . 0.0 106.835 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -125.47 84.09 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 1 N-CA-C 94.46 -6.126 . . . . 0.0 94.46 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.41 -82.03 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 113.516 -1.675 . . . . 0.0 109.438 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -137.94 165.66 25.98 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.504 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.404 HD11 ' HD3' ' A' ' 25' ' ' PRO . 60.0 mt -130.09 137.94 55.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 1 N-CA-C 97.61 -4.959 . . . . 0.0 97.61 179.705 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.17 -56.16 2.63 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 124.251 0.97 . . . . 0.0 108.592 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.4 t -112.68 126.44 28.31 Favored Pre-proline 0 C--N 1.295 -1.793 1 N-CA-C 96.939 -5.208 . . . . 0.0 96.939 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -79.81 -84.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 CA-C-N 121.461 1.557 . . . . 0.0 108.19 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.24 -151.8 0.47 Allowed 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 100.614 -3.846 . . . . 0.0 100.614 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.93 -42.97 0.16 Allowed Glycine 0 C--N 1.283 -2.377 0 CA-C-N 111.029 -2.805 . . . . 0.0 115.116 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.8 m -109.37 -176.43 3.02 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.6 t -111.16 156.07 12.42 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.32 171.25 11.11 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 3.8 t -128.12 -159.79 0.97 Allowed 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 102.846 -3.02 . . . . 0.0 102.846 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.593 HG13 ' H ' ' A' ' 9' ' ' ILE 0.256 57.8 t -117.68 155.38 19.46 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.268 1 N-CA-C 94.431 -6.137 . . . . 0.0 94.431 179.025 . . . . . . . . 4 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . 0.477 ' N ' HG11 ' A' ' 68' ' ' VAL . . . 98.27 -27.61 18.59 Favored Glycine 0 N--CA 1.485 1.932 1 N-CA-C 102.398 -4.281 . . . . 0.0 102.398 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.445 ' H ' ' C ' ' A' ' 68' ' ' VAL . 38.9 tt0 -105.01 154.65 19.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 102.042 -3.318 . . . . 0.0 102.042 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -94.9 179.55 5.19 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 102.201 -3.259 . . . . 0.0 102.201 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 35.8 tp -138.26 -69.9 0.44 Allowed 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.6 tt -141.99 162.22 19.98 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 102.937 -2.986 . . . . 0.0 102.937 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.3 t -137.39 160.04 40.22 Favored 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.413 HD22 ' H ' ' A' ' 76' ' ' ASP . 1.2 tt -133.39 149.87 51.82 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 112.669 -2.06 . . . . 0.0 107.862 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.413 ' H ' HD22 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -109.2 150.68 27.55 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 101.97 -3.345 . . . . 0.0 101.97 179.562 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -141.83 94.72 7.18 Favored Pre-proline 0 C--N 1.289 -2.026 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -45.0 70.51 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 123.803 3.002 . . . . 0.0 116.486 174.524 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 126.89 9.63 4.2 Favored Glycine 0 N--CA 1.485 1.929 0 CA-C-O 116.495 -2.281 . . . . 0.0 113.157 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 14.3 m-30 . . . . . 0 N--CA 1.501 2.087 0 N-CA-C 105.524 -2.028 . . . . 0.0 105.524 179.51 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -120.53 159.47 25.13 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 100.893 -3.743 . . . . 0.0 100.893 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 -160.97 0.8 Allowed 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.03 -21.95 3.88 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-N 113.531 -1.668 . . . . 0.0 110.297 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.542 ' HB3' HG22 ' A' ' 68' ' ' VAL . 48.2 mmtt -132.5 145.18 50.96 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 105.479 -2.045 . . . . 0.0 105.479 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.43 173.33 6.08 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 104.071 -2.566 . . . . 0.0 104.071 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -42.48 80.93 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.379 2.053 . . . . 0.0 115.013 158.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.408 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.3 t70 -121.7 -72.64 0.68 Allowed 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 103.584 -2.747 . . . . 0.0 103.584 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.494 ' H ' HG11 ' A' ' 68' ' ' VAL . 35.5 pt 37.41 40.58 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 124.302 1.001 . . . . 0.0 112.863 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.68 -14.34 0.07 OUTLIER Glycine 0 C--N 1.305 -1.188 0 CA-C-O 117.194 -1.892 . . . . 0.0 115.614 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -101.21 -177.93 3.59 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 120.439 2.119 . . . . 0.0 114.733 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -4.47 -66.74 0.0 OUTLIER Glycine 0 N--CA 1.494 2.509 0 CA-C-N 110.178 -3.192 . . . . 0.0 116.182 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.0 mm -127.28 76.42 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -81.97 4.34 23.06 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 112.725 -2.034 . . . . 0.0 111.787 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.519 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 4.5 pt-20 -132.4 -176.7 4.17 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.252 0.549 . . . . 0.0 110.864 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.81 116.29 0.84 Allowed Glycine 0 N--CA 1.494 2.517 0 CA-C-O 118.079 -1.401 . . . . 0.0 111.679 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -102.97 109.87 21.57 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 99.966 -4.087 . . . . 0.0 99.966 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.419 ' HB ' ' HA ' ' A' ' 62' ' ' GLU . 2.7 mt -99.17 126.66 52.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.8 t -93.85 -61.76 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 124.666 1.229 . . . . 0.0 109.971 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.58 ' NZ ' ' CE1' ' A' ' 22' ' ' PHE . 25.1 tttm -130.43 151.04 51.35 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.574 -179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.6 m95 -119.63 173.47 6.99 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 179.246 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.711 ' CG ' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -133.34 -1.25 3.21 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 -179.783 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.598 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 4.2 m -98.62 170.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 115.318 1.599 . . . . 0.0 115.318 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.424 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.1 mptp? -139.2 48.03 1.56 Allowed Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 125.574 1.796 . . . . 0.0 111.829 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 27' ' ' ASP . 67.2 Cg_exo -8.61 174.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 N-CA-C 118.865 2.602 . . . . 0.0 118.865 -70.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.598 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.11 28.41 8.83 Favored Glycine 0 N--CA 1.505 3.275 0 N-CA-C 107.84 -2.104 . . . . 0.0 107.84 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 25' ' ' PRO . 19.2 t70 8.79 -85.24 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 110.985 -2.608 . . . . 0.0 111.474 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.63 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS . 2.6 mt-10 -104.22 115.53 30.56 Favored 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 105.606 -1.998 . . . . 0.0 105.606 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 p -108.65 161.57 7.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 124.819 2.247 . . . . 0.0 110.562 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 29.3 p30 -98.15 -164.16 1.11 Allowed 'General case' 0 C--N 1.284 -2.248 0 CA-C-N 109.965 -3.288 . . . . 0.0 108.883 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.675 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.274 0.3 OUTLIER -122.35 69.71 0.97 Allowed 'General case' 0 C--N 1.292 -1.896 1 N-CA-C 99.497 -4.26 . . . . 0.0 99.497 -179.323 . . . . . . . . 5 4 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.493 ' C ' ' OG ' ' A' ' 49' ' ' SER . 3.5 p30 -177.34 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.489 0 C-N-CA 125.705 1.602 . . . . 0.0 111.735 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 8.9 t70 18.13 -137.74 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.264 0 N-CA-C 119.661 3.208 . . . . 0.0 119.661 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.711 HG11 ' CG ' ' A' ' 22' ' ' PHE . 1.2 t -114.87 167.4 7.53 Favored 'Isoleucine or valine' 0 CA--C 1.445 -3.095 0 CA-C-O 124.3 2.0 . . . . 0.0 114.29 -179.127 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.615 ' HA ' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -108.57 120.23 41.85 Favored 'General case' 0 N--CA 1.412 -2.363 3 CA-C-N 106.151 -5.022 . . . . 0.0 99.251 179.877 . . . . . . . . 4 4 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.7 m -73.57 151.8 40.8 Favored 'General case' 0 C--N 1.263 -3.193 2 N-CA-C 97.986 -4.82 . . . . 0.0 97.986 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -104.52 102.89 12.51 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-N 112.371 -2.195 . . . . 0.0 107.806 -179.065 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.6 146.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 N-CA-C 104.682 -2.34 . . . . 0.0 104.682 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -115.15 152.43 32.61 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -141.13 -178.13 5.44 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -7.58 -72.43 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 116.952 2.205 . . . . 0.0 116.952 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -136.82 -11.61 1.76 Allowed 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 114.318 -1.31 . . . . 0.0 109.255 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -111.58 178.7 4.24 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 120.91 0.386 . . . . 0.0 111.886 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.5 t -130.86 147.55 33.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.465 -2.42 . . . . 0.0 104.465 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -120.37 161.78 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 122.655 1.217 . . . . 0.0 111.242 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.508 ' C ' HD12 ' A' ' 47' ' ' ILE . 12.1 pt-20 -122.24 122.75 39.87 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 110.489 -3.05 . . . . 0.0 108.186 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.615 ' C ' ' HA ' ' A' ' 35' ' ' LEU . 1.9 mp -115.02 83.16 9.31 Favored Pre-proline 0 CA--C 1.572 1.798 0 CA-C-O 115.946 -1.978 . . . . 0.0 108.729 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 34' ' ' VAL . 75.9 Cg_endo -62.93 -167.09 0.06 OUTLIER 'Trans proline' 0 N--CA 1.52 3.036 0 C-N-CA 123.952 3.102 . . . . 0.0 105.716 176.675 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.493 ' OG ' ' C ' ' A' ' 32' ' ' ASP . 19.2 p -108.73 86.48 3.71 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -32.22 -49.21 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 121.887 1.725 . . . . 0.0 115.308 163.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.675 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -132.49 164.84 33.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-O 121.817 0.817 . . . . 0.0 110.328 179.646 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.647 ' HD2' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.54 173.32 6.4 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 128.827 3.829 . . . . 0.0 110.11 179.724 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.24 -136.87 5.98 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 104.995 -3.242 . . . . 0.0 104.995 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.63 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 41.0 tptt -112.73 173.26 6.46 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 -179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.499 ' HB ' ' C ' ' A' ' 26' ' ' GLY . 50.5 t -127.35 70.05 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.975 1 N-CA-C 97.342 -5.058 . . . . 0.0 97.342 179.665 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 75.4 mt -38.06 -79.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 111.623 -2.535 . . . . 0.0 114.227 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -143.04 167.48 21.97 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.759 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.1 mp -131.11 141.21 46.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 1 N-CA-C 98.004 -4.813 . . . . 0.0 98.004 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -103.7 -58.85 1.81 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 123.772 0.67 . . . . 0.0 110.555 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.414 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 24.1 t -113.62 75.92 2.77 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -49.76 -83.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.851 2.367 . . . . 0.0 115.2 -167.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.419 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -134.86 -179.91 5.9 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 76.81 -38.57 1.51 Allowed Glycine 0 N--CA 1.49 2.266 0 CA-C-N 114.14 -1.391 . . . . 0.0 114.335 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 2.0 m -103.25 177.14 4.92 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 43.9 t -117.74 148.99 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.8 166.67 14.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.519 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 8.8 t -117.87 -155.45 0.6 Allowed 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 104.783 -2.303 . . . . 0.0 104.783 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.542 HG22 ' HB3' ' A' ' 5' ' ' LYS . 84.4 t -120.44 151.51 23.24 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 1 N-CA-C 97.25 -5.093 . . . . 0.0 97.25 179.106 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 104.58 -38.74 3.12 Favored Glycine 0 N--CA 1.494 2.565 1 N-CA-C 99.768 -5.333 . . . . 0.0 99.768 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 68' ' ' VAL . 35.2 tt0 -100.09 164.49 11.96 Favored 'General case' 0 C--N 1.304 -1.373 1 N-CA-C 99.929 -4.101 . . . . 0.0 99.929 179.501 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.98 -175.52 2.8 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 33.1 tp -135.23 -67.19 0.55 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 103.652 -2.721 . . . . 0.0 103.652 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.2 tt -135.03 165.04 32.13 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 102.988 -2.967 . . . . 0.0 102.988 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.8 t -137.25 161.38 36.37 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.45 -2.796 . . . . 0.0 103.45 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.83 152.33 48.99 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 112.456 -2.156 . . . . 0.0 106.385 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.86 131.57 56.92 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 100.48 -3.896 . . . . 0.0 100.48 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.46 60.19 13.54 Favored Pre-proline 0 C--N 1.295 -1.78 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -53.09 68.34 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.618 0 C-N-CA 124.777 3.651 . . . . 0.0 115.855 -176.304 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 132.7 68.75 0.08 OUTLIER Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.505 1 N-CA-C 100.096 -4.039 . . . . 0.0 100.096 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 101.771 -3.418 . . . . 0.0 101.771 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.421 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.8 OUTLIER -100.67 85.94 3.02 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 105.622 -1.992 . . . . 0.0 105.622 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -77.96 -178.33 5.45 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -99.91 -29.57 12.5 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 117.903 2.557 . . . . 0.0 117.903 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB3' HG22 ' A' ' 68' ' ' VAL . 30.5 mmtp -127.57 173.64 9.7 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 102.411 -3.181 . . . . 0.0 102.411 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 88.6 mt -101.14 176.18 2.01 Favored Pre-proline 0 C--N 1.299 -1.618 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -66.12 82.04 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 N-CA-C 104.098 -3.078 . . . . 0.0 104.098 158.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -123.87 -80.68 0.63 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 124.583 1.177 . . . . 0.0 109.628 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.417 ' CG2' ' HB ' ' A' ' 68' ' ' VAL . 45.9 pt 41.96 26.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.515 0 O-C-N 123.38 0.425 . . . . 0.0 110.454 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.24 -69.67 0.18 Allowed Glycine 0 N--CA 1.483 1.776 0 C-N-CA 120.683 -0.77 . . . . 0.0 114.064 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.406 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -61.27 171.17 1.44 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 124.537 2.113 . . . . 0.0 116.358 -179.435 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -6.84 -53.1 0.0 OUTLIER Glycine 0 N--CA 1.493 2.469 0 CA-C-N 109.956 -3.293 . . . . 0.0 119.953 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.2 mm -118.96 116.99 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.495 ' O ' HG23 ' A' ' 68' ' ' VAL . 9.5 p80 -96.26 -45.62 6.76 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 114.68 -1.145 . . . . 0.0 112.232 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.563 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 33.8 mt-10 -107.83 -173.2 2.22 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 123.043 1.401 . . . . 0.0 113.059 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.05 122.33 1.98 Allowed Glycine 0 C--N 1.286 -2.205 0 CA-C-N 111.722 -2.49 . . . . 0.0 106.881 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 78.7 tt0 -102.23 96.15 6.79 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 103.399 -2.815 . . . . 0.0 103.399 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.8 mt -86.17 120.62 36.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 -56.09 5.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.969 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.052 -179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.46 ' NZ ' ' OE1' ' A' ' 37' ' ' GLU . 0.1 OUTLIER -136.15 150.68 49.17 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 124.206 0.941 . . . . 0.0 112.12 -179.432 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.757 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 10.1 m95 -114.38 174.62 5.86 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 124.821 1.325 . . . . 0.0 108.112 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CD2' HG21 ' A' ' 34' ' ' VAL . 6.6 m-85 -128.03 -13.76 5.07 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 112.382 -2.19 . . . . 0.0 112.885 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.625 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 14.7 m -98.89 -172.96 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.653 -0.654 . . . . 0.0 111.761 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.734 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.3 mptp? -123.08 -30.11 0.05 OUTLIER Pre-proline 0 N--CA 1.503 2.208 0 N-CA-C 119.266 3.061 . . . . 0.0 119.266 179.077 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.734 ' C ' ' H ' ' A' ' 24' ' ' LYS . 11.3 Cg_endo -39.17 162.82 0.23 Allowed 'Cis proline' 0 N--CA 1.498 1.764 1 N-CA-C 122.747 4.095 . . . . 0.0 122.747 13.208 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.625 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -95.5 32.42 6.27 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 -179.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.482 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.9 t70 11.79 -100.94 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.248 0 O-C-N 129.749 3.852 . . . . 0.0 109.606 179.477 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.437 ' OE2' ' HE2' ' A' ' 54' ' ' LYS . 3.6 mt-10 -103.33 130.38 50.59 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 30' ' ' ASN . 7.6 p -120.48 177.91 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 122.348 1.07 . . . . 0.0 112.918 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.488 ' OD1' ' C ' ' A' ' 30' ' ' ASN . 45.0 p30 -95.42 -166.47 1.46 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.961 -1.927 . . . . 0.0 107.422 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.561 ' HB2' ' HB3' ' A' ' 52' ' ' LYS 0.25 2.4 tt0 -124.86 50.75 1.71 Allowed 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 100.467 -3.901 . . . . 0.0 100.467 -179.498 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -175.93 28.32 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.043 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 30' ' ' ASN . 0.5 OUTLIER -96.32 -176.25 3.59 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.945 0.878 . . . . 0.0 111.335 -179.308 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.525 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -74.77 -172.53 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.482 -1.648 0 CA-C-O 127.654 3.597 . . . . 0.0 117.582 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.567 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.13 -160.21 0.74 Allowed 'General case' 0 C--N 1.276 -2.624 2 CA-C-N 102.377 -6.738 . . . . 0.0 106.959 -179.214 . . . . . . . . 4 4 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.757 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 9.2 m -120.09 156.51 30.86 Favored 'General case' 0 C--N 1.273 -2.748 2 N-CA-C 94.215 -6.217 . . . . 0.0 94.215 179.212 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.46 ' OE1' ' NZ ' ' A' ' 20' ' ' LYS . 5.3 tt0 -107.94 109.83 21.42 Favored 'General case' 0 C--N 1.285 -2.236 1 N-CA-C 98.676 -4.564 . . . . 0.0 98.676 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.473 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 56.1 t -121.43 154.9 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 tt0 -114.82 147.2 40.15 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 16.4 p-10 -136.43 -176.0 4.19 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -6.73 -67.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.176 0 O-C-N 126.175 2.172 . . . . 0.0 115.838 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 40.0 mtmt -138.19 -22.18 1.05 Allowed 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 123.011 0.525 . . . . 0.0 109.957 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.75 -168.57 1.54 Allowed 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 29.8 t -123.69 133.7 68.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 N-CA-C 103.309 -2.849 . . . . 0.0 103.309 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.94 153.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 122.515 1.15 . . . . 0.0 109.012 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.505 ' C ' HD12 ' A' ' 47' ' ' ILE . 10.0 pt-20 -119.58 127.79 53.3 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 110.86 -2.882 . . . . 0.0 108.526 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.57 HD12 ' N ' ' A' ' 47' ' ' ILE . 1.7 mp -117.2 79.54 11.19 Favored Pre-proline 0 C--N 1.299 -1.588 0 N-CA-C 101.573 -3.491 . . . . 0.0 101.573 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.441 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 86.3 Cg_endo -62.29 -166.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.513 2.639 0 C-N-CA 123.569 2.846 . . . . 0.0 107.854 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 45.9 p -98.78 106.66 38.67 Favored Pre-proline 0 C--N 1.286 -2.153 0 CA-C-N 113.483 -1.69 . . . . 0.0 111.879 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 89.2 Cg_exo -55.32 -44.46 48.66 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.012 1.808 . . . . 0.0 114.979 166.181 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.509 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -132.13 171.58 17.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 123.837 0.711 . . . . 0.0 109.858 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.561 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -105.01 167.85 9.44 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 127.347 2.905 . . . . 0.0 107.614 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 76' ' ' ASP . . . 144.1 -121.77 1.69 Allowed Glycine 0 C--N 1.285 -2.282 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.669 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -117.41 166.41 12.35 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.452 ' CG1' ' H ' ' A' ' 26' ' ' GLY . 23.9 t -129.91 59.29 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 1 N-CA-C 99.459 -4.274 . . . . 0.0 99.459 179.527 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 21.9 mt -29.1 -76.88 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 111.143 -2.753 . . . . 0.0 115.02 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -143.79 167.16 22.95 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.284 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 58' ' ' ILE . 4.1 mp -135.55 139.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 1 N-CA-C 98.527 -4.619 . . . . 0.0 98.527 179.601 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.7 mp -101.56 -56.91 2.18 Favored 'General case' 0 C--N 1.296 -1.756 0 O-C-N 124.003 0.814 . . . . 0.0 110.604 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 t -117.93 67.96 6.34 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -41.93 -78.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 122.709 2.273 . . . . 0.0 117.989 -167.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -142.97 174.58 10.55 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.66 -52.97 0.91 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.868 -1.158 . . . . 0.0 111.462 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.5 m -102.42 -177.5 3.42 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.2 t -109.95 145.49 16.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 103.733 -2.692 . . . . 0.0 103.733 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -120.55 147.83 44.66 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.287 14.7 t -99.84 -151.7 0.4 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.478 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.529 ' C ' ' H ' ' A' ' 70' ' ' GLN . 61.8 t -118.62 160.75 18.18 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 178.877 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 97.61 -47.28 1.57 Allowed Glycine 0 N--CA 1.499 2.852 1 N-CA-C 98.408 -5.877 . . . . 0.0 98.408 -179.386 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.529 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -89.58 153.61 20.63 Favored 'General case' 0 C--N 1.304 -1.393 1 N-CA-C 99.953 -4.091 . . . . 0.0 99.953 179.325 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.56 -175.94 3.0 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 103.104 -2.924 . . . . 0.0 103.104 179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.7 tp -139.9 -70.44 0.4 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.404 HD11 ' CG1' ' A' ' 55' ' ' VAL . 12.9 tt -139.05 166.33 22.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 104.203 -2.517 . . . . 0.0 104.203 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.2 t -138.92 160.08 40.59 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 102.439 -3.171 . . . . 0.0 102.439 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.421 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -129.98 148.53 51.85 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.022 -179.721 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.432 ' OD2' ' NZ ' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -113.09 150.26 32.35 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 102.227 -3.249 . . . . 0.0 102.227 179.135 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.601 ' H ' ' HA ' ' A' ' 78' ' ' PRO . . . -114.36 -40.94 0.08 OUTLIER Pre-proline 0 C--N 1.295 -1.774 0 O-C-N 124.883 1.365 . . . . 0.0 107.696 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.601 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 10.2 Cg_endo -94.72 176.84 11.42 Favored 'Cis proline' 0 C--N 1.312 -1.375 0 CA-C-N 121.628 1.617 . . . . 0.0 111.328 -22.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.81 -36.72 4.19 Favored Glycine 0 N--CA 1.498 2.8 1 N-CA-C 99.058 -5.617 . . . . 0.0 99.058 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.494 ' H ' ' C ' ' A' ' 78' ' ' PRO . 52.1 t80 . . . . . 0 CA--C 1.573 1.831 1 N-CA-C 98.597 -4.594 . . . . 0.0 98.597 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.474 1 N-CA-C 98.138 -4.764 . . . . 0.0 98.138 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -137.13 90.76 2.56 Favored 'General case' 0 C--N 1.288 -2.078 1 N-CA-C 88.977 -8.157 . . . . 0.0 88.977 178.473 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 3' ' ' GLU . 1.3 pm0 -87.57 -168.1 2.11 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 122.638 1.208 . . . . 0.0 113.843 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.484 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 22.5 t80 -88.22 -46.99 8.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 117.853 2.538 . . . . 0.0 117.853 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.484 ' HE2' ' CZ ' ' A' ' 4' ' ' PHE . 0.3 OUTLIER -131.57 174.68 9.86 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 179.63 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.13 172.96 3.69 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 104.187 -2.523 . . . . 0.0 104.187 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -56.31 89.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 121.43 1.42 . . . . 0.0 111.374 164.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.503 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.5 t0 -122.45 -82.05 0.65 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 102.968 -2.975 . . . . 0.0 102.968 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.5 pt 36.8 37.0 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 CA-C-O 121.601 0.715 . . . . 0.0 109.821 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.7 -154.58 11.94 Favored Glycine 0 N--CA 1.48 1.575 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.32 138.53 37.75 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.44 -74.1 0.33 Allowed Glycine 0 N--CA 1.486 1.968 0 N-CA-C 106.907 -2.477 . . . . 0.0 106.907 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.2 mm -133.46 141.4 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-N 118.363 1.081 . . . . 0.0 108.297 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -131.9 -51.88 0.98 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.635 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -116.59 172.11 7.43 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.463 -1.244 . . . . 0.0 111.995 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.82 155.51 26.17 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 106.542 -2.623 . . . . 0.0 106.542 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.412 ' O ' HG13 ' A' ' 38' ' ' VAL . 0.7 OUTLIER -122.54 136.74 54.96 Favored 'General case' 0 C--N 1.303 -1.445 1 N-CA-C 98.968 -4.456 . . . . 0.0 98.968 179.87 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.437 ' HB ' ' HA ' ' A' ' 62' ' ' GLU 0.285 2.6 mt -103.95 113.67 41.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.278 0 N-CA-C 102.734 -3.062 . . . . 0.0 102.734 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.9 t -76.5 -55.07 12.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HE3' ' CE2' ' A' ' 22' ' ' PHE . 22.4 tttp -141.41 158.32 44.02 Favored 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 118.981 -1.088 . . . . 0.0 113.579 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.509 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 36.9 m95 -113.86 170.89 7.93 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 178.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.494 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.5 m-85 -128.28 -46.43 1.35 Allowed 'General case' 0 C--N 1.3 -1.584 0 CA-C-N 114.126 -1.397 . . . . 0.0 109.735 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 m -97.39 175.68 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -128.04 165.98 26.91 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 105.593 -2.003 . . . . 0.0 105.593 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -76.52 122.71 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 121.915 1.744 . . . . 0.0 110.776 -172.188 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.13 -7.27 19.02 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.226 -2.349 . . . . 0.0 107.226 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -79.52 173.23 12.79 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 124.177 1.941 . . . . 0.0 111.041 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.667 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.2 OUTLIER -118.55 146.26 44.72 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 100.584 -3.858 . . . . 0.0 100.584 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.542 HG22 ' HB2' ' A' ' 31' ' ' GLU 0.25 0.9 OUTLIER -122.19 171.2 11.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 -179.776 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.461 ' O ' ' HE2' ' A' ' 52' ' ' LYS . 53.7 t30 -119.42 -29.51 5.11 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 125.03 2.348 . . . . 0.0 115.135 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.542 ' HB2' HG22 ' A' ' 29' ' ' VAL 0.366 11.9 tp10 47.26 78.74 0.07 Allowed 'General case' 0 C--N 1.267 -2.995 5 N-CA-C 131.644 7.646 . . . . 0.0 131.644 -179.213 . . . . . . . . 4 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -155.43 31.5 0.38 Allowed 'General case' 0 C--N 1.28 -2.434 4 CA-C-N 94.066 -10.515 . . . . 0.0 93.984 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.482 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 10.0 m-20 -117.22 -168.7 1.52 Allowed 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 126.927 2.091 . . . . 0.0 107.82 -178.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.494 ' HB ' ' CG ' ' A' ' 22' ' ' PHE . 3.6 t -134.47 161.85 39.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 N-CA-C 100.597 -3.853 . . . . 0.0 100.597 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.551 ' HB2' HG21 ' A' ' 47' ' ' ILE . 3.4 mm? -125.54 -84.85 0.63 Allowed 'General case' 0 C--N 1.272 -2.77 0 CA-C-N 109.874 -3.33 . . . . 0.0 102.389 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.403 ' SG ' ' OE1' ' A' ' 46' ' ' GLU . 11.2 p -123.97 172.77 8.69 Favored 'General case' 0 N--CA 1.495 1.777 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.582 -178.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.367 18.5 tt0 -134.34 138.25 44.77 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 -179.287 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.497 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 25.5 t -139.77 145.57 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.427 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 35.6 tt0 -107.29 107.65 18.68 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 6.4 p-10 -136.77 174.57 10.47 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 2.8 p-10 -3.78 -59.49 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 118.234 2.679 . . . . 0.0 118.234 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 28.3 mttm -131.15 -4.05 3.91 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 123.687 0.617 . . . . 0.0 110.029 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -106.09 164.43 11.99 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.75 -43.11 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 111.392 -2.64 . . . . 0.0 109.178 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 18.3 t -111.83 167.35 5.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 -179.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.579 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.0 mt-10 -120.5 -73.32 0.65 Allowed 'General case' 0 C--N 1.294 -1.846 0 O-C-N 128.016 3.323 . . . . 0.0 116.556 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.579 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -84.37 142.54 40.65 Favored Pre-proline 0 C--N 1.274 -2.68 0 CA-C-N 108.487 -3.961 . . . . 0.0 110.225 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.536 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -96.64 177.59 0.59 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 N-CA-C 105.248 -2.635 . . . . 0.0 105.248 82.646 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.491 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 1.6 m -124.36 -177.61 0.57 Allowed Pre-proline 0 C--N 1.278 -2.512 0 CA-C-N 114.462 -1.244 . . . . 0.0 109.243 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -87.51 -31.43 0.22 Allowed 'Trans proline' 0 C--N 1.314 -1.285 0 N-CA-C 117.236 1.975 . . . . 0.0 117.236 164.6 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.525 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.6 p -138.34 167.97 20.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 120.246 3.425 . . . . 0.0 120.246 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.525 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 2.2 ptmm? -97.06 177.26 5.66 Favored 'General case' 0 C--N 1.292 -1.9 1 CA-C-N 106.212 -4.995 . . . . 0.0 110.266 -179.395 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.02 -141.71 9.21 Favored Glycine 0 C--N 1.286 -2.237 0 N-CA-C 103.331 -3.908 . . . . 0.0 103.331 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.667 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 12.3 tppt? -110.97 173.23 6.43 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 103.915 -2.624 . . . . 0.0 103.915 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 39.3 t -125.72 68.84 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.166 1 N-CA-C 97.963 -4.829 . . . . 0.0 97.963 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 38.3 mt -30.48 -76.02 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 126.135 2.147 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -142.04 161.58 37.64 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 77.8 mt -132.99 114.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 1 N-CA-C 93.882 -6.34 . . . . 0.0 93.882 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.5 mt -90.9 -40.4 11.75 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 114.759 1.392 . . . . 0.0 114.759 -179.456 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.71 79.97 23.61 Favored Pre-proline 0 N--CA 1.496 1.864 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.817 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_exo -34.8 -107.66 0.0 OUTLIER 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 124.426 3.417 . . . . 0.0 120.532 -175.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.437 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 3.6 pt-20 -132.73 173.8 10.98 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 56.92 30.94 60.73 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.7 m -138.24 160.28 39.87 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 102.014 -3.328 . . . . 0.0 102.014 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -97.56 135.6 31.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -127.06 144.98 50.89 Favored 'General case' 0 C--N 1.294 -1.834 1 N-CA-C 99.764 -4.162 . . . . 0.0 99.764 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.635 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.259 66.8 p -116.87 -144.78 0.38 Allowed 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 124.296 1.998 . . . . 0.0 107.413 -179.855 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.503 HG11 ' HB3' ' A' ' 8' ' ' ASP . 74.8 t -121.65 155.07 25.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 1 N-CA-C 93.247 -6.575 . . . . 0.0 93.247 179.056 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 93.27 -47.04 2.39 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 103.148 -3.981 . . . . 0.0 103.148 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.424 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.2 tt0 -94.0 155.0 17.36 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 102.426 -3.176 . . . . 0.0 102.426 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.55 -174.61 2.6 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 102.769 -3.048 . . . . 0.0 102.769 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.6 tp -145.99 -66.84 0.29 Allowed 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 113.349 -1.751 . . . . 0.0 106.874 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 11.8 tt -133.21 166.58 28.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 110.852 -2.886 . . . . 0.0 105.609 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 t -140.19 159.8 41.38 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 102.152 -3.277 . . . . 0.0 102.152 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.403 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.0 OUTLIER -136.62 154.92 50.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.403 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -123.36 145.89 48.39 Favored 'General case' 0 C--N 1.295 -1.798 1 N-CA-C 99.536 -4.246 . . . . 0.0 99.536 179.282 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.401 ' HB3' ' CA ' ' A' ' 78' ' ' PRO . . . -140.79 -49.95 0.02 OUTLIER Pre-proline 0 C--N 1.295 -1.765 0 O-C-N 123.746 0.653 . . . . 0.0 111.581 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.401 ' CA ' ' HB3' ' A' ' 77' ' ' ALA . 51.2 Cg_endo -84.4 -45.85 0.3 Allowed 'Cis proline' 0 C--N 1.315 -1.224 0 CA-C-N 119.722 0.936 . . . . 0.0 109.98 -22.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -141.89 124.84 2.55 Favored Glycine 0 C--N 1.293 -1.818 1 N-CA-C 98.749 -5.74 . . . . 0.0 98.749 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 36.6 p90 . . . . . 0 C--N 1.283 -2.317 0 O-C-N 127.109 2.299 . . . . 0.0 106.007 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.51 2.531 0 N-CA-C 102.668 -3.086 . . . . 0.0 102.668 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.1 t80 16.37 102.96 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 127.051 2.72 . . . . 0.0 112.813 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.722 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 2.6 pm0 -82.53 -171.0 3.24 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-N 110.482 -3.054 . . . . 0.0 112.917 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.469 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.2 t80 -93.86 -49.94 5.58 Favored 'General case' 0 N--CA 1.494 1.725 0 CA-C-N 113.684 -1.598 . . . . 0.0 114.063 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HD3' ' CE2' ' A' ' 4' ' ' PHE . 11.8 mmmm -126.1 165.93 17.95 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 101.633 -3.469 . . . . 0.0 101.633 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 61.0 mt -105.48 -178.03 0.57 Allowed Pre-proline 0 C--N 1.3 -1.564 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.45 96.43 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.356 0 C-N-CA 121.685 1.59 . . . . 0.0 110.855 170.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.779 ' HB3' HG11 ' A' ' 68' ' ' VAL . 24.2 t0 -122.34 -99.3 0.43 Allowed 'General case' 0 C--N 1.302 -1.478 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 179.795 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.501 HG23 ' CG1' ' A' ' 68' ' ' VAL . 32.4 pt 34.74 42.05 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 O-C-N 124.572 1.17 . . . . 0.0 108.239 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.79 -137.27 4.77 Favored Glycine 0 N--CA 1.482 1.725 0 CA-C-N 114.45 -1.25 . . . . 0.0 113.895 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.63 146.64 28.64 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 104.695 -2.335 . . . . 0.0 104.695 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.31 -76.24 0.22 Allowed Glycine 0 N--CA 1.486 1.969 0 N-CA-C 103.249 -3.94 . . . . 0.0 103.249 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 14' ' ' HIS . 42.1 mm -131.21 173.5 14.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 N-CA-C 103.427 -2.805 . . . . 0.0 103.427 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.429 ' N ' HG22 ' A' ' 13' ' ' ILE . 57.3 t-80 -155.0 -33.09 0.1 Allowed 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.159 1.457 . . . . 0.0 107.701 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.07 -165.54 1.08 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 113.975 -1.466 . . . . 0.0 113.355 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.89 128.18 2.81 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 103.735 -3.746 . . . . 0.0 103.735 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.449 ' HG3' HG22 ' A' ' 65' ' ' VAL . 30.4 tt0 -104.64 91.49 3.88 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 101.146 -3.65 . . . . 0.0 101.146 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.405 HG23 ' HB2' ' A' ' 36' ' ' CYS . 2.5 mt -81.86 110.62 17.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 103.969 -2.604 . . . . 0.0 103.969 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -88.81 -45.28 15.58 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 113.563 -1.653 . . . . 0.0 106.62 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HZ2' ' HB3' ' A' ' 20' ' ' LYS . 2.4 ttmp? -130.9 161.46 31.82 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.117 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.489 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 11.3 m95 -124.28 168.74 12.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 101.457 -3.534 . . . . 0.0 101.457 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 22' ' ' PHE . 6.9 m-85 -123.0 -47.41 2.04 Favored 'General case' 0 C--N 1.295 -1.782 0 O-C-N 124.542 1.151 . . . . 0.0 108.245 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -99.58 178.13 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.331 1.062 . . . . 0.0 110.775 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 ptmt -115.17 172.63 3.48 Favored Pre-proline 0 C--N 1.295 -1.79 0 CA-C-N 112.104 -2.316 . . . . 0.0 105.025 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HB3' HG13 ' A' ' 58' ' ' ILE . 34.3 Cg_endo -93.78 143.45 1.86 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.228 1.952 . . . . 0.0 110.384 166.547 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.64 -10.33 38.37 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.231 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -108.53 -175.9 2.9 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.773 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.6 OUTLIER -118.82 163.99 16.07 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.226 -179.724 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.591 HG22 ' HB2' ' A' ' 31' ' ' GLU . 3.1 p -133.01 174.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.525 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 19.8 t-20 -116.21 -35.85 4.23 Favored 'General case' 0 N--CA 1.523 3.203 0 CA-C-O 126.903 3.24 . . . . 0.0 115.649 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.622 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.395 33.0 tt0 20.18 123.08 0.0 OUTLIER 'General case' 0 C--N 1.273 -2.759 5 N-CA-C 151.831 15.123 . . . . 0.0 151.831 -179.537 . . . . . . . . 4 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' CG ' ' N ' ' A' ' 33' ' ' ASP . 11.2 p-10 -123.01 -48.23 2.01 Favored 'General case' 0 C--N 1.287 -2.117 4 CA-C-N 93.237 -10.892 . . . . 0.0 97.625 178.999 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' CG ' ' A' ' 32' ' ' ASP . 3.7 t0 -22.55 176.6 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.617 0 C-N-CA 131.427 3.891 . . . . 0.0 116.186 179.001 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -107.39 167.52 3.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 127.366 3.46 . . . . 0.0 114.292 -179.597 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.55 ' H ' HG12 ' A' ' 34' ' ' VAL . 10.1 mp -130.9 -87.34 0.49 Allowed 'General case' 0 C--N 1.283 -2.289 1 CA-C-N 106.562 -4.836 . . . . 0.0 103.688 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.405 ' HB2' HG23 ' A' ' 18' ' ' ILE . 0.5 OUTLIER -127.89 169.63 13.73 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.794 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.679 ' HG3' HG22 ' A' ' 45' ' ' VAL . 1.2 tm-20 -135.09 156.88 48.26 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 126.341 2.276 . . . . 0.0 104.946 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.503 HG23 ' HG3' ' A' ' 46' ' ' GLU . 54.0 t -139.5 179.58 2.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 125.481 1.738 . . . . 0.0 111.439 -179.304 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.483 ' N ' HG12 ' A' ' 38' ' ' VAL . 25.0 tt0 -137.8 102.72 4.8 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 113.313 -1.767 . . . . 0.0 108.234 178.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.433 HD22 ' CG ' ' A' ' 41' ' ' ASP . 9.9 p-10 -147.41 175.8 10.53 Favored 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.916 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.433 ' CG ' HD22 ' A' ' 40' ' ' ASN . 1.0 OUTLIER -15.7 -68.66 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 119.139 3.014 . . . . 0.0 119.139 -179.601 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.14 -8.85 6.49 Favored 'General case' 0 C--N 1.289 -2.023 0 CA-C-N 114.794 -1.093 . . . . 0.0 110.958 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.413 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -111.39 156.03 22.23 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.874 -1.13 . . . . 0.0 109.734 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.47 -88.98 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 114.135 -1.393 . . . . 0.0 108.742 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.679 HG22 ' HG3' ' A' ' 37' ' ' GLU . 61.5 t -68.27 162.86 3.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 104.566 -2.383 . . . . 0.0 104.566 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.511 ' HB3' HD12 ' A' ' 47' ' ' ILE . 2.4 mt-10 -108.3 -60.65 1.7 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 126.806 2.566 . . . . 0.0 115.479 -179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 34' ' ' VAL . 1.6 mp -96.1 143.21 25.73 Favored Pre-proline 0 C--N 1.273 -2.745 1 CA-C-N 108.033 -4.167 . . . . 0.0 108.904 -179.507 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.567 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.03 177.11 0.46 Allowed 'Trans proline' 0 C--N 1.305 -1.731 1 C-N-CA 126.281 4.654 . . . . 0.0 106.509 90.036 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.622 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 16.1 m -128.45 171.15 9.04 Favored Pre-proline 0 C--N 1.28 -2.434 0 O-C-N 125.144 1.528 . . . . 0.0 114.285 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -105.35 -17.13 0.05 OUTLIER 'Trans proline' 0 CA--C 1.555 1.549 0 C-N-CA 124.575 3.517 . . . . 0.0 119.653 173.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.577 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.2 p -135.24 170.35 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.705 0 CA-C-O 122.896 1.331 . . . . 0.0 111.789 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.702 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -125.07 178.3 5.61 Favored 'General case' 0 C--N 1.286 -2.195 1 CA-C-N 108.239 -4.073 . . . . 0.0 111.266 -179.555 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.61 -134.93 4.35 Favored Glycine 0 C--N 1.287 -2.177 1 N-CA-C 100.3 -5.12 . . . . 0.0 100.3 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.773 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 15.1 tppt? -112.93 176.55 4.97 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 104.497 -2.409 . . . . 0.0 104.497 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 24.0 t -123.75 100.84 8.25 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 1 N-CA-C 93.148 -6.612 . . . . 0.0 93.148 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.5 mt -74.61 -83.08 0.06 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 117.582 -1.647 . . . . 0.0 106.946 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.2 160.99 30.37 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.001 . . . . 0.0 112.668 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.405 HG13 ' HB3' ' A' ' 25' ' ' PRO . 96.7 mt -132.75 118.36 33.79 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 1 N-CA-C 92.761 -6.755 . . . . 0.0 92.761 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.446 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -92.69 -41.18 10.3 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 123.727 0.642 . . . . 0.0 111.787 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.42 ' HB ' ' CD2' ' A' ' 72' ' ' LEU . 3.4 t -111.32 124.59 32.33 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 101.632 -3.47 . . . . 0.0 101.632 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -57.07 -124.16 0.0 OUTLIER 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 123.921 3.081 . . . . 0.0 116.453 176.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.494 ' C ' ' H ' ' A' ' 64' ' ' THR . 0.0 OUTLIER -127.49 -170.34 2.21 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 100.885 -3.746 . . . . 0.0 100.885 179.928 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.07 -19.95 0.12 Allowed Glycine 0 N--CA 1.491 2.347 0 CA-C-N 113.277 -1.783 . . . . 0.0 113.711 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.494 ' H ' ' C ' ' A' ' 62' ' ' GLU . 2.2 m -101.97 170.03 8.39 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 104.394 -2.447 . . . . 0.0 104.394 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.449 HG22 ' HG3' ' A' ' 17' ' ' GLU . 45.0 t -105.77 148.8 9.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 103.816 -2.661 . . . . 0.0 103.816 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -119.5 156.66 29.82 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.6 p -101.06 -160.86 0.82 Allowed 'General case' 0 C--N 1.283 -2.289 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.779 HG11 ' HB3' ' A' ' 8' ' ' ASP . 52.2 t -126.69 153.17 35.23 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.39 1 N-CA-C 94.353 -6.166 . . . . 0.0 94.353 178.386 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 94.44 -36.16 3.89 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 103.588 -3.805 . . . . 0.0 103.588 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.472 ' H ' ' C ' ' A' ' 68' ' ' VAL . 31.6 tt0 -92.93 163.75 13.57 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 101.817 -3.401 . . . . 0.0 101.817 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.3 m -108.84 -179.02 3.74 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 101.724 -3.435 . . . . 0.0 101.724 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.42 ' CD2' ' HB ' ' A' ' 60' ' ' VAL . 0.4 OUTLIER -149.06 -65.64 0.23 Allowed 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 -179.371 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 7.8 tt -130.19 163.56 35.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.2 t -140.42 158.32 44.18 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 103.142 -2.91 . . . . 0.0 103.142 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -132.39 149.54 52.33 Favored 'General case' 0 C--N 1.287 -2.11 0 CA-C-N 111.83 -2.441 . . . . 0.0 104.855 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.26 123.17 48.12 Favored 'General case' 0 C--N 1.292 -1.913 1 N-CA-C 96.511 -5.366 . . . . 0.0 96.511 179.716 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -139.77 58.72 12.09 Favored Pre-proline 0 N--CA 1.491 1.607 1 N-CA-C 99.786 -4.153 . . . . 0.0 99.786 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -78.1 67.77 8.03 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 121.778 1.652 . . . . 0.0 112.066 -153.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.3 59.06 0.05 OUTLIER Glycine 0 N--CA 1.501 2.972 0 C-N-CA 119.72 -1.228 . . . . 0.0 112.806 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 116.338 -1.791 . . . . 0.0 107.554 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 2.097 0 N-CA-C 103.73 -2.692 . . . . 0.0 103.73 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.47 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -121.78 128.27 51.54 Favored 'General case' 0 C--N 1.29 -2.015 1 N-CA-C 99.962 -4.088 . . . . 0.0 99.962 -179.635 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -102.23 -173.29 2.3 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.414 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.7 t80 -101.14 -43.16 6.09 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.609 0.719 . . . . 0.0 112.509 -179.266 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HB2' HG13 ' A' ' 68' ' ' VAL . 0.1 OUTLIER -128.49 160.27 32.84 Favored 'General case' 0 C--N 1.297 -1.685 1 N-CA-C 99.338 -4.319 . . . . 0.0 99.338 179.79 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.43 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 25.5 mt -103.31 -169.37 0.18 Allowed Pre-proline 0 C--N 1.296 -1.745 0 N-CA-C 105.319 -2.104 . . . . 0.0 105.319 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB3' ' A' ' 6' ' ' LEU . 77.0 Cg_exo -55.48 85.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.12 1.88 . . . . 0.0 107.577 148.033 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.58 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.2 t0 -123.15 -88.65 0.61 Allowed 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.565 ' H ' HG11 ' A' ' 68' ' ' VAL . 1.3 pt 37.77 43.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.321 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.33 -176.1 50.51 Favored Glycine 0 N--CA 1.493 2.453 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.551 -179.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -80.72 144.73 31.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.86 -77.89 0.26 Allowed Glycine 0 C--N 1.294 -1.786 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.2 mt -137.93 103.79 2.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 102.736 -3.061 . . . . 0.0 102.736 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.67 20.71 18.61 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-N 122.178 2.263 . . . . 0.0 108.35 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 1.4 pm0 -121.95 -174.26 2.84 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 123.725 1.726 . . . . 0.0 114.09 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.4 101.65 0.27 Allowed Glycine 0 N--CA 1.492 2.43 0 CA-C-N 112.483 -2.144 . . . . 0.0 109.7 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -92.94 89.2 6.45 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 66' ' ' ALA . 3.9 mt -84.18 103.89 11.9 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 100.851 -3.759 . . . . 0.0 100.851 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.7 t -84.33 -46.17 17.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.331 -179.29 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.455 ' HG2' ' N ' ' A' ' 21' ' ' TRP . 25.8 tttt -142.24 159.77 41.57 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 114.983 -1.008 . . . . 0.0 111.1 -179.543 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.53 ' CE3' HG22 ' A' ' 23' ' ' VAL . 17.7 m95 -122.16 162.52 21.18 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 179.4 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -120.68 -20.74 6.94 Favored 'General case' 0 C--N 1.292 -1.895 0 O-C-N 124.984 1.428 . . . . 0.0 108.76 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.53 HG22 ' CE3' ' A' ' 21' ' ' TRP . 5.1 m -99.89 179.31 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-O 123.753 1.74 . . . . 0.0 112.147 -179.335 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.647 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -130.42 140.13 37.73 Favored Pre-proline 0 C--N 1.288 -2.095 1 N-CA-C 97.743 -4.91 . . . . 0.0 97.743 -179.71 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -54.69 162.56 4.73 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.42 1.413 . . . . 0.0 114.945 -175.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.52 26.55 0.08 OUTLIER Glycine 0 C--N 1.294 -1.764 0 CA-C-N 110.785 -2.916 . . . . 0.0 117.662 179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.508 ' C ' ' HZ2' ' A' ' 54' ' ' LYS . 23.0 t0 -87.0 -168.48 2.26 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 113.498 -3.281 . . . . 0.0 107.115 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.479 ' H ' ' CG ' ' A' ' 27' ' ' ASP . 5.5 mm-40 -102.92 127.55 50.08 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 100.391 -3.929 . . . . 0.0 100.391 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.465 HG23 ' HB3' ' A' ' 33' ' ' ASP . 2.9 p -109.55 160.74 8.33 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 3.0 t30 -96.72 -164.17 1.12 Allowed 'General case' 0 C--N 1.292 -1.901 0 CA-C-N 113.472 -1.695 . . . . 0.0 109.137 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.619 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.284 9.9 tt0 -117.87 56.21 0.86 Allowed 'General case' 0 C--N 1.289 -2.048 1 N-CA-C 98.332 -4.692 . . . . 0.0 98.332 -178.88 . . . . . . . . 4 3 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -178.04 1.39 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.84 0 CA-C-N 112.049 -2.341 . . . . 0.0 116.442 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.485 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 42.3 t0 -90.31 -172.14 3.35 Favored 'General case' 0 N--CA 1.508 2.463 0 CA-C-N 118.789 0.722 . . . . 0.0 111.371 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.545 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -112.51 176.34 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 126.375 2.988 . . . . 0.0 102.956 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.545 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -140.08 -83.29 0.25 Allowed 'General case' 0 C--N 1.274 -2.697 1 CA-C-N 107.485 -4.416 . . . . 0.0 100.504 179.317 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.431 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -126.08 172.34 10.07 Favored 'General case' 0 N--CA 1.51 2.568 0 CA-C-N 122.179 2.263 . . . . 0.0 115.153 -179.287 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.452 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 2.1 tt0 -119.77 101.33 7.82 Favored 'General case' 0 N--CA 1.493 1.707 1 N-CA-C 92.966 -6.679 . . . . 0.0 92.966 179.443 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 t -108.18 150.43 10.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.517 HE21 HG22 ' A' ' 44' ' ' VAL . 35.2 tt0 -121.23 164.53 16.81 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 104.116 -2.55 . . . . 0.0 104.116 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.4 HD21 ' HB3' ' A' ' 43' ' ' ALA . 5.2 p-10 -152.98 -178.75 7.11 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 102.623 -3.102 . . . . 0.0 102.623 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -5.79 -57.62 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 118.231 2.678 . . . . 0.0 118.231 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -146.36 -34.3 0.29 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.4 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -75.31 149.88 38.63 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.86 -1.064 . . . . 0.0 113.2 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.517 HG22 HE21 ' A' ' 39' ' ' GLN . 21.9 t -122.6 110.99 28.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 1 N-CA-C 95.696 -5.668 . . . . 0.0 95.696 179.582 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t -114.71 162.61 12.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 CA-C-O 124.709 2.195 . . . . 0.0 108.455 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.431 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -118.35 153.12 34.55 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 109.044 -3.707 . . . . 0.0 106.766 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.431 HD12 ' C ' ' A' ' 46' ' ' GLU . 1.7 mp -121.43 126.25 26.57 Favored Pre-proline 0 C--N 1.302 -1.47 1 N-CA-C 94.132 -6.247 . . . . 0.0 94.132 179.208 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.401 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -90.77 -176.69 1.02 Allowed 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.537 2.158 . . . . 0.0 107.934 167.106 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -91.85 112.8 56.51 Favored Pre-proline 0 C--N 1.288 -2.079 0 CA-C-N 113.207 -1.815 . . . . 0.0 108.228 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 25.3 Cg_exo -69.7 -34.59 14.49 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 121.497 1.465 . . . . 0.0 108.363 168.613 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.619 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -136.52 168.79 21.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 125.458 1.723 . . . . 0.0 111.94 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.82 162.18 13.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 127.32 2.888 . . . . 0.0 105.307 179.19 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 163.12 -141.84 7.44 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.508 ' HZ2' ' C ' ' A' ' 27' ' ' ASP . 0.5 OUTLIER -117.96 175.28 5.75 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 104.405 -2.442 . . . . 0.0 104.405 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' LEU . 21.7 t -128.52 57.19 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.048 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.414 ' HB2' HG23 ' A' ' 74' ' ' THR . 85.0 mt -26.9 -76.77 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 CA-C-N 112.729 -2.032 . . . . 0.0 113.632 -179.126 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -130.59 153.5 48.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 124.77 1.294 . . . . 0.0 110.161 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -131.25 119.62 44.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 1 N-CA-C 93.425 -6.509 . . . . 0.0 93.425 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.471 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.0 mp -90.9 -44.86 9.12 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.9 t -119.42 140.65 29.47 Favored Pre-proline 0 C--N 1.296 -1.757 1 N-CA-C 97.802 -4.888 . . . . 0.0 97.802 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.401 ' HG2' ' H ' ' A' ' 62' ' ' GLU . 13.3 Cg_endo -91.51 -101.34 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.033 1.155 . . . . 0.0 110.214 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.401 ' H ' ' HG2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -129.18 -168.71 1.97 Allowed 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 102.071 -3.307 . . . . 0.0 102.071 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 79.67 -45.87 2.98 Favored Glycine 0 C--N 1.287 -2.186 0 CA-C-N 113.404 -1.725 . . . . 0.0 112.101 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.6 m -98.83 172.51 7.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.4 t -108.03 150.63 10.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 104.614 -2.365 . . . . 0.0 104.614 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.485 ' HB3' HD11 ' A' ' 18' ' ' ILE . . . -123.97 168.11 13.25 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 103.661 -2.718 . . . . 0.0 103.661 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.564 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 12.2 t -129.02 -151.32 0.47 Allowed 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.58 HG11 ' HB3' ' A' ' 8' ' ' ASP . 97.4 t -121.98 159.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.322 0 N-CA-C 101.028 -3.693 . . . . 0.0 101.028 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.32 -43.86 1.7 Allowed Glycine 0 CA--C 1.549 2.211 1 N-CA-C 97.142 -6.383 . . . . 0.0 97.142 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.511 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.1 tt0 -88.81 162.56 16.13 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 102.289 -3.226 . . . . 0.0 102.289 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.7 m -109.6 -176.93 3.14 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 101.965 -3.346 . . . . 0.0 101.965 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.3 tp -146.91 -65.49 0.28 Allowed 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 1.4 tt -133.25 166.13 30.23 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-N 112.125 -2.307 . . . . 0.0 105.174 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 56' ' ' LEU . 0.8 OUTLIER -138.49 156.71 47.29 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 101.42 -3.548 . . . . 0.0 101.42 179.07 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.47 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -136.11 147.57 47.85 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.742 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.51 142.34 42.43 Favored 'General case' 0 C--N 1.299 -1.63 1 N-CA-C 97.946 -4.835 . . . . 0.0 97.946 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.13 36.6 0.25 Allowed Pre-proline 0 C--N 1.293 -1.853 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.386 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -37.21 61.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 124.921 3.747 . . . . 0.0 119.406 -143.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 153.5 42.3 0.02 OUTLIER Glycine 0 N--CA 1.495 2.59 0 N-CA-C 106.472 -2.651 . . . . 0.0 106.472 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.304 -1.398 0 N-CA-C 100.634 -3.839 . . . . 0.0 100.634 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.069 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -126.07 127.84 46.46 Favored 'General case' 0 N--CA 1.503 2.224 0 N-CA-C 102.569 -3.123 . . . . 0.0 102.569 -179.582 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.12 -151.25 0.47 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 125.319 1.637 . . . . 0.0 111.818 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.56 ' CE2' ' HE2' ' A' ' 5' ' ' LYS . 8.2 t80 -113.3 -49.68 2.9 Favored 'General case' 0 N--CA 1.502 2.162 0 CA-C-N 113.375 -1.738 . . . . 0.0 114.655 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.56 ' HE2' ' CE2' ' A' ' 4' ' ' PHE . 28.4 mmtt -131.45 155.11 47.92 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 66.0 mt -84.05 173.66 7.0 Favored Pre-proline 0 C--N 1.296 -1.724 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.818 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -54.18 85.91 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.585 2.19 . . . . 0.0 109.791 162.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.496 ' HB3' HG11 ' A' ' 68' ' ' VAL . 10.4 t0 -122.9 -80.22 0.62 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.3 pt 37.07 39.03 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.575 0 CA-C-O 121.896 0.855 . . . . 0.0 109.447 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.12 -150.56 11.33 Favored Glycine 0 N--CA 1.48 1.629 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.594 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -95.01 139.19 31.71 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 103.309 -2.848 . . . . 0.0 103.309 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.97 -79.27 0.33 Allowed Glycine 0 N--CA 1.487 2.081 0 N-CA-C 103.774 -3.731 . . . . 0.0 103.774 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.3 mm -130.73 133.25 63.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 22.1 t-80 -130.34 -19.23 3.14 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.643 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.503 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 0.5 OUTLIER -131.32 178.1 6.97 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 122.975 1.369 . . . . 0.0 110.55 -179.524 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.83 125.44 4.12 Favored Glycine 0 C--N 1.29 -2.019 0 N-CA-C 104.8 -3.32 . . . . 0.0 104.8 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 37.5 tt0 -100.31 96.31 7.36 Favored 'General case' 0 C--N 1.307 -1.272 1 N-CA-C 97.28 -5.081 . . . . 0.0 97.28 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mt -81.96 125.12 39.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 N-CA-C 103.573 -2.751 . . . . 0.0 103.573 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.6 t -86.38 -64.0 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 103.26 -2.867 . . . . 0.0 103.26 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.454 ' HE3' ' O ' ' A' ' 21' ' ' TRP . 1.3 tmtp? -142.99 167.75 21.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 124.018 0.824 . . . . 0.0 113.22 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.512 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 30.3 m95 -113.73 173.06 6.61 Favored 'General case' 0 N--CA 1.502 2.131 0 C-N-CA 123.92 0.888 . . . . 0.0 109.004 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.419 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.3 m-85 -126.92 -48.51 1.49 Allowed 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.541 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 m -100.23 178.69 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.172 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.02 161.77 26.34 Favored Pre-proline 0 C--N 1.295 -1.785 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.814 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -78.16 122.56 5.76 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.249 1.966 . . . . 0.0 110.857 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.16 -15.99 22.78 Favored Glycine 0 N--CA 1.483 1.816 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.23 174.37 7.32 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 123.018 1.389 . . . . 0.0 111.74 -178.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.93 117.41 28.01 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 111.166 -2.743 . . . . 0.0 104.242 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.498 HG13 ' HB2' ' A' ' 31' ' ' GLU . 9.7 p -108.58 176.59 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.719 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.422 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -104.65 -26.3 12.37 Favored 'General case' 0 N--CA 1.522 3.166 0 CA-C-O 126.698 3.142 . . . . 0.0 112.94 -179.697 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.498 ' HB2' HG13 ' A' ' 29' ' ' VAL 0.377 10.8 tp10 35.46 78.71 0.03 OUTLIER 'General case' 0 C--N 1.272 -2.796 5 N-CA-C 138.398 10.147 . . . . 0.0 138.398 -179.389 . . . . . . . . 4 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -141.67 27.21 1.87 Allowed 'General case' 0 C--N 1.287 -2.127 4 CA-C-N 94.721 -10.218 . . . . 0.0 96.273 179.251 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -108.94 -165.59 1.04 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 126.105 1.762 . . . . 0.0 107.343 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.476 HG12 ' H ' ' A' ' 35' ' ' LEU . 1.6 t -120.3 163.02 18.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 CA-C-O 125.554 2.597 . . . . 0.0 108.893 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.512 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.6 mp -126.45 -84.0 0.62 Allowed 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 108.726 -3.852 . . . . 0.0 103.033 179.15 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.573 ' SG ' HG23 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -123.66 172.69 8.62 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 -178.979 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.369 18.5 tt0 -134.04 140.31 46.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 127.064 2.728 . . . . 0.0 103.646 -179.244 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.573 HG23 ' SG ' ' A' ' 36' ' ' CYS . 25.0 t -139.39 151.34 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 CA-C-N 119.145 0.884 . . . . 0.0 109.7 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 43.4 tp60 -106.5 128.25 53.95 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 8.6 p-10 -156.01 -173.09 4.36 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -11.69 -73.63 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.608 0 O-C-N 126.479 2.362 . . . . 0.0 116.608 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -128.38 -7.27 5.27 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.408 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -97.81 159.2 15.08 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.276 -0.97 . . . . 0.0 113.15 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.9 t -124.65 -35.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 126.678 2.486 . . . . 0.0 112.942 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 10.9 t -113.1 169.51 4.78 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 125.239 1.415 . . . . 0.0 108.282 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.484 ' N ' HG12 ' A' ' 45' ' ' VAL . 3.6 mt-10 -120.45 -67.8 0.95 Allowed 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 121.422 3.86 . . . . 0.0 121.422 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.6 mp -92.85 149.49 37.84 Favored Pre-proline 0 C--N 1.273 -2.73 0 CA-C-N 108.746 -3.843 . . . . 0.0 108.672 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.463 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -103.18 -178.31 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.708 1.373 . . . . 0.0 109.152 83.395 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.432 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 0.7 OUTLIER -130.96 179.53 1.32 Allowed Pre-proline 0 C--N 1.286 -2.164 0 CA-C-N 113.481 -1.69 . . . . 0.0 108.428 -179.798 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -102.32 -26.53 0.03 OUTLIER 'Trans proline' 0 CA--C 1.548 1.179 0 N-CA-C 120.016 3.045 . . . . 0.0 120.016 171.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.517 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.9 OUTLIER -127.89 160.6 37.32 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.454 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.655 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -106.75 167.61 9.75 Favored 'General case' 0 C--N 1.294 -1.825 1 CA-C-N 107.451 -4.431 . . . . 0.0 111.148 -179.625 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.28 -141.37 6.75 Favored Glycine 0 C--N 1.292 -1.909 1 N-CA-C 100.024 -5.23 . . . . 0.0 100.024 -179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.445 ' HG3' ' H ' ' A' ' 55' ' ' VAL . 14.4 tppt? -105.79 175.1 5.61 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 102.151 -3.277 . . . . 0.0 102.151 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.445 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 47.4 t -126.1 60.69 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.216 1 N-CA-C 96.549 -5.352 . . . . 0.0 96.549 179.39 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.406 ' C ' ' O ' ' A' ' 55' ' ' VAL . 91.2 mt -22.55 -80.34 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.163 0 CA-C-N 112.816 -1.993 . . . . 0.0 112.999 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -139.76 164.18 30.64 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 125.049 1.468 . . . . 0.0 107.817 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.9 mt -132.47 130.99 60.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 1 N-CA-C 95.67 -5.678 . . . . 0.0 95.67 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.45 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.9 mp -87.74 -52.61 5.21 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 123.8 0.688 . . . . 0.0 109.689 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.5 t -116.67 140.54 26.89 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 101.135 -3.654 . . . . 0.0 101.135 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -87.5 -106.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.694 1.596 . . . . 0.0 111.004 178.087 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -129.56 159.57 35.95 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 102.567 -3.123 . . . . 0.0 102.567 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 107.17 -33.09 6.63 Favored Glycine 0 N--CA 1.498 2.782 0 C-N-CA 119.278 -1.439 . . . . 0.0 114.61 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.2 m -109.28 -175.9 2.88 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.2 t -112.43 150.93 14.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.88 163.73 18.73 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -107.57 -160.77 0.75 Allowed 'General case' 0 C--N 1.285 -2.224 0 N-CA-C 104.234 -2.506 . . . . 0.0 104.234 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.496 HG11 ' HB3' ' A' ' 8' ' ' ASP 0.265 44.6 t -124.0 153.86 30.38 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 1 N-CA-C 92.643 -6.799 . . . . 0.0 92.643 178.226 . . . . . . . . 4 3 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 95.6 -45.8 1.99 Allowed Glycine 0 N--CA 1.498 2.77 0 N-CA-C 103.294 -3.922 . . . . 0.0 103.294 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.42 ' H ' ' C ' ' A' ' 68' ' ' VAL . 37.3 tt0 -85.84 160.21 19.51 Favored 'General case' 0 C--N 1.303 -1.452 1 N-CA-C 99.777 -4.157 . . . . 0.0 99.777 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.4 m -106.54 -178.43 3.65 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 102.122 -3.288 . . . . 0.0 102.122 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.508 HD22 ' CE2' ' A' ' 4' ' ' PHE . 47.9 tp -143.33 -60.07 0.42 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.419 HD11 HG13 ' A' ' 55' ' ' VAL . 14.2 tt -132.96 161.97 40.76 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 104.573 -2.38 . . . . 0.0 104.573 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 t -140.09 164.73 29.25 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -134.01 144.21 48.58 Favored 'General case' 0 N--CA 1.505 2.275 0 CA-C-N 113.873 -1.512 . . . . 0.0 109.587 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -110.07 55.19 0.65 Allowed 'General case' 0 N--CA 1.504 2.249 0 CA-C-O 125.05 2.357 . . . . 0.0 112.32 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -91.37 132.26 34.23 Favored Pre-proline 0 C--N 1.293 -1.848 0 CA-C-N 112.456 -2.156 . . . . 0.0 107.652 -179.151 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -91.43 171.61 2.94 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 124.012 3.141 . . . . 0.0 106.949 150.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.95 -34.04 4.91 Favored Glycine 0 N--CA 1.493 2.487 1 N-CA-C 102.037 -4.425 . . . . 0.0 102.037 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 7.1 m-85 . . . . . 0 C--N 1.302 -1.482 0 N-CA-C 103.078 -2.934 . . . . 0.0 103.078 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -119.22 139.39 51.95 Favored 'General case' 0 N--CA 1.512 2.668 0 N-CA-C 100.732 -3.803 . . . . 0.0 100.732 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.449 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 0.0 OUTLIER -114.99 -161.03 0.76 Allowed 'General case' 0 N--CA 1.502 2.17 0 CA-C-N 120.798 1.635 . . . . 0.0 109.401 -179.67 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.421 ' CD2' ' HD3' ' A' ' 5' ' ' LYS . 8.8 t80 -126.99 -29.1 2.83 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 116.828 2.158 . . . . 0.0 116.828 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.465 ' HB2' HG13 ' A' ' 68' ' ' VAL . 17.9 mmmt -128.26 169.38 14.25 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-N 122.21 2.277 . . . . 0.0 105.279 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 64.6 mt -91.45 177.34 2.26 Favored Pre-proline 0 N--CA 1.493 1.705 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.741 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -61.14 80.05 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.649 0 N-CA-C 106.954 -1.979 . . . . 0.0 106.954 148.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.48 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.9 t70 -123.09 -80.05 0.62 Allowed 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.495 ' H ' HG11 ' A' ' 68' ' ' VAL . 45.5 pt 38.4 34.78 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.51 0 CA-C-N 119.794 1.179 . . . . 0.0 110.168 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.08 -115.03 2.89 Favored Glycine 0 N--CA 1.48 1.587 0 C-N-CA 120.84 -0.695 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -103.46 133.45 48.49 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.278 0.561 . . . . 0.0 110.873 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 116.92 -78.43 0.29 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 106.613 -2.595 . . . . 0.0 106.613 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.5 mm -133.45 134.1 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.089 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -119.22 -41.96 2.71 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 102.013 -3.328 . . . . 0.0 102.013 179.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.64 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.7 OUTLIER -130.65 167.47 18.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 124.005 0.816 . . . . 0.0 110.098 179.601 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.95 149.27 19.12 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -99.05 97.62 8.74 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 104.11 -2.552 . . . . 0.0 104.11 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.433 HG21 ' O ' ' A' ' 61' ' ' PRO . 17.7 mm -83.85 115.04 25.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 t -97.02 -48.32 12.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 O-C-N 125.061 1.475 . . . . 0.0 111.12 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.589 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -137.79 144.66 41.67 Favored 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.488 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 24.1 m95 -114.25 170.14 8.51 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CZ ' ' HE2' ' A' ' 20' ' ' LYS . 2.6 m-85 -121.47 -51.17 2.08 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 113.87 -1.514 . . . . 0.0 111.161 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 m -100.49 175.01 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.145 -1.022 . . . . 0.0 110.311 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.737 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -116.0 156.87 46.21 Favored Pre-proline 0 C--N 1.299 -1.63 0 N-CA-C 104.323 -2.473 . . . . 0.0 104.323 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -64.67 145.16 86.29 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 120.865 1.044 . . . . 0.0 111.22 171.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.56 19.73 28.94 Favored Glycine 0 N--CA 1.488 2.149 0 CA-C-O 118.733 -1.037 . . . . 0.0 111.864 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -106.33 170.05 8.15 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.63 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.466 ' HG2' ' HE3' ' A' ' 54' ' ' LYS . 21.0 mt-10 -129.25 88.4 2.7 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.454 ' O ' ' HB2' ' A' ' 52' ' ' LYS . 10.3 p -74.36 178.38 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-N 110.718 -2.946 . . . . 0.0 108.892 -179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.468 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 9.2 t-20 -107.39 -29.71 9.1 Favored 'General case' 0 N--CA 1.517 2.892 0 CA-C-O 124.693 2.187 . . . . 0.0 112.097 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.483 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.387 11.1 tp10 44.63 75.22 0.11 Allowed 'General case' 0 C--N 1.279 -2.474 5 N-CA-C 135.413 9.042 . . . . 0.0 135.413 -179.742 . . . . . . . . 4 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 32' ' ' ASP . 11.8 p-10 -144.31 27.36 1.41 Allowed 'General case' 0 C--N 1.284 -2.248 4 CA-C-N 94.649 -10.251 . . . . 0.0 94.709 178.69 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.466 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 4.2 m-20 -112.19 -169.56 1.49 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 127.652 2.381 . . . . 0.0 110.833 -178.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.55 ' HA ' HG22 ' A' ' 47' ' ' ILE . 1.5 t -119.94 162.17 18.64 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 CA-C-O 124.302 2.001 . . . . 0.0 107.994 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.573 ' HB2' HG21 ' A' ' 47' ' ' ILE . 7.1 mp -126.22 -85.35 0.62 Allowed 'General case' 0 C--N 1.282 -2.356 1 CA-C-N 108.162 -4.108 . . . . 0.0 102.485 179.075 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.459 ' SG ' HD13 ' A' ' 47' ' ' ILE . 14.6 p -123.81 174.99 7.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -178.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.655 ' HG2' ' HA ' ' A' ' 45' ' ' VAL . 1.9 tt0 -133.27 140.07 47.27 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 126.925 2.641 . . . . 0.0 105.887 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.431 ' CG2' HD13 ' A' ' 18' ' ' ILE . 29.1 t -137.73 153.56 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-N 119.705 1.139 . . . . 0.0 108.32 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -112.15 122.65 48.33 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 4.6 p-10 -159.63 170.78 20.87 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.424 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 6.0 p-10 -3.88 -67.57 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 117.537 2.421 . . . . 0.0 117.537 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.424 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 84.9 mttt -126.19 -0.88 7.07 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 124.42 1.075 . . . . 0.0 111.459 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -104.01 154.45 19.66 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 114.41 1.263 . . . . 0.0 114.41 -179.506 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.7 t -129.95 -47.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 CA-C-N 111.109 -2.769 . . . . 0.0 109.0 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.655 ' HA ' ' HG2' ' A' ' 37' ' ' GLU . 21.8 t -105.8 160.98 5.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 CA-C-N 112.68 -2.054 . . . . 0.0 106.878 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.537 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.8 mt-10 -119.36 -67.14 1.01 Allowed 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 120.619 3.563 . . . . 0.0 120.619 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.573 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.1 mp -90.81 147.38 35.91 Favored Pre-proline 0 C--N 1.272 -2.768 0 CA-C-N 109.781 -3.372 . . . . 0.0 109.587 -179.379 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.561 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -100.71 178.57 0.23 Allowed 'Trans proline' 0 C--N 1.314 -1.283 0 N-CA-C 107.378 -1.816 . . . . 0.0 107.378 84.303 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.483 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 14.5 m -128.78 -176.55 0.54 Allowed Pre-proline 0 C--N 1.285 -2.232 0 CA-C-N 113.609 -1.632 . . . . 0.0 107.41 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.451 ' CD ' ' HB3' ' A' ' 49' ' ' SER . 87.7 Cg_endo -100.64 -30.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 123.121 2.547 . . . . 0.0 118.093 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -138.18 162.41 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.33 0 CA-C-O 123.559 1.647 . . . . 0.0 114.381 -179.348 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.532 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -112.52 169.81 8.62 Favored 'General case' 0 C--N 1.296 -1.723 1 CA-C-N 107.796 -4.275 . . . . 0.0 110.213 -179.645 . . . . . . . . 4 4 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 167.23 -141.25 6.76 Favored Glycine 0 C--N 1.288 -2.113 1 N-CA-C 96.799 -6.52 . . . . 0.0 96.799 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.466 ' HE3' ' HG2' ' A' ' 28' ' ' GLU . 0.6 OUTLIER -93.6 -179.31 4.98 Favored 'General case' 0 C--N 1.288 -2.066 1 N-CA-C 99.785 -4.154 . . . . 0.0 99.785 179.99 . . . . . . . . 4 4 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 48.1 t -127.9 98.39 4.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.451 1 N-CA-C 91.689 -7.152 . . . . 0.0 91.689 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 55.1 mt -58.81 -88.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 124.787 1.304 . . . . 0.0 109.874 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -139.43 166.16 25.31 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -126.57 134.7 65.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 1 N-CA-C 94.43 -6.137 . . . . 0.0 94.43 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.439 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.8 mp -94.6 -57.25 2.53 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.276 -0.97 . . . . 0.0 112.238 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 22.8 t -113.05 94.22 29.02 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 101.061 -3.681 . . . . 0.0 101.061 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.433 ' O ' HG21 ' A' ' 18' ' ' ILE . 13.2 Cg_exo -71.93 -81.31 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 CA-C-N 120.09 1.068 . . . . 0.0 109.558 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -137.11 164.2 28.99 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.53 -49.46 1.2 Allowed Glycine 0 N--CA 1.499 2.881 0 C-N-CA 119.962 -1.113 . . . . 0.0 113.133 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.78 -172.27 2.56 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 105.511 -2.033 . . . . 0.0 105.511 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.1 t -114.92 144.82 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.39 147.84 49.7 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.64 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 7.8 p -106.54 -160.04 0.72 Allowed 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.658 1.694 . . . . 0.0 108.367 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.495 HG11 ' H ' ' A' ' 9' ' ' ILE . 44.8 t -115.07 155.85 16.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.309 1 N-CA-C 91.751 -7.129 . . . . 0.0 91.751 178.477 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.19 -36.79 3.77 Favored Glycine 0 N--CA 1.49 2.264 1 N-CA-C 102.464 -4.254 . . . . 0.0 102.464 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.451 ' H ' ' C ' ' A' ' 68' ' ' VAL . 33.0 tt0 -104.2 164.19 11.89 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 102.316 -3.216 . . . . 0.0 102.316 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -98.69 -178.15 3.89 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 103.658 -2.719 . . . . 0.0 103.658 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 36.4 tp -138.66 -72.03 0.41 Allowed 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.001 -2.222 . . . . 0.0 105.001 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 10.9 tt -132.7 159.79 42.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.6 t -137.99 163.92 30.33 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 125.869 1.98 . . . . 0.0 106.496 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.9 155.58 49.58 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 125.636 1.835 . . . . 0.0 110.984 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -120.06 144.8 47.38 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 104.265 -2.494 . . . . 0.0 104.265 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 80' ' ' TYR . . . -143.68 84.07 10.16 Favored Pre-proline 0 N--CA 1.492 1.636 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -61.73 53.68 0.11 Allowed 'Trans proline' 0 N--CA 1.507 2.292 0 C-N-CA 124.792 3.662 . . . . 0.0 118.723 -168.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.21 63.5 0.19 Allowed Glycine 0 N--CA 1.489 2.169 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 1.8 t80 . . . . . 0 N--CA 1.497 1.883 0 N-CA-C 102.821 -3.029 . . . . 0.0 102.821 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.4 ' N ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.494 1.731 1 N-CA-C 97.812 -4.884 . . . . 0.0 97.812 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.468 ' HB3' ' CB ' ' A' ' 75' ' ' LEU . 18.8 t80 -117.2 93.15 4.07 Favored 'General case' 0 C--N 1.297 -1.689 1 N-CA-C 95.009 -5.923 . . . . 0.0 95.009 178.849 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.4 ' OE2' ' N ' ' A' ' 1' ' ' ALA . 7.1 mp0 -68.41 -177.45 0.92 Allowed 'General case' 0 C--N 1.302 -1.493 0 O-C-N 125.6 1.813 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -110.31 -30.15 7.83 Favored 'General case' 0 N--CA 1.51 2.553 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -179.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.572 ' CG ' HG22 ' A' ' 68' ' ' VAL . 36.5 mmtt -127.06 166.59 17.32 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 103.074 -2.935 . . . . 0.0 103.074 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 74.2 mt -108.79 -173.65 0.27 Allowed Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -54.29 85.36 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.856 1.704 . . . . 0.0 109.031 158.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.505 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.7 t70 -121.88 -74.73 0.61 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 101.761 -3.422 . . . . 0.0 101.761 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.618 ' H ' HG11 ' A' ' 68' ' ' VAL . 40.2 pt 30.47 38.62 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.975 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.53 -46.83 1.01 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 119.439 -1.362 . . . . 0.0 112.706 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.02 80.9 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 124.355 2.026 . . . . 0.0 113.987 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.68 -68.18 0.26 Allowed Glycine 0 C--N 1.277 -2.746 0 CA-C-N 111.877 -2.42 . . . . 0.0 107.637 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 14' ' ' HIS . 40.4 mm -127.2 -172.96 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.444 ' N ' HG22 ' A' ' 13' ' ' ILE . 2.1 p80 -144.02 -50.97 0.31 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.583 0.706 . . . . 0.0 111.276 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.7 pt-20 -103.24 -168.81 1.56 Allowed 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 116.381 1.993 . . . . 0.0 116.381 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.09 112.15 0.59 Allowed Glycine 0 C--N 1.286 -2.227 0 CA-C-N 112.795 -2.002 . . . . 0.0 108.202 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -98.95 92.02 5.32 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 101.567 -3.494 . . . . 0.0 101.567 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.7 mt -85.01 104.2 12.89 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.9 t -86.82 -47.49 16.05 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.476 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.423 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 41.1 tttt -126.22 146.31 50.04 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-N 114.431 -1.258 . . . . 0.0 113.394 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.463 ' CZ2' ' SG ' ' A' ' 36' ' ' CYS . 4.8 m95 -121.6 176.76 5.54 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 103.846 -2.65 . . . . 0.0 103.846 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.504 ' CD2' HG21 ' A' ' 34' ' ' VAL . 13.8 m-85 -123.76 -34.91 2.96 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 126.257 2.223 . . . . 0.0 112.189 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.531 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 10.3 m -103.74 176.54 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.977 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -140.9 61.31 14.58 Favored Pre-proline 0 N--CA 1.492 1.627 0 N-CA-C 117.933 2.568 . . . . 0.0 117.933 -179.438 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 23' ' ' VAL . 5.8 Cg_exo -21.54 -179.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 N-CA-C 119.699 2.923 . . . . 0.0 119.699 -60.079 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.531 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.33 28.61 8.69 Favored Glycine 0 N--CA 1.497 2.713 0 CA-C-N 111.597 -2.547 . . . . 0.0 108.198 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 54' ' ' LYS . 5.2 t0 7.86 -95.6 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.16 0 O-C-N 128.527 3.133 . . . . 0.0 110.905 179.427 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.428 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 3.1 mm-40 -98.44 119.7 37.59 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 100.818 -3.771 . . . . 0.0 100.818 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -120.23 168.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 122.296 1.046 . . . . 0.0 109.208 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.7 m-20 -99.85 -168.13 1.56 Allowed 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 112.535 -2.12 . . . . 0.0 107.729 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.731 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.263 4.6 tt0 -120.62 52.36 1.17 Allowed 'General case' 0 N--CA 1.494 1.753 1 N-CA-C 97.838 -4.875 . . . . 0.0 97.838 -179.727 . . . . . . . . 4 3 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -171.37 36.89 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 111.403 -2.635 . . . . 0.0 111.711 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.46 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 19.1 t70 -112.96 -178.38 3.37 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.455 -0.778 . . . . 0.0 109.116 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.504 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -84.77 -166.06 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 127.314 3.435 . . . . 0.0 117.664 179.75 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.685 ' HB3' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -115.27 -150.68 0.47 Allowed 'General case' 0 C--N 1.281 -2.404 2 CA-C-N 103.319 -6.31 . . . . 0.0 108.645 -179.553 . . . . . . . . 4 4 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.463 ' SG ' ' CZ2' ' A' ' 21' ' ' TRP . 1.8 m -127.19 159.38 34.47 Favored 'General case' 0 C--N 1.284 -2.282 2 N-CA-C 97.025 -5.176 . . . . 0.0 97.025 179.193 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -114.64 108.6 17.02 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 100.492 -3.892 . . . . 0.0 100.492 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 49.1 t -112.96 147.61 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 37.4 tt0 -113.09 155.53 24.76 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.088 -1.045 . . . . 0.0 108.886 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -140.49 -168.97 2.68 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 104.683 -2.339 . . . . 0.0 104.683 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.457 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.9 OUTLIER -11.13 -64.0 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 126.427 2.33 . . . . 0.0 115.301 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.457 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 17.2 mttp -144.82 -21.87 0.51 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 124.065 0.853 . . . . 0.0 110.439 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.44 -176.33 3.08 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.628 1.204 . . . . 0.0 112.431 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 38.3 t -125.94 137.58 57.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 103.398 -2.816 . . . . 0.0 103.398 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.5 t -112.05 157.8 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.569 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -119.8 141.26 49.66 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 111.572 -2.558 . . . . 0.0 109.952 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.685 ' C ' ' HB3' ' A' ' 35' ' ' LEU . 1.9 mp -125.92 75.22 71.47 Favored Pre-proline 0 CA--C 1.574 1.87 0 N-CA-C 101.556 -3.498 . . . . 0.0 101.556 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.462 ' N ' ' HB3' ' A' ' 35' ' ' LEU . 78.3 Cg_endo -62.07 -172.42 0.11 Allowed 'Trans proline' 0 N--CA 1.512 2.574 0 C-N-CA 122.894 2.396 . . . . 0.0 108.173 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.7 p -105.07 85.22 1.2 Allowed Pre-proline 0 C--N 1.286 -2.19 0 CA-C-N 112.934 -1.939 . . . . 0.0 111.567 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -46.31 -31.98 10.08 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.588 1.525 . . . . 0.0 112.926 176.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.731 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -131.09 167.61 25.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.547 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.76 165.15 11.22 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 127.141 2.776 . . . . 0.0 108.097 179.408 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 148.23 -139.85 7.95 Favored Glycine 0 C--N 1.293 -1.808 0 N-CA-C 106.237 -2.745 . . . . 0.0 106.237 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.601 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -111.91 169.03 9.12 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 -179.503 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.406 HG11 ' H ' ' A' ' 26' ' ' GLY . 33.4 t -128.38 61.55 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 100.856 -3.757 . . . . 0.0 100.856 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.439 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 40.8 mt -31.37 -74.11 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 110.845 -2.889 . . . . 0.0 114.227 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -138.75 163.76 31.34 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 114.127 1.158 . . . . 0.0 114.127 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.4 HD12 ' HD3' ' A' ' 25' ' ' PRO . 56.1 mt -136.36 136.94 48.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 1 N-CA-C 100.062 -4.051 . . . . 0.0 100.062 179.762 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.3 mt -94.25 -63.56 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.727 0.775 . . . . 0.0 110.453 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.473 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 15.8 t -115.94 73.8 4.91 Favored Pre-proline 0 N--CA 1.491 1.622 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 -179.608 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -45.88 -77.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.067 1.845 . . . . 0.0 113.335 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.2 -177.14 4.7 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.45 -49.96 4.32 Favored Glycine 0 N--CA 1.492 2.4 0 CA-C-N 113.929 -1.487 . . . . 0.0 113.007 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.473 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 5.3 m -103.51 -176.22 3.02 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.4 150.05 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.87 160.8 26.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 9.5 t -115.25 -161.29 0.77 Allowed 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.618 HG11 ' H ' ' A' ' 9' ' ' ILE . 73.3 t -120.25 153.78 23.28 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 95.036 -5.913 . . . . 0.0 95.036 178.618 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.58 -37.99 3.42 Favored Glycine 0 N--CA 1.492 2.427 1 N-CA-C 101.513 -4.635 . . . . 0.0 101.513 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -97.53 159.43 14.93 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 100.71 -3.811 . . . . 0.0 100.71 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.5 179.25 5.07 Favored 'General case' 0 C--N 1.288 -2.082 0 N-CA-C 100.222 -3.992 . . . . 0.0 100.222 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 52.4 tp -138.81 -67.22 0.46 Allowed 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.78 161.94 37.65 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 103.107 -2.924 . . . . 0.0 103.107 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.8 t -137.42 157.45 46.55 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 126.327 2.267 . . . . 0.0 105.714 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.468 ' CB ' ' HB3' ' A' ' 2' ' ' PHE . 0.6 OUTLIER -137.43 150.92 47.99 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -114.26 151.35 32.98 Favored 'General case' 0 C--N 1.296 -1.72 1 N-CA-C 98.865 -4.494 . . . . 0.0 98.865 179.388 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.433 ' HB3' ' HA ' ' A' ' 78' ' ' PRO . . . -117.76 -36.68 0.07 OUTLIER Pre-proline 0 N--CA 1.501 2.078 0 C-N-CA 119.465 -0.894 . . . . 0.0 112.747 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 77' ' ' ALA . 38.2 Cg_exo -64.02 -178.87 0.65 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 125.701 2.421 . . . . 0.0 107.647 -62.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.44 -39.23 2.1 Favored Glycine 0 N--CA 1.5 2.926 1 N-CA-C 101.933 -4.467 . . . . 0.0 101.933 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.581 0 N-CA-C 101.476 -3.527 . . . . 0.0 101.476 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.476 ' N ' ' O ' ' A' ' 80' ' ' TYR . . . . . . . . 0 N--CA 1.508 2.462 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.531 ' HB2' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -141.38 159.21 42.69 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.869 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.59 -142.42 0.27 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.755 ' CZ ' ' HD3' ' A' ' 5' ' ' LYS . 14.1 t80 -126.37 -60.75 1.24 Allowed 'General case' 0 N--CA 1.504 2.228 0 O-C-N 124.422 1.076 . . . . 0.0 113.34 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.755 ' HD3' ' CZ ' ' A' ' 4' ' ' PHE . 20.9 mmmt -132.1 143.61 50.14 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 67.9 mt -90.27 173.46 5.69 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 125.053 1.471 . . . . 0.0 107.963 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -40.88 81.59 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.294 0 N-CA-C 118.414 2.429 . . . . 0.0 118.414 168.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.466 ' HB3' HG11 ' A' ' 68' ' ' VAL . 12.2 t70 -122.68 -76.82 0.59 Allowed 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 103.604 -2.739 . . . . 0.0 103.604 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 27.4 pt 37.4 44.45 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.251 0 CA-C-O 122.683 1.23 . . . . 0.0 108.865 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 14' ' ' HIS . . . -90.62 -161.95 37.84 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -109.59 160.83 15.93 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 118.551 1.176 . . . . 0.0 108.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.28 -72.49 0.38 Allowed Glycine 0 N--CA 1.485 1.934 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.5 mm -132.4 82.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 124.933 1.02 . . . . 0.0 110.248 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -105.57 16.13 25.92 Favored 'General case' 0 N--CA 1.507 2.38 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.092 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 7.8 pt-20 -140.09 166.92 23.35 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 113.923 -1.49 . . . . 0.0 108.01 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.03 125.3 4.65 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 107.417 -2.273 . . . . 0.0 107.417 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.464 ' H ' HG13 ' A' ' 38' ' ' VAL . 33.8 tt0 -96.9 100.45 11.97 Favored 'General case' 0 C--N 1.302 -1.471 1 N-CA-C 99.04 -4.43 . . . . 0.0 99.04 179.77 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG22 ' A' ' 38' ' ' VAL . 16.0 mm -82.4 124.57 39.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 1 N-CA-C 99.599 -4.223 . . . . 0.0 99.599 -179.766 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.447 HG21 ' HB2' ' A' ' 39' ' ' GLN . 2.0 t -105.24 -39.79 5.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.821 ' HE3' ' CZ ' ' A' ' 22' ' ' PHE . 20.5 tttp -136.7 155.25 50.12 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.169 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.423 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 14.8 m95 -122.77 178.81 4.86 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 125.495 1.747 . . . . 0.0 106.489 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.821 ' CZ ' ' HE3' ' A' ' 20' ' ' LYS . 28.3 m-85 -132.94 -52.58 0.91 Allowed 'General case' 0 N--CA 1.504 2.259 0 O-C-N 124.373 1.045 . . . . 0.0 112.638 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 m -99.16 175.86 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 124.062 0.851 . . . . 0.0 109.596 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.486 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -117.35 161.99 30.5 Favored Pre-proline 0 C--N 1.295 -1.788 0 O-C-N 125.724 1.89 . . . . 0.0 108.443 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -56.07 112.77 1.17 Allowed 'Trans proline' 0 C--N 1.316 -1.153 0 C-N-CA 121.703 1.602 . . . . 0.0 113.013 174.319 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.51 16.81 14.89 Favored Glycine 0 N--CA 1.484 1.887 0 CA-C-O 117.167 -1.907 . . . . 0.0 113.501 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -86.76 161.12 18.56 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 116.652 -2.019 . . . . 0.0 108.008 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.45 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -109.71 92.16 3.94 Favored 'General case' 0 C--N 1.294 -1.816 1 N-CA-C 99.813 -4.143 . . . . 0.0 99.813 -179.574 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 31' ' ' GLU . 6.1 p -91.64 176.16 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 C-N-CA 117.308 -1.757 . . . . 0.0 106.368 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.594 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 26.9 t30 -105.72 -21.72 13.12 Favored 'General case' 0 N--CA 1.529 3.498 0 CA-C-O 123.701 1.715 . . . . 0.0 112.243 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.541 ' H ' HG22 ' A' ' 29' ' ' VAL 0.404 3.8 tp10 36.41 67.9 0.29 Allowed 'General case' 0 C--N 1.281 -2.389 5 N-CA-C 135.059 8.911 . . . . 0.0 135.059 179.566 . . . . . . . . 4 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.9 p-10 -137.4 22.66 2.96 Favored 'General case' 0 C--N 1.288 -2.108 4 CA-C-N 95.715 -9.766 . . . . 0.0 96.572 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.548 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 28.5 t70 -115.23 -148.94 0.44 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 127.15 2.18 . . . . 0.0 105.54 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.548 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 1.9 t -120.08 163.32 17.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 126.531 3.062 . . . . 0.0 109.054 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.58 ' CB ' HG21 ' A' ' 47' ' ' ILE . 13.4 tp -123.27 -81.95 0.64 Allowed 'General case' 0 C--N 1.283 -2.319 2 CA-C-N 107.451 -4.432 . . . . 0.0 99.368 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.455 ' SG ' HD13 ' A' ' 47' ' ' ILE . 16.9 p -132.44 172.46 12.45 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.58 ' HA ' ' HA ' ' A' ' 45' ' ' VAL . 3.7 tt0 -130.42 138.51 50.37 Favored 'General case' 0 N--CA 1.5 2.067 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 ' H ' ' A' ' 17' ' ' GLU . 25.2 t -135.26 145.53 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.335 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.499 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 4.7 tt0 -109.12 138.81 44.9 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -164.31 -161.17 0.58 Allowed 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 105.805 -1.924 . . . . 0.0 105.805 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.506 ' C ' ' HG3' ' A' ' 42' ' ' LYS . 5.6 p-10 -29.03 -58.31 0.14 Allowed 'General case' 0 C--N 1.297 -1.713 0 O-C-N 126.562 2.414 . . . . 0.0 114.475 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.506 ' HG3' ' C ' ' A' ' 41' ' ' ASP . 2.9 mttt -137.9 -8.85 1.59 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.678 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -93.73 158.26 15.76 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 114.609 1.337 . . . . 0.0 114.609 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.88 -44.28 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 126.335 2.272 . . . . 0.0 109.451 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 23.4 t -103.53 155.86 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 C-N-CA 125.574 1.55 . . . . 0.0 108.749 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.673 ' HB3' HD12 ' A' ' 47' ' ' ILE . 7.9 mt-10 -114.27 -63.42 1.45 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 126.683 2.489 . . . . 0.0 114.608 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.673 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -92.88 149.64 38.07 Favored Pre-proline 0 C--N 1.281 -2.374 0 CA-C-N 108.821 -3.809 . . . . 0.0 115.094 -178.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.662 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.25 177.59 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.112 0 N-CA-C 107.569 -1.743 . . . . 0.0 107.569 87.582 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 9.7 m -119.13 177.33 1.37 Allowed Pre-proline 0 C--N 1.284 -2.257 0 CA-C-N 112.838 -1.983 . . . . 0.0 113.315 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -95.94 -44.79 0.02 OUTLIER 'Trans proline' 0 CA--C 1.555 1.572 0 N-CA-C 118.57 2.488 . . . . 0.0 118.57 169.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.645 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.8 OUTLIER -130.76 166.24 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 123.191 1.472 . . . . 0.0 114.947 -179.375 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.645 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -121.1 170.57 9.41 Favored 'General case' 0 C--N 1.3 -1.561 1 CA-C-N 107.835 -4.257 . . . . 0.0 112.314 179.971 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.22 -124.64 1.21 Allowed Glycine 0 N--CA 1.49 2.281 1 N-CA-C 96.897 -6.481 . . . . 0.0 96.897 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.542 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 16.8 tttp -107.35 -174.92 2.65 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.415 ' H ' ' HG2' ' A' ' 54' ' ' LYS . 60.3 t -130.93 65.75 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.279 1 N-CA-C 97.292 -5.077 . . . . 0.0 97.292 -179.617 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.458 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 80.1 mt -29.53 -78.09 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 112.242 -2.253 . . . . 0.0 110.956 -179.607 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -145.68 165.88 27.46 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 33.3 mt -132.78 139.93 48.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 1 N-CA-C 98.258 -4.719 . . . . 0.0 98.258 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -106.97 -31.34 8.36 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 123.819 0.7 . . . . 0.0 111.199 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.452 HG21 HD12 ' A' ' 72' ' ' LEU . 19.8 t -107.39 130.31 23.02 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -49.91 -150.38 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 124.254 3.302 . . . . 0.0 116.487 158.143 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 39.93 3.57 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 111.86 -2.427 . . . . 0.0 107.847 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -142.82 -6.2 0.71 Allowed Glycine 0 N--CA 1.497 2.734 0 CA-C-N 111.504 -2.589 . . . . 0.0 116.071 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.1 m -121.63 172.67 7.94 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 105.244 -2.132 . . . . 0.0 105.244 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.39 144.31 16.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 102.672 -3.084 . . . . 0.0 102.672 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -118.79 164.97 14.6 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.0 p -109.28 -163.2 0.85 Allowed 'General case' 0 C--N 1.283 -2.307 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.471 HG22 ' CB ' ' A' ' 5' ' ' LYS . 52.2 t -119.39 154.16 21.94 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 1 N-CA-C 92.681 -6.785 . . . . 0.0 92.681 178.748 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 101.06 -38.62 3.06 Favored Glycine 0 N--CA 1.49 2.291 1 N-CA-C 100.416 -5.073 . . . . 0.0 100.416 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.46 ' H ' ' C ' ' A' ' 68' ' ' VAL . 25.4 tt0 -99.94 160.57 14.21 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 101.013 -3.699 . . . . 0.0 101.013 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -105.89 -175.6 2.84 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 101.687 -3.449 . . . . 0.0 101.687 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.68 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . 0.9 OUTLIER -145.15 -57.46 0.33 Allowed 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 16.0 tt -137.13 163.48 32.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 t -135.86 159.21 42.36 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 103.114 -2.921 . . . . 0.0 103.114 179.051 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.531 ' HB3' ' HB2' ' A' ' 2' ' ' PHE . 1.0 OUTLIER -138.58 147.16 42.68 Favored 'General case' 0 C--N 1.289 -2.062 0 O-C-N 125.392 1.682 . . . . 0.0 107.734 -179.502 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.542 ' CG ' ' H ' ' A' ' 54' ' ' LYS . 2.1 p30 -115.64 158.19 23.09 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 104.154 -2.536 . . . . 0.0 104.154 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.567 ' CB ' ' HB2' ' A' ' 80' ' ' TYR . . . -139.38 139.02 21.46 Favored Pre-proline 0 C--N 1.29 -1.994 0 N-CA-C 102.627 -3.101 . . . . 0.0 102.627 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -70.53 -37.35 7.42 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 121.974 1.783 . . . . 0.0 110.466 173.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.541 ' O ' ' CD1' ' A' ' 80' ' ' TYR . . . -121.97 27.11 6.27 Favored Glycine 0 N--CA 1.493 2.494 0 CA-C-O 115.992 -2.56 . . . . 0.0 113.086 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.567 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 21.7 m-85 . . . . . 0 N--CA 1.503 2.215 0 CA-C-O 115.509 -2.186 . . . . 0.0 108.283 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.047 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -115.34 147.11 40.87 Favored 'General case' 0 N--CA 1.498 1.946 1 N-CA-C 99.897 -4.112 . . . . 0.0 99.897 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -113.65 -168.79 1.39 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 118.878 0.763 . . . . 0.0 112.639 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.439 ' CD2' HD13 ' A' ' 72' ' ' LEU . 41.7 t80 -105.69 -22.94 12.85 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 -179.53 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.467 ' CG ' HG22 ' A' ' 68' ' ' VAL . 11.0 mmtm -127.55 177.64 6.64 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 102.638 -3.097 . . . . 0.0 102.638 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 83.5 mt -105.62 176.22 1.8 Allowed Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -54.44 82.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.676 1.584 . . . . 0.0 110.111 153.332 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.509 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.6 t70 -122.06 -82.65 0.65 Allowed 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.485 -2.043 . . . . 0.0 105.485 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.46 HG23 HG12 ' A' ' 68' ' ' VAL . 24.0 pt 39.16 27.71 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 124.055 0.847 . . . . 0.0 111.647 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.18 -70.99 0.05 OUTLIER Glycine 0 N--CA 1.477 1.423 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.825 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.407 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 1.1 mp0 -51.06 153.08 2.01 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 124.415 2.055 . . . . 0.0 116.312 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -22.16 -41.01 0.01 OUTLIER Glycine 0 N--CA 1.498 2.824 0 CA-C-N 110.908 -2.86 . . . . 0.0 118.439 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.466 HD12 ' N ' ' A' ' 13' ' ' ILE . 3.2 mp -115.94 64.0 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.216 1.008 . . . . 0.0 108.81 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.408 ' O ' HG23 ' A' ' 68' ' ' VAL . 2.1 p80 -85.72 7.61 22.92 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-N 114.72 -1.127 . . . . 0.0 112.493 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.1 pt-20 -129.68 -165.89 1.59 Allowed 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.992 0.901 . . . . 0.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.14 112.51 0.55 Allowed Glycine 0 N--CA 1.503 3.106 0 CA-C-O 117.484 -1.731 . . . . 0.0 112.808 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 56.4 tt0 -104.17 85.95 2.47 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 103.223 -2.881 . . . . 0.0 103.223 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.569 HD11 HD11 ' A' ' 72' ' ' LEU . 1.9 mp -87.48 124.63 40.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.9 t -101.8 -46.85 11.32 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 O-C-N 124.53 1.144 . . . . 0.0 109.252 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.433 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 12.1 ttmt -131.69 145.18 51.5 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 124.564 1.165 . . . . 0.0 112.123 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -115.98 -178.64 3.45 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 178.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -126.56 -27.15 3.17 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 111.248 -2.706 . . . . 0.0 111.169 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.575 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 7.4 m -101.49 -177.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.172 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.433 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.2 mptp? -100.19 -41.23 0.22 Allowed Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.502 ' C ' ' H ' ' A' ' 27' ' ' ASP . 43.1 Cg_endo -49.56 170.84 1.38 Allowed 'Cis proline' 0 N--CA 1.498 1.762 1 N-CA-C 124.991 4.958 . . . . 0.0 124.991 29.714 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.575 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -94.22 37.39 3.42 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 105.846 -2.902 . . . . 0.0 105.846 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.544 ' OD1' ' HE3' ' A' ' 54' ' ' LYS . 14.9 t70 3.1 -90.46 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.175 0 O-C-N 127.796 2.703 . . . . 0.0 110.131 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.579 ' HG2' ' CE ' ' A' ' 54' ' ' LYS . 6.7 mt-10 -99.53 111.58 23.91 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 101.972 -3.344 . . . . 0.0 101.972 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 163.98 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 CA-C-O 124.49 2.091 . . . . 0.0 114.704 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.653 HD22 ' CG ' ' A' ' 32' ' ' ASP . 10.2 p-10 -98.22 -171.27 2.11 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 110.075 -3.239 . . . . 0.0 112.17 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 4.7 tt0 -121.88 68.11 0.92 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.653 ' CG ' HD22 ' A' ' 30' ' ' ASN . 3.5 p30 -179.7 -27.61 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 112.965 -1.925 . . . . 0.0 110.808 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.475 ' HB3' ' HB2' ' A' ' 49' ' ' SER . 4.2 t0 -28.77 154.04 0.0 OUTLIER 'General case' 0 N--CA 1.514 2.768 0 CA-C-O 122.992 1.377 . . . . 0.0 114.279 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.677 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -56.17 -176.73 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 124.188 4.885 . . . . 0.0 124.188 -179.251 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.677 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.1 mm? -86.69 174.25 8.97 Favored 'General case' 0 N--CA 1.411 -2.393 2 CA-C-N 101.792 -7.004 . . . . 0.0 101.488 -179.38 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.0 m -127.97 155.08 44.83 Favored 'General case' 0 C--N 1.265 -3.082 2 N-CA-C 97.587 -4.968 . . . . 0.0 97.587 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.433 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 12.9 mt-10 -118.26 103.53 9.91 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 38.4 t -116.59 155.68 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 CA-C-N 113.429 -1.714 . . . . 0.0 107.158 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -118.37 162.07 18.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -155.23 -172.31 4.13 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -17.57 -62.44 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 126.409 2.318 . . . . 0.0 115.2 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.3 mttp -140.45 -13.91 0.99 Allowed 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.185 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -109.71 175.21 5.53 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 116.598 2.073 . . . . 0.0 116.598 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.4 t -122.59 136.48 59.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 1 N-CA-C 99.611 -4.218 . . . . 0.0 99.611 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.7 t -117.47 161.27 16.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.448 1.118 . . . . 0.0 109.589 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 47' ' ' ILE . 11.9 pt-20 -123.67 129.13 50.64 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 110.227 -3.17 . . . . 0.0 106.758 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.522 HD12 ' N ' ' A' ' 47' ' ' ILE . 3.7 mp -125.07 96.71 39.3 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 115.806 -2.045 . . . . 0.0 106.266 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 35' ' ' LEU . 60.7 Cg_endo -68.62 -164.85 0.12 Allowed 'Trans proline' 0 N--CA 1.515 2.742 0 C-N-CA 124.446 3.431 . . . . 0.0 106.917 -174.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.475 ' HB2' ' HB3' ' A' ' 33' ' ' ASP . 14.4 t -104.02 103.25 36.74 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 111.875 -2.42 . . . . 0.0 108.962 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 85.3 Cg_exo -49.31 -55.24 4.33 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.659 2.906 . . . . 0.0 119.01 161.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.402 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.59 168.43 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-O 121.933 0.873 . . . . 0.0 112.748 -179.613 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 4.1 pttt -96.33 167.89 10.9 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 111.409 -2.632 . . . . 0.0 106.719 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.08 -135.87 5.87 Favored Glycine 0 C--N 1.289 -2.071 0 N-CA-C 105.955 -2.858 . . . . 0.0 105.955 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.579 ' CE ' ' HG2' ' A' ' 28' ' ' GLU . 4.3 tptt -116.82 164.92 13.93 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 104.966 -2.235 . . . . 0.0 104.966 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.453 HG11 ' H ' ' A' ' 26' ' ' GLY . 22.1 t -126.43 58.11 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.809 1 N-CA-C 100.164 -4.013 . . . . 0.0 100.164 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 18.0 mt -29.51 -73.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 CA-C-N 110.29 -3.141 . . . . 0.0 115.084 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -137.03 163.9 29.66 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.973 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.5 mt -138.61 144.56 29.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 1 N-CA-C 98.87 -4.493 . . . . 0.0 98.87 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -111.33 -54.79 2.57 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.5 t -113.42 78.77 3.67 Favored Pre-proline 0 C--N 1.3 -1.571 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -55.18 -85.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 121.708 1.605 . . . . 0.0 113.455 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -139.7 170.63 15.54 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 78.41 -35.71 1.78 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.11 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.7 m -99.63 171.98 7.57 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 67.1 t -115.06 142.97 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.66 160.18 31.5 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.8 t -105.41 -156.91 0.59 Allowed 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.509 HG11 ' HB3' ' A' ' 8' ' ' ASP . 61.5 t -121.69 158.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 1 N-CA-C 94.886 -5.968 . . . . 0.0 94.886 178.408 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.43 -29.36 9.73 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 104.675 -3.37 . . . . 0.0 104.675 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.449 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -109.41 156.71 19.72 Favored 'General case' 0 C--N 1.302 -1.483 1 N-CA-C 99.119 -4.4 . . . . 0.0 99.119 179.793 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -87.2 -174.15 4.74 Favored 'General case' 0 C--N 1.288 -2.089 0 N-CA-C 100.93 -3.73 . . . . 0.0 100.93 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.569 HD11 HD11 ' A' ' 18' ' ' ILE . 3.9 tt -145.99 -62.97 0.32 Allowed 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 104.554 -2.387 . . . . 0.0 104.554 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 tt -138.42 162.17 30.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 102.092 -3.299 . . . . 0.0 102.092 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 t -136.92 159.73 41.0 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 103.96 -2.608 . . . . 0.0 103.96 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.4 146.05 36.1 Favored 'General case' 0 C--N 1.284 -2.255 0 CA-C-N 111.806 -2.452 . . . . 0.0 105.113 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.07 159.31 16.68 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 98.895 -4.483 . . . . 0.0 98.895 179.318 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.514 ' H ' ' CA ' ' A' ' 78' ' ' PRO . . . -138.13 -36.79 0.02 OUTLIER Pre-proline 0 C--N 1.289 -2.03 0 CA-C-N 114.274 -1.33 . . . . 0.0 111.093 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.514 ' CA ' ' H ' ' A' ' 77' ' ' ALA . 18.6 Cg_endo -104.18 138.39 1.03 Allowed 'Cis proline' 0 C--N 1.316 -1.139 0 C-N-CA 129.235 0.931 . . . . 0.0 111.334 -24.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.85 41.79 0.76 Allowed Glycine 0 N--CA 1.498 2.825 0 N-CA-C 105.974 -2.851 . . . . 0.0 105.974 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.9 m-30 . . . . . 0 C--N 1.299 -1.591 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.133 0 N-CA-C 104.184 -2.524 . . . . 0.0 104.184 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.442 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -125.17 160.69 28.55 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 103.026 -2.953 . . . . 0.0 103.026 -179.608 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.8 -158.53 0.87 Allowed 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -112.22 -45.14 3.31 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 125.582 1.801 . . . . 0.0 111.819 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HG3' HG22 ' A' ' 68' ' ' VAL . 0.3 OUTLIER -124.24 -175.07 3.15 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 100.815 -3.772 . . . . 0.0 100.815 179.36 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -115.45 -176.39 0.37 Allowed Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 104.288 -2.486 . . . . 0.0 104.288 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.83 88.07 0.05 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 N-CA-C 103.094 -3.464 . . . . 0.0 103.094 145.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.584 ' HB3' HG11 ' A' ' 68' ' ' VAL 0.313 0.8 OUTLIER -121.6 -91.43 0.56 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 111.874 -2.421 . . . . 0.0 104.803 -179.616 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.66 ' H ' HG11 ' A' ' 68' ' ' VAL . 38.8 pt 45.66 37.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -88.65 -171.31 46.03 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.712 -1.755 . . . . 0.0 108.712 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -89.46 163.62 15.18 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-O 122.983 1.373 . . . . 0.0 110.595 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -74.44 0.21 Allowed Glycine 0 C--N 1.293 -1.845 0 CA-C-N 112.346 -2.206 . . . . 0.0 108.824 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.7 mt -131.93 114.66 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 101.612 -3.477 . . . . 0.0 101.612 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -125.26 18.0 8.32 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 121.827 2.103 . . . . 0.0 107.712 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.537 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.5 OUTLIER -127.34 -177.93 4.26 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 123.116 1.436 . . . . 0.0 113.146 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.25 101.03 0.33 Allowed Glycine 0 N--CA 1.503 3.103 0 CA-C-N 112.664 -2.062 . . . . 0.0 110.827 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -101.92 102.25 12.78 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 105.166 -2.161 . . . . 0.0 105.166 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 mt -89.24 131.92 35.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 105.639 -1.986 . . . . 0.0 105.639 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.78 -57.91 4.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -129.37 169.74 14.52 Favored 'General case' 0 N--CA 1.508 2.447 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.789 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 23.8 m95 -130.49 171.64 12.78 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 126.017 2.073 . . . . 0.0 106.763 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.485 ' CD2' HG21 ' A' ' 34' ' ' VAL . 21.8 m-85 -124.94 -52.12 1.67 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 124.937 1.398 . . . . 0.0 109.102 -179.812 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.5 m -99.32 179.1 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.473 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -119.9 168.26 10.67 Favored Pre-proline 0 C--N 1.292 -1.904 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.439 ' HD3' HD12 ' A' ' 58' ' ' ILE . 83.9 Cg_endo -74.19 144.45 33.42 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 121.453 1.435 . . . . 0.0 108.888 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.401 ' O ' ' NZ ' ' A' ' 54' ' ' LYS . . . 97.95 -14.97 62.28 Favored Glycine 0 CA--C 1.476 -2.383 0 CA-C-O 116.654 -2.192 . . . . 0.0 110.166 179.223 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 4.3 m-20 -82.61 -173.07 4.41 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.493 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS 0.25 6.5 mt-10 -122.42 158.35 29.91 Favored 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 101.593 -3.484 . . . . 0.0 101.593 179.92 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.4 p -121.93 157.57 26.0 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 CA-C-O 122.228 1.013 . . . . 0.0 110.261 -179.193 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.459 ' HA ' ' HB2' ' A' ' 52' ' ' LYS . 5.3 m-20 -98.58 -167.65 1.53 Allowed 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 111.066 -2.788 . . . . 0.0 113.283 -178.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 19.9 tt0 -122.98 52.5 1.35 Allowed 'General case' 0 C--N 1.298 -1.641 1 N-CA-C 96.789 -5.263 . . . . 0.0 96.789 -179.818 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.452 ' CG ' ' HB3' ' A' ' 30' ' ' ASN . 0.6 OUTLIER -164.1 -59.21 0.04 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.902 -179.42 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.655 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 14.3 t70 -52.17 -168.91 0.0 OUTLIER 'General case' 0 N--CA 1.513 2.692 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.655 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -97.42 -168.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 129.135 2.974 . . . . 0.0 109.837 -179.357 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.644 ' H ' HG12 ' A' ' 34' ' ' VAL . 24.0 tp -141.23 -95.59 0.14 Allowed 'General case' 0 C--N 1.294 -1.836 1 CA-C-N 107.74 -4.3 . . . . 0.0 100.861 178.704 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -122.47 -179.08 4.08 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-N 118.634 0.652 . . . . 0.0 111.364 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -119.75 111.89 18.57 Favored 'General case' 0 N--CA 1.499 1.979 1 N-CA-C 97.524 -4.991 . . . . 0.0 97.524 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 46.3 t -120.13 151.67 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 119.501 1.046 . . . . 0.0 112.315 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 20.7 tt0 -117.81 151.72 36.77 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.728 -1.124 . . . . 0.0 108.302 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -146.24 -179.88 7.04 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 104.597 -2.371 . . . . 0.0 104.597 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -6.1 -69.67 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.031 0 N-CA-C 116.069 1.877 . . . . 0.0 116.069 -179.381 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.513 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 40.2 mttp -136.73 -20.25 1.33 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 123.319 0.647 . . . . 0.0 110.318 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -100.36 165.56 11.4 Favored 'General case' 0 N--CA 1.492 1.673 0 C-N-CA 118.453 -1.299 . . . . 0.0 111.399 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 10.5 t -132.45 130.57 60.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 N-CA-C 102.896 -3.002 . . . . 0.0 102.896 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 46' ' ' GLU . 1.5 t -127.79 173.56 12.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 CA-C-O 124.755 2.217 . . . . 0.0 105.406 179.277 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.561 ' H ' HG12 ' A' ' 45' ' ' VAL . 10.6 pt-20 -121.32 164.15 17.49 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 108.479 -3.964 . . . . 0.0 105.047 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 46' ' ' GLU . 2.7 mp -125.69 130.54 24.03 Favored Pre-proline 0 C--N 1.295 -1.773 0 N-CA-C 101.548 -3.501 . . . . 0.0 101.548 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.44 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -93.02 -171.98 0.33 Allowed 'Trans proline' 0 N--CA 1.497 1.725 1 C-N-CA 126.087 4.525 . . . . 0.0 108.796 173.457 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.33 98.53 12.42 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 72.2 Cg_exo -48.45 -44.67 29.27 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.549 1.5 . . . . 0.0 110.671 157.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -133.15 166.11 30.35 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 122.463 1.125 . . . . 0.0 109.253 179.436 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.568 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -110.89 146.04 37.22 Favored 'General case' 0 C--N 1.297 -1.688 2 O-C-N 130.118 4.636 . . . . 0.0 104.483 179.784 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.86 -151.06 13.22 Favored Glycine 0 N--CA 1.504 3.199 0 N-CA-C 105.206 -3.158 . . . . 0.0 105.206 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.493 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 53.6 tptt -96.27 171.99 8.24 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 119.993 1.897 . . . . 0.0 106.835 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -125.47 84.09 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 1 N-CA-C 94.46 -6.126 . . . . 0.0 94.46 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.41 -82.03 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 113.516 -1.675 . . . . 0.0 109.438 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -137.94 165.66 25.98 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.504 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.439 HD12 ' HD3' ' A' ' 25' ' ' PRO . 60.0 mt -130.09 137.94 55.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 1 N-CA-C 97.61 -4.959 . . . . 0.0 97.61 179.705 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.408 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.2 mp -97.17 -56.16 2.63 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 124.251 0.97 . . . . 0.0 108.592 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.4 t -112.68 126.44 28.31 Favored Pre-proline 0 C--N 1.295 -1.793 1 N-CA-C 96.939 -5.208 . . . . 0.0 96.939 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.404 ' HB2' ' OE2' ' A' ' 62' ' ' GLU . 2.7 Cg_exo -79.81 -84.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 CA-C-N 121.461 1.557 . . . . 0.0 108.19 174.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.404 ' OE2' ' HB2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -132.24 -151.8 0.47 Allowed 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 100.614 -3.846 . . . . 0.0 100.614 -179.202 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.93 -42.97 0.16 Allowed Glycine 0 C--N 1.283 -2.377 0 CA-C-N 111.029 -2.805 . . . . 0.0 115.116 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.8 m -109.37 -176.43 3.02 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.6 t -111.16 156.07 12.42 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.32 171.25 11.11 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 3.8 t -128.12 -159.79 0.97 Allowed 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 102.846 -3.02 . . . . 0.0 102.846 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.66 HG11 ' H ' ' A' ' 9' ' ' ILE 0.256 57.8 t -117.68 155.38 19.46 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.268 1 N-CA-C 94.431 -6.137 . . . . 0.0 94.431 179.025 . . . . . . . . 4 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLY . . . . . 0.515 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 98.27 -27.61 18.59 Favored Glycine 0 N--CA 1.485 1.932 1 N-CA-C 102.398 -4.281 . . . . 0.0 102.398 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLN . . . . . 0.459 ' H ' ' C ' ' A' ' 68' ' ' VAL . 38.9 tt0 -105.01 154.65 19.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 102.042 -3.318 . . . . 0.0 102.042 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -94.9 179.55 5.19 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 102.201 -3.259 . . . . 0.0 102.201 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 35.8 tp -138.26 -69.9 0.44 Allowed 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.6 tt -141.99 162.22 19.98 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 102.937 -2.986 . . . . 0.0 102.937 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.3 t -137.39 160.04 40.22 Favored 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.457 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.2 tt -133.39 149.87 51.82 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 112.669 -2.06 . . . . 0.0 107.862 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.457 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -109.2 150.68 27.55 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 101.97 -3.345 . . . . 0.0 101.97 179.562 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -141.83 94.72 7.18 Favored Pre-proline 0 C--N 1.289 -2.026 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.418 ' HD3' ' OD1' ' A' ' 76' ' ' ASP . 21.1 Cg_endo -45.0 70.51 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 123.803 3.002 . . . . 0.0 116.486 174.524 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 126.89 9.63 4.2 Favored Glycine 0 N--CA 1.485 1.929 0 CA-C-O 116.495 -2.281 . . . . 0.0 113.157 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.43 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 14.3 m-30 . . . . . 0 N--CA 1.501 2.087 0 N-CA-C 105.524 -2.028 . . . . 0.0 105.524 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -120.53 159.47 25.13 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 100.893 -3.743 . . . . 0.0 100.893 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 -160.97 0.8 Allowed 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.03 -21.95 3.88 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-N 113.531 -1.668 . . . . 0.0 110.297 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.542 ' HB3' HG22 ' A' ' 68' ' ' VAL . 48.2 mmtt -132.5 145.18 50.96 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 105.479 -2.045 . . . . 0.0 105.479 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.43 173.33 6.08 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 104.071 -2.566 . . . . 0.0 104.071 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -42.48 80.93 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.379 2.053 . . . . 0.0 115.013 158.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.408 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.3 t70 -121.7 -72.64 0.68 Allowed 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 103.584 -2.747 . . . . 0.0 103.584 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.494 ' H ' HG11 ' A' ' 68' ' ' VAL . 35.5 pt 37.41 40.58 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 124.302 1.001 . . . . 0.0 112.863 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.68 -14.34 0.07 OUTLIER Glycine 0 C--N 1.305 -1.188 0 CA-C-O 117.194 -1.892 . . . . 0.0 115.614 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -101.21 -177.93 3.59 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 120.439 2.119 . . . . 0.0 114.733 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -4.47 -66.74 0.0 OUTLIER Glycine 0 N--CA 1.494 2.509 0 CA-C-N 110.178 -3.192 . . . . 0.0 116.182 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.0 mm -127.28 76.42 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -81.97 4.34 23.06 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 112.725 -2.034 . . . . 0.0 111.787 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.519 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 4.5 pt-20 -132.4 -176.7 4.17 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.252 0.549 . . . . 0.0 110.864 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.81 116.29 0.84 Allowed Glycine 0 N--CA 1.494 2.517 0 CA-C-O 118.079 -1.401 . . . . 0.0 111.679 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -102.97 109.87 21.57 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 99.966 -4.087 . . . . 0.0 99.966 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.419 ' HB ' ' HA ' ' A' ' 62' ' ' GLU . 2.7 mt -99.17 126.66 52.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.8 t -93.85 -61.76 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 124.666 1.229 . . . . 0.0 109.971 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.58 ' NZ ' ' CE1' ' A' ' 22' ' ' PHE . 25.1 tttm -130.43 151.04 51.35 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.574 -179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.6 m95 -119.63 173.47 6.99 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 179.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.711 ' CG ' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -133.34 -1.25 3.21 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 -179.783 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.598 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 4.2 m -98.62 170.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 115.318 1.599 . . . . 0.0 115.318 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.424 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.1 mptp? -139.2 48.03 1.56 Allowed Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 125.574 1.796 . . . . 0.0 111.829 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 27' ' ' ASP . 67.2 Cg_exo -8.61 174.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 N-CA-C 118.865 2.602 . . . . 0.0 118.865 -70.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.598 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.11 28.41 8.83 Favored Glycine 0 N--CA 1.505 3.275 0 N-CA-C 107.84 -2.104 . . . . 0.0 107.84 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 25' ' ' PRO . 19.2 t70 8.79 -85.24 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 110.985 -2.608 . . . . 0.0 111.474 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.63 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS . 2.6 mt-10 -104.22 115.53 30.56 Favored 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 105.606 -1.998 . . . . 0.0 105.606 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 p -108.65 161.57 7.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 124.819 2.247 . . . . 0.0 110.562 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 29.3 p30 -98.15 -164.16 1.11 Allowed 'General case' 0 C--N 1.284 -2.248 0 CA-C-N 109.965 -3.288 . . . . 0.0 108.883 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.675 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.274 0.3 OUTLIER -122.35 69.71 0.97 Allowed 'General case' 0 C--N 1.292 -1.896 1 N-CA-C 99.497 -4.26 . . . . 0.0 99.497 -179.323 . . . . . . . . 5 4 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.493 ' C ' ' OG ' ' A' ' 49' ' ' SER . 3.5 p30 -177.34 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.489 0 C-N-CA 125.705 1.602 . . . . 0.0 111.735 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 8.9 t70 18.13 -137.74 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.264 0 N-CA-C 119.661 3.208 . . . . 0.0 119.661 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.711 HG11 ' CG ' ' A' ' 22' ' ' PHE . 1.2 t -114.87 167.4 7.53 Favored 'Isoleucine or valine' 0 CA--C 1.445 -3.095 0 CA-C-O 124.3 2.0 . . . . 0.0 114.29 -179.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.615 ' HA ' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -108.57 120.23 41.85 Favored 'General case' 0 N--CA 1.412 -2.363 3 CA-C-N 106.151 -5.022 . . . . 0.0 99.251 179.877 . . . . . . . . 4 4 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.7 m -73.57 151.8 40.8 Favored 'General case' 0 C--N 1.263 -3.193 2 N-CA-C 97.986 -4.82 . . . . 0.0 97.986 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -104.52 102.89 12.51 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-N 112.371 -2.195 . . . . 0.0 107.806 -179.065 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.6 146.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 N-CA-C 104.682 -2.34 . . . . 0.0 104.682 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -115.15 152.43 32.61 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -141.13 -178.13 5.44 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -7.58 -72.43 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 116.952 2.205 . . . . 0.0 116.952 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -136.82 -11.61 1.76 Allowed 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 114.318 -1.31 . . . . 0.0 109.255 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -111.58 178.7 4.24 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 120.91 0.386 . . . . 0.0 111.886 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.5 t -130.86 147.55 33.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.465 -2.42 . . . . 0.0 104.465 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -120.37 161.78 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 122.655 1.217 . . . . 0.0 111.242 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.508 ' C ' HD12 ' A' ' 47' ' ' ILE . 12.1 pt-20 -122.24 122.75 39.87 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 110.489 -3.05 . . . . 0.0 108.186 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.615 ' C ' ' HA ' ' A' ' 35' ' ' LEU . 1.9 mp -115.02 83.16 9.31 Favored Pre-proline 0 CA--C 1.572 1.798 0 CA-C-O 115.946 -1.978 . . . . 0.0 108.729 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 34' ' ' VAL . 75.9 Cg_endo -62.93 -167.09 0.06 OUTLIER 'Trans proline' 0 N--CA 1.52 3.036 0 C-N-CA 123.952 3.102 . . . . 0.0 105.716 176.675 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.493 ' OG ' ' C ' ' A' ' 32' ' ' ASP . 19.2 p -108.73 86.48 3.71 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -32.22 -49.21 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 121.887 1.725 . . . . 0.0 115.308 163.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.675 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -132.49 164.84 33.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-O 121.817 0.817 . . . . 0.0 110.328 179.646 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.647 ' HD2' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.54 173.32 6.4 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 128.827 3.829 . . . . 0.0 110.11 179.724 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.24 -136.87 5.98 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 104.995 -3.242 . . . . 0.0 104.995 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.63 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 41.0 tptt -112.73 173.26 6.46 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 -179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.499 ' HB ' ' C ' ' A' ' 26' ' ' GLY . 50.5 t -127.35 70.05 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.975 1 N-CA-C 97.342 -5.058 . . . . 0.0 97.342 179.665 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 75.4 mt -38.06 -79.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 111.623 -2.535 . . . . 0.0 114.227 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -143.04 167.48 21.97 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.759 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.1 mp -131.11 141.21 46.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 1 N-CA-C 98.004 -4.813 . . . . 0.0 98.004 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -103.7 -58.85 1.81 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 123.772 0.67 . . . . 0.0 110.555 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.414 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 24.1 t -113.62 75.92 2.77 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -49.76 -83.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.851 2.367 . . . . 0.0 115.2 -167.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.419 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -134.86 -179.91 5.9 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 76.81 -38.57 1.51 Allowed Glycine 0 N--CA 1.49 2.266 0 CA-C-N 114.14 -1.391 . . . . 0.0 114.335 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 2.0 m -103.25 177.14 4.92 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 43.9 t -117.74 148.99 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.8 166.67 14.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.519 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 8.8 t -117.87 -155.45 0.6 Allowed 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 104.783 -2.303 . . . . 0.0 104.783 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.542 HG22 ' HB3' ' A' ' 5' ' ' LYS . 84.4 t -120.44 151.51 23.24 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 1 N-CA-C 97.25 -5.093 . . . . 0.0 97.25 179.106 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 104.58 -38.74 3.12 Favored Glycine 0 N--CA 1.494 2.565 1 N-CA-C 99.768 -5.333 . . . . 0.0 99.768 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 68' ' ' VAL . 35.2 tt0 -100.09 164.49 11.96 Favored 'General case' 0 C--N 1.304 -1.373 1 N-CA-C 99.929 -4.101 . . . . 0.0 99.929 179.501 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.98 -175.52 2.8 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 33.1 tp -135.23 -67.19 0.55 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 103.652 -2.721 . . . . 0.0 103.652 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.2 tt -135.03 165.04 32.13 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 102.988 -2.967 . . . . 0.0 102.988 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.8 t -137.25 161.38 36.37 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.45 -2.796 . . . . 0.0 103.45 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.83 152.33 48.99 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 112.456 -2.156 . . . . 0.0 106.385 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.86 131.57 56.92 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 100.48 -3.896 . . . . 0.0 100.48 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.46 60.19 13.54 Favored Pre-proline 0 C--N 1.295 -1.78 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -53.09 68.34 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.618 0 C-N-CA 124.777 3.651 . . . . 0.0 115.855 -176.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 132.7 68.75 0.08 OUTLIER Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.505 1 N-CA-C 100.096 -4.039 . . . . 0.0 100.096 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 101.771 -3.418 . . . . 0.0 101.771 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.421 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.8 OUTLIER -100.67 85.94 3.02 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 105.622 -1.992 . . . . 0.0 105.622 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -77.96 -178.33 5.45 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -99.91 -29.57 12.5 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 117.903 2.557 . . . . 0.0 117.903 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB3' HG22 ' A' ' 68' ' ' VAL . 30.5 mmtp -127.57 173.64 9.7 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 102.411 -3.181 . . . . 0.0 102.411 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 88.6 mt -101.14 176.18 2.01 Favored Pre-proline 0 C--N 1.299 -1.618 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -66.12 82.04 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 N-CA-C 104.098 -3.078 . . . . 0.0 104.098 158.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -123.87 -80.68 0.63 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 124.583 1.177 . . . . 0.0 109.628 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.417 ' CG2' ' HB ' ' A' ' 68' ' ' VAL . 45.9 pt 41.96 26.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.515 0 O-C-N 123.38 0.425 . . . . 0.0 110.454 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.24 -69.67 0.18 Allowed Glycine 0 N--CA 1.483 1.776 0 C-N-CA 120.683 -0.77 . . . . 0.0 114.064 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -61.27 171.17 1.44 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 124.537 2.113 . . . . 0.0 116.358 -179.435 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -6.84 -53.1 0.0 OUTLIER Glycine 0 N--CA 1.493 2.469 0 CA-C-N 109.956 -3.293 . . . . 0.0 119.953 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.2 mm -118.96 116.99 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.495 ' O ' HG23 ' A' ' 68' ' ' VAL . 9.5 p80 -96.26 -45.62 6.76 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 114.68 -1.145 . . . . 0.0 112.232 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.563 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 33.8 mt-10 -107.83 -173.2 2.22 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 123.043 1.401 . . . . 0.0 113.059 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.05 122.33 1.98 Allowed Glycine 0 C--N 1.286 -2.205 0 CA-C-N 111.722 -2.49 . . . . 0.0 106.881 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 78.7 tt0 -102.23 96.15 6.79 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 103.399 -2.815 . . . . 0.0 103.399 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.8 mt -86.17 120.62 36.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 -56.09 5.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.969 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.052 -179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.46 ' NZ ' ' OE1' ' A' ' 37' ' ' GLU . 0.1 OUTLIER -136.15 150.68 49.17 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 124.206 0.941 . . . . 0.0 112.12 -179.432 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.757 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 10.1 m95 -114.38 174.62 5.86 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 124.821 1.325 . . . . 0.0 108.112 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CD2' HG21 ' A' ' 34' ' ' VAL . 6.6 m-85 -128.03 -13.76 5.07 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 112.382 -2.19 . . . . 0.0 112.885 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.625 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 14.7 m -98.89 -172.96 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.653 -0.654 . . . . 0.0 111.761 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.734 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.3 mptp? -123.08 -30.11 0.05 OUTLIER Pre-proline 0 N--CA 1.503 2.208 0 N-CA-C 119.266 3.061 . . . . 0.0 119.266 179.077 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.734 ' C ' ' H ' ' A' ' 24' ' ' LYS . 11.3 Cg_endo -39.17 162.82 0.23 Allowed 'Cis proline' 0 N--CA 1.498 1.764 1 N-CA-C 122.747 4.095 . . . . 0.0 122.747 13.208 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.625 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -95.5 32.42 6.27 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 -179.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.482 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.9 t70 11.79 -100.94 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.248 0 O-C-N 129.749 3.852 . . . . 0.0 109.606 179.477 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.437 ' OE2' ' HE2' ' A' ' 54' ' ' LYS . 3.6 mt-10 -103.33 130.38 50.59 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 30' ' ' ASN . 7.6 p -120.48 177.91 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 122.348 1.07 . . . . 0.0 112.918 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.488 ' OD1' ' C ' ' A' ' 30' ' ' ASN . 45.0 p30 -95.42 -166.47 1.46 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.961 -1.927 . . . . 0.0 107.422 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.561 ' HB2' ' HB3' ' A' ' 52' ' ' LYS 0.25 2.4 tt0 -124.86 50.75 1.71 Allowed 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 100.467 -3.901 . . . . 0.0 100.467 -179.498 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -175.93 28.32 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.043 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 30' ' ' ASN . 0.5 OUTLIER -96.32 -176.25 3.59 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.945 0.878 . . . . 0.0 111.335 -179.308 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.525 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -74.77 -172.53 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.482 -1.648 0 CA-C-O 127.654 3.597 . . . . 0.0 117.582 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.567 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.13 -160.21 0.74 Allowed 'General case' 0 C--N 1.276 -2.624 2 CA-C-N 102.377 -6.738 . . . . 0.0 106.959 -179.214 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.757 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 9.2 m -120.09 156.51 30.86 Favored 'General case' 0 C--N 1.273 -2.748 2 N-CA-C 94.215 -6.217 . . . . 0.0 94.215 179.212 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.46 ' OE1' ' NZ ' ' A' ' 20' ' ' LYS . 5.3 tt0 -107.94 109.83 21.42 Favored 'General case' 0 C--N 1.285 -2.236 1 N-CA-C 98.676 -4.564 . . . . 0.0 98.676 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.473 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 56.1 t -121.43 154.9 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 tt0 -114.82 147.2 40.15 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 16.4 p-10 -136.43 -176.0 4.19 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -6.73 -67.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.176 0 O-C-N 126.175 2.172 . . . . 0.0 115.838 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 40.0 mtmt -138.19 -22.18 1.05 Allowed 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 123.011 0.525 . . . . 0.0 109.957 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.75 -168.57 1.54 Allowed 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 29.8 t -123.69 133.7 68.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 N-CA-C 103.309 -2.849 . . . . 0.0 103.309 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.94 153.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 122.515 1.15 . . . . 0.0 109.012 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.505 ' C ' HD12 ' A' ' 47' ' ' ILE . 10.0 pt-20 -119.58 127.79 53.3 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 110.86 -2.882 . . . . 0.0 108.526 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.57 HD12 ' N ' ' A' ' 47' ' ' ILE . 1.7 mp -117.2 79.54 11.19 Favored Pre-proline 0 C--N 1.299 -1.588 0 N-CA-C 101.573 -3.491 . . . . 0.0 101.573 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.441 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 86.3 Cg_endo -62.29 -166.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.513 2.639 0 C-N-CA 123.569 2.846 . . . . 0.0 107.854 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 45.9 p -98.78 106.66 38.67 Favored Pre-proline 0 C--N 1.286 -2.153 0 CA-C-N 113.483 -1.69 . . . . 0.0 111.879 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 89.2 Cg_exo -55.32 -44.46 48.66 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.012 1.808 . . . . 0.0 114.979 166.181 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.509 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -132.13 171.58 17.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 123.837 0.711 . . . . 0.0 109.858 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.561 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -105.01 167.85 9.44 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 127.347 2.905 . . . . 0.0 107.614 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 76' ' ' ASP . . . 144.1 -121.77 1.69 Allowed Glycine 0 C--N 1.285 -2.282 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.669 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -117.41 166.41 12.35 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.452 ' CG1' ' H ' ' A' ' 26' ' ' GLY . 23.9 t -129.91 59.29 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 1 N-CA-C 99.459 -4.274 . . . . 0.0 99.459 179.527 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 21.9 mt -29.1 -76.88 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 111.143 -2.753 . . . . 0.0 115.02 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -143.79 167.16 22.95 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.284 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 58' ' ' ILE . 4.1 mp -135.55 139.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 1 N-CA-C 98.527 -4.619 . . . . 0.0 98.527 179.601 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.7 mp -101.56 -56.91 2.18 Favored 'General case' 0 C--N 1.296 -1.756 0 O-C-N 124.003 0.814 . . . . 0.0 110.604 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 t -117.93 67.96 6.34 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -41.93 -78.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 122.709 2.273 . . . . 0.0 117.989 -167.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -142.97 174.58 10.55 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.66 -52.97 0.91 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.868 -1.158 . . . . 0.0 111.462 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.5 m -102.42 -177.5 3.42 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.2 t -109.95 145.49 16.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 103.733 -2.692 . . . . 0.0 103.733 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -120.55 147.83 44.66 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.287 14.7 t -99.84 -151.7 0.4 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.478 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.529 ' C ' ' H ' ' A' ' 70' ' ' GLN . 61.8 t -118.62 160.75 18.18 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 178.877 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 97.61 -47.28 1.57 Allowed Glycine 0 N--CA 1.499 2.852 1 N-CA-C 98.408 -5.877 . . . . 0.0 98.408 -179.386 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.529 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -89.58 153.61 20.63 Favored 'General case' 0 C--N 1.304 -1.393 1 N-CA-C 99.953 -4.091 . . . . 0.0 99.953 179.325 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.56 -175.94 3.0 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 103.104 -2.924 . . . . 0.0 103.104 179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.7 tp -139.9 -70.44 0.4 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.404 HD11 ' CG1' ' A' ' 55' ' ' VAL . 12.9 tt -139.05 166.33 22.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 104.203 -2.517 . . . . 0.0 104.203 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.2 t -138.92 160.08 40.59 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 102.439 -3.171 . . . . 0.0 102.439 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.421 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -129.98 148.53 51.85 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.022 -179.721 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.432 ' OD2' ' NZ ' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -113.09 150.26 32.35 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 102.227 -3.249 . . . . 0.0 102.227 179.135 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.601 ' H ' ' HA ' ' A' ' 78' ' ' PRO . . . -114.36 -40.94 0.08 OUTLIER Pre-proline 0 C--N 1.295 -1.774 0 O-C-N 124.883 1.365 . . . . 0.0 107.696 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.601 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 10.2 Cg_endo -94.72 176.84 11.42 Favored 'Cis proline' 0 C--N 1.312 -1.375 0 CA-C-N 121.628 1.617 . . . . 0.0 111.328 -22.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.81 -36.72 4.19 Favored Glycine 0 N--CA 1.498 2.8 1 N-CA-C 99.058 -5.617 . . . . 0.0 99.058 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.494 ' H ' ' C ' ' A' ' 78' ' ' PRO . 52.1 t80 . . . . . 0 CA--C 1.573 1.831 1 N-CA-C 98.597 -4.594 . . . . 0.0 98.597 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.474 1 N-CA-C 98.138 -4.764 . . . . 0.0 98.138 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -137.13 90.76 2.56 Favored 'General case' 0 C--N 1.288 -2.078 1 N-CA-C 88.977 -8.157 . . . . 0.0 88.977 178.473 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 3' ' ' GLU . 1.3 pm0 -87.57 -168.1 2.11 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 122.638 1.208 . . . . 0.0 113.843 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.484 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 22.5 t80 -88.22 -46.99 8.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 117.853 2.538 . . . . 0.0 117.853 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.484 ' HE2' ' CZ ' ' A' ' 4' ' ' PHE . 0.3 OUTLIER -131.57 174.68 9.86 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 179.63 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.13 172.96 3.69 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 104.187 -2.523 . . . . 0.0 104.187 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -56.31 89.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 121.43 1.42 . . . . 0.0 111.374 164.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.503 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.5 t0 -122.45 -82.05 0.65 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 102.968 -2.975 . . . . 0.0 102.968 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.5 pt 36.8 37.0 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 CA-C-O 121.601 0.715 . . . . 0.0 109.821 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.7 -154.58 11.94 Favored Glycine 0 N--CA 1.48 1.575 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.32 138.53 37.75 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.44 -74.1 0.33 Allowed Glycine 0 N--CA 1.486 1.968 0 N-CA-C 106.907 -2.477 . . . . 0.0 106.907 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.2 mm -133.46 141.4 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-N 118.363 1.081 . . . . 0.0 108.297 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -131.9 -51.88 0.98 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.635 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -116.59 172.11 7.43 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.463 -1.244 . . . . 0.0 111.995 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.82 155.51 26.17 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 106.542 -2.623 . . . . 0.0 106.542 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.412 ' O ' HG13 ' A' ' 38' ' ' VAL . 0.7 OUTLIER -122.54 136.74 54.96 Favored 'General case' 0 C--N 1.303 -1.445 1 N-CA-C 98.968 -4.456 . . . . 0.0 98.968 179.87 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.437 ' HB ' ' HA ' ' A' ' 62' ' ' GLU 0.285 2.6 mt -103.95 113.67 41.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.278 0 N-CA-C 102.734 -3.062 . . . . 0.0 102.734 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.9 t -76.5 -55.07 12.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HE3' ' CE2' ' A' ' 22' ' ' PHE . 22.4 tttp -141.41 158.32 44.02 Favored 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 118.981 -1.088 . . . . 0.0 113.579 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.509 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 36.9 m95 -113.86 170.89 7.93 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 178.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.494 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.5 m-85 -128.28 -46.43 1.35 Allowed 'General case' 0 C--N 1.3 -1.584 0 CA-C-N 114.126 -1.397 . . . . 0.0 109.735 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 m -97.39 175.68 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -128.04 165.98 26.91 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 105.593 -2.003 . . . . 0.0 105.593 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -76.52 122.71 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 121.915 1.744 . . . . 0.0 110.776 -172.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.13 -7.27 19.02 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.226 -2.349 . . . . 0.0 107.226 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -79.52 173.23 12.79 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 124.177 1.941 . . . . 0.0 111.041 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.667 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.2 OUTLIER -118.55 146.26 44.72 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 100.584 -3.858 . . . . 0.0 100.584 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.542 HG22 ' HB2' ' A' ' 31' ' ' GLU 0.25 0.9 OUTLIER -122.19 171.2 11.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 -179.776 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.461 ' O ' ' HE2' ' A' ' 52' ' ' LYS . 53.7 t30 -119.42 -29.51 5.11 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 125.03 2.348 . . . . 0.0 115.135 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.542 ' HB2' HG22 ' A' ' 29' ' ' VAL 0.366 11.9 tp10 47.26 78.74 0.07 Allowed 'General case' 0 C--N 1.267 -2.995 5 N-CA-C 131.644 7.646 . . . . 0.0 131.644 -179.213 . . . . . . . . 4 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -155.43 31.5 0.38 Allowed 'General case' 0 C--N 1.28 -2.434 4 CA-C-N 94.066 -10.515 . . . . 0.0 93.984 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.482 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 10.0 m-20 -117.22 -168.7 1.52 Allowed 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 126.927 2.091 . . . . 0.0 107.82 -178.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.494 ' HB ' ' CG ' ' A' ' 22' ' ' PHE . 3.6 t -134.47 161.85 39.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 N-CA-C 100.597 -3.853 . . . . 0.0 100.597 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.551 ' HB2' HG21 ' A' ' 47' ' ' ILE . 3.4 mm? -125.54 -84.85 0.63 Allowed 'General case' 0 C--N 1.272 -2.77 0 CA-C-N 109.874 -3.33 . . . . 0.0 102.389 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.403 ' SG ' ' OE1' ' A' ' 46' ' ' GLU . 11.2 p -123.97 172.77 8.69 Favored 'General case' 0 N--CA 1.495 1.777 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.582 -178.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.367 18.5 tt0 -134.34 138.25 44.77 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 -179.287 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.497 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 25.5 t -139.77 145.57 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.427 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 35.6 tt0 -107.29 107.65 18.68 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 6.4 p-10 -136.77 174.57 10.47 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 2.8 p-10 -3.78 -59.49 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 118.234 2.679 . . . . 0.0 118.234 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 28.3 mttm -131.15 -4.05 3.91 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 123.687 0.617 . . . . 0.0 110.029 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -106.09 164.43 11.99 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.75 -43.11 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 111.392 -2.64 . . . . 0.0 109.178 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 18.3 t -111.83 167.35 5.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 -179.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.579 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.0 mt-10 -120.5 -73.32 0.65 Allowed 'General case' 0 C--N 1.294 -1.846 0 O-C-N 128.016 3.323 . . . . 0.0 116.556 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.579 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -84.37 142.54 40.65 Favored Pre-proline 0 C--N 1.274 -2.68 0 CA-C-N 108.487 -3.961 . . . . 0.0 110.225 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.536 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -96.64 177.59 0.59 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 N-CA-C 105.248 -2.635 . . . . 0.0 105.248 82.646 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.491 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 1.6 m -124.36 -177.61 0.57 Allowed Pre-proline 0 C--N 1.278 -2.512 0 CA-C-N 114.462 -1.244 . . . . 0.0 109.243 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -87.51 -31.43 0.22 Allowed 'Trans proline' 0 C--N 1.314 -1.285 0 N-CA-C 117.236 1.975 . . . . 0.0 117.236 164.6 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.525 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.6 p -138.34 167.97 20.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 120.246 3.425 . . . . 0.0 120.246 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.525 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 2.2 ptmm? -97.06 177.26 5.66 Favored 'General case' 0 C--N 1.292 -1.9 1 CA-C-N 106.212 -4.995 . . . . 0.0 110.266 -179.395 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.02 -141.71 9.21 Favored Glycine 0 C--N 1.286 -2.237 0 N-CA-C 103.331 -3.908 . . . . 0.0 103.331 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.667 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 12.3 tppt? -110.97 173.23 6.43 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 103.915 -2.624 . . . . 0.0 103.915 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 39.3 t -125.72 68.84 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.166 1 N-CA-C 97.963 -4.829 . . . . 0.0 97.963 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 38.3 mt -30.48 -76.02 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 126.135 2.147 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -142.04 161.58 37.64 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 77.8 mt -132.99 114.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 1 N-CA-C 93.882 -6.34 . . . . 0.0 93.882 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.5 mt -90.9 -40.4 11.75 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 114.759 1.392 . . . . 0.0 114.759 -179.456 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.71 79.97 23.61 Favored Pre-proline 0 N--CA 1.496 1.864 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.817 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_exo -34.8 -107.66 0.0 OUTLIER 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 124.426 3.417 . . . . 0.0 120.532 -175.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.437 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 3.6 pt-20 -132.73 173.8 10.98 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 56.92 30.94 60.73 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.7 m -138.24 160.28 39.87 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 102.014 -3.328 . . . . 0.0 102.014 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -97.56 135.6 31.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -127.06 144.98 50.89 Favored 'General case' 0 C--N 1.294 -1.834 1 N-CA-C 99.764 -4.162 . . . . 0.0 99.764 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.635 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.259 66.8 p -116.87 -144.78 0.38 Allowed 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 124.296 1.998 . . . . 0.0 107.413 -179.855 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.503 HG11 ' HB3' ' A' ' 8' ' ' ASP . 74.8 t -121.65 155.07 25.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 1 N-CA-C 93.247 -6.575 . . . . 0.0 93.247 179.056 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 93.27 -47.04 2.39 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 103.148 -3.981 . . . . 0.0 103.148 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.424 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.2 tt0 -94.0 155.0 17.36 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 102.426 -3.176 . . . . 0.0 102.426 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.55 -174.61 2.6 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 102.769 -3.048 . . . . 0.0 102.769 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.6 tp -145.99 -66.84 0.29 Allowed 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 113.349 -1.751 . . . . 0.0 106.874 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 11.8 tt -133.21 166.58 28.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 110.852 -2.886 . . . . 0.0 105.609 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 t -140.19 159.8 41.38 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 102.152 -3.277 . . . . 0.0 102.152 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.403 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.0 OUTLIER -136.62 154.92 50.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.403 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -123.36 145.89 48.39 Favored 'General case' 0 C--N 1.295 -1.798 1 N-CA-C 99.536 -4.246 . . . . 0.0 99.536 179.282 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.401 ' HB3' ' CA ' ' A' ' 78' ' ' PRO . . . -140.79 -49.95 0.02 OUTLIER Pre-proline 0 C--N 1.295 -1.765 0 O-C-N 123.746 0.653 . . . . 0.0 111.581 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.401 ' CA ' ' HB3' ' A' ' 77' ' ' ALA . 51.2 Cg_endo -84.4 -45.85 0.3 Allowed 'Cis proline' 0 C--N 1.315 -1.224 0 CA-C-N 119.722 0.936 . . . . 0.0 109.98 -22.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -141.89 124.84 2.55 Favored Glycine 0 C--N 1.293 -1.818 1 N-CA-C 98.749 -5.74 . . . . 0.0 98.749 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 36.6 p90 . . . . . 0 C--N 1.283 -2.317 0 O-C-N 127.109 2.299 . . . . 0.0 106.007 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.51 2.531 0 N-CA-C 102.668 -3.086 . . . . 0.0 102.668 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.1 t80 16.37 102.96 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 127.051 2.72 . . . . 0.0 112.813 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.722 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 2.6 pm0 -82.53 -171.0 3.24 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-N 110.482 -3.054 . . . . 0.0 112.917 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.469 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.2 t80 -93.86 -49.94 5.58 Favored 'General case' 0 N--CA 1.494 1.725 0 CA-C-N 113.684 -1.598 . . . . 0.0 114.063 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HD3' ' CE2' ' A' ' 4' ' ' PHE . 11.8 mmmm -126.1 165.93 17.95 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 101.633 -3.469 . . . . 0.0 101.633 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 61.0 mt -105.48 -178.03 0.57 Allowed Pre-proline 0 C--N 1.3 -1.564 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.45 96.43 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.356 0 C-N-CA 121.685 1.59 . . . . 0.0 110.855 170.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.779 ' HB3' HG11 ' A' ' 68' ' ' VAL . 24.2 t0 -122.34 -99.3 0.43 Allowed 'General case' 0 C--N 1.302 -1.478 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 179.795 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.501 HG23 ' CG1' ' A' ' 68' ' ' VAL . 32.4 pt 34.74 42.05 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 O-C-N 124.572 1.17 . . . . 0.0 108.239 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.79 -137.27 4.77 Favored Glycine 0 N--CA 1.482 1.725 0 CA-C-N 114.45 -1.25 . . . . 0.0 113.895 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.63 146.64 28.64 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 104.695 -2.335 . . . . 0.0 104.695 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.31 -76.24 0.22 Allowed Glycine 0 N--CA 1.486 1.969 0 N-CA-C 103.249 -3.94 . . . . 0.0 103.249 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 14' ' ' HIS . 42.1 mm -131.21 173.5 14.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 N-CA-C 103.427 -2.805 . . . . 0.0 103.427 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.429 ' N ' HG22 ' A' ' 13' ' ' ILE . 57.3 t-80 -155.0 -33.09 0.1 Allowed 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.159 1.457 . . . . 0.0 107.701 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.07 -165.54 1.08 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 113.975 -1.466 . . . . 0.0 113.355 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.89 128.18 2.81 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 103.735 -3.746 . . . . 0.0 103.735 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.449 ' HG3' HG22 ' A' ' 65' ' ' VAL . 30.4 tt0 -104.64 91.49 3.88 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 101.146 -3.65 . . . . 0.0 101.146 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.405 HG23 ' HB2' ' A' ' 36' ' ' CYS . 2.5 mt -81.86 110.62 17.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 103.969 -2.604 . . . . 0.0 103.969 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -88.81 -45.28 15.58 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 113.563 -1.653 . . . . 0.0 106.62 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HZ2' ' HB3' ' A' ' 20' ' ' LYS . 2.4 ttmp? -130.9 161.46 31.82 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.117 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.489 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 11.3 m95 -124.28 168.74 12.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 101.457 -3.534 . . . . 0.0 101.457 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 22' ' ' PHE . 6.9 m-85 -123.0 -47.41 2.04 Favored 'General case' 0 C--N 1.295 -1.782 0 O-C-N 124.542 1.151 . . . . 0.0 108.245 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -99.58 178.13 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.331 1.062 . . . . 0.0 110.775 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 ptmt -115.17 172.63 3.48 Favored Pre-proline 0 C--N 1.295 -1.79 0 CA-C-N 112.104 -2.316 . . . . 0.0 105.025 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HB3' HG13 ' A' ' 58' ' ' ILE . 34.3 Cg_endo -93.78 143.45 1.86 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.228 1.952 . . . . 0.0 110.384 166.547 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.64 -10.33 38.37 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.231 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -108.53 -175.9 2.9 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.773 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.6 OUTLIER -118.82 163.99 16.07 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.226 -179.724 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.591 HG22 ' HB2' ' A' ' 31' ' ' GLU . 3.1 p -133.01 174.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.525 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 19.8 t-20 -116.21 -35.85 4.23 Favored 'General case' 0 N--CA 1.523 3.203 0 CA-C-O 126.903 3.24 . . . . 0.0 115.649 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.622 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.395 33.0 tt0 20.18 123.08 0.0 OUTLIER 'General case' 0 C--N 1.273 -2.759 5 N-CA-C 151.831 15.123 . . . . 0.0 151.831 -179.537 . . . . . . . . 4 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' CG ' ' N ' ' A' ' 33' ' ' ASP . 11.2 p-10 -123.01 -48.23 2.01 Favored 'General case' 0 C--N 1.287 -2.117 4 CA-C-N 93.237 -10.892 . . . . 0.0 97.625 178.999 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' CG ' ' A' ' 32' ' ' ASP . 3.7 t0 -22.55 176.6 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.617 0 C-N-CA 131.427 3.891 . . . . 0.0 116.186 179.001 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -107.39 167.52 3.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 127.366 3.46 . . . . 0.0 114.292 -179.597 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.55 ' H ' HG12 ' A' ' 34' ' ' VAL . 10.1 mp -130.9 -87.34 0.49 Allowed 'General case' 0 C--N 1.283 -2.289 1 CA-C-N 106.562 -4.836 . . . . 0.0 103.688 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.405 ' HB2' HG23 ' A' ' 18' ' ' ILE . 0.5 OUTLIER -127.89 169.63 13.73 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.794 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.679 ' HG3' HG22 ' A' ' 45' ' ' VAL . 1.2 tm-20 -135.09 156.88 48.26 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 126.341 2.276 . . . . 0.0 104.946 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.503 HG23 ' HG3' ' A' ' 46' ' ' GLU . 54.0 t -139.5 179.58 2.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 125.481 1.738 . . . . 0.0 111.439 -179.304 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.483 ' N ' HG12 ' A' ' 38' ' ' VAL . 25.0 tt0 -137.8 102.72 4.8 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 113.313 -1.767 . . . . 0.0 108.234 178.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.433 HD22 ' CG ' ' A' ' 41' ' ' ASP . 9.9 p-10 -147.41 175.8 10.53 Favored 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.916 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.433 ' CG ' HD22 ' A' ' 40' ' ' ASN . 1.0 OUTLIER -15.7 -68.66 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 119.139 3.014 . . . . 0.0 119.139 -179.601 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.14 -8.85 6.49 Favored 'General case' 0 C--N 1.289 -2.023 0 CA-C-N 114.794 -1.093 . . . . 0.0 110.958 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.413 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -111.39 156.03 22.23 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.874 -1.13 . . . . 0.0 109.734 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.47 -88.98 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 114.135 -1.393 . . . . 0.0 108.742 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.679 HG22 ' HG3' ' A' ' 37' ' ' GLU . 61.5 t -68.27 162.86 3.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 104.566 -2.383 . . . . 0.0 104.566 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.511 ' HB3' HD12 ' A' ' 47' ' ' ILE . 2.4 mt-10 -108.3 -60.65 1.7 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 126.806 2.566 . . . . 0.0 115.479 -179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 34' ' ' VAL . 1.6 mp -96.1 143.21 25.73 Favored Pre-proline 0 C--N 1.273 -2.745 1 CA-C-N 108.033 -4.167 . . . . 0.0 108.904 -179.507 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.567 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.03 177.11 0.46 Allowed 'Trans proline' 0 C--N 1.305 -1.731 1 C-N-CA 126.281 4.654 . . . . 0.0 106.509 90.036 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.622 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 16.1 m -128.45 171.15 9.04 Favored Pre-proline 0 C--N 1.28 -2.434 0 O-C-N 125.144 1.528 . . . . 0.0 114.285 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -105.35 -17.13 0.05 OUTLIER 'Trans proline' 0 CA--C 1.555 1.549 0 C-N-CA 124.575 3.517 . . . . 0.0 119.653 173.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.577 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.2 p -135.24 170.35 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.705 0 CA-C-O 122.896 1.331 . . . . 0.0 111.789 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.702 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -125.07 178.3 5.61 Favored 'General case' 0 C--N 1.286 -2.195 1 CA-C-N 108.239 -4.073 . . . . 0.0 111.266 -179.555 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.61 -134.93 4.35 Favored Glycine 0 C--N 1.287 -2.177 1 N-CA-C 100.3 -5.12 . . . . 0.0 100.3 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.773 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 15.1 tppt? -112.93 176.55 4.97 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 104.497 -2.409 . . . . 0.0 104.497 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 24.0 t -123.75 100.84 8.25 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 1 N-CA-C 93.148 -6.612 . . . . 0.0 93.148 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.5 mt -74.61 -83.08 0.06 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 117.582 -1.647 . . . . 0.0 106.946 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.2 160.99 30.37 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.001 . . . . 0.0 112.668 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.405 HG13 ' HB3' ' A' ' 25' ' ' PRO . 96.7 mt -132.75 118.36 33.79 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 1 N-CA-C 92.761 -6.755 . . . . 0.0 92.761 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.446 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -92.69 -41.18 10.3 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 123.727 0.642 . . . . 0.0 111.787 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.42 ' HB ' ' CD2' ' A' ' 72' ' ' LEU . 3.4 t -111.32 124.59 32.33 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 101.632 -3.47 . . . . 0.0 101.632 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -57.07 -124.16 0.0 OUTLIER 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 123.921 3.081 . . . . 0.0 116.453 176.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.494 ' C ' ' H ' ' A' ' 64' ' ' THR . 0.0 OUTLIER -127.49 -170.34 2.21 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 100.885 -3.746 . . . . 0.0 100.885 179.928 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.07 -19.95 0.12 Allowed Glycine 0 N--CA 1.491 2.347 0 CA-C-N 113.277 -1.783 . . . . 0.0 113.711 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.494 ' H ' ' C ' ' A' ' 62' ' ' GLU . 2.2 m -101.97 170.03 8.39 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 104.394 -2.447 . . . . 0.0 104.394 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.449 HG22 ' HG3' ' A' ' 17' ' ' GLU . 45.0 t -105.77 148.8 9.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 103.816 -2.661 . . . . 0.0 103.816 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -119.5 156.66 29.82 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.6 p -101.06 -160.86 0.82 Allowed 'General case' 0 C--N 1.283 -2.289 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.779 HG11 ' HB3' ' A' ' 8' ' ' ASP . 52.2 t -126.69 153.17 35.23 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.39 1 N-CA-C 94.353 -6.166 . . . . 0.0 94.353 178.386 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 94.44 -36.16 3.89 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 103.588 -3.805 . . . . 0.0 103.588 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.472 ' H ' ' C ' ' A' ' 68' ' ' VAL . 31.6 tt0 -92.93 163.75 13.57 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 101.817 -3.401 . . . . 0.0 101.817 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.3 m -108.84 -179.02 3.74 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 101.724 -3.435 . . . . 0.0 101.724 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.42 ' CD2' ' HB ' ' A' ' 60' ' ' VAL . 0.4 OUTLIER -149.06 -65.64 0.23 Allowed 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 -179.371 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 7.8 tt -130.19 163.56 35.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.2 t -140.42 158.32 44.18 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 103.142 -2.91 . . . . 0.0 103.142 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -132.39 149.54 52.33 Favored 'General case' 0 C--N 1.287 -2.11 0 CA-C-N 111.83 -2.441 . . . . 0.0 104.855 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.26 123.17 48.12 Favored 'General case' 0 C--N 1.292 -1.913 1 N-CA-C 96.511 -5.366 . . . . 0.0 96.511 179.716 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -139.77 58.72 12.09 Favored Pre-proline 0 N--CA 1.491 1.607 1 N-CA-C 99.786 -4.153 . . . . 0.0 99.786 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -78.1 67.77 8.03 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 121.778 1.652 . . . . 0.0 112.066 -153.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.3 59.06 0.05 OUTLIER Glycine 0 N--CA 1.501 2.972 0 C-N-CA 119.72 -1.228 . . . . 0.0 112.806 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 116.338 -1.791 . . . . 0.0 107.554 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 2.097 0 N-CA-C 103.73 -2.692 . . . . 0.0 103.73 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.47 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -121.78 128.27 51.54 Favored 'General case' 0 C--N 1.29 -2.015 1 N-CA-C 99.962 -4.088 . . . . 0.0 99.962 -179.635 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -102.23 -173.29 2.3 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.414 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.7 t80 -101.14 -43.16 6.09 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.609 0.719 . . . . 0.0 112.509 -179.266 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HB2' HG13 ' A' ' 68' ' ' VAL . 0.1 OUTLIER -128.49 160.27 32.84 Favored 'General case' 0 C--N 1.297 -1.685 1 N-CA-C 99.338 -4.319 . . . . 0.0 99.338 179.79 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.43 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 25.5 mt -103.31 -169.37 0.18 Allowed Pre-proline 0 C--N 1.296 -1.745 0 N-CA-C 105.319 -2.104 . . . . 0.0 105.319 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB3' ' A' ' 6' ' ' LEU . 77.0 Cg_exo -55.48 85.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.12 1.88 . . . . 0.0 107.577 148.033 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.58 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.2 t0 -123.15 -88.65 0.61 Allowed 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.565 ' H ' HG11 ' A' ' 68' ' ' VAL . 1.3 pt 37.77 43.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.321 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.33 -176.1 50.51 Favored Glycine 0 N--CA 1.493 2.453 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.551 -179.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -80.72 144.73 31.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.86 -77.89 0.26 Allowed Glycine 0 C--N 1.294 -1.786 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.2 mt -137.93 103.79 2.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 102.736 -3.061 . . . . 0.0 102.736 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.67 20.71 18.61 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-N 122.178 2.263 . . . . 0.0 108.35 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 1.4 pm0 -121.95 -174.26 2.84 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 123.725 1.726 . . . . 0.0 114.09 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.4 101.65 0.27 Allowed Glycine 0 N--CA 1.492 2.43 0 CA-C-N 112.483 -2.144 . . . . 0.0 109.7 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -92.94 89.2 6.45 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 66' ' ' ALA . 3.9 mt -84.18 103.89 11.9 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 100.851 -3.759 . . . . 0.0 100.851 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.7 t -84.33 -46.17 17.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.331 -179.29 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.455 ' HG2' ' N ' ' A' ' 21' ' ' TRP . 25.8 tttt -142.24 159.77 41.57 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 114.983 -1.008 . . . . 0.0 111.1 -179.543 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.53 ' CE3' HG22 ' A' ' 23' ' ' VAL . 17.7 m95 -122.16 162.52 21.18 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 179.4 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -120.68 -20.74 6.94 Favored 'General case' 0 C--N 1.292 -1.895 0 O-C-N 124.984 1.428 . . . . 0.0 108.76 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.53 HG22 ' CE3' ' A' ' 21' ' ' TRP . 5.1 m -99.89 179.31 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-O 123.753 1.74 . . . . 0.0 112.147 -179.335 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.647 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -130.42 140.13 37.73 Favored Pre-proline 0 C--N 1.288 -2.095 1 N-CA-C 97.743 -4.91 . . . . 0.0 97.743 -179.71 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -54.69 162.56 4.73 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.42 1.413 . . . . 0.0 114.945 -175.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.52 26.55 0.08 OUTLIER Glycine 0 C--N 1.294 -1.764 0 CA-C-N 110.785 -2.916 . . . . 0.0 117.662 179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.508 ' C ' ' HZ2' ' A' ' 54' ' ' LYS . 23.0 t0 -87.0 -168.48 2.26 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 113.498 -3.281 . . . . 0.0 107.115 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.479 ' H ' ' CG ' ' A' ' 27' ' ' ASP . 5.5 mm-40 -102.92 127.55 50.08 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 100.391 -3.929 . . . . 0.0 100.391 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.465 HG23 ' HB3' ' A' ' 33' ' ' ASP . 2.9 p -109.55 160.74 8.33 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 3.0 t30 -96.72 -164.17 1.12 Allowed 'General case' 0 C--N 1.292 -1.901 0 CA-C-N 113.472 -1.695 . . . . 0.0 109.137 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.619 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.284 9.9 tt0 -117.87 56.21 0.86 Allowed 'General case' 0 C--N 1.289 -2.048 1 N-CA-C 98.332 -4.692 . . . . 0.0 98.332 -178.88 . . . . . . . . 4 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -178.04 1.39 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.84 0 CA-C-N 112.049 -2.341 . . . . 0.0 116.442 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.485 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 42.3 t0 -90.31 -172.14 3.35 Favored 'General case' 0 N--CA 1.508 2.463 0 CA-C-N 118.789 0.722 . . . . 0.0 111.371 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.545 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -112.51 176.34 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 126.375 2.988 . . . . 0.0 102.956 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.545 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -140.08 -83.29 0.25 Allowed 'General case' 0 C--N 1.274 -2.697 1 CA-C-N 107.485 -4.416 . . . . 0.0 100.504 179.317 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.431 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -126.08 172.34 10.07 Favored 'General case' 0 N--CA 1.51 2.568 0 CA-C-N 122.179 2.263 . . . . 0.0 115.153 -179.287 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.452 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 2.1 tt0 -119.77 101.33 7.82 Favored 'General case' 0 N--CA 1.493 1.707 1 N-CA-C 92.966 -6.679 . . . . 0.0 92.966 179.443 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 t -108.18 150.43 10.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.517 HE21 HG22 ' A' ' 44' ' ' VAL . 35.2 tt0 -121.23 164.53 16.81 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 104.116 -2.55 . . . . 0.0 104.116 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.4 HD21 ' HB3' ' A' ' 43' ' ' ALA . 5.2 p-10 -152.98 -178.75 7.11 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 102.623 -3.102 . . . . 0.0 102.623 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -5.79 -57.62 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 118.231 2.678 . . . . 0.0 118.231 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -146.36 -34.3 0.29 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.4 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -75.31 149.88 38.63 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.86 -1.064 . . . . 0.0 113.2 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.517 HG22 HE21 ' A' ' 39' ' ' GLN . 21.9 t -122.6 110.99 28.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 1 N-CA-C 95.696 -5.668 . . . . 0.0 95.696 179.582 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t -114.71 162.61 12.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 CA-C-O 124.709 2.195 . . . . 0.0 108.455 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.431 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -118.35 153.12 34.55 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 109.044 -3.707 . . . . 0.0 106.766 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.431 HD12 ' C ' ' A' ' 46' ' ' GLU . 1.7 mp -121.43 126.25 26.57 Favored Pre-proline 0 C--N 1.302 -1.47 1 N-CA-C 94.132 -6.247 . . . . 0.0 94.132 179.208 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.401 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -90.77 -176.69 1.02 Allowed 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.537 2.158 . . . . 0.0 107.934 167.106 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -91.85 112.8 56.51 Favored Pre-proline 0 C--N 1.288 -2.079 0 CA-C-N 113.207 -1.815 . . . . 0.0 108.228 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 25.3 Cg_exo -69.7 -34.59 14.49 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 121.497 1.465 . . . . 0.0 108.363 168.613 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.619 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -136.52 168.79 21.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 125.458 1.723 . . . . 0.0 111.94 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.82 162.18 13.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 127.32 2.888 . . . . 0.0 105.307 179.19 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 163.12 -141.84 7.44 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.508 ' HZ2' ' C ' ' A' ' 27' ' ' ASP . 0.5 OUTLIER -117.96 175.28 5.75 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 104.405 -2.442 . . . . 0.0 104.405 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' LEU . 21.7 t -128.52 57.19 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.048 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.414 ' HB2' HG23 ' A' ' 74' ' ' THR . 85.0 mt -26.9 -76.77 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 CA-C-N 112.729 -2.032 . . . . 0.0 113.632 -179.126 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -130.59 153.5 48.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 124.77 1.294 . . . . 0.0 110.161 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -131.25 119.62 44.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 1 N-CA-C 93.425 -6.509 . . . . 0.0 93.425 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.471 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.0 mp -90.9 -44.86 9.12 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.9 t -119.42 140.65 29.47 Favored Pre-proline 0 C--N 1.296 -1.757 1 N-CA-C 97.802 -4.888 . . . . 0.0 97.802 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.401 ' HG2' ' H ' ' A' ' 62' ' ' GLU . 13.3 Cg_endo -91.51 -101.34 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.033 1.155 . . . . 0.0 110.214 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.401 ' H ' ' HG2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -129.18 -168.71 1.97 Allowed 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 102.071 -3.307 . . . . 0.0 102.071 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 79.67 -45.87 2.98 Favored Glycine 0 C--N 1.287 -2.186 0 CA-C-N 113.404 -1.725 . . . . 0.0 112.101 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.6 m -98.83 172.51 7.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.4 t -108.03 150.63 10.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 104.614 -2.365 . . . . 0.0 104.614 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.485 ' HB3' HD11 ' A' ' 18' ' ' ILE . . . -123.97 168.11 13.25 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 103.661 -2.718 . . . . 0.0 103.661 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.564 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 12.2 t -129.02 -151.32 0.47 Allowed 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.58 HG11 ' HB3' ' A' ' 8' ' ' ASP . 97.4 t -121.98 159.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.322 0 N-CA-C 101.028 -3.693 . . . . 0.0 101.028 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.32 -43.86 1.7 Allowed Glycine 0 CA--C 1.549 2.211 1 N-CA-C 97.142 -6.383 . . . . 0.0 97.142 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.511 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.1 tt0 -88.81 162.56 16.13 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 102.289 -3.226 . . . . 0.0 102.289 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.7 m -109.6 -176.93 3.14 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 101.965 -3.346 . . . . 0.0 101.965 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.3 tp -146.91 -65.49 0.28 Allowed 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 1.4 tt -133.25 166.13 30.23 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-N 112.125 -2.307 . . . . 0.0 105.174 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 56' ' ' LEU . 0.8 OUTLIER -138.49 156.71 47.29 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 101.42 -3.548 . . . . 0.0 101.42 179.07 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.47 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -136.11 147.57 47.85 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.742 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.51 142.34 42.43 Favored 'General case' 0 C--N 1.299 -1.63 1 N-CA-C 97.946 -4.835 . . . . 0.0 97.946 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.13 36.6 0.25 Allowed Pre-proline 0 C--N 1.293 -1.853 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.386 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -37.21 61.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 124.921 3.747 . . . . 0.0 119.406 -143.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 153.5 42.3 0.02 OUTLIER Glycine 0 N--CA 1.495 2.59 0 N-CA-C 106.472 -2.651 . . . . 0.0 106.472 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.304 -1.398 0 N-CA-C 100.634 -3.839 . . . . 0.0 100.634 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.069 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -126.07 127.84 46.46 Favored 'General case' 0 N--CA 1.503 2.224 0 N-CA-C 102.569 -3.123 . . . . 0.0 102.569 -179.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.12 -151.25 0.47 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 125.319 1.637 . . . . 0.0 111.818 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.56 ' CE2' ' HE2' ' A' ' 5' ' ' LYS . 8.2 t80 -113.3 -49.68 2.9 Favored 'General case' 0 N--CA 1.502 2.162 0 CA-C-N 113.375 -1.738 . . . . 0.0 114.655 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.56 ' HE2' ' CE2' ' A' ' 4' ' ' PHE . 28.4 mmtt -131.45 155.11 47.92 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 66.0 mt -84.05 173.66 7.0 Favored Pre-proline 0 C--N 1.296 -1.724 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.818 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -54.18 85.91 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.585 2.19 . . . . 0.0 109.791 162.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.496 ' HB3' HG11 ' A' ' 68' ' ' VAL . 10.4 t0 -122.9 -80.22 0.62 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.3 pt 37.07 39.03 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.575 0 CA-C-O 121.896 0.855 . . . . 0.0 109.447 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.12 -150.56 11.33 Favored Glycine 0 N--CA 1.48 1.629 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.594 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -95.01 139.19 31.71 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 103.309 -2.848 . . . . 0.0 103.309 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.97 -79.27 0.33 Allowed Glycine 0 N--CA 1.487 2.081 0 N-CA-C 103.774 -3.731 . . . . 0.0 103.774 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.3 mm -130.73 133.25 63.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 22.1 t-80 -130.34 -19.23 3.14 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.643 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.503 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 0.5 OUTLIER -131.32 178.1 6.97 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 122.975 1.369 . . . . 0.0 110.55 -179.524 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.83 125.44 4.12 Favored Glycine 0 C--N 1.29 -2.019 0 N-CA-C 104.8 -3.32 . . . . 0.0 104.8 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 37.5 tt0 -100.31 96.31 7.36 Favored 'General case' 0 C--N 1.307 -1.272 1 N-CA-C 97.28 -5.081 . . . . 0.0 97.28 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mt -81.96 125.12 39.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 N-CA-C 103.573 -2.751 . . . . 0.0 103.573 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.6 t -86.38 -64.0 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 103.26 -2.867 . . . . 0.0 103.26 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.454 ' HE3' ' O ' ' A' ' 21' ' ' TRP . 1.3 tmtp? -142.99 167.75 21.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 124.018 0.824 . . . . 0.0 113.22 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.512 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 30.3 m95 -113.73 173.06 6.61 Favored 'General case' 0 N--CA 1.502 2.131 0 C-N-CA 123.92 0.888 . . . . 0.0 109.004 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.419 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.3 m-85 -126.92 -48.51 1.49 Allowed 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.541 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 m -100.23 178.69 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.172 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.02 161.77 26.34 Favored Pre-proline 0 C--N 1.295 -1.785 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.814 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -78.16 122.56 5.76 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.249 1.966 . . . . 0.0 110.857 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.16 -15.99 22.78 Favored Glycine 0 N--CA 1.483 1.816 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.23 174.37 7.32 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 123.018 1.389 . . . . 0.0 111.74 -178.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.93 117.41 28.01 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 111.166 -2.743 . . . . 0.0 104.242 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.498 HG13 ' HB2' ' A' ' 31' ' ' GLU . 9.7 p -108.58 176.59 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.719 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.422 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -104.65 -26.3 12.37 Favored 'General case' 0 N--CA 1.522 3.166 0 CA-C-O 126.698 3.142 . . . . 0.0 112.94 -179.697 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.498 ' HB2' HG13 ' A' ' 29' ' ' VAL 0.377 10.8 tp10 35.46 78.71 0.03 OUTLIER 'General case' 0 C--N 1.272 -2.796 5 N-CA-C 138.398 10.147 . . . . 0.0 138.398 -179.389 . . . . . . . . 4 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -141.67 27.21 1.87 Allowed 'General case' 0 C--N 1.287 -2.127 4 CA-C-N 94.721 -10.218 . . . . 0.0 96.273 179.251 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -108.94 -165.59 1.04 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 126.105 1.762 . . . . 0.0 107.343 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.476 HG12 ' H ' ' A' ' 35' ' ' LEU . 1.6 t -120.3 163.02 18.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 CA-C-O 125.554 2.597 . . . . 0.0 108.893 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.512 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.6 mp -126.45 -84.0 0.62 Allowed 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 108.726 -3.852 . . . . 0.0 103.033 179.15 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.573 ' SG ' HG23 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -123.66 172.69 8.62 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 -178.979 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.369 18.5 tt0 -134.04 140.31 46.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 127.064 2.728 . . . . 0.0 103.646 -179.244 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.573 HG23 ' SG ' ' A' ' 36' ' ' CYS . 25.0 t -139.39 151.34 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 CA-C-N 119.145 0.884 . . . . 0.0 109.7 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 43.4 tp60 -106.5 128.25 53.95 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 8.6 p-10 -156.01 -173.09 4.36 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -11.69 -73.63 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.608 0 O-C-N 126.479 2.362 . . . . 0.0 116.608 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -128.38 -7.27 5.27 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.408 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -97.81 159.2 15.08 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.276 -0.97 . . . . 0.0 113.15 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.9 t -124.65 -35.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 126.678 2.486 . . . . 0.0 112.942 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 10.9 t -113.1 169.51 4.78 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 125.239 1.415 . . . . 0.0 108.282 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.484 ' N ' HG12 ' A' ' 45' ' ' VAL . 3.6 mt-10 -120.45 -67.8 0.95 Allowed 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 121.422 3.86 . . . . 0.0 121.422 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.6 mp -92.85 149.49 37.84 Favored Pre-proline 0 C--N 1.273 -2.73 0 CA-C-N 108.746 -3.843 . . . . 0.0 108.672 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.463 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -103.18 -178.31 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.708 1.373 . . . . 0.0 109.152 83.395 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.432 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 0.7 OUTLIER -130.96 179.53 1.32 Allowed Pre-proline 0 C--N 1.286 -2.164 0 CA-C-N 113.481 -1.69 . . . . 0.0 108.428 -179.798 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -102.32 -26.53 0.03 OUTLIER 'Trans proline' 0 CA--C 1.548 1.179 0 N-CA-C 120.016 3.045 . . . . 0.0 120.016 171.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.517 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.9 OUTLIER -127.89 160.6 37.32 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.454 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.655 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -106.75 167.61 9.75 Favored 'General case' 0 C--N 1.294 -1.825 1 CA-C-N 107.451 -4.431 . . . . 0.0 111.148 -179.625 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.28 -141.37 6.75 Favored Glycine 0 C--N 1.292 -1.909 1 N-CA-C 100.024 -5.23 . . . . 0.0 100.024 -179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.445 ' HG3' ' H ' ' A' ' 55' ' ' VAL . 14.4 tppt? -105.79 175.1 5.61 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 102.151 -3.277 . . . . 0.0 102.151 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.445 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 47.4 t -126.1 60.69 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.216 1 N-CA-C 96.549 -5.352 . . . . 0.0 96.549 179.39 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.406 ' C ' ' O ' ' A' ' 55' ' ' VAL . 91.2 mt -22.55 -80.34 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.163 0 CA-C-N 112.816 -1.993 . . . . 0.0 112.999 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -139.76 164.18 30.64 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 125.049 1.468 . . . . 0.0 107.817 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.9 mt -132.47 130.99 60.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 1 N-CA-C 95.67 -5.678 . . . . 0.0 95.67 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.45 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.9 mp -87.74 -52.61 5.21 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 123.8 0.688 . . . . 0.0 109.689 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.5 t -116.67 140.54 26.89 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 101.135 -3.654 . . . . 0.0 101.135 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -87.5 -106.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.694 1.596 . . . . 0.0 111.004 178.087 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -129.56 159.57 35.95 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 102.567 -3.123 . . . . 0.0 102.567 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 107.17 -33.09 6.63 Favored Glycine 0 N--CA 1.498 2.782 0 C-N-CA 119.278 -1.439 . . . . 0.0 114.61 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.2 m -109.28 -175.9 2.88 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.2 t -112.43 150.93 14.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.88 163.73 18.73 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -107.57 -160.77 0.75 Allowed 'General case' 0 C--N 1.285 -2.224 0 N-CA-C 104.234 -2.506 . . . . 0.0 104.234 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.496 HG11 ' HB3' ' A' ' 8' ' ' ASP 0.265 44.6 t -124.0 153.86 30.38 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 1 N-CA-C 92.643 -6.799 . . . . 0.0 92.643 178.226 . . . . . . . . 4 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 95.6 -45.8 1.99 Allowed Glycine 0 N--CA 1.498 2.77 0 N-CA-C 103.294 -3.922 . . . . 0.0 103.294 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.42 ' H ' ' C ' ' A' ' 68' ' ' VAL . 37.3 tt0 -85.84 160.21 19.51 Favored 'General case' 0 C--N 1.303 -1.452 1 N-CA-C 99.777 -4.157 . . . . 0.0 99.777 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.4 m -106.54 -178.43 3.65 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 102.122 -3.288 . . . . 0.0 102.122 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.508 HD22 ' CE2' ' A' ' 4' ' ' PHE . 47.9 tp -143.33 -60.07 0.42 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.419 HD11 HG13 ' A' ' 55' ' ' VAL . 14.2 tt -132.96 161.97 40.76 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 104.573 -2.38 . . . . 0.0 104.573 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 t -140.09 164.73 29.25 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -134.01 144.21 48.58 Favored 'General case' 0 N--CA 1.505 2.275 0 CA-C-N 113.873 -1.512 . . . . 0.0 109.587 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -110.07 55.19 0.65 Allowed 'General case' 0 N--CA 1.504 2.249 0 CA-C-O 125.05 2.357 . . . . 0.0 112.32 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -91.37 132.26 34.23 Favored Pre-proline 0 C--N 1.293 -1.848 0 CA-C-N 112.456 -2.156 . . . . 0.0 107.652 -179.151 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -91.43 171.61 2.94 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 124.012 3.141 . . . . 0.0 106.949 150.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.95 -34.04 4.91 Favored Glycine 0 N--CA 1.493 2.487 1 N-CA-C 102.037 -4.425 . . . . 0.0 102.037 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 7.1 m-85 . . . . . 0 C--N 1.302 -1.482 0 N-CA-C 103.078 -2.934 . . . . 0.0 103.078 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -119.22 139.39 51.95 Favored 'General case' 0 N--CA 1.512 2.668 0 N-CA-C 100.732 -3.803 . . . . 0.0 100.732 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.449 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 0.0 OUTLIER -114.99 -161.03 0.76 Allowed 'General case' 0 N--CA 1.502 2.17 0 CA-C-N 120.798 1.635 . . . . 0.0 109.401 -179.67 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.421 ' CD2' ' HD3' ' A' ' 5' ' ' LYS . 8.8 t80 -126.99 -29.1 2.83 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 116.828 2.158 . . . . 0.0 116.828 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.465 ' HB2' HG13 ' A' ' 68' ' ' VAL . 17.9 mmmt -128.26 169.38 14.25 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-N 122.21 2.277 . . . . 0.0 105.279 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 64.6 mt -91.45 177.34 2.26 Favored Pre-proline 0 N--CA 1.493 1.705 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.741 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -61.14 80.05 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.649 0 N-CA-C 106.954 -1.979 . . . . 0.0 106.954 148.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.48 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.9 t70 -123.09 -80.05 0.62 Allowed 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.495 ' H ' HG11 ' A' ' 68' ' ' VAL . 45.5 pt 38.4 34.78 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.51 0 CA-C-N 119.794 1.179 . . . . 0.0 110.168 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.08 -115.03 2.89 Favored Glycine 0 N--CA 1.48 1.587 0 C-N-CA 120.84 -0.695 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -103.46 133.45 48.49 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.278 0.561 . . . . 0.0 110.873 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 116.92 -78.43 0.29 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 106.613 -2.595 . . . . 0.0 106.613 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.5 mm -133.45 134.1 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.089 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -119.22 -41.96 2.71 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 102.013 -3.328 . . . . 0.0 102.013 179.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.64 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.7 OUTLIER -130.65 167.47 18.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 124.005 0.816 . . . . 0.0 110.098 179.601 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.95 149.27 19.12 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -99.05 97.62 8.74 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 104.11 -2.552 . . . . 0.0 104.11 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.433 HG21 ' O ' ' A' ' 61' ' ' PRO . 17.7 mm -83.85 115.04 25.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 t -97.02 -48.32 12.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 O-C-N 125.061 1.475 . . . . 0.0 111.12 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.589 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -137.79 144.66 41.67 Favored 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.488 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 24.1 m95 -114.25 170.14 8.51 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CZ ' ' HE2' ' A' ' 20' ' ' LYS . 2.6 m-85 -121.47 -51.17 2.08 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 113.87 -1.514 . . . . 0.0 111.161 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 m -100.49 175.01 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.145 -1.022 . . . . 0.0 110.311 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.737 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -116.0 156.87 46.21 Favored Pre-proline 0 C--N 1.299 -1.63 0 N-CA-C 104.323 -2.473 . . . . 0.0 104.323 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -64.67 145.16 86.29 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 120.865 1.044 . . . . 0.0 111.22 171.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.56 19.73 28.94 Favored Glycine 0 N--CA 1.488 2.149 0 CA-C-O 118.733 -1.037 . . . . 0.0 111.864 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -106.33 170.05 8.15 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.63 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.466 ' HG2' ' HE3' ' A' ' 54' ' ' LYS . 21.0 mt-10 -129.25 88.4 2.7 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.454 ' O ' ' HB2' ' A' ' 52' ' ' LYS . 10.3 p -74.36 178.38 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-N 110.718 -2.946 . . . . 0.0 108.892 -179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.468 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 9.2 t-20 -107.39 -29.71 9.1 Favored 'General case' 0 N--CA 1.517 2.892 0 CA-C-O 124.693 2.187 . . . . 0.0 112.097 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.483 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.387 11.1 tp10 44.63 75.22 0.11 Allowed 'General case' 0 C--N 1.279 -2.474 5 N-CA-C 135.413 9.042 . . . . 0.0 135.413 -179.742 . . . . . . . . 4 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 32' ' ' ASP . 11.8 p-10 -144.31 27.36 1.41 Allowed 'General case' 0 C--N 1.284 -2.248 4 CA-C-N 94.649 -10.251 . . . . 0.0 94.709 178.69 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.466 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 4.2 m-20 -112.19 -169.56 1.49 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 127.652 2.381 . . . . 0.0 110.833 -178.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.55 ' HA ' HG22 ' A' ' 47' ' ' ILE . 1.5 t -119.94 162.17 18.64 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 CA-C-O 124.302 2.001 . . . . 0.0 107.994 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.573 ' HB2' HG21 ' A' ' 47' ' ' ILE . 7.1 mp -126.22 -85.35 0.62 Allowed 'General case' 0 C--N 1.282 -2.356 1 CA-C-N 108.162 -4.108 . . . . 0.0 102.485 179.075 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.459 ' SG ' HD13 ' A' ' 47' ' ' ILE . 14.6 p -123.81 174.99 7.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -178.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.655 ' HG2' ' HA ' ' A' ' 45' ' ' VAL . 1.9 tt0 -133.27 140.07 47.27 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 126.925 2.641 . . . . 0.0 105.887 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.431 ' CG2' HD13 ' A' ' 18' ' ' ILE . 29.1 t -137.73 153.56 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-N 119.705 1.139 . . . . 0.0 108.32 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -112.15 122.65 48.33 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 4.6 p-10 -159.63 170.78 20.87 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.424 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 6.0 p-10 -3.88 -67.57 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 117.537 2.421 . . . . 0.0 117.537 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.424 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 84.9 mttt -126.19 -0.88 7.07 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 124.42 1.075 . . . . 0.0 111.459 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -104.01 154.45 19.66 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 114.41 1.263 . . . . 0.0 114.41 -179.506 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.7 t -129.95 -47.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 CA-C-N 111.109 -2.769 . . . . 0.0 109.0 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.655 ' HA ' ' HG2' ' A' ' 37' ' ' GLU . 21.8 t -105.8 160.98 5.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 CA-C-N 112.68 -2.054 . . . . 0.0 106.878 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.537 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.8 mt-10 -119.36 -67.14 1.01 Allowed 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 120.619 3.563 . . . . 0.0 120.619 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.573 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.1 mp -90.81 147.38 35.91 Favored Pre-proline 0 C--N 1.272 -2.768 0 CA-C-N 109.781 -3.372 . . . . 0.0 109.587 -179.379 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.561 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -100.71 178.57 0.23 Allowed 'Trans proline' 0 C--N 1.314 -1.283 0 N-CA-C 107.378 -1.816 . . . . 0.0 107.378 84.303 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.483 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 14.5 m -128.78 -176.55 0.54 Allowed Pre-proline 0 C--N 1.285 -2.232 0 CA-C-N 113.609 -1.632 . . . . 0.0 107.41 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.451 ' CD ' ' HB3' ' A' ' 49' ' ' SER . 87.7 Cg_endo -100.64 -30.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 123.121 2.547 . . . . 0.0 118.093 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -138.18 162.41 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.33 0 CA-C-O 123.559 1.647 . . . . 0.0 114.381 -179.348 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.532 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -112.52 169.81 8.62 Favored 'General case' 0 C--N 1.296 -1.723 1 CA-C-N 107.796 -4.275 . . . . 0.0 110.213 -179.645 . . . . . . . . 4 4 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 167.23 -141.25 6.76 Favored Glycine 0 C--N 1.288 -2.113 1 N-CA-C 96.799 -6.52 . . . . 0.0 96.799 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.466 ' HE3' ' HG2' ' A' ' 28' ' ' GLU . 0.6 OUTLIER -93.6 -179.31 4.98 Favored 'General case' 0 C--N 1.288 -2.066 1 N-CA-C 99.785 -4.154 . . . . 0.0 99.785 179.99 . . . . . . . . 4 4 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 48.1 t -127.9 98.39 4.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.451 1 N-CA-C 91.689 -7.152 . . . . 0.0 91.689 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 55.1 mt -58.81 -88.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 124.787 1.304 . . . . 0.0 109.874 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -139.43 166.16 25.31 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -126.57 134.7 65.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 1 N-CA-C 94.43 -6.137 . . . . 0.0 94.43 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.439 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.8 mp -94.6 -57.25 2.53 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.276 -0.97 . . . . 0.0 112.238 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 22.8 t -113.05 94.22 29.02 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 101.061 -3.681 . . . . 0.0 101.061 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.433 ' O ' HG21 ' A' ' 18' ' ' ILE . 13.2 Cg_exo -71.93 -81.31 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 CA-C-N 120.09 1.068 . . . . 0.0 109.558 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -137.11 164.2 28.99 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.53 -49.46 1.2 Allowed Glycine 0 N--CA 1.499 2.881 0 C-N-CA 119.962 -1.113 . . . . 0.0 113.133 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.78 -172.27 2.56 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 105.511 -2.033 . . . . 0.0 105.511 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.1 t -114.92 144.82 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.39 147.84 49.7 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.64 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 7.8 p -106.54 -160.04 0.72 Allowed 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.658 1.694 . . . . 0.0 108.367 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.495 HG11 ' H ' ' A' ' 9' ' ' ILE . 44.8 t -115.07 155.85 16.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.309 1 N-CA-C 91.751 -7.129 . . . . 0.0 91.751 178.477 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.19 -36.79 3.77 Favored Glycine 0 N--CA 1.49 2.264 1 N-CA-C 102.464 -4.254 . . . . 0.0 102.464 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.451 ' H ' ' C ' ' A' ' 68' ' ' VAL . 33.0 tt0 -104.2 164.19 11.89 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 102.316 -3.216 . . . . 0.0 102.316 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -98.69 -178.15 3.89 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 103.658 -2.719 . . . . 0.0 103.658 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 36.4 tp -138.66 -72.03 0.41 Allowed 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.001 -2.222 . . . . 0.0 105.001 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 10.9 tt -132.7 159.79 42.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.6 t -137.99 163.92 30.33 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 125.869 1.98 . . . . 0.0 106.496 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.9 155.58 49.58 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 125.636 1.835 . . . . 0.0 110.984 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -120.06 144.8 47.38 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 104.265 -2.494 . . . . 0.0 104.265 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 80' ' ' TYR . . . -143.68 84.07 10.16 Favored Pre-proline 0 N--CA 1.492 1.636 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -61.73 53.68 0.11 Allowed 'Trans proline' 0 N--CA 1.507 2.292 0 C-N-CA 124.792 3.662 . . . . 0.0 118.723 -168.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.21 63.5 0.19 Allowed Glycine 0 N--CA 1.489 2.169 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 1.8 t80 . . . . . 0 N--CA 1.497 1.883 0 N-CA-C 102.821 -3.029 . . . . 0.0 102.821 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.4 ' N ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.494 1.731 1 N-CA-C 97.812 -4.884 . . . . 0.0 97.812 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.468 ' HB3' ' CB ' ' A' ' 75' ' ' LEU . 18.8 t80 -117.2 93.15 4.07 Favored 'General case' 0 C--N 1.297 -1.689 1 N-CA-C 95.009 -5.923 . . . . 0.0 95.009 178.849 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.4 ' OE2' ' N ' ' A' ' 1' ' ' ALA . 7.1 mp0 -68.41 -177.45 0.92 Allowed 'General case' 0 C--N 1.302 -1.493 0 O-C-N 125.6 1.813 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -110.31 -30.15 7.83 Favored 'General case' 0 N--CA 1.51 2.553 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -179.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.572 ' CG ' HG22 ' A' ' 68' ' ' VAL . 36.5 mmtt -127.06 166.59 17.32 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 103.074 -2.935 . . . . 0.0 103.074 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 74.2 mt -108.79 -173.65 0.27 Allowed Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -54.29 85.36 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.856 1.704 . . . . 0.0 109.031 158.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.505 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.7 t70 -121.88 -74.73 0.61 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 101.761 -3.422 . . . . 0.0 101.761 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.618 ' H ' HG11 ' A' ' 68' ' ' VAL . 40.2 pt 30.47 38.62 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.975 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.53 -46.83 1.01 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 119.439 -1.362 . . . . 0.0 112.706 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.02 80.9 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 124.355 2.026 . . . . 0.0 113.987 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.68 -68.18 0.26 Allowed Glycine 0 C--N 1.277 -2.746 0 CA-C-N 111.877 -2.42 . . . . 0.0 107.637 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 14' ' ' HIS . 40.4 mm -127.2 -172.96 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.444 ' N ' HG22 ' A' ' 13' ' ' ILE . 2.1 p80 -144.02 -50.97 0.31 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.583 0.706 . . . . 0.0 111.276 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.7 pt-20 -103.24 -168.81 1.56 Allowed 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 116.381 1.993 . . . . 0.0 116.381 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.09 112.15 0.59 Allowed Glycine 0 C--N 1.286 -2.227 0 CA-C-N 112.795 -2.002 . . . . 0.0 108.202 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -98.95 92.02 5.32 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 101.567 -3.494 . . . . 0.0 101.567 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.7 mt -85.01 104.2 12.89 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.9 t -86.82 -47.49 16.05 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.476 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.423 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 41.1 tttt -126.22 146.31 50.04 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-N 114.431 -1.258 . . . . 0.0 113.394 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.463 ' CZ2' ' SG ' ' A' ' 36' ' ' CYS . 4.8 m95 -121.6 176.76 5.54 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 103.846 -2.65 . . . . 0.0 103.846 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.504 ' CD2' HG21 ' A' ' 34' ' ' VAL . 13.8 m-85 -123.76 -34.91 2.96 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 126.257 2.223 . . . . 0.0 112.189 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.531 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 10.3 m -103.74 176.54 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.977 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -140.9 61.31 14.58 Favored Pre-proline 0 N--CA 1.492 1.627 0 N-CA-C 117.933 2.568 . . . . 0.0 117.933 -179.438 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 23' ' ' VAL . 5.8 Cg_exo -21.54 -179.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 N-CA-C 119.699 2.923 . . . . 0.0 119.699 -60.079 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.531 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.33 28.61 8.69 Favored Glycine 0 N--CA 1.497 2.713 0 CA-C-N 111.597 -2.547 . . . . 0.0 108.198 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 54' ' ' LYS . 5.2 t0 7.86 -95.6 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.16 0 O-C-N 128.527 3.133 . . . . 0.0 110.905 179.427 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.428 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 3.1 mm-40 -98.44 119.7 37.59 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 100.818 -3.771 . . . . 0.0 100.818 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -120.23 168.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 122.296 1.046 . . . . 0.0 109.208 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.7 m-20 -99.85 -168.13 1.56 Allowed 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 112.535 -2.12 . . . . 0.0 107.729 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.731 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.263 4.6 tt0 -120.62 52.36 1.17 Allowed 'General case' 0 N--CA 1.494 1.753 1 N-CA-C 97.838 -4.875 . . . . 0.0 97.838 -179.727 . . . . . . . . 4 3 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -171.37 36.89 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 111.403 -2.635 . . . . 0.0 111.711 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.46 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 19.1 t70 -112.96 -178.38 3.37 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.455 -0.778 . . . . 0.0 109.116 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.504 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -84.77 -166.06 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 127.314 3.435 . . . . 0.0 117.664 179.75 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.685 ' HB3' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -115.27 -150.68 0.47 Allowed 'General case' 0 C--N 1.281 -2.404 2 CA-C-N 103.319 -6.31 . . . . 0.0 108.645 -179.553 . . . . . . . . 4 4 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.463 ' SG ' ' CZ2' ' A' ' 21' ' ' TRP . 1.8 m -127.19 159.38 34.47 Favored 'General case' 0 C--N 1.284 -2.282 2 N-CA-C 97.025 -5.176 . . . . 0.0 97.025 179.193 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -114.64 108.6 17.02 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 100.492 -3.892 . . . . 0.0 100.492 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 49.1 t -112.96 147.61 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 37.4 tt0 -113.09 155.53 24.76 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.088 -1.045 . . . . 0.0 108.886 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -140.49 -168.97 2.68 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 104.683 -2.339 . . . . 0.0 104.683 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.457 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.9 OUTLIER -11.13 -64.0 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 126.427 2.33 . . . . 0.0 115.301 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.457 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 17.2 mttp -144.82 -21.87 0.51 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 124.065 0.853 . . . . 0.0 110.439 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.44 -176.33 3.08 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.628 1.204 . . . . 0.0 112.431 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 38.3 t -125.94 137.58 57.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 103.398 -2.816 . . . . 0.0 103.398 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.5 t -112.05 157.8 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.569 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -119.8 141.26 49.66 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 111.572 -2.558 . . . . 0.0 109.952 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.685 ' C ' ' HB3' ' A' ' 35' ' ' LEU . 1.9 mp -125.92 75.22 71.47 Favored Pre-proline 0 CA--C 1.574 1.87 0 N-CA-C 101.556 -3.498 . . . . 0.0 101.556 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.462 ' N ' ' HB3' ' A' ' 35' ' ' LEU . 78.3 Cg_endo -62.07 -172.42 0.11 Allowed 'Trans proline' 0 N--CA 1.512 2.574 0 C-N-CA 122.894 2.396 . . . . 0.0 108.173 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.7 p -105.07 85.22 1.2 Allowed Pre-proline 0 C--N 1.286 -2.19 0 CA-C-N 112.934 -1.939 . . . . 0.0 111.567 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -46.31 -31.98 10.08 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.588 1.525 . . . . 0.0 112.926 176.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.731 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -131.09 167.61 25.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.547 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.76 165.15 11.22 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 127.141 2.776 . . . . 0.0 108.097 179.408 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 148.23 -139.85 7.95 Favored Glycine 0 C--N 1.293 -1.808 0 N-CA-C 106.237 -2.745 . . . . 0.0 106.237 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.601 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -111.91 169.03 9.12 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 -179.503 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.406 HG11 ' H ' ' A' ' 26' ' ' GLY . 33.4 t -128.38 61.55 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 100.856 -3.757 . . . . 0.0 100.856 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.439 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 40.8 mt -31.37 -74.11 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 110.845 -2.889 . . . . 0.0 114.227 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -138.75 163.76 31.34 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 114.127 1.158 . . . . 0.0 114.127 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.4 HD12 ' HD3' ' A' ' 25' ' ' PRO . 56.1 mt -136.36 136.94 48.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 1 N-CA-C 100.062 -4.051 . . . . 0.0 100.062 179.762 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.3 mt -94.25 -63.56 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.727 0.775 . . . . 0.0 110.453 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.473 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 15.8 t -115.94 73.8 4.91 Favored Pre-proline 0 N--CA 1.491 1.622 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 -179.608 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -45.88 -77.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.067 1.845 . . . . 0.0 113.335 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.2 -177.14 4.7 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.45 -49.96 4.32 Favored Glycine 0 N--CA 1.492 2.4 0 CA-C-N 113.929 -1.487 . . . . 0.0 113.007 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.473 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 5.3 m -103.51 -176.22 3.02 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.4 150.05 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.87 160.8 26.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 9.5 t -115.25 -161.29 0.77 Allowed 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.618 HG11 ' H ' ' A' ' 9' ' ' ILE . 73.3 t -120.25 153.78 23.28 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 95.036 -5.913 . . . . 0.0 95.036 178.618 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.58 -37.99 3.42 Favored Glycine 0 N--CA 1.492 2.427 1 N-CA-C 101.513 -4.635 . . . . 0.0 101.513 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -97.53 159.43 14.93 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 100.71 -3.811 . . . . 0.0 100.71 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.5 179.25 5.07 Favored 'General case' 0 C--N 1.288 -2.082 0 N-CA-C 100.222 -3.992 . . . . 0.0 100.222 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 52.4 tp -138.81 -67.22 0.46 Allowed 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.78 161.94 37.65 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 103.107 -2.924 . . . . 0.0 103.107 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.8 t -137.42 157.45 46.55 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 126.327 2.267 . . . . 0.0 105.714 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.468 ' CB ' ' HB3' ' A' ' 2' ' ' PHE . 0.6 OUTLIER -137.43 150.92 47.99 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -114.26 151.35 32.98 Favored 'General case' 0 C--N 1.296 -1.72 1 N-CA-C 98.865 -4.494 . . . . 0.0 98.865 179.388 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.433 ' HB3' ' HA ' ' A' ' 78' ' ' PRO . . . -117.76 -36.68 0.07 OUTLIER Pre-proline 0 N--CA 1.501 2.078 0 C-N-CA 119.465 -0.894 . . . . 0.0 112.747 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 77' ' ' ALA . 38.2 Cg_exo -64.02 -178.87 0.65 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 125.701 2.421 . . . . 0.0 107.647 -62.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.44 -39.23 2.1 Favored Glycine 0 N--CA 1.5 2.926 1 N-CA-C 101.933 -4.467 . . . . 0.0 101.933 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.581 0 N-CA-C 101.476 -3.527 . . . . 0.0 101.476 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.476 ' N ' ' O ' ' A' ' 80' ' ' TYR . . . . . . . . 0 N--CA 1.508 2.462 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.531 ' HB2' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -141.38 159.21 42.69 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.869 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.59 -142.42 0.27 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.755 ' CZ ' ' HD3' ' A' ' 5' ' ' LYS . 14.1 t80 -126.37 -60.75 1.24 Allowed 'General case' 0 N--CA 1.504 2.228 0 O-C-N 124.422 1.076 . . . . 0.0 113.34 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.755 ' HD3' ' CZ ' ' A' ' 4' ' ' PHE . 20.9 mmmt -132.1 143.61 50.14 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 67.9 mt -90.27 173.46 5.69 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 125.053 1.471 . . . . 0.0 107.963 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -40.88 81.59 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.294 0 N-CA-C 118.414 2.429 . . . . 0.0 118.414 168.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.466 ' HB3' HG11 ' A' ' 68' ' ' VAL . 12.2 t70 -122.68 -76.82 0.59 Allowed 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 103.604 -2.739 . . . . 0.0 103.604 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 27.4 pt 37.4 44.45 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.251 0 CA-C-O 122.683 1.23 . . . . 0.0 108.865 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 14' ' ' HIS . . . -90.62 -161.95 37.84 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -109.59 160.83 15.93 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 118.551 1.176 . . . . 0.0 108.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.28 -72.49 0.38 Allowed Glycine 0 N--CA 1.485 1.934 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.5 mm -132.4 82.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 124.933 1.02 . . . . 0.0 110.248 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -105.57 16.13 25.92 Favored 'General case' 0 N--CA 1.507 2.38 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.092 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 7.8 pt-20 -140.09 166.92 23.35 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 113.923 -1.49 . . . . 0.0 108.01 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.03 125.3 4.65 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 107.417 -2.273 . . . . 0.0 107.417 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.464 ' H ' HG13 ' A' ' 38' ' ' VAL . 33.8 tt0 -96.9 100.45 11.97 Favored 'General case' 0 C--N 1.302 -1.471 1 N-CA-C 99.04 -4.43 . . . . 0.0 99.04 179.77 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG22 ' A' ' 38' ' ' VAL . 16.0 mm -82.4 124.57 39.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 1 N-CA-C 99.599 -4.223 . . . . 0.0 99.599 -179.766 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.447 HG21 ' HB2' ' A' ' 39' ' ' GLN . 2.0 t -105.24 -39.79 5.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.821 ' HE3' ' CZ ' ' A' ' 22' ' ' PHE . 20.5 tttp -136.7 155.25 50.12 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.169 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.423 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 14.8 m95 -122.77 178.81 4.86 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 125.495 1.747 . . . . 0.0 106.489 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.821 ' CZ ' ' HE3' ' A' ' 20' ' ' LYS . 28.3 m-85 -132.94 -52.58 0.91 Allowed 'General case' 0 N--CA 1.504 2.259 0 O-C-N 124.373 1.045 . . . . 0.0 112.638 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 m -99.16 175.86 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 124.062 0.851 . . . . 0.0 109.596 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.486 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -117.35 161.99 30.5 Favored Pre-proline 0 C--N 1.295 -1.788 0 O-C-N 125.724 1.89 . . . . 0.0 108.443 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -56.07 112.77 1.17 Allowed 'Trans proline' 0 C--N 1.316 -1.153 0 C-N-CA 121.703 1.602 . . . . 0.0 113.013 174.319 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.51 16.81 14.89 Favored Glycine 0 N--CA 1.484 1.887 0 CA-C-O 117.167 -1.907 . . . . 0.0 113.501 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -86.76 161.12 18.56 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 116.652 -2.019 . . . . 0.0 108.008 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.45 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -109.71 92.16 3.94 Favored 'General case' 0 C--N 1.294 -1.816 1 N-CA-C 99.813 -4.143 . . . . 0.0 99.813 -179.574 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 31' ' ' GLU . 6.1 p -91.64 176.16 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 C-N-CA 117.308 -1.757 . . . . 0.0 106.368 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.594 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 26.9 t30 -105.72 -21.72 13.12 Favored 'General case' 0 N--CA 1.529 3.498 0 CA-C-O 123.701 1.715 . . . . 0.0 112.243 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.541 ' H ' HG22 ' A' ' 29' ' ' VAL 0.404 3.8 tp10 36.41 67.9 0.29 Allowed 'General case' 0 C--N 1.281 -2.389 5 N-CA-C 135.059 8.911 . . . . 0.0 135.059 179.566 . . . . . . . . 4 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.9 p-10 -137.4 22.66 2.96 Favored 'General case' 0 C--N 1.288 -2.108 4 CA-C-N 95.715 -9.766 . . . . 0.0 96.572 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.548 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 28.5 t70 -115.23 -148.94 0.44 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 127.15 2.18 . . . . 0.0 105.54 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.548 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 1.9 t -120.08 163.32 17.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 126.531 3.062 . . . . 0.0 109.054 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.58 ' CB ' HG21 ' A' ' 47' ' ' ILE . 13.4 tp -123.27 -81.95 0.64 Allowed 'General case' 0 C--N 1.283 -2.319 2 CA-C-N 107.451 -4.432 . . . . 0.0 99.368 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.455 ' SG ' HD13 ' A' ' 47' ' ' ILE . 16.9 p -132.44 172.46 12.45 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.58 ' HA ' ' HA ' ' A' ' 45' ' ' VAL . 3.7 tt0 -130.42 138.51 50.37 Favored 'General case' 0 N--CA 1.5 2.067 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 ' H ' ' A' ' 17' ' ' GLU . 25.2 t -135.26 145.53 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.335 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.499 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 4.7 tt0 -109.12 138.81 44.9 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -164.31 -161.17 0.58 Allowed 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 105.805 -1.924 . . . . 0.0 105.805 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.506 ' C ' ' HG3' ' A' ' 42' ' ' LYS . 5.6 p-10 -29.03 -58.31 0.14 Allowed 'General case' 0 C--N 1.297 -1.713 0 O-C-N 126.562 2.414 . . . . 0.0 114.475 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.506 ' HG3' ' C ' ' A' ' 41' ' ' ASP . 2.9 mttt -137.9 -8.85 1.59 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.678 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -93.73 158.26 15.76 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 114.609 1.337 . . . . 0.0 114.609 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.88 -44.28 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 126.335 2.272 . . . . 0.0 109.451 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 23.4 t -103.53 155.86 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 C-N-CA 125.574 1.55 . . . . 0.0 108.749 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.673 ' HB3' HD12 ' A' ' 47' ' ' ILE . 7.9 mt-10 -114.27 -63.42 1.45 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 126.683 2.489 . . . . 0.0 114.608 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.673 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -92.88 149.64 38.07 Favored Pre-proline 0 C--N 1.281 -2.374 0 CA-C-N 108.821 -3.809 . . . . 0.0 115.094 -178.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.662 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.25 177.59 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.112 0 N-CA-C 107.569 -1.743 . . . . 0.0 107.569 87.582 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 9.7 m -119.13 177.33 1.37 Allowed Pre-proline 0 C--N 1.284 -2.257 0 CA-C-N 112.838 -1.983 . . . . 0.0 113.315 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -95.94 -44.79 0.02 OUTLIER 'Trans proline' 0 CA--C 1.555 1.572 0 N-CA-C 118.57 2.488 . . . . 0.0 118.57 169.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.645 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.8 OUTLIER -130.76 166.24 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 123.191 1.472 . . . . 0.0 114.947 -179.375 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.645 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -121.1 170.57 9.41 Favored 'General case' 0 C--N 1.3 -1.561 1 CA-C-N 107.835 -4.257 . . . . 0.0 112.314 179.971 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.22 -124.64 1.21 Allowed Glycine 0 N--CA 1.49 2.281 1 N-CA-C 96.897 -6.481 . . . . 0.0 96.897 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.542 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 16.8 tttp -107.35 -174.92 2.65 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.415 ' H ' ' HG2' ' A' ' 54' ' ' LYS . 60.3 t -130.93 65.75 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.279 1 N-CA-C 97.292 -5.077 . . . . 0.0 97.292 -179.617 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.458 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 80.1 mt -29.53 -78.09 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 112.242 -2.253 . . . . 0.0 110.956 -179.607 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -145.68 165.88 27.46 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 33.3 mt -132.78 139.93 48.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 1 N-CA-C 98.258 -4.719 . . . . 0.0 98.258 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -106.97 -31.34 8.36 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 123.819 0.7 . . . . 0.0 111.199 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.452 HG21 HD12 ' A' ' 72' ' ' LEU . 19.8 t -107.39 130.31 23.02 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -49.91 -150.38 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 124.254 3.302 . . . . 0.0 116.487 158.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 39.93 3.57 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 111.86 -2.427 . . . . 0.0 107.847 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -142.82 -6.2 0.71 Allowed Glycine 0 N--CA 1.497 2.734 0 CA-C-N 111.504 -2.589 . . . . 0.0 116.071 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.1 m -121.63 172.67 7.94 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 105.244 -2.132 . . . . 0.0 105.244 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.39 144.31 16.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 102.672 -3.084 . . . . 0.0 102.672 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -118.79 164.97 14.6 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.0 p -109.28 -163.2 0.85 Allowed 'General case' 0 C--N 1.283 -2.307 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.471 HG22 ' CB ' ' A' ' 5' ' ' LYS . 52.2 t -119.39 154.16 21.94 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 1 N-CA-C 92.681 -6.785 . . . . 0.0 92.681 178.748 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 101.06 -38.62 3.06 Favored Glycine 0 N--CA 1.49 2.291 1 N-CA-C 100.416 -5.073 . . . . 0.0 100.416 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.46 ' H ' ' C ' ' A' ' 68' ' ' VAL . 25.4 tt0 -99.94 160.57 14.21 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 101.013 -3.699 . . . . 0.0 101.013 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -105.89 -175.6 2.84 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 101.687 -3.449 . . . . 0.0 101.687 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.68 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . 0.9 OUTLIER -145.15 -57.46 0.33 Allowed 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 16.0 tt -137.13 163.48 32.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 t -135.86 159.21 42.36 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 103.114 -2.921 . . . . 0.0 103.114 179.051 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.531 ' HB3' ' HB2' ' A' ' 2' ' ' PHE . 1.0 OUTLIER -138.58 147.16 42.68 Favored 'General case' 0 C--N 1.289 -2.062 0 O-C-N 125.392 1.682 . . . . 0.0 107.734 -179.502 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.542 ' CG ' ' H ' ' A' ' 54' ' ' LYS . 2.1 p30 -115.64 158.19 23.09 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 104.154 -2.536 . . . . 0.0 104.154 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.567 ' CB ' ' HB2' ' A' ' 80' ' ' TYR . . . -139.38 139.02 21.46 Favored Pre-proline 0 C--N 1.29 -1.994 0 N-CA-C 102.627 -3.101 . . . . 0.0 102.627 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -70.53 -37.35 7.42 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 121.974 1.783 . . . . 0.0 110.466 173.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.541 ' O ' ' CD1' ' A' ' 80' ' ' TYR . . . -121.97 27.11 6.27 Favored Glycine 0 N--CA 1.493 2.494 0 CA-C-O 115.992 -2.56 . . . . 0.0 113.086 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.567 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 21.7 m-85 . . . . . 0 N--CA 1.503 2.215 0 CA-C-O 115.509 -2.186 . . . . 0.0 108.283 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.047 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -115.34 147.11 40.87 Favored 'General case' 0 N--CA 1.498 1.946 1 N-CA-C 99.897 -4.112 . . . . 0.0 99.897 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -113.65 -168.79 1.39 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 118.878 0.763 . . . . 0.0 112.639 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.439 ' CD2' HD13 ' A' ' 72' ' ' LEU . 41.7 t80 -105.69 -22.94 12.85 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 -179.53 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' CG ' HG22 ' A' ' 68' ' ' VAL . 11.0 mmtm -127.55 177.64 6.64 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 102.638 -3.097 . . . . 0.0 102.638 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 83.5 mt -105.62 176.22 1.8 Allowed Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -54.44 82.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.676 1.584 . . . . 0.0 110.111 153.332 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.509 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.6 t70 -122.06 -82.65 0.65 Allowed 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.485 -2.043 . . . . 0.0 105.485 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.46 HG23 HG12 ' A' ' 68' ' ' VAL . 24.0 pt 39.16 27.71 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 124.055 0.847 . . . . 0.0 111.647 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.18 -70.99 0.05 OUTLIER Glycine 0 N--CA 1.477 1.423 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.825 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.407 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 1.1 mp0 -51.06 153.08 2.01 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 124.415 2.055 . . . . 0.0 116.312 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -22.16 -41.01 0.01 OUTLIER Glycine 0 N--CA 1.498 2.824 0 CA-C-N 110.908 -2.86 . . . . 0.0 118.439 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.466 HD12 ' N ' ' A' ' 13' ' ' ILE . 3.2 mp -115.94 64.0 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.216 1.008 . . . . 0.0 108.81 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.408 ' O ' HG23 ' A' ' 68' ' ' VAL . 2.1 p80 -85.72 7.61 22.92 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-N 114.72 -1.127 . . . . 0.0 112.493 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.1 pt-20 -129.68 -165.89 1.59 Allowed 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.992 0.901 . . . . 0.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.14 112.51 0.55 Allowed Glycine 0 N--CA 1.503 3.106 0 CA-C-O 117.484 -1.731 . . . . 0.0 112.808 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 56.4 tt0 -104.17 85.95 2.47 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 103.223 -2.881 . . . . 0.0 103.223 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.569 HD11 HD11 ' A' ' 72' ' ' LEU . 1.9 mp -87.48 124.63 40.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.9 t -101.8 -46.85 11.32 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 O-C-N 124.53 1.144 . . . . 0.0 109.252 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.433 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 12.1 ttmt -131.69 145.18 51.5 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 124.564 1.165 . . . . 0.0 112.123 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -115.98 -178.64 3.45 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 178.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -126.56 -27.15 3.17 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 111.248 -2.706 . . . . 0.0 111.169 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.575 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 7.4 m -101.49 -177.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.172 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.433 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.2 mptp? -100.19 -41.23 0.22 Allowed Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.502 ' C ' ' H ' ' A' ' 27' ' ' ASP . 43.1 Cg_endo -49.56 170.84 1.38 Allowed 'Cis proline' 0 N--CA 1.498 1.762 1 N-CA-C 124.991 4.958 . . . . 0.0 124.991 29.714 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.575 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -94.22 37.39 3.42 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 105.846 -2.902 . . . . 0.0 105.846 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.544 ' OD1' ' HE3' ' A' ' 54' ' ' LYS . 14.9 t70 3.1 -90.46 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.175 0 O-C-N 127.796 2.703 . . . . 0.0 110.131 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.579 ' HG2' ' CE ' ' A' ' 54' ' ' LYS . 6.7 mt-10 -99.53 111.58 23.91 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 101.972 -3.344 . . . . 0.0 101.972 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 163.98 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 CA-C-O 124.49 2.091 . . . . 0.0 114.704 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.653 HD22 ' CG ' ' A' ' 32' ' ' ASP . 10.2 p-10 -98.22 -171.27 2.11 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 110.075 -3.239 . . . . 0.0 112.17 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 4.7 tt0 -121.88 68.11 0.92 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.653 ' CG ' HD22 ' A' ' 30' ' ' ASN . 3.5 p30 -179.7 -27.61 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 112.965 -1.925 . . . . 0.0 110.808 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.475 ' HB3' ' HB2' ' A' ' 49' ' ' SER . 4.2 t0 -28.77 154.04 0.0 OUTLIER 'General case' 0 N--CA 1.514 2.768 0 CA-C-O 122.992 1.377 . . . . 0.0 114.279 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.677 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -56.17 -176.73 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 124.188 4.885 . . . . 0.0 124.188 -179.251 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.677 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.1 mm? -86.69 174.25 8.97 Favored 'General case' 0 N--CA 1.411 -2.393 2 CA-C-N 101.792 -7.004 . . . . 0.0 101.488 -179.38 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.0 m -127.97 155.08 44.83 Favored 'General case' 0 C--N 1.265 -3.082 2 N-CA-C 97.587 -4.968 . . . . 0.0 97.587 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.433 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 12.9 mt-10 -118.26 103.53 9.91 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 38.4 t -116.59 155.68 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 CA-C-N 113.429 -1.714 . . . . 0.0 107.158 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -118.37 162.07 18.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -155.23 -172.31 4.13 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -17.57 -62.44 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 126.409 2.318 . . . . 0.0 115.2 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.3 mttp -140.45 -13.91 0.99 Allowed 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.185 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -109.71 175.21 5.53 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 116.598 2.073 . . . . 0.0 116.598 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.4 t -122.59 136.48 59.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 1 N-CA-C 99.611 -4.218 . . . . 0.0 99.611 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.7 t -117.47 161.27 16.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.448 1.118 . . . . 0.0 109.589 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 47' ' ' ILE . 11.9 pt-20 -123.67 129.13 50.64 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 110.227 -3.17 . . . . 0.0 106.758 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.522 HD12 ' N ' ' A' ' 47' ' ' ILE . 3.7 mp -125.07 96.71 39.3 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 115.806 -2.045 . . . . 0.0 106.266 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 35' ' ' LEU . 60.7 Cg_endo -68.62 -164.85 0.12 Allowed 'Trans proline' 0 N--CA 1.515 2.742 0 C-N-CA 124.446 3.431 . . . . 0.0 106.917 -174.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.475 ' HB2' ' HB3' ' A' ' 33' ' ' ASP . 14.4 t -104.02 103.25 36.74 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 111.875 -2.42 . . . . 0.0 108.962 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 85.3 Cg_exo -49.31 -55.24 4.33 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.659 2.906 . . . . 0.0 119.01 161.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.402 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.59 168.43 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-O 121.933 0.873 . . . . 0.0 112.748 -179.613 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 4.1 pttt -96.33 167.89 10.9 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 111.409 -2.632 . . . . 0.0 106.719 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.08 -135.87 5.87 Favored Glycine 0 C--N 1.289 -2.071 0 N-CA-C 105.955 -2.858 . . . . 0.0 105.955 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.579 ' CE ' ' HG2' ' A' ' 28' ' ' GLU . 4.3 tptt -116.82 164.92 13.93 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 104.966 -2.235 . . . . 0.0 104.966 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.453 HG11 ' H ' ' A' ' 26' ' ' GLY . 22.1 t -126.43 58.11 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.809 1 N-CA-C 100.164 -4.013 . . . . 0.0 100.164 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 18.0 mt -29.51 -73.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 CA-C-N 110.29 -3.141 . . . . 0.0 115.084 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -137.03 163.9 29.66 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.973 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.5 mt -138.61 144.56 29.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 1 N-CA-C 98.87 -4.493 . . . . 0.0 98.87 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -111.33 -54.79 2.57 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.5 t -113.42 78.77 3.67 Favored Pre-proline 0 C--N 1.3 -1.571 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -55.18 -85.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 121.708 1.605 . . . . 0.0 113.455 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -139.7 170.63 15.54 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 78.41 -35.71 1.78 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.11 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.7 m -99.63 171.98 7.57 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 67.1 t -115.06 142.97 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.66 160.18 31.5 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.8 t -105.41 -156.91 0.59 Allowed 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.509 HG11 ' HB3' ' A' ' 8' ' ' ASP . 61.5 t -121.69 158.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 1 N-CA-C 94.886 -5.968 . . . . 0.0 94.886 178.408 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.43 -29.36 9.73 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 104.675 -3.37 . . . . 0.0 104.675 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.449 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -109.41 156.71 19.72 Favored 'General case' 0 C--N 1.302 -1.483 1 N-CA-C 99.119 -4.4 . . . . 0.0 99.119 179.793 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -87.2 -174.15 4.74 Favored 'General case' 0 C--N 1.288 -2.089 0 N-CA-C 100.93 -3.73 . . . . 0.0 100.93 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.569 HD11 HD11 ' A' ' 18' ' ' ILE . 3.9 tt -145.99 -62.97 0.32 Allowed 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 104.554 -2.387 . . . . 0.0 104.554 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 tt -138.42 162.17 30.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 102.092 -3.299 . . . . 0.0 102.092 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 t -136.92 159.73 41.0 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 103.96 -2.608 . . . . 0.0 103.96 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.4 146.05 36.1 Favored 'General case' 0 C--N 1.284 -2.255 0 CA-C-N 111.806 -2.452 . . . . 0.0 105.113 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.07 159.31 16.68 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 98.895 -4.483 . . . . 0.0 98.895 179.318 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.514 ' H ' ' CA ' ' A' ' 78' ' ' PRO . . . -138.13 -36.79 0.02 OUTLIER Pre-proline 0 C--N 1.289 -2.03 0 CA-C-N 114.274 -1.33 . . . . 0.0 111.093 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.514 ' CA ' ' H ' ' A' ' 77' ' ' ALA . 18.6 Cg_endo -104.18 138.39 1.03 Allowed 'Cis proline' 0 C--N 1.316 -1.139 0 C-N-CA 129.235 0.931 . . . . 0.0 111.334 -24.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.85 41.79 0.76 Allowed Glycine 0 N--CA 1.498 2.825 0 N-CA-C 105.974 -2.851 . . . . 0.0 105.974 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.9 m-30 . . . . . 0 C--N 1.299 -1.591 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.133 0 N-CA-C 104.184 -2.524 . . . . 0.0 104.184 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.442 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -125.17 160.69 28.55 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 103.026 -2.953 . . . . 0.0 103.026 -179.608 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.8 -158.53 0.87 Allowed 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -112.22 -45.14 3.31 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 125.582 1.801 . . . . 0.0 111.819 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HG3' HG22 ' A' ' 68' ' ' VAL . 0.3 OUTLIER -124.24 -175.07 3.15 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 100.815 -3.772 . . . . 0.0 100.815 179.36 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -115.45 -176.39 0.37 Allowed Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 104.288 -2.486 . . . . 0.0 104.288 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.83 88.07 0.05 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 N-CA-C 103.094 -3.464 . . . . 0.0 103.094 145.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.584 ' HB3' HG11 ' A' ' 68' ' ' VAL 0.313 0.8 OUTLIER -121.6 -91.43 0.56 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 111.874 -2.421 . . . . 0.0 104.803 -179.616 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.66 ' H ' HG11 ' A' ' 68' ' ' VAL . 38.8 pt 45.66 37.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -88.65 -171.31 46.03 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.712 -1.755 . . . . 0.0 108.712 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -89.46 163.62 15.18 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-O 122.983 1.373 . . . . 0.0 110.595 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -74.44 0.21 Allowed Glycine 0 C--N 1.293 -1.845 0 CA-C-N 112.346 -2.206 . . . . 0.0 108.824 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.7 mt -131.93 114.66 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 101.612 -3.477 . . . . 0.0 101.612 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -125.26 18.0 8.32 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 121.827 2.103 . . . . 0.0 107.712 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.537 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.5 OUTLIER -127.34 -177.93 4.26 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 123.116 1.436 . . . . 0.0 113.146 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.25 101.03 0.33 Allowed Glycine 0 N--CA 1.503 3.103 0 CA-C-N 112.664 -2.062 . . . . 0.0 110.827 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -101.92 102.25 12.78 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 105.166 -2.161 . . . . 0.0 105.166 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 mt -89.24 131.92 35.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 105.639 -1.986 . . . . 0.0 105.639 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.78 -57.91 4.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -129.37 169.74 14.52 Favored 'General case' 0 N--CA 1.508 2.447 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.789 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 23.8 m95 -130.49 171.64 12.78 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 126.017 2.073 . . . . 0.0 106.763 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.485 ' CD2' HG21 ' A' ' 34' ' ' VAL . 21.8 m-85 -124.94 -52.12 1.67 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 124.937 1.398 . . . . 0.0 109.102 -179.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.5 m -99.32 179.1 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.473 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -119.9 168.26 10.67 Favored Pre-proline 0 C--N 1.292 -1.904 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.439 ' HD3' HD12 ' A' ' 58' ' ' ILE . 83.9 Cg_endo -74.19 144.45 33.42 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 121.453 1.435 . . . . 0.0 108.888 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.401 ' O ' ' NZ ' ' A' ' 54' ' ' LYS . . . 97.95 -14.97 62.28 Favored Glycine 0 CA--C 1.476 -2.383 0 CA-C-O 116.654 -2.192 . . . . 0.0 110.166 179.223 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 4.3 m-20 -82.61 -173.07 4.41 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.493 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS 0.25 6.5 mt-10 -122.42 158.35 29.91 Favored 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 101.593 -3.484 . . . . 0.0 101.593 179.92 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.4 p -121.93 157.57 26.0 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 CA-C-O 122.228 1.013 . . . . 0.0 110.261 -179.193 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.459 ' HA ' ' HB2' ' A' ' 52' ' ' LYS . 5.3 m-20 -98.58 -167.65 1.53 Allowed 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 111.066 -2.788 . . . . 0.0 113.283 -178.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 19.9 tt0 -122.98 52.5 1.35 Allowed 'General case' 0 C--N 1.298 -1.641 1 N-CA-C 96.789 -5.263 . . . . 0.0 96.789 -179.818 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.452 ' CG ' ' HB3' ' A' ' 30' ' ' ASN . 0.6 OUTLIER -164.1 -59.21 0.04 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.902 -179.42 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.655 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 14.3 t70 -52.17 -168.91 0.0 OUTLIER 'General case' 0 N--CA 1.513 2.692 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.655 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -97.42 -168.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 129.135 2.974 . . . . 0.0 109.837 -179.357 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.644 ' H ' HG12 ' A' ' 34' ' ' VAL . 24.0 tp -141.23 -95.59 0.14 Allowed 'General case' 0 C--N 1.294 -1.836 1 CA-C-N 107.74 -4.3 . . . . 0.0 100.861 178.704 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -122.47 -179.08 4.08 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-N 118.634 0.652 . . . . 0.0 111.364 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -119.75 111.89 18.57 Favored 'General case' 0 N--CA 1.499 1.979 1 N-CA-C 97.524 -4.991 . . . . 0.0 97.524 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 46.3 t -120.13 151.67 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 119.501 1.046 . . . . 0.0 112.315 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 20.7 tt0 -117.81 151.72 36.77 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.728 -1.124 . . . . 0.0 108.302 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -146.24 -179.88 7.04 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 104.597 -2.371 . . . . 0.0 104.597 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -6.1 -69.67 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.031 0 N-CA-C 116.069 1.877 . . . . 0.0 116.069 -179.381 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.513 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 40.2 mttp -136.73 -20.25 1.33 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 123.319 0.647 . . . . 0.0 110.318 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -100.36 165.56 11.4 Favored 'General case' 0 N--CA 1.492 1.673 0 C-N-CA 118.453 -1.299 . . . . 0.0 111.399 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 10.5 t -132.45 130.57 60.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 N-CA-C 102.896 -3.002 . . . . 0.0 102.896 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 46' ' ' GLU . 1.5 t -127.79 173.56 12.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 CA-C-O 124.755 2.217 . . . . 0.0 105.406 179.277 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.561 ' H ' HG12 ' A' ' 45' ' ' VAL . 10.6 pt-20 -121.32 164.15 17.49 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 108.479 -3.964 . . . . 0.0 105.047 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 46' ' ' GLU . 2.7 mp -125.69 130.54 24.03 Favored Pre-proline 0 C--N 1.295 -1.773 0 N-CA-C 101.548 -3.501 . . . . 0.0 101.548 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.44 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -93.02 -171.98 0.33 Allowed 'Trans proline' 0 N--CA 1.497 1.725 1 C-N-CA 126.087 4.525 . . . . 0.0 108.796 173.457 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.33 98.53 12.42 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 72.2 Cg_exo -48.45 -44.67 29.27 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.549 1.5 . . . . 0.0 110.671 157.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -133.15 166.11 30.35 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 122.463 1.125 . . . . 0.0 109.253 179.436 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.568 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -110.89 146.04 37.22 Favored 'General case' 0 C--N 1.297 -1.688 2 O-C-N 130.118 4.636 . . . . 0.0 104.483 179.784 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.86 -151.06 13.22 Favored Glycine 0 N--CA 1.504 3.199 0 N-CA-C 105.206 -3.158 . . . . 0.0 105.206 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.493 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 53.6 tptt -96.27 171.99 8.24 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 119.993 1.897 . . . . 0.0 106.835 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -125.47 84.09 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 1 N-CA-C 94.46 -6.126 . . . . 0.0 94.46 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.41 -82.03 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 113.516 -1.675 . . . . 0.0 109.438 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -137.94 165.66 25.98 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.504 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.439 HD12 ' HD3' ' A' ' 25' ' ' PRO . 60.0 mt -130.09 137.94 55.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 1 N-CA-C 97.61 -4.959 . . . . 0.0 97.61 179.705 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.408 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.2 mp -97.17 -56.16 2.63 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 124.251 0.97 . . . . 0.0 108.592 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.4 t -112.68 126.44 28.31 Favored Pre-proline 0 C--N 1.295 -1.793 1 N-CA-C 96.939 -5.208 . . . . 0.0 96.939 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.404 ' HB2' ' OE2' ' A' ' 62' ' ' GLU . 2.7 Cg_exo -79.81 -84.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 CA-C-N 121.461 1.557 . . . . 0.0 108.19 174.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.404 ' OE2' ' HB2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -132.24 -151.8 0.47 Allowed 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 100.614 -3.846 . . . . 0.0 100.614 -179.202 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.93 -42.97 0.16 Allowed Glycine 0 C--N 1.283 -2.377 0 CA-C-N 111.029 -2.805 . . . . 0.0 115.116 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.8 m -109.37 -176.43 3.02 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.6 t -111.16 156.07 12.42 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.32 171.25 11.11 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 3.8 t -128.12 -159.79 0.97 Allowed 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 102.846 -3.02 . . . . 0.0 102.846 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.66 HG11 ' H ' ' A' ' 9' ' ' ILE 0.256 57.8 t -117.68 155.38 19.46 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.268 1 N-CA-C 94.431 -6.137 . . . . 0.0 94.431 179.025 . . . . . . . . 4 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . 0.515 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 98.27 -27.61 18.59 Favored Glycine 0 N--CA 1.485 1.932 1 N-CA-C 102.398 -4.281 . . . . 0.0 102.398 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.459 ' H ' ' C ' ' A' ' 68' ' ' VAL . 38.9 tt0 -105.01 154.65 19.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 102.042 -3.318 . . . . 0.0 102.042 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -94.9 179.55 5.19 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 102.201 -3.259 . . . . 0.0 102.201 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 35.8 tp -138.26 -69.9 0.44 Allowed 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.6 tt -141.99 162.22 19.98 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 102.937 -2.986 . . . . 0.0 102.937 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.3 t -137.39 160.04 40.22 Favored 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.457 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.2 tt -133.39 149.87 51.82 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 112.669 -2.06 . . . . 0.0 107.862 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.457 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -109.2 150.68 27.55 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 101.97 -3.345 . . . . 0.0 101.97 179.562 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -141.83 94.72 7.18 Favored Pre-proline 0 C--N 1.289 -2.026 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.418 ' HD3' ' OD1' ' A' ' 76' ' ' ASP . 21.1 Cg_endo -45.0 70.51 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 123.803 3.002 . . . . 0.0 116.486 174.524 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 126.89 9.63 4.2 Favored Glycine 0 N--CA 1.485 1.929 0 CA-C-O 116.495 -2.281 . . . . 0.0 113.157 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.43 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 14.3 m-30 . . . . . 0 N--CA 1.501 2.087 0 N-CA-C 105.524 -2.028 . . . . 0.0 105.524 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -120.53 159.47 25.13 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 100.893 -3.743 . . . . 0.0 100.893 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 -160.97 0.8 Allowed 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.03 -21.95 3.88 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-N 113.531 -1.668 . . . . 0.0 110.297 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.542 ' HB3' HG22 ' A' ' 68' ' ' VAL . 48.2 mmtt -132.5 145.18 50.96 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 105.479 -2.045 . . . . 0.0 105.479 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.43 173.33 6.08 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 104.071 -2.566 . . . . 0.0 104.071 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -42.48 80.93 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.379 2.053 . . . . 0.0 115.013 158.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.408 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.3 t70 -121.7 -72.64 0.68 Allowed 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 103.584 -2.747 . . . . 0.0 103.584 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.494 ' H ' HG11 ' A' ' 68' ' ' VAL . 35.5 pt 37.41 40.58 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 124.302 1.001 . . . . 0.0 112.863 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.68 -14.34 0.07 OUTLIER Glycine 0 C--N 1.305 -1.188 0 CA-C-O 117.194 -1.892 . . . . 0.0 115.614 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -101.21 -177.93 3.59 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 120.439 2.119 . . . . 0.0 114.733 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -4.47 -66.74 0.0 OUTLIER Glycine 0 N--CA 1.494 2.509 0 CA-C-N 110.178 -3.192 . . . . 0.0 116.182 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.0 mm -127.28 76.42 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -81.97 4.34 23.06 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 112.725 -2.034 . . . . 0.0 111.787 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.519 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 4.5 pt-20 -132.4 -176.7 4.17 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.252 0.549 . . . . 0.0 110.864 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.81 116.29 0.84 Allowed Glycine 0 N--CA 1.494 2.517 0 CA-C-O 118.079 -1.401 . . . . 0.0 111.679 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -102.97 109.87 21.57 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 99.966 -4.087 . . . . 0.0 99.966 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.419 ' HB ' ' HA ' ' A' ' 62' ' ' GLU . 2.7 mt -99.17 126.66 52.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.8 t -93.85 -61.76 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 124.666 1.229 . . . . 0.0 109.971 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.58 ' NZ ' ' CE1' ' A' ' 22' ' ' PHE . 25.1 tttm -130.43 151.04 51.35 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.574 -179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.6 m95 -119.63 173.47 6.99 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 179.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.711 ' CG ' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -133.34 -1.25 3.21 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 -179.783 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.598 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 4.2 m -98.62 170.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 115.318 1.599 . . . . 0.0 115.318 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.424 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.1 mptp? -139.2 48.03 1.56 Allowed Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 125.574 1.796 . . . . 0.0 111.829 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 27' ' ' ASP . 67.2 Cg_exo -8.61 174.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 N-CA-C 118.865 2.602 . . . . 0.0 118.865 -70.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.598 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.11 28.41 8.83 Favored Glycine 0 N--CA 1.505 3.275 0 N-CA-C 107.84 -2.104 . . . . 0.0 107.84 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 25' ' ' PRO . 19.2 t70 8.79 -85.24 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 110.985 -2.608 . . . . 0.0 111.474 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.63 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS . 2.6 mt-10 -104.22 115.53 30.56 Favored 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 105.606 -1.998 . . . . 0.0 105.606 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 p -108.65 161.57 7.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 124.819 2.247 . . . . 0.0 110.562 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 29.3 p30 -98.15 -164.16 1.11 Allowed 'General case' 0 C--N 1.284 -2.248 0 CA-C-N 109.965 -3.288 . . . . 0.0 108.883 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.675 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.274 0.3 OUTLIER -122.35 69.71 0.97 Allowed 'General case' 0 C--N 1.292 -1.896 1 N-CA-C 99.497 -4.26 . . . . 0.0 99.497 -179.323 . . . . . . . . 5 4 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.493 ' C ' ' OG ' ' A' ' 49' ' ' SER . 3.5 p30 -177.34 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.489 0 C-N-CA 125.705 1.602 . . . . 0.0 111.735 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 8.9 t70 18.13 -137.74 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.264 0 N-CA-C 119.661 3.208 . . . . 0.0 119.661 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.711 HG11 ' CG ' ' A' ' 22' ' ' PHE . 1.2 t -114.87 167.4 7.53 Favored 'Isoleucine or valine' 0 CA--C 1.445 -3.095 0 CA-C-O 124.3 2.0 . . . . 0.0 114.29 -179.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.615 ' HA ' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -108.57 120.23 41.85 Favored 'General case' 0 N--CA 1.412 -2.363 3 CA-C-N 106.151 -5.022 . . . . 0.0 99.251 179.877 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.7 m -73.57 151.8 40.8 Favored 'General case' 0 C--N 1.263 -3.193 2 N-CA-C 97.986 -4.82 . . . . 0.0 97.986 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -104.52 102.89 12.51 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-N 112.371 -2.195 . . . . 0.0 107.806 -179.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.6 146.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 N-CA-C 104.682 -2.34 . . . . 0.0 104.682 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -115.15 152.43 32.61 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.521 HD21 ' HB3' ' A' ' 43' ' ' ALA . 6.7 p-10 -141.13 -178.13 5.44 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.438 ' CG ' HD22 ' A' ' 40' ' ' ASN . 0.3 OUTLIER -7.58 -72.43 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 116.952 2.205 . . . . 0.0 116.952 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -136.82 -11.61 1.76 Allowed 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 114.318 -1.31 . . . . 0.0 109.255 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.521 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -111.58 178.7 4.24 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 120.91 0.386 . . . . 0.0 111.886 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.5 t -130.86 147.55 33.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.465 -2.42 . . . . 0.0 104.465 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -120.37 161.78 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 122.655 1.217 . . . . 0.0 111.242 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.508 ' C ' HD12 ' A' ' 47' ' ' ILE . 12.1 pt-20 -122.24 122.75 39.87 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 110.489 -3.05 . . . . 0.0 108.186 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.615 ' C ' ' HA ' ' A' ' 35' ' ' LEU . 1.9 mp -115.02 83.16 9.31 Favored Pre-proline 0 CA--C 1.572 1.798 0 CA-C-O 115.946 -1.978 . . . . 0.0 108.729 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 34' ' ' VAL . 75.9 Cg_endo -62.93 -167.09 0.06 OUTLIER 'Trans proline' 0 N--CA 1.52 3.036 0 C-N-CA 123.952 3.102 . . . . 0.0 105.716 176.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.493 ' OG ' ' C ' ' A' ' 32' ' ' ASP . 19.2 p -108.73 86.48 3.71 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -32.22 -49.21 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 121.887 1.725 . . . . 0.0 115.308 163.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.675 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -132.49 164.84 33.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-O 121.817 0.817 . . . . 0.0 110.328 179.646 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.647 ' HD2' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.54 173.32 6.4 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 128.827 3.829 . . . . 0.0 110.11 179.724 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.24 -136.87 5.98 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 104.995 -3.242 . . . . 0.0 104.995 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.63 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 41.0 tptt -112.73 173.26 6.46 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 -179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.499 ' HB ' ' C ' ' A' ' 26' ' ' GLY . 50.5 t -127.35 70.05 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.975 1 N-CA-C 97.342 -5.058 . . . . 0.0 97.342 179.665 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 75.4 mt -38.06 -79.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 111.623 -2.535 . . . . 0.0 114.227 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -143.04 167.48 21.97 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.759 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.1 mp -131.11 141.21 46.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 1 N-CA-C 98.004 -4.813 . . . . 0.0 98.004 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -103.7 -58.85 1.81 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 123.772 0.67 . . . . 0.0 110.555 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.414 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 24.1 t -113.62 75.92 2.77 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -49.76 -83.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.851 2.367 . . . . 0.0 115.2 -167.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.419 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -134.86 -179.91 5.9 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 76.81 -38.57 1.51 Allowed Glycine 0 N--CA 1.49 2.266 0 CA-C-N 114.14 -1.391 . . . . 0.0 114.335 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 2.0 m -103.25 177.14 4.92 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 43.9 t -117.74 148.99 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.8 166.67 14.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.519 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 8.8 t -117.87 -155.45 0.6 Allowed 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 104.783 -2.303 . . . . 0.0 104.783 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.542 HG22 ' HB3' ' A' ' 5' ' ' LYS . 84.4 t -120.44 151.51 23.24 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 1 N-CA-C 97.25 -5.093 . . . . 0.0 97.25 179.106 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 104.58 -38.74 3.12 Favored Glycine 0 N--CA 1.494 2.565 1 N-CA-C 99.768 -5.333 . . . . 0.0 99.768 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 68' ' ' VAL . 35.2 tt0 -100.09 164.49 11.96 Favored 'General case' 0 C--N 1.304 -1.373 1 N-CA-C 99.929 -4.101 . . . . 0.0 99.929 179.501 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.98 -175.52 2.8 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 33.1 tp -135.23 -67.19 0.55 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 103.652 -2.721 . . . . 0.0 103.652 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.2 tt -135.03 165.04 32.13 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 102.988 -2.967 . . . . 0.0 102.988 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.8 t -137.25 161.38 36.37 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.45 -2.796 . . . . 0.0 103.45 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.83 152.33 48.99 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 112.456 -2.156 . . . . 0.0 106.385 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.86 131.57 56.92 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 100.48 -3.896 . . . . 0.0 100.48 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.46 60.19 13.54 Favored Pre-proline 0 C--N 1.295 -1.78 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -53.09 68.34 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.618 0 C-N-CA 124.777 3.651 . . . . 0.0 115.855 -176.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 132.7 68.75 0.08 OUTLIER Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.505 1 N-CA-C 100.096 -4.039 . . . . 0.0 100.096 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 101.771 -3.418 . . . . 0.0 101.771 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.421 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.8 OUTLIER -100.67 85.94 3.02 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 105.622 -1.992 . . . . 0.0 105.622 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -77.96 -178.33 5.45 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -99.91 -29.57 12.5 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 117.903 2.557 . . . . 0.0 117.903 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB3' HG22 ' A' ' 68' ' ' VAL . 30.5 mmtp -127.57 173.64 9.7 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 102.411 -3.181 . . . . 0.0 102.411 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 88.6 mt -101.14 176.18 2.01 Favored Pre-proline 0 C--N 1.299 -1.618 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -66.12 82.04 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 N-CA-C 104.098 -3.078 . . . . 0.0 104.098 158.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -123.87 -80.68 0.63 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 124.583 1.177 . . . . 0.0 109.628 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.417 ' CG2' ' HB ' ' A' ' 68' ' ' VAL . 45.9 pt 41.96 26.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.515 0 O-C-N 123.38 0.425 . . . . 0.0 110.454 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.24 -69.67 0.18 Allowed Glycine 0 N--CA 1.483 1.776 0 C-N-CA 120.683 -0.77 . . . . 0.0 114.064 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.406 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -61.27 171.17 1.44 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 124.537 2.113 . . . . 0.0 116.358 -179.435 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -6.84 -53.1 0.0 OUTLIER Glycine 0 N--CA 1.493 2.469 0 CA-C-N 109.956 -3.293 . . . . 0.0 119.953 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.2 mm -118.96 116.99 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.495 ' O ' HG23 ' A' ' 68' ' ' VAL . 9.5 p80 -96.26 -45.62 6.76 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 114.68 -1.145 . . . . 0.0 112.232 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.563 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 33.8 mt-10 -107.83 -173.2 2.22 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 123.043 1.401 . . . . 0.0 113.059 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.05 122.33 1.98 Allowed Glycine 0 C--N 1.286 -2.205 0 CA-C-N 111.722 -2.49 . . . . 0.0 106.881 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 78.7 tt0 -102.23 96.15 6.79 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 103.399 -2.815 . . . . 0.0 103.399 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.8 mt -86.17 120.62 36.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 -56.09 5.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.969 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.052 -179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.46 ' NZ ' ' OE1' ' A' ' 37' ' ' GLU . 0.1 OUTLIER -136.15 150.68 49.17 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 124.206 0.941 . . . . 0.0 112.12 -179.432 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.757 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 10.1 m95 -114.38 174.62 5.86 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 124.821 1.325 . . . . 0.0 108.112 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CD2' HG21 ' A' ' 34' ' ' VAL . 6.6 m-85 -128.03 -13.76 5.07 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 112.382 -2.19 . . . . 0.0 112.885 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.625 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 14.7 m -98.89 -172.96 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.653 -0.654 . . . . 0.0 111.761 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.734 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.3 mptp? -123.08 -30.11 0.05 OUTLIER Pre-proline 0 N--CA 1.503 2.208 0 N-CA-C 119.266 3.061 . . . . 0.0 119.266 179.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.734 ' C ' ' H ' ' A' ' 24' ' ' LYS . 11.3 Cg_endo -39.17 162.82 0.23 Allowed 'Cis proline' 0 N--CA 1.498 1.764 1 N-CA-C 122.747 4.095 . . . . 0.0 122.747 13.208 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.625 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -95.5 32.42 6.27 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 -179.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.482 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.9 t70 11.79 -100.94 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.248 0 O-C-N 129.749 3.852 . . . . 0.0 109.606 179.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.437 ' OE2' ' HE2' ' A' ' 54' ' ' LYS . 3.6 mt-10 -103.33 130.38 50.59 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 30' ' ' ASN . 7.6 p -120.48 177.91 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 122.348 1.07 . . . . 0.0 112.918 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.488 ' OD1' ' C ' ' A' ' 30' ' ' ASN . 45.0 p30 -95.42 -166.47 1.46 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.961 -1.927 . . . . 0.0 107.422 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.561 ' HB2' ' HB3' ' A' ' 52' ' ' LYS 0.25 2.4 tt0 -124.86 50.75 1.71 Allowed 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 100.467 -3.901 . . . . 0.0 100.467 -179.498 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -175.93 28.32 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.043 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 30' ' ' ASN . 0.5 OUTLIER -96.32 -176.25 3.59 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.945 0.878 . . . . 0.0 111.335 -179.308 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.525 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -74.77 -172.53 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.482 -1.648 0 CA-C-O 127.654 3.597 . . . . 0.0 117.582 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.567 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.13 -160.21 0.74 Allowed 'General case' 0 C--N 1.276 -2.624 2 CA-C-N 102.377 -6.738 . . . . 0.0 106.959 -179.214 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.757 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 9.2 m -120.09 156.51 30.86 Favored 'General case' 0 C--N 1.273 -2.748 2 N-CA-C 94.215 -6.217 . . . . 0.0 94.215 179.212 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.46 ' OE1' ' NZ ' ' A' ' 20' ' ' LYS . 5.3 tt0 -107.94 109.83 21.42 Favored 'General case' 0 C--N 1.285 -2.236 1 N-CA-C 98.676 -4.564 . . . . 0.0 98.676 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.473 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 56.1 t -121.43 154.9 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 tt0 -114.82 147.2 40.15 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 16.4 p-10 -136.43 -176.0 4.19 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -6.73 -67.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.176 0 O-C-N 126.175 2.172 . . . . 0.0 115.838 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 40.0 mtmt -138.19 -22.18 1.05 Allowed 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 123.011 0.525 . . . . 0.0 109.957 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.75 -168.57 1.54 Allowed 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 29.8 t -123.69 133.7 68.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 N-CA-C 103.309 -2.849 . . . . 0.0 103.309 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.94 153.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 122.515 1.15 . . . . 0.0 109.012 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.505 ' C ' HD12 ' A' ' 47' ' ' ILE . 10.0 pt-20 -119.58 127.79 53.3 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 110.86 -2.882 . . . . 0.0 108.526 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.57 HD12 ' N ' ' A' ' 47' ' ' ILE . 1.7 mp -117.2 79.54 11.19 Favored Pre-proline 0 C--N 1.299 -1.588 0 N-CA-C 101.573 -3.491 . . . . 0.0 101.573 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.441 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 86.3 Cg_endo -62.29 -166.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.513 2.639 0 C-N-CA 123.569 2.846 . . . . 0.0 107.854 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 45.9 p -98.78 106.66 38.67 Favored Pre-proline 0 C--N 1.286 -2.153 0 CA-C-N 113.483 -1.69 . . . . 0.0 111.879 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 89.2 Cg_exo -55.32 -44.46 48.66 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.012 1.808 . . . . 0.0 114.979 166.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.509 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -132.13 171.58 17.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 123.837 0.711 . . . . 0.0 109.858 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.561 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -105.01 167.85 9.44 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 127.347 2.905 . . . . 0.0 107.614 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 76' ' ' ASP . . . 144.1 -121.77 1.69 Allowed Glycine 0 C--N 1.285 -2.282 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.669 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -117.41 166.41 12.35 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.452 ' CG1' ' H ' ' A' ' 26' ' ' GLY . 23.9 t -129.91 59.29 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 1 N-CA-C 99.459 -4.274 . . . . 0.0 99.459 179.527 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 21.9 mt -29.1 -76.88 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 111.143 -2.753 . . . . 0.0 115.02 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -143.79 167.16 22.95 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.284 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 58' ' ' ILE . 4.1 mp -135.55 139.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 1 N-CA-C 98.527 -4.619 . . . . 0.0 98.527 179.601 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.7 mp -101.56 -56.91 2.18 Favored 'General case' 0 C--N 1.296 -1.756 0 O-C-N 124.003 0.814 . . . . 0.0 110.604 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 t -117.93 67.96 6.34 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -41.93 -78.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 122.709 2.273 . . . . 0.0 117.989 -167.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -142.97 174.58 10.55 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.66 -52.97 0.91 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.868 -1.158 . . . . 0.0 111.462 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.5 m -102.42 -177.5 3.42 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.2 t -109.95 145.49 16.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 103.733 -2.692 . . . . 0.0 103.733 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -120.55 147.83 44.66 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.287 14.7 t -99.84 -151.7 0.4 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.478 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.529 ' C ' ' H ' ' A' ' 70' ' ' GLN . 61.8 t -118.62 160.75 18.18 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 178.877 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 97.61 -47.28 1.57 Allowed Glycine 0 N--CA 1.499 2.852 1 N-CA-C 98.408 -5.877 . . . . 0.0 98.408 -179.386 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.529 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -89.58 153.61 20.63 Favored 'General case' 0 C--N 1.304 -1.393 1 N-CA-C 99.953 -4.091 . . . . 0.0 99.953 179.325 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.56 -175.94 3.0 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 103.104 -2.924 . . . . 0.0 103.104 179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.7 tp -139.9 -70.44 0.4 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.404 HD11 ' CG1' ' A' ' 55' ' ' VAL . 12.9 tt -139.05 166.33 22.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 104.203 -2.517 . . . . 0.0 104.203 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.2 t -138.92 160.08 40.59 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 102.439 -3.171 . . . . 0.0 102.439 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.421 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -129.98 148.53 51.85 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.022 -179.721 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.432 ' OD2' ' NZ ' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -113.09 150.26 32.35 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 102.227 -3.249 . . . . 0.0 102.227 179.135 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.601 ' H ' ' HA ' ' A' ' 78' ' ' PRO . . . -114.36 -40.94 0.08 OUTLIER Pre-proline 0 C--N 1.295 -1.774 0 O-C-N 124.883 1.365 . . . . 0.0 107.696 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.601 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 10.2 Cg_endo -94.72 176.84 11.42 Favored 'Cis proline' 0 C--N 1.312 -1.375 0 CA-C-N 121.628 1.617 . . . . 0.0 111.328 -22.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.81 -36.72 4.19 Favored Glycine 0 N--CA 1.498 2.8 1 N-CA-C 99.058 -5.617 . . . . 0.0 99.058 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.494 ' H ' ' C ' ' A' ' 78' ' ' PRO . 52.1 t80 . . . . . 0 CA--C 1.573 1.831 1 N-CA-C 98.597 -4.594 . . . . 0.0 98.597 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.474 1 N-CA-C 98.138 -4.764 . . . . 0.0 98.138 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -137.13 90.76 2.56 Favored 'General case' 0 C--N 1.288 -2.078 1 N-CA-C 88.977 -8.157 . . . . 0.0 88.977 178.473 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 3' ' ' GLU . 1.3 pm0 -87.57 -168.1 2.11 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 122.638 1.208 . . . . 0.0 113.843 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.484 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 22.5 t80 -88.22 -46.99 8.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 117.853 2.538 . . . . 0.0 117.853 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.484 ' HE2' ' CZ ' ' A' ' 4' ' ' PHE . 0.3 OUTLIER -131.57 174.68 9.86 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 179.63 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.13 172.96 3.69 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 104.187 -2.523 . . . . 0.0 104.187 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -56.31 89.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 121.43 1.42 . . . . 0.0 111.374 164.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.503 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.5 t0 -122.45 -82.05 0.65 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 102.968 -2.975 . . . . 0.0 102.968 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.5 pt 36.8 37.0 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 CA-C-O 121.601 0.715 . . . . 0.0 109.821 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.7 -154.58 11.94 Favored Glycine 0 N--CA 1.48 1.575 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.32 138.53 37.75 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.44 -74.1 0.33 Allowed Glycine 0 N--CA 1.486 1.968 0 N-CA-C 106.907 -2.477 . . . . 0.0 106.907 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.2 mm -133.46 141.4 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-N 118.363 1.081 . . . . 0.0 108.297 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -131.9 -51.88 0.98 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.635 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -116.59 172.11 7.43 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.463 -1.244 . . . . 0.0 111.995 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.82 155.51 26.17 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 106.542 -2.623 . . . . 0.0 106.542 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.412 ' O ' HG13 ' A' ' 38' ' ' VAL . 0.7 OUTLIER -122.54 136.74 54.96 Favored 'General case' 0 C--N 1.303 -1.445 1 N-CA-C 98.968 -4.456 . . . . 0.0 98.968 179.87 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.437 ' HB ' ' HA ' ' A' ' 62' ' ' GLU 0.285 2.6 mt -103.95 113.67 41.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.278 0 N-CA-C 102.734 -3.062 . . . . 0.0 102.734 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.9 t -76.5 -55.07 12.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HE3' ' CE2' ' A' ' 22' ' ' PHE . 22.4 tttp -141.41 158.32 44.02 Favored 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 118.981 -1.088 . . . . 0.0 113.579 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.509 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 36.9 m95 -113.86 170.89 7.93 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 178.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.494 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.5 m-85 -128.28 -46.43 1.35 Allowed 'General case' 0 C--N 1.3 -1.584 0 CA-C-N 114.126 -1.397 . . . . 0.0 109.735 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 m -97.39 175.68 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -128.04 165.98 26.91 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 105.593 -2.003 . . . . 0.0 105.593 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -76.52 122.71 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 121.915 1.744 . . . . 0.0 110.776 -172.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.13 -7.27 19.02 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.226 -2.349 . . . . 0.0 107.226 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -79.52 173.23 12.79 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 124.177 1.941 . . . . 0.0 111.041 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.667 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.2 OUTLIER -118.55 146.26 44.72 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 100.584 -3.858 . . . . 0.0 100.584 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.542 HG22 ' HB2' ' A' ' 31' ' ' GLU 0.25 0.9 OUTLIER -122.19 171.2 11.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 -179.776 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.461 ' O ' ' HE2' ' A' ' 52' ' ' LYS . 53.7 t30 -119.42 -29.51 5.11 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 125.03 2.348 . . . . 0.0 115.135 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.542 ' HB2' HG22 ' A' ' 29' ' ' VAL 0.366 11.9 tp10 47.26 78.74 0.07 Allowed 'General case' 0 C--N 1.267 -2.995 5 N-CA-C 131.644 7.646 . . . . 0.0 131.644 -179.213 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -155.43 31.5 0.38 Allowed 'General case' 0 C--N 1.28 -2.434 4 CA-C-N 94.066 -10.515 . . . . 0.0 93.984 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.482 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 10.0 m-20 -117.22 -168.7 1.52 Allowed 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 126.927 2.091 . . . . 0.0 107.82 -178.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.494 ' HB ' ' CG ' ' A' ' 22' ' ' PHE . 3.6 t -134.47 161.85 39.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 N-CA-C 100.597 -3.853 . . . . 0.0 100.597 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.551 ' HB2' HG21 ' A' ' 47' ' ' ILE . 3.4 mm? -125.54 -84.85 0.63 Allowed 'General case' 0 C--N 1.272 -2.77 0 CA-C-N 109.874 -3.33 . . . . 0.0 102.389 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.403 ' SG ' ' OE1' ' A' ' 46' ' ' GLU . 11.2 p -123.97 172.77 8.69 Favored 'General case' 0 N--CA 1.495 1.777 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.582 -178.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.367 18.5 tt0 -134.34 138.25 44.77 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 -179.287 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.497 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 25.5 t -139.77 145.57 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.427 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 35.6 tt0 -107.29 107.65 18.68 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 6.4 p-10 -136.77 174.57 10.47 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 2.8 p-10 -3.78 -59.49 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 118.234 2.679 . . . . 0.0 118.234 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 28.3 mttm -131.15 -4.05 3.91 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 123.687 0.617 . . . . 0.0 110.029 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -106.09 164.43 11.99 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.75 -43.11 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 111.392 -2.64 . . . . 0.0 109.178 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 18.3 t -111.83 167.35 5.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 -179.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.579 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.0 mt-10 -120.5 -73.32 0.65 Allowed 'General case' 0 C--N 1.294 -1.846 0 O-C-N 128.016 3.323 . . . . 0.0 116.556 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.579 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -84.37 142.54 40.65 Favored Pre-proline 0 C--N 1.274 -2.68 0 CA-C-N 108.487 -3.961 . . . . 0.0 110.225 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.536 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -96.64 177.59 0.59 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 N-CA-C 105.248 -2.635 . . . . 0.0 105.248 82.646 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.491 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 1.6 m -124.36 -177.61 0.57 Allowed Pre-proline 0 C--N 1.278 -2.512 0 CA-C-N 114.462 -1.244 . . . . 0.0 109.243 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -87.51 -31.43 0.22 Allowed 'Trans proline' 0 C--N 1.314 -1.285 0 N-CA-C 117.236 1.975 . . . . 0.0 117.236 164.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.525 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.6 p -138.34 167.97 20.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 120.246 3.425 . . . . 0.0 120.246 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.525 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 2.2 ptmm? -97.06 177.26 5.66 Favored 'General case' 0 C--N 1.292 -1.9 1 CA-C-N 106.212 -4.995 . . . . 0.0 110.266 -179.395 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.02 -141.71 9.21 Favored Glycine 0 C--N 1.286 -2.237 0 N-CA-C 103.331 -3.908 . . . . 0.0 103.331 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.667 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 12.3 tppt? -110.97 173.23 6.43 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 103.915 -2.624 . . . . 0.0 103.915 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 39.3 t -125.72 68.84 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.166 1 N-CA-C 97.963 -4.829 . . . . 0.0 97.963 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 38.3 mt -30.48 -76.02 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 126.135 2.147 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -142.04 161.58 37.64 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 77.8 mt -132.99 114.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 1 N-CA-C 93.882 -6.34 . . . . 0.0 93.882 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.5 mt -90.9 -40.4 11.75 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 114.759 1.392 . . . . 0.0 114.759 -179.456 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.71 79.97 23.61 Favored Pre-proline 0 N--CA 1.496 1.864 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.817 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_exo -34.8 -107.66 0.0 OUTLIER 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 124.426 3.417 . . . . 0.0 120.532 -175.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.437 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 3.6 pt-20 -132.73 173.8 10.98 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 56.92 30.94 60.73 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.7 m -138.24 160.28 39.87 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 102.014 -3.328 . . . . 0.0 102.014 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -97.56 135.6 31.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -127.06 144.98 50.89 Favored 'General case' 0 C--N 1.294 -1.834 1 N-CA-C 99.764 -4.162 . . . . 0.0 99.764 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.635 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.259 66.8 p -116.87 -144.78 0.38 Allowed 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 124.296 1.998 . . . . 0.0 107.413 -179.855 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.503 HG11 ' HB3' ' A' ' 8' ' ' ASP . 74.8 t -121.65 155.07 25.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 1 N-CA-C 93.247 -6.575 . . . . 0.0 93.247 179.056 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 93.27 -47.04 2.39 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 103.148 -3.981 . . . . 0.0 103.148 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.424 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.2 tt0 -94.0 155.0 17.36 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 102.426 -3.176 . . . . 0.0 102.426 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.55 -174.61 2.6 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 102.769 -3.048 . . . . 0.0 102.769 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.6 tp -145.99 -66.84 0.29 Allowed 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 113.349 -1.751 . . . . 0.0 106.874 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 11.8 tt -133.21 166.58 28.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 110.852 -2.886 . . . . 0.0 105.609 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 t -140.19 159.8 41.38 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 102.152 -3.277 . . . . 0.0 102.152 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.403 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.0 OUTLIER -136.62 154.92 50.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.403 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -123.36 145.89 48.39 Favored 'General case' 0 C--N 1.295 -1.798 1 N-CA-C 99.536 -4.246 . . . . 0.0 99.536 179.282 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.401 ' HB3' ' CA ' ' A' ' 78' ' ' PRO . . . -140.79 -49.95 0.02 OUTLIER Pre-proline 0 C--N 1.295 -1.765 0 O-C-N 123.746 0.653 . . . . 0.0 111.581 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.401 ' CA ' ' HB3' ' A' ' 77' ' ' ALA . 51.2 Cg_endo -84.4 -45.85 0.3 Allowed 'Cis proline' 0 C--N 1.315 -1.224 0 CA-C-N 119.722 0.936 . . . . 0.0 109.98 -22.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -141.89 124.84 2.55 Favored Glycine 0 C--N 1.293 -1.818 1 N-CA-C 98.749 -5.74 . . . . 0.0 98.749 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 36.6 p90 . . . . . 0 C--N 1.283 -2.317 0 O-C-N 127.109 2.299 . . . . 0.0 106.007 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.51 2.531 0 N-CA-C 102.668 -3.086 . . . . 0.0 102.668 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.1 t80 16.37 102.96 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 127.051 2.72 . . . . 0.0 112.813 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.722 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 2.6 pm0 -82.53 -171.0 3.24 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-N 110.482 -3.054 . . . . 0.0 112.917 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.469 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.2 t80 -93.86 -49.94 5.58 Favored 'General case' 0 N--CA 1.494 1.725 0 CA-C-N 113.684 -1.598 . . . . 0.0 114.063 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HD3' ' CE2' ' A' ' 4' ' ' PHE . 11.8 mmmm -126.1 165.93 17.95 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 101.633 -3.469 . . . . 0.0 101.633 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 61.0 mt -105.48 -178.03 0.57 Allowed Pre-proline 0 C--N 1.3 -1.564 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.45 96.43 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.356 0 C-N-CA 121.685 1.59 . . . . 0.0 110.855 170.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.779 ' HB3' HG11 ' A' ' 68' ' ' VAL . 24.2 t0 -122.34 -99.3 0.43 Allowed 'General case' 0 C--N 1.302 -1.478 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 179.795 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.501 HG23 ' CG1' ' A' ' 68' ' ' VAL . 32.4 pt 34.74 42.05 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 O-C-N 124.572 1.17 . . . . 0.0 108.239 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.79 -137.27 4.77 Favored Glycine 0 N--CA 1.482 1.725 0 CA-C-N 114.45 -1.25 . . . . 0.0 113.895 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.63 146.64 28.64 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 104.695 -2.335 . . . . 0.0 104.695 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.31 -76.24 0.22 Allowed Glycine 0 N--CA 1.486 1.969 0 N-CA-C 103.249 -3.94 . . . . 0.0 103.249 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 14' ' ' HIS . 42.1 mm -131.21 173.5 14.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 N-CA-C 103.427 -2.805 . . . . 0.0 103.427 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.429 ' N ' HG22 ' A' ' 13' ' ' ILE . 57.3 t-80 -155.0 -33.09 0.1 Allowed 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.159 1.457 . . . . 0.0 107.701 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.07 -165.54 1.08 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 113.975 -1.466 . . . . 0.0 113.355 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.89 128.18 2.81 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 103.735 -3.746 . . . . 0.0 103.735 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.449 ' HG3' HG22 ' A' ' 65' ' ' VAL . 30.4 tt0 -104.64 91.49 3.88 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 101.146 -3.65 . . . . 0.0 101.146 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.405 HG23 ' HB2' ' A' ' 36' ' ' CYS . 2.5 mt -81.86 110.62 17.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 103.969 -2.604 . . . . 0.0 103.969 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -88.81 -45.28 15.58 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 113.563 -1.653 . . . . 0.0 106.62 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HZ2' ' HB3' ' A' ' 20' ' ' LYS . 2.4 ttmp? -130.9 161.46 31.82 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.117 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.489 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 11.3 m95 -124.28 168.74 12.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 101.457 -3.534 . . . . 0.0 101.457 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 22' ' ' PHE . 6.9 m-85 -123.0 -47.41 2.04 Favored 'General case' 0 C--N 1.295 -1.782 0 O-C-N 124.542 1.151 . . . . 0.0 108.245 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -99.58 178.13 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.331 1.062 . . . . 0.0 110.775 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 ptmt -115.17 172.63 3.48 Favored Pre-proline 0 C--N 1.295 -1.79 0 CA-C-N 112.104 -2.316 . . . . 0.0 105.025 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HB3' HG13 ' A' ' 58' ' ' ILE . 34.3 Cg_endo -93.78 143.45 1.86 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.228 1.952 . . . . 0.0 110.384 166.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.64 -10.33 38.37 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.231 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -108.53 -175.9 2.9 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.773 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.6 OUTLIER -118.82 163.99 16.07 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.226 -179.724 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.591 HG22 ' HB2' ' A' ' 31' ' ' GLU . 3.1 p -133.01 174.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.525 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 19.8 t-20 -116.21 -35.85 4.23 Favored 'General case' 0 N--CA 1.523 3.203 0 CA-C-O 126.903 3.24 . . . . 0.0 115.649 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.622 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.395 33.0 tt0 20.18 123.08 0.0 OUTLIER 'General case' 0 C--N 1.273 -2.759 5 N-CA-C 151.831 15.123 . . . . 0.0 151.831 -179.537 . . . . . . . . 4 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' CG ' ' N ' ' A' ' 33' ' ' ASP . 11.2 p-10 -123.01 -48.23 2.01 Favored 'General case' 0 C--N 1.287 -2.117 4 CA-C-N 93.237 -10.892 . . . . 0.0 97.625 178.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' CG ' ' A' ' 32' ' ' ASP . 3.7 t0 -22.55 176.6 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.617 0 C-N-CA 131.427 3.891 . . . . 0.0 116.186 179.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -107.39 167.52 3.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 127.366 3.46 . . . . 0.0 114.292 -179.597 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.55 ' H ' HG12 ' A' ' 34' ' ' VAL . 10.1 mp -130.9 -87.34 0.49 Allowed 'General case' 0 C--N 1.283 -2.289 1 CA-C-N 106.562 -4.836 . . . . 0.0 103.688 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.405 ' HB2' HG23 ' A' ' 18' ' ' ILE . 0.5 OUTLIER -127.89 169.63 13.73 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.794 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.679 ' HG3' HG22 ' A' ' 45' ' ' VAL . 1.2 tm-20 -135.09 156.88 48.26 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 126.341 2.276 . . . . 0.0 104.946 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.503 HG23 ' HG3' ' A' ' 46' ' ' GLU . 54.0 t -139.5 179.58 2.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 125.481 1.738 . . . . 0.0 111.439 -179.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.483 ' N ' HG12 ' A' ' 38' ' ' VAL . 25.0 tt0 -137.8 102.72 4.8 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 113.313 -1.767 . . . . 0.0 108.234 178.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.433 HD22 ' CG ' ' A' ' 41' ' ' ASP . 9.9 p-10 -147.41 175.8 10.53 Favored 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.916 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.433 ' CG ' HD22 ' A' ' 40' ' ' ASN . 1.0 OUTLIER -15.7 -68.66 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 119.139 3.014 . . . . 0.0 119.139 -179.601 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.14 -8.85 6.49 Favored 'General case' 0 C--N 1.289 -2.023 0 CA-C-N 114.794 -1.093 . . . . 0.0 110.958 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.413 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -111.39 156.03 22.23 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.874 -1.13 . . . . 0.0 109.734 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.47 -88.98 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 114.135 -1.393 . . . . 0.0 108.742 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.679 HG22 ' HG3' ' A' ' 37' ' ' GLU . 61.5 t -68.27 162.86 3.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 104.566 -2.383 . . . . 0.0 104.566 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.511 ' HB3' HD12 ' A' ' 47' ' ' ILE . 2.4 mt-10 -108.3 -60.65 1.7 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 126.806 2.566 . . . . 0.0 115.479 -179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 34' ' ' VAL . 1.6 mp -96.1 143.21 25.73 Favored Pre-proline 0 C--N 1.273 -2.745 1 CA-C-N 108.033 -4.167 . . . . 0.0 108.904 -179.507 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.567 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.03 177.11 0.46 Allowed 'Trans proline' 0 C--N 1.305 -1.731 1 C-N-CA 126.281 4.654 . . . . 0.0 106.509 90.036 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.622 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 16.1 m -128.45 171.15 9.04 Favored Pre-proline 0 C--N 1.28 -2.434 0 O-C-N 125.144 1.528 . . . . 0.0 114.285 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -105.35 -17.13 0.05 OUTLIER 'Trans proline' 0 CA--C 1.555 1.549 0 C-N-CA 124.575 3.517 . . . . 0.0 119.653 173.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.577 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.2 p -135.24 170.35 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.705 0 CA-C-O 122.896 1.331 . . . . 0.0 111.789 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.702 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -125.07 178.3 5.61 Favored 'General case' 0 C--N 1.286 -2.195 1 CA-C-N 108.239 -4.073 . . . . 0.0 111.266 -179.555 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.61 -134.93 4.35 Favored Glycine 0 C--N 1.287 -2.177 1 N-CA-C 100.3 -5.12 . . . . 0.0 100.3 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.773 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 15.1 tppt? -112.93 176.55 4.97 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 104.497 -2.409 . . . . 0.0 104.497 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 24.0 t -123.75 100.84 8.25 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 1 N-CA-C 93.148 -6.612 . . . . 0.0 93.148 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.5 mt -74.61 -83.08 0.06 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 117.582 -1.647 . . . . 0.0 106.946 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.2 160.99 30.37 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.001 . . . . 0.0 112.668 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.405 HG13 ' HB3' ' A' ' 25' ' ' PRO . 96.7 mt -132.75 118.36 33.79 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 1 N-CA-C 92.761 -6.755 . . . . 0.0 92.761 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.446 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -92.69 -41.18 10.3 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 123.727 0.642 . . . . 0.0 111.787 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.42 ' HB ' ' CD2' ' A' ' 72' ' ' LEU . 3.4 t -111.32 124.59 32.33 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 101.632 -3.47 . . . . 0.0 101.632 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -57.07 -124.16 0.0 OUTLIER 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 123.921 3.081 . . . . 0.0 116.453 176.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.494 ' C ' ' H ' ' A' ' 64' ' ' THR . 0.0 OUTLIER -127.49 -170.34 2.21 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 100.885 -3.746 . . . . 0.0 100.885 179.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.07 -19.95 0.12 Allowed Glycine 0 N--CA 1.491 2.347 0 CA-C-N 113.277 -1.783 . . . . 0.0 113.711 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.494 ' H ' ' C ' ' A' ' 62' ' ' GLU . 2.2 m -101.97 170.03 8.39 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 104.394 -2.447 . . . . 0.0 104.394 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.449 HG22 ' HG3' ' A' ' 17' ' ' GLU . 45.0 t -105.77 148.8 9.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 103.816 -2.661 . . . . 0.0 103.816 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -119.5 156.66 29.82 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.6 p -101.06 -160.86 0.82 Allowed 'General case' 0 C--N 1.283 -2.289 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.779 HG11 ' HB3' ' A' ' 8' ' ' ASP . 52.2 t -126.69 153.17 35.23 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.39 1 N-CA-C 94.353 -6.166 . . . . 0.0 94.353 178.386 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 94.44 -36.16 3.89 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 103.588 -3.805 . . . . 0.0 103.588 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.472 ' H ' ' C ' ' A' ' 68' ' ' VAL . 31.6 tt0 -92.93 163.75 13.57 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 101.817 -3.401 . . . . 0.0 101.817 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.3 m -108.84 -179.02 3.74 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 101.724 -3.435 . . . . 0.0 101.724 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.42 ' CD2' ' HB ' ' A' ' 60' ' ' VAL . 0.4 OUTLIER -149.06 -65.64 0.23 Allowed 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 -179.371 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 7.8 tt -130.19 163.56 35.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.2 t -140.42 158.32 44.18 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 103.142 -2.91 . . . . 0.0 103.142 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -132.39 149.54 52.33 Favored 'General case' 0 C--N 1.287 -2.11 0 CA-C-N 111.83 -2.441 . . . . 0.0 104.855 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.26 123.17 48.12 Favored 'General case' 0 C--N 1.292 -1.913 1 N-CA-C 96.511 -5.366 . . . . 0.0 96.511 179.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -139.77 58.72 12.09 Favored Pre-proline 0 N--CA 1.491 1.607 1 N-CA-C 99.786 -4.153 . . . . 0.0 99.786 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -78.1 67.77 8.03 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 121.778 1.652 . . . . 0.0 112.066 -153.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.3 59.06 0.05 OUTLIER Glycine 0 N--CA 1.501 2.972 0 C-N-CA 119.72 -1.228 . . . . 0.0 112.806 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 116.338 -1.791 . . . . 0.0 107.554 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 2.097 0 N-CA-C 103.73 -2.692 . . . . 0.0 103.73 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.47 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -121.78 128.27 51.54 Favored 'General case' 0 C--N 1.29 -2.015 1 N-CA-C 99.962 -4.088 . . . . 0.0 99.962 -179.635 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -102.23 -173.29 2.3 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.414 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.7 t80 -101.14 -43.16 6.09 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.609 0.719 . . . . 0.0 112.509 -179.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HB2' HG13 ' A' ' 68' ' ' VAL . 0.1 OUTLIER -128.49 160.27 32.84 Favored 'General case' 0 C--N 1.297 -1.685 1 N-CA-C 99.338 -4.319 . . . . 0.0 99.338 179.79 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.43 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 25.5 mt -103.31 -169.37 0.18 Allowed Pre-proline 0 C--N 1.296 -1.745 0 N-CA-C 105.319 -2.104 . . . . 0.0 105.319 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB3' ' A' ' 6' ' ' LEU . 77.0 Cg_exo -55.48 85.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.12 1.88 . . . . 0.0 107.577 148.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.58 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.2 t0 -123.15 -88.65 0.61 Allowed 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.565 ' H ' HG11 ' A' ' 68' ' ' VAL . 1.3 pt 37.77 43.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.321 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.33 -176.1 50.51 Favored Glycine 0 N--CA 1.493 2.453 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.551 -179.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -80.72 144.73 31.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.86 -77.89 0.26 Allowed Glycine 0 C--N 1.294 -1.786 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.2 mt -137.93 103.79 2.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 102.736 -3.061 . . . . 0.0 102.736 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.67 20.71 18.61 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-N 122.178 2.263 . . . . 0.0 108.35 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 1.4 pm0 -121.95 -174.26 2.84 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 123.725 1.726 . . . . 0.0 114.09 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.4 101.65 0.27 Allowed Glycine 0 N--CA 1.492 2.43 0 CA-C-N 112.483 -2.144 . . . . 0.0 109.7 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.614 ' CD ' HE21 ' A' ' 39' ' ' GLN . 54.3 tt0 -92.94 89.2 6.45 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 66' ' ' ALA . 3.9 mt -84.18 103.89 11.9 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 100.851 -3.759 . . . . 0.0 100.851 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.7 t -84.33 -46.17 17.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.331 -179.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.455 ' HG2' ' N ' ' A' ' 21' ' ' TRP . 25.8 tttt -142.24 159.77 41.57 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 114.983 -1.008 . . . . 0.0 111.1 -179.543 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.53 ' CE3' HG22 ' A' ' 23' ' ' VAL . 17.7 m95 -122.16 162.52 21.18 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 179.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -120.68 -20.74 6.94 Favored 'General case' 0 C--N 1.292 -1.895 0 O-C-N 124.984 1.428 . . . . 0.0 108.76 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.53 HG22 ' CE3' ' A' ' 21' ' ' TRP . 5.1 m -99.89 179.31 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-O 123.753 1.74 . . . . 0.0 112.147 -179.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.647 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -130.42 140.13 37.73 Favored Pre-proline 0 C--N 1.288 -2.095 1 N-CA-C 97.743 -4.91 . . . . 0.0 97.743 -179.71 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -54.69 162.56 4.73 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.42 1.413 . . . . 0.0 114.945 -175.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.52 26.55 0.08 OUTLIER Glycine 0 C--N 1.294 -1.764 0 CA-C-N 110.785 -2.916 . . . . 0.0 117.662 179.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.508 ' C ' ' HZ2' ' A' ' 54' ' ' LYS . 23.0 t0 -87.0 -168.48 2.26 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 113.498 -3.281 . . . . 0.0 107.115 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.479 ' H ' ' CG ' ' A' ' 27' ' ' ASP . 5.5 mm-40 -102.92 127.55 50.08 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 100.391 -3.929 . . . . 0.0 100.391 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.465 HG23 ' HB3' ' A' ' 33' ' ' ASP . 2.9 p -109.55 160.74 8.33 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 3.0 t30 -96.72 -164.17 1.12 Allowed 'General case' 0 C--N 1.292 -1.901 0 CA-C-N 113.472 -1.695 . . . . 0.0 109.137 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.619 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.284 9.9 tt0 -117.87 56.21 0.86 Allowed 'General case' 0 C--N 1.289 -2.048 1 N-CA-C 98.332 -4.692 . . . . 0.0 98.332 -178.88 . . . . . . . . 4 3 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -178.04 1.39 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.84 0 CA-C-N 112.049 -2.341 . . . . 0.0 116.442 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.485 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 42.3 t0 -90.31 -172.14 3.35 Favored 'General case' 0 N--CA 1.508 2.463 0 CA-C-N 118.789 0.722 . . . . 0.0 111.371 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.545 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -112.51 176.34 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 126.375 2.988 . . . . 0.0 102.956 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.545 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -140.08 -83.29 0.25 Allowed 'General case' 0 C--N 1.274 -2.697 1 CA-C-N 107.485 -4.416 . . . . 0.0 100.504 179.317 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.431 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -126.08 172.34 10.07 Favored 'General case' 0 N--CA 1.51 2.568 0 CA-C-N 122.179 2.263 . . . . 0.0 115.153 -179.287 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.452 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 2.1 tt0 -119.77 101.33 7.82 Favored 'General case' 0 N--CA 1.493 1.707 1 N-CA-C 92.966 -6.679 . . . . 0.0 92.966 179.443 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 t -108.18 150.43 10.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.614 HE21 ' CD ' ' A' ' 17' ' ' GLU . 26.7 tt0 -121.23 164.53 16.81 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 104.116 -2.55 . . . . 0.0 104.116 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.4 HD21 ' HB3' ' A' ' 43' ' ' ALA . 5.2 p-10 -152.98 -178.75 7.11 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 102.623 -3.102 . . . . 0.0 102.623 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -5.79 -57.62 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 118.231 2.678 . . . . 0.0 118.231 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -146.36 -34.3 0.29 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.4 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -75.31 149.88 38.63 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.86 -1.064 . . . . 0.0 113.2 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 21.9 t -122.6 110.99 28.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 1 N-CA-C 95.696 -5.668 . . . . 0.0 95.696 179.582 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t -114.71 162.61 12.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 CA-C-O 124.709 2.195 . . . . 0.0 108.455 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.431 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -118.35 153.12 34.55 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 109.044 -3.707 . . . . 0.0 106.766 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.431 HD12 ' C ' ' A' ' 46' ' ' GLU . 1.7 mp -121.43 126.25 26.57 Favored Pre-proline 0 C--N 1.302 -1.47 1 N-CA-C 94.132 -6.247 . . . . 0.0 94.132 179.208 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.401 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -90.77 -176.69 1.02 Allowed 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.537 2.158 . . . . 0.0 107.934 167.106 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -91.85 112.8 56.51 Favored Pre-proline 0 C--N 1.288 -2.079 0 CA-C-N 113.207 -1.815 . . . . 0.0 108.228 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 25.3 Cg_exo -69.7 -34.59 14.49 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 121.497 1.465 . . . . 0.0 108.363 168.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.619 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -136.52 168.79 21.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 125.458 1.723 . . . . 0.0 111.94 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.82 162.18 13.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 127.32 2.888 . . . . 0.0 105.307 179.19 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 163.12 -141.84 7.44 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.508 ' HZ2' ' C ' ' A' ' 27' ' ' ASP . 0.5 OUTLIER -117.96 175.28 5.75 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 104.405 -2.442 . . . . 0.0 104.405 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' LEU . 21.7 t -128.52 57.19 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.048 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.414 ' HB2' HG23 ' A' ' 74' ' ' THR . 85.0 mt -26.9 -76.77 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 CA-C-N 112.729 -2.032 . . . . 0.0 113.632 -179.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -130.59 153.5 48.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 124.77 1.294 . . . . 0.0 110.161 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -131.25 119.62 44.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 1 N-CA-C 93.425 -6.509 . . . . 0.0 93.425 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.471 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.0 mp -90.9 -44.86 9.12 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.9 t -119.42 140.65 29.47 Favored Pre-proline 0 C--N 1.296 -1.757 1 N-CA-C 97.802 -4.888 . . . . 0.0 97.802 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.401 ' HG2' ' H ' ' A' ' 62' ' ' GLU . 13.3 Cg_endo -91.51 -101.34 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.033 1.155 . . . . 0.0 110.214 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.401 ' H ' ' HG2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -129.18 -168.71 1.97 Allowed 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 102.071 -3.307 . . . . 0.0 102.071 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 79.67 -45.87 2.98 Favored Glycine 0 C--N 1.287 -2.186 0 CA-C-N 113.404 -1.725 . . . . 0.0 112.101 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.6 m -98.83 172.51 7.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.4 t -108.03 150.63 10.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 104.614 -2.365 . . . . 0.0 104.614 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.485 ' HB3' HD11 ' A' ' 18' ' ' ILE . . . -123.97 168.11 13.25 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 103.661 -2.718 . . . . 0.0 103.661 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.564 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 12.2 t -129.02 -151.32 0.47 Allowed 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.58 HG11 ' HB3' ' A' ' 8' ' ' ASP . 97.4 t -121.98 159.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.322 0 N-CA-C 101.028 -3.693 . . . . 0.0 101.028 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.32 -43.86 1.7 Allowed Glycine 0 CA--C 1.549 2.211 1 N-CA-C 97.142 -6.383 . . . . 0.0 97.142 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.511 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.1 tt0 -88.81 162.56 16.13 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 102.289 -3.226 . . . . 0.0 102.289 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.7 m -109.6 -176.93 3.14 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 101.965 -3.346 . . . . 0.0 101.965 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.3 tp -146.91 -65.49 0.28 Allowed 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 1.4 tt -133.25 166.13 30.23 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-N 112.125 -2.307 . . . . 0.0 105.174 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 56' ' ' LEU . 0.8 OUTLIER -138.49 156.71 47.29 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 101.42 -3.548 . . . . 0.0 101.42 179.07 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.47 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -136.11 147.57 47.85 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.742 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.51 142.34 42.43 Favored 'General case' 0 C--N 1.299 -1.63 1 N-CA-C 97.946 -4.835 . . . . 0.0 97.946 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.13 36.6 0.25 Allowed Pre-proline 0 C--N 1.293 -1.853 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.386 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -37.21 61.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 124.921 3.747 . . . . 0.0 119.406 -143.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 153.5 42.3 0.02 OUTLIER Glycine 0 N--CA 1.495 2.59 0 N-CA-C 106.472 -2.651 . . . . 0.0 106.472 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.304 -1.398 0 N-CA-C 100.634 -3.839 . . . . 0.0 100.634 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.069 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -126.07 127.84 46.46 Favored 'General case' 0 N--CA 1.503 2.224 0 N-CA-C 102.569 -3.123 . . . . 0.0 102.569 -179.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.12 -151.25 0.47 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 125.319 1.637 . . . . 0.0 111.818 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.56 ' CE2' ' HE2' ' A' ' 5' ' ' LYS . 8.2 t80 -113.3 -49.68 2.9 Favored 'General case' 0 N--CA 1.502 2.162 0 CA-C-N 113.375 -1.738 . . . . 0.0 114.655 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.56 ' HE2' ' CE2' ' A' ' 4' ' ' PHE . 28.4 mmtt -131.45 155.11 47.92 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 66.0 mt -84.05 173.66 7.0 Favored Pre-proline 0 C--N 1.296 -1.724 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.818 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -54.18 85.91 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.585 2.19 . . . . 0.0 109.791 162.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.496 ' HB3' HG11 ' A' ' 68' ' ' VAL . 10.4 t0 -122.9 -80.22 0.62 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.3 pt 37.07 39.03 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.575 0 CA-C-O 121.896 0.855 . . . . 0.0 109.447 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.12 -150.56 11.33 Favored Glycine 0 N--CA 1.48 1.629 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.594 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -95.01 139.19 31.71 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 103.309 -2.848 . . . . 0.0 103.309 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.97 -79.27 0.33 Allowed Glycine 0 N--CA 1.487 2.081 0 N-CA-C 103.774 -3.731 . . . . 0.0 103.774 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.3 mm -130.73 133.25 63.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 22.1 t-80 -130.34 -19.23 3.14 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.503 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 0.5 OUTLIER -131.32 178.1 6.97 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 122.975 1.369 . . . . 0.0 110.55 -179.524 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.83 125.44 4.12 Favored Glycine 0 C--N 1.29 -2.019 0 N-CA-C 104.8 -3.32 . . . . 0.0 104.8 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 37.5 tt0 -100.31 96.31 7.36 Favored 'General case' 0 C--N 1.307 -1.272 1 N-CA-C 97.28 -5.081 . . . . 0.0 97.28 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mt -81.96 125.12 39.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 N-CA-C 103.573 -2.751 . . . . 0.0 103.573 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.6 t -86.38 -64.0 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 103.26 -2.867 . . . . 0.0 103.26 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.454 ' HE3' ' O ' ' A' ' 21' ' ' TRP . 1.3 tmtp? -142.99 167.75 21.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 124.018 0.824 . . . . 0.0 113.22 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.512 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 30.3 m95 -113.73 173.06 6.61 Favored 'General case' 0 N--CA 1.502 2.131 0 C-N-CA 123.92 0.888 . . . . 0.0 109.004 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.419 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.3 m-85 -126.92 -48.51 1.49 Allowed 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.541 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 m -100.23 178.69 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.172 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.02 161.77 26.34 Favored Pre-proline 0 C--N 1.295 -1.785 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.814 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -78.16 122.56 5.76 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.249 1.966 . . . . 0.0 110.857 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.16 -15.99 22.78 Favored Glycine 0 N--CA 1.483 1.816 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.23 174.37 7.32 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 123.018 1.389 . . . . 0.0 111.74 -178.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.93 117.41 28.01 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 111.166 -2.743 . . . . 0.0 104.242 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.498 HG13 ' HB2' ' A' ' 31' ' ' GLU . 9.7 p -108.58 176.59 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.719 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.422 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -104.65 -26.3 12.37 Favored 'General case' 0 N--CA 1.522 3.166 0 CA-C-O 126.698 3.142 . . . . 0.0 112.94 -179.697 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.498 ' HB2' HG13 ' A' ' 29' ' ' VAL 0.377 10.8 tp10 35.46 78.71 0.03 OUTLIER 'General case' 0 C--N 1.272 -2.796 5 N-CA-C 138.398 10.147 . . . . 0.0 138.398 -179.389 . . . . . . . . 4 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -141.67 27.21 1.87 Allowed 'General case' 0 C--N 1.287 -2.127 4 CA-C-N 94.721 -10.218 . . . . 0.0 96.273 179.251 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -108.94 -165.59 1.04 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 126.105 1.762 . . . . 0.0 107.343 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.476 HG12 ' H ' ' A' ' 35' ' ' LEU . 1.6 t -120.3 163.02 18.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 CA-C-O 125.554 2.597 . . . . 0.0 108.893 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.512 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.6 mp -126.45 -84.0 0.62 Allowed 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 108.726 -3.852 . . . . 0.0 103.033 179.15 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.573 ' SG ' HG23 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -123.66 172.69 8.62 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 -178.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.369 18.5 tt0 -134.04 140.31 46.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 127.064 2.728 . . . . 0.0 103.646 -179.244 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.573 HG23 ' SG ' ' A' ' 36' ' ' CYS . 25.0 t -139.39 151.34 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 CA-C-N 119.145 0.884 . . . . 0.0 109.7 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 43.4 tp60 -106.5 128.25 53.95 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 8.6 p-10 -156.01 -173.09 4.36 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -11.69 -73.63 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.608 0 O-C-N 126.479 2.362 . . . . 0.0 116.608 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -128.38 -7.27 5.27 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.408 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -97.81 159.2 15.08 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.276 -0.97 . . . . 0.0 113.15 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.9 t -124.65 -35.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 126.678 2.486 . . . . 0.0 112.942 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 10.9 t -113.1 169.51 4.78 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 125.239 1.415 . . . . 0.0 108.282 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.484 ' N ' HG12 ' A' ' 45' ' ' VAL . 3.6 mt-10 -120.45 -67.8 0.95 Allowed 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 121.422 3.86 . . . . 0.0 121.422 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.6 mp -92.85 149.49 37.84 Favored Pre-proline 0 C--N 1.273 -2.73 0 CA-C-N 108.746 -3.843 . . . . 0.0 108.672 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.463 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -103.18 -178.31 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.708 1.373 . . . . 0.0 109.152 83.395 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.432 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 0.7 OUTLIER -130.96 179.53 1.32 Allowed Pre-proline 0 C--N 1.286 -2.164 0 CA-C-N 113.481 -1.69 . . . . 0.0 108.428 -179.798 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -102.32 -26.53 0.03 OUTLIER 'Trans proline' 0 CA--C 1.548 1.179 0 N-CA-C 120.016 3.045 . . . . 0.0 120.016 171.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.517 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.9 OUTLIER -127.89 160.6 37.32 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.454 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.655 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -106.75 167.61 9.75 Favored 'General case' 0 C--N 1.294 -1.825 1 CA-C-N 107.451 -4.431 . . . . 0.0 111.148 -179.625 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.28 -141.37 6.75 Favored Glycine 0 C--N 1.292 -1.909 1 N-CA-C 100.024 -5.23 . . . . 0.0 100.024 -179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.445 ' HG3' ' H ' ' A' ' 55' ' ' VAL . 14.4 tppt? -105.79 175.1 5.61 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 102.151 -3.277 . . . . 0.0 102.151 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.445 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 47.4 t -126.1 60.69 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.216 1 N-CA-C 96.549 -5.352 . . . . 0.0 96.549 179.39 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.406 ' C ' ' O ' ' A' ' 55' ' ' VAL . 91.2 mt -22.55 -80.34 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.163 0 CA-C-N 112.816 -1.993 . . . . 0.0 112.999 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -139.76 164.18 30.64 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 125.049 1.468 . . . . 0.0 107.817 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.9 mt -132.47 130.99 60.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 1 N-CA-C 95.67 -5.678 . . . . 0.0 95.67 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.45 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.9 mp -87.74 -52.61 5.21 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 123.8 0.688 . . . . 0.0 109.689 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.5 t -116.67 140.54 26.89 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 101.135 -3.654 . . . . 0.0 101.135 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -87.5 -106.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.694 1.596 . . . . 0.0 111.004 178.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -129.56 159.57 35.95 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 102.567 -3.123 . . . . 0.0 102.567 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 107.17 -33.09 6.63 Favored Glycine 0 N--CA 1.498 2.782 0 C-N-CA 119.278 -1.439 . . . . 0.0 114.61 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.2 m -109.28 -175.9 2.88 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.2 t -112.43 150.93 14.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.88 163.73 18.73 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -107.57 -160.77 0.75 Allowed 'General case' 0 C--N 1.285 -2.224 0 N-CA-C 104.234 -2.506 . . . . 0.0 104.234 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.496 HG11 ' HB3' ' A' ' 8' ' ' ASP 0.265 44.6 t -124.0 153.86 30.38 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 1 N-CA-C 92.643 -6.799 . . . . 0.0 92.643 178.226 . . . . . . . . 4 3 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 95.6 -45.8 1.99 Allowed Glycine 0 N--CA 1.498 2.77 0 N-CA-C 103.294 -3.922 . . . . 0.0 103.294 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.42 ' H ' ' C ' ' A' ' 68' ' ' VAL . 37.3 tt0 -85.84 160.21 19.51 Favored 'General case' 0 C--N 1.303 -1.452 1 N-CA-C 99.777 -4.157 . . . . 0.0 99.777 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.4 m -106.54 -178.43 3.65 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 102.122 -3.288 . . . . 0.0 102.122 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.508 HD22 ' CE2' ' A' ' 4' ' ' PHE . 47.9 tp -143.33 -60.07 0.42 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.419 HD11 HG13 ' A' ' 55' ' ' VAL . 14.2 tt -132.96 161.97 40.76 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 104.573 -2.38 . . . . 0.0 104.573 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 t -140.09 164.73 29.25 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -134.01 144.21 48.58 Favored 'General case' 0 N--CA 1.505 2.275 0 CA-C-N 113.873 -1.512 . . . . 0.0 109.587 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -110.07 55.19 0.65 Allowed 'General case' 0 N--CA 1.504 2.249 0 CA-C-O 125.05 2.357 . . . . 0.0 112.32 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -91.37 132.26 34.23 Favored Pre-proline 0 C--N 1.293 -1.848 0 CA-C-N 112.456 -2.156 . . . . 0.0 107.652 -179.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -91.43 171.61 2.94 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 124.012 3.141 . . . . 0.0 106.949 150.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.95 -34.04 4.91 Favored Glycine 0 N--CA 1.493 2.487 1 N-CA-C 102.037 -4.425 . . . . 0.0 102.037 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 7.1 m-85 . . . . . 0 C--N 1.302 -1.482 0 N-CA-C 103.078 -2.934 . . . . 0.0 103.078 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -119.22 139.39 51.95 Favored 'General case' 0 N--CA 1.512 2.668 0 N-CA-C 100.732 -3.803 . . . . 0.0 100.732 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.449 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 0.0 OUTLIER -114.99 -161.03 0.76 Allowed 'General case' 0 N--CA 1.502 2.17 0 CA-C-N 120.798 1.635 . . . . 0.0 109.401 -179.67 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.421 ' CD2' ' HD3' ' A' ' 5' ' ' LYS . 8.8 t80 -126.99 -29.1 2.83 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 116.828 2.158 . . . . 0.0 116.828 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.465 ' HB2' HG13 ' A' ' 68' ' ' VAL . 17.9 mmmt -128.26 169.38 14.25 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-N 122.21 2.277 . . . . 0.0 105.279 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 64.6 mt -91.45 177.34 2.26 Favored Pre-proline 0 N--CA 1.493 1.705 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.741 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -61.14 80.05 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.649 0 N-CA-C 106.954 -1.979 . . . . 0.0 106.954 148.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.48 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.9 t70 -123.09 -80.05 0.62 Allowed 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.495 ' H ' HG11 ' A' ' 68' ' ' VAL . 45.5 pt 38.4 34.78 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.51 0 CA-C-N 119.794 1.179 . . . . 0.0 110.168 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.08 -115.03 2.89 Favored Glycine 0 N--CA 1.48 1.587 0 C-N-CA 120.84 -0.695 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -103.46 133.45 48.49 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.278 0.561 . . . . 0.0 110.873 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 116.92 -78.43 0.29 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 106.613 -2.595 . . . . 0.0 106.613 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.5 mm -133.45 134.1 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.089 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -119.22 -41.96 2.71 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 102.013 -3.328 . . . . 0.0 102.013 179.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.64 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.7 OUTLIER -130.65 167.47 18.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 124.005 0.816 . . . . 0.0 110.098 179.601 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.95 149.27 19.12 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -99.05 97.62 8.74 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 104.11 -2.552 . . . . 0.0 104.11 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.433 HG21 ' O ' ' A' ' 61' ' ' PRO . 17.7 mm -83.85 115.04 25.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 t -97.02 -48.32 12.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 O-C-N 125.061 1.475 . . . . 0.0 111.12 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.589 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -137.79 144.66 41.67 Favored 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.488 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 24.1 m95 -114.25 170.14 8.51 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CZ ' ' HE2' ' A' ' 20' ' ' LYS . 2.6 m-85 -121.47 -51.17 2.08 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 113.87 -1.514 . . . . 0.0 111.161 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 m -100.49 175.01 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.145 -1.022 . . . . 0.0 110.311 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.737 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -116.0 156.87 46.21 Favored Pre-proline 0 C--N 1.299 -1.63 0 N-CA-C 104.323 -2.473 . . . . 0.0 104.323 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -64.67 145.16 86.29 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 120.865 1.044 . . . . 0.0 111.22 171.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.56 19.73 28.94 Favored Glycine 0 N--CA 1.488 2.149 0 CA-C-O 118.733 -1.037 . . . . 0.0 111.864 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -106.33 170.05 8.15 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.63 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.466 ' HG2' ' HE3' ' A' ' 54' ' ' LYS . 21.0 mt-10 -129.25 88.4 2.7 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.454 ' O ' ' HB2' ' A' ' 52' ' ' LYS . 10.3 p -74.36 178.38 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-N 110.718 -2.946 . . . . 0.0 108.892 -179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.468 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 42.6 t30 -107.39 -29.71 9.1 Favored 'General case' 0 N--CA 1.517 2.892 0 CA-C-O 124.693 2.187 . . . . 0.0 112.097 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.483 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.387 11.1 tp10 44.63 75.22 0.11 Allowed 'General case' 0 C--N 1.279 -2.474 5 N-CA-C 135.413 9.042 . . . . 0.0 135.413 -179.742 . . . . . . . . 4 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 32' ' ' ASP . 11.8 p-10 -144.31 27.36 1.41 Allowed 'General case' 0 C--N 1.284 -2.248 4 CA-C-N 94.649 -10.251 . . . . 0.0 94.709 178.69 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.466 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 4.2 m-20 -112.19 -169.56 1.49 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 127.652 2.381 . . . . 0.0 110.833 -178.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.55 ' HA ' HG22 ' A' ' 47' ' ' ILE . 1.5 t -119.94 162.17 18.64 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 CA-C-O 124.302 2.001 . . . . 0.0 107.994 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.573 ' HB2' HG21 ' A' ' 47' ' ' ILE . 7.1 mp -126.22 -85.35 0.62 Allowed 'General case' 0 C--N 1.282 -2.356 1 CA-C-N 108.162 -4.108 . . . . 0.0 102.485 179.075 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.459 ' SG ' HD13 ' A' ' 47' ' ' ILE . 14.6 p -123.81 174.99 7.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -178.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.655 ' HG2' ' HA ' ' A' ' 45' ' ' VAL . 1.9 tt0 -133.27 140.07 47.27 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 126.925 2.641 . . . . 0.0 105.887 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.431 ' CG2' HD13 ' A' ' 18' ' ' ILE . 29.1 t -137.73 153.56 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-N 119.705 1.139 . . . . 0.0 108.32 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -112.15 122.65 48.33 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 4.6 p-10 -159.63 170.78 20.87 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.424 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 6.0 p-10 -3.88 -67.57 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 117.537 2.421 . . . . 0.0 117.537 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.424 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 84.9 mttt -126.19 -0.88 7.07 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 124.42 1.075 . . . . 0.0 111.459 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -104.01 154.45 19.66 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 114.41 1.263 . . . . 0.0 114.41 -179.506 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.7 t -129.95 -47.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 CA-C-N 111.109 -2.769 . . . . 0.0 109.0 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.655 ' HA ' ' HG2' ' A' ' 37' ' ' GLU . 21.8 t -105.8 160.98 5.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 CA-C-N 112.68 -2.054 . . . . 0.0 106.878 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.537 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.8 mt-10 -119.36 -67.14 1.01 Allowed 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 120.619 3.563 . . . . 0.0 120.619 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.573 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.1 mp -90.81 147.38 35.91 Favored Pre-proline 0 C--N 1.272 -2.768 0 CA-C-N 109.781 -3.372 . . . . 0.0 109.587 -179.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.561 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -100.71 178.57 0.23 Allowed 'Trans proline' 0 C--N 1.314 -1.283 0 N-CA-C 107.378 -1.816 . . . . 0.0 107.378 84.303 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.483 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 14.5 m -128.78 -176.55 0.54 Allowed Pre-proline 0 C--N 1.285 -2.232 0 CA-C-N 113.609 -1.632 . . . . 0.0 107.41 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.451 ' CD ' ' HB3' ' A' ' 49' ' ' SER . 87.7 Cg_endo -100.64 -30.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 123.121 2.547 . . . . 0.0 118.093 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -138.18 162.41 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.33 0 CA-C-O 123.559 1.647 . . . . 0.0 114.381 -179.348 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.532 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -112.52 169.81 8.62 Favored 'General case' 0 C--N 1.296 -1.723 1 CA-C-N 107.796 -4.275 . . . . 0.0 110.213 -179.645 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 167.23 -141.25 6.76 Favored Glycine 0 C--N 1.288 -2.113 1 N-CA-C 96.799 -6.52 . . . . 0.0 96.799 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.466 ' HE3' ' HG2' ' A' ' 28' ' ' GLU . 0.6 OUTLIER -93.6 -179.31 4.98 Favored 'General case' 0 C--N 1.288 -2.066 1 N-CA-C 99.785 -4.154 . . . . 0.0 99.785 179.99 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 48.1 t -127.9 98.39 4.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.451 1 N-CA-C 91.689 -7.152 . . . . 0.0 91.689 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 55.1 mt -58.81 -88.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 124.787 1.304 . . . . 0.0 109.874 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -139.43 166.16 25.31 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -126.57 134.7 65.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 1 N-CA-C 94.43 -6.137 . . . . 0.0 94.43 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.439 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.8 mp -94.6 -57.25 2.53 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.276 -0.97 . . . . 0.0 112.238 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 22.8 t -113.05 94.22 29.02 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 101.061 -3.681 . . . . 0.0 101.061 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.433 ' O ' HG21 ' A' ' 18' ' ' ILE . 13.2 Cg_exo -71.93 -81.31 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 CA-C-N 120.09 1.068 . . . . 0.0 109.558 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -137.11 164.2 28.99 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.53 -49.46 1.2 Allowed Glycine 0 N--CA 1.499 2.881 0 C-N-CA 119.962 -1.113 . . . . 0.0 113.133 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.78 -172.27 2.56 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 105.511 -2.033 . . . . 0.0 105.511 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.1 t -114.92 144.82 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.39 147.84 49.7 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.64 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 7.8 p -106.54 -160.04 0.72 Allowed 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.658 1.694 . . . . 0.0 108.367 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.495 HG11 ' H ' ' A' ' 9' ' ' ILE . 44.8 t -115.07 155.85 16.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.309 1 N-CA-C 91.751 -7.129 . . . . 0.0 91.751 178.477 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.19 -36.79 3.77 Favored Glycine 0 N--CA 1.49 2.264 1 N-CA-C 102.464 -4.254 . . . . 0.0 102.464 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.451 ' H ' ' C ' ' A' ' 68' ' ' VAL . 33.0 tt0 -104.2 164.19 11.89 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 102.316 -3.216 . . . . 0.0 102.316 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -98.69 -178.15 3.89 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 103.658 -2.719 . . . . 0.0 103.658 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 36.4 tp -138.66 -72.03 0.41 Allowed 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.001 -2.222 . . . . 0.0 105.001 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 10.9 tt -132.7 159.79 42.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.6 t -137.99 163.92 30.33 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 125.869 1.98 . . . . 0.0 106.496 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.9 155.58 49.58 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 125.636 1.835 . . . . 0.0 110.984 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -120.06 144.8 47.38 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 104.265 -2.494 . . . . 0.0 104.265 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 80' ' ' TYR . . . -143.68 84.07 10.16 Favored Pre-proline 0 N--CA 1.492 1.636 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -61.73 53.68 0.11 Allowed 'Trans proline' 0 N--CA 1.507 2.292 0 C-N-CA 124.792 3.662 . . . . 0.0 118.723 -168.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.21 63.5 0.19 Allowed Glycine 0 N--CA 1.489 2.169 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 1.8 t80 . . . . . 0 N--CA 1.497 1.883 0 N-CA-C 102.821 -3.029 . . . . 0.0 102.821 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.4 ' N ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.494 1.731 1 N-CA-C 97.812 -4.884 . . . . 0.0 97.812 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.468 ' HB3' ' CB ' ' A' ' 75' ' ' LEU . 18.8 t80 -117.2 93.15 4.07 Favored 'General case' 0 C--N 1.297 -1.689 1 N-CA-C 95.009 -5.923 . . . . 0.0 95.009 178.849 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.4 ' OE2' ' N ' ' A' ' 1' ' ' ALA . 7.1 mp0 -68.41 -177.45 0.92 Allowed 'General case' 0 C--N 1.302 -1.493 0 O-C-N 125.6 1.813 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -110.31 -30.15 7.83 Favored 'General case' 0 N--CA 1.51 2.553 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -179.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.572 ' CG ' HG22 ' A' ' 68' ' ' VAL . 36.5 mmtt -127.06 166.59 17.32 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 103.074 -2.935 . . . . 0.0 103.074 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 74.2 mt -108.79 -173.65 0.27 Allowed Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -54.29 85.36 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.856 1.704 . . . . 0.0 109.031 158.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.505 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.7 t70 -121.88 -74.73 0.61 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 101.761 -3.422 . . . . 0.0 101.761 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.618 ' H ' HG11 ' A' ' 68' ' ' VAL . 40.2 pt 30.47 38.62 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.975 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.53 -46.83 1.01 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 119.439 -1.362 . . . . 0.0 112.706 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.02 80.9 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 124.355 2.026 . . . . 0.0 113.987 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.68 -68.18 0.26 Allowed Glycine 0 C--N 1.277 -2.746 0 CA-C-N 111.877 -2.42 . . . . 0.0 107.637 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 14' ' ' HIS . 40.4 mm -127.2 -172.96 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.444 ' N ' HG22 ' A' ' 13' ' ' ILE . 2.1 p80 -144.02 -50.97 0.31 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.583 0.706 . . . . 0.0 111.276 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.7 pt-20 -103.24 -168.81 1.56 Allowed 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 116.381 1.993 . . . . 0.0 116.381 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.09 112.15 0.59 Allowed Glycine 0 C--N 1.286 -2.227 0 CA-C-N 112.795 -2.002 . . . . 0.0 108.202 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -98.95 92.02 5.32 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 101.567 -3.494 . . . . 0.0 101.567 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.7 mt -85.01 104.2 12.89 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.9 t -86.82 -47.49 16.05 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.476 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.423 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 41.1 tttt -126.22 146.31 50.04 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-N 114.431 -1.258 . . . . 0.0 113.394 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.463 ' CZ2' ' SG ' ' A' ' 36' ' ' CYS . 4.8 m95 -121.6 176.76 5.54 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 103.846 -2.65 . . . . 0.0 103.846 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.504 ' CD2' HG21 ' A' ' 34' ' ' VAL . 13.8 m-85 -123.76 -34.91 2.96 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 126.257 2.223 . . . . 0.0 112.189 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.531 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 10.3 m -103.74 176.54 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.977 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -140.9 61.31 14.58 Favored Pre-proline 0 N--CA 1.492 1.627 0 N-CA-C 117.933 2.568 . . . . 0.0 117.933 -179.438 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 23' ' ' VAL . 5.8 Cg_exo -21.54 -179.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 N-CA-C 119.699 2.923 . . . . 0.0 119.699 -60.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.531 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.33 28.61 8.69 Favored Glycine 0 N--CA 1.497 2.713 0 CA-C-N 111.597 -2.547 . . . . 0.0 108.198 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 54' ' ' LYS . 5.2 t0 7.86 -95.6 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.16 0 O-C-N 128.527 3.133 . . . . 0.0 110.905 179.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.428 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 3.1 mm-40 -98.44 119.7 37.59 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 100.818 -3.771 . . . . 0.0 100.818 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -120.23 168.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 122.296 1.046 . . . . 0.0 109.208 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.7 m-20 -99.85 -168.13 1.56 Allowed 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 112.535 -2.12 . . . . 0.0 107.729 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.731 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.263 4.6 tt0 -120.62 52.36 1.17 Allowed 'General case' 0 N--CA 1.494 1.753 1 N-CA-C 97.838 -4.875 . . . . 0.0 97.838 -179.727 . . . . . . . . 4 3 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -171.37 36.89 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 111.403 -2.635 . . . . 0.0 111.711 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.46 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 19.1 t70 -112.96 -178.38 3.37 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.455 -0.778 . . . . 0.0 109.116 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.504 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -84.77 -166.06 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 127.314 3.435 . . . . 0.0 117.664 179.75 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.685 ' HB3' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -115.27 -150.68 0.47 Allowed 'General case' 0 C--N 1.281 -2.404 2 CA-C-N 103.319 -6.31 . . . . 0.0 108.645 -179.553 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.463 ' SG ' ' CZ2' ' A' ' 21' ' ' TRP . 1.8 m -127.19 159.38 34.47 Favored 'General case' 0 C--N 1.284 -2.282 2 N-CA-C 97.025 -5.176 . . . . 0.0 97.025 179.193 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -114.64 108.6 17.02 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 100.492 -3.892 . . . . 0.0 100.492 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 49.1 t -112.96 147.61 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 37.4 tt0 -113.09 155.53 24.76 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.088 -1.045 . . . . 0.0 108.886 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -140.49 -168.97 2.68 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 104.683 -2.339 . . . . 0.0 104.683 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.457 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.9 OUTLIER -11.13 -64.0 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 126.427 2.33 . . . . 0.0 115.301 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.457 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 17.2 mttp -144.82 -21.87 0.51 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 124.065 0.853 . . . . 0.0 110.439 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.44 -176.33 3.08 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.628 1.204 . . . . 0.0 112.431 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 38.3 t -125.94 137.58 57.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 103.398 -2.816 . . . . 0.0 103.398 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.5 t -112.05 157.8 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.569 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -119.8 141.26 49.66 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 111.572 -2.558 . . . . 0.0 109.952 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.685 ' C ' ' HB3' ' A' ' 35' ' ' LEU . 1.9 mp -125.92 75.22 71.47 Favored Pre-proline 0 CA--C 1.574 1.87 0 N-CA-C 101.556 -3.498 . . . . 0.0 101.556 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.462 ' N ' ' HB3' ' A' ' 35' ' ' LEU . 78.3 Cg_endo -62.07 -172.42 0.11 Allowed 'Trans proline' 0 N--CA 1.512 2.574 0 C-N-CA 122.894 2.396 . . . . 0.0 108.173 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.7 p -105.07 85.22 1.2 Allowed Pre-proline 0 C--N 1.286 -2.19 0 CA-C-N 112.934 -1.939 . . . . 0.0 111.567 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -46.31 -31.98 10.08 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.588 1.525 . . . . 0.0 112.926 176.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.731 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -131.09 167.61 25.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.547 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.76 165.15 11.22 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 127.141 2.776 . . . . 0.0 108.097 179.408 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 148.23 -139.85 7.95 Favored Glycine 0 C--N 1.293 -1.808 0 N-CA-C 106.237 -2.745 . . . . 0.0 106.237 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.601 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -111.91 169.03 9.12 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 -179.503 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.406 HG11 ' H ' ' A' ' 26' ' ' GLY . 33.4 t -128.38 61.55 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 100.856 -3.757 . . . . 0.0 100.856 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.439 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 40.8 mt -31.37 -74.11 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 110.845 -2.889 . . . . 0.0 114.227 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -138.75 163.76 31.34 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 114.127 1.158 . . . . 0.0 114.127 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.4 HD12 ' HD3' ' A' ' 25' ' ' PRO . 56.1 mt -136.36 136.94 48.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 1 N-CA-C 100.062 -4.051 . . . . 0.0 100.062 179.762 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.3 mt -94.25 -63.56 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.727 0.775 . . . . 0.0 110.453 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.473 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 15.8 t -115.94 73.8 4.91 Favored Pre-proline 0 N--CA 1.491 1.622 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 -179.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -45.88 -77.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.067 1.845 . . . . 0.0 113.335 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.2 -177.14 4.7 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.45 -49.96 4.32 Favored Glycine 0 N--CA 1.492 2.4 0 CA-C-N 113.929 -1.487 . . . . 0.0 113.007 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.473 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 5.3 m -103.51 -176.22 3.02 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.4 150.05 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.87 160.8 26.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 9.5 t -115.25 -161.29 0.77 Allowed 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.618 HG11 ' H ' ' A' ' 9' ' ' ILE . 73.3 t -120.25 153.78 23.28 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 95.036 -5.913 . . . . 0.0 95.036 178.618 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.58 -37.99 3.42 Favored Glycine 0 N--CA 1.492 2.427 1 N-CA-C 101.513 -4.635 . . . . 0.0 101.513 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -97.53 159.43 14.93 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 100.71 -3.811 . . . . 0.0 100.71 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.5 179.25 5.07 Favored 'General case' 0 C--N 1.288 -2.082 0 N-CA-C 100.222 -3.992 . . . . 0.0 100.222 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 52.4 tp -138.81 -67.22 0.46 Allowed 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.78 161.94 37.65 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 103.107 -2.924 . . . . 0.0 103.107 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.8 t -137.42 157.45 46.55 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 126.327 2.267 . . . . 0.0 105.714 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.468 ' CB ' ' HB3' ' A' ' 2' ' ' PHE . 0.6 OUTLIER -137.43 150.92 47.99 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -114.26 151.35 32.98 Favored 'General case' 0 C--N 1.296 -1.72 1 N-CA-C 98.865 -4.494 . . . . 0.0 98.865 179.388 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.433 ' HB3' ' HA ' ' A' ' 78' ' ' PRO . . . -117.76 -36.68 0.07 OUTLIER Pre-proline 0 N--CA 1.501 2.078 0 C-N-CA 119.465 -0.894 . . . . 0.0 112.747 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 77' ' ' ALA . 38.2 Cg_exo -64.02 -178.87 0.65 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 125.701 2.421 . . . . 0.0 107.647 -62.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.44 -39.23 2.1 Favored Glycine 0 N--CA 1.5 2.926 1 N-CA-C 101.933 -4.467 . . . . 0.0 101.933 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.581 0 N-CA-C 101.476 -3.527 . . . . 0.0 101.476 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.476 ' N ' ' O ' ' A' ' 80' ' ' TYR . . . . . . . . 0 N--CA 1.508 2.462 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.531 ' HB2' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -141.38 159.21 42.69 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.869 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.59 -142.42 0.27 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.755 ' CZ ' ' HD3' ' A' ' 5' ' ' LYS . 14.1 t80 -126.37 -60.75 1.24 Allowed 'General case' 0 N--CA 1.504 2.228 0 O-C-N 124.422 1.076 . . . . 0.0 113.34 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.755 ' HD3' ' CZ ' ' A' ' 4' ' ' PHE . 20.9 mmmt -132.1 143.61 50.14 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 67.9 mt -90.27 173.46 5.69 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 125.053 1.471 . . . . 0.0 107.963 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -40.88 81.59 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.294 0 N-CA-C 118.414 2.429 . . . . 0.0 118.414 168.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.466 ' HB3' HG11 ' A' ' 68' ' ' VAL . 12.2 t70 -122.68 -76.82 0.59 Allowed 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 103.604 -2.739 . . . . 0.0 103.604 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 27.4 pt 37.4 44.45 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.251 0 CA-C-O 122.683 1.23 . . . . 0.0 108.865 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 14' ' ' HIS . . . -90.62 -161.95 37.84 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -109.59 160.83 15.93 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 118.551 1.176 . . . . 0.0 108.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.28 -72.49 0.38 Allowed Glycine 0 N--CA 1.485 1.934 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.5 mm -132.4 82.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 124.933 1.02 . . . . 0.0 110.248 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -105.57 16.13 25.92 Favored 'General case' 0 N--CA 1.507 2.38 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.092 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 7.8 pt-20 -140.09 166.92 23.35 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 113.923 -1.49 . . . . 0.0 108.01 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.03 125.3 4.65 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 107.417 -2.273 . . . . 0.0 107.417 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.464 ' H ' HG13 ' A' ' 38' ' ' VAL . 33.8 tt0 -96.9 100.45 11.97 Favored 'General case' 0 C--N 1.302 -1.471 1 N-CA-C 99.04 -4.43 . . . . 0.0 99.04 179.77 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG22 ' A' ' 38' ' ' VAL . 16.0 mm -82.4 124.57 39.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 1 N-CA-C 99.599 -4.223 . . . . 0.0 99.599 -179.766 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.447 HG21 ' HB2' ' A' ' 39' ' ' GLN . 2.0 t -105.24 -39.79 5.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.821 ' HE3' ' CZ ' ' A' ' 22' ' ' PHE . 20.5 tttp -136.7 155.25 50.12 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.169 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.423 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 14.8 m95 -122.77 178.81 4.86 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 125.495 1.747 . . . . 0.0 106.489 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.821 ' CZ ' ' HE3' ' A' ' 20' ' ' LYS . 28.3 m-85 -132.94 -52.58 0.91 Allowed 'General case' 0 N--CA 1.504 2.259 0 O-C-N 124.373 1.045 . . . . 0.0 112.638 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 m -99.16 175.86 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 124.062 0.851 . . . . 0.0 109.596 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.486 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -117.35 161.99 30.5 Favored Pre-proline 0 C--N 1.295 -1.788 0 O-C-N 125.724 1.89 . . . . 0.0 108.443 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -56.07 112.77 1.17 Allowed 'Trans proline' 0 C--N 1.316 -1.153 0 C-N-CA 121.703 1.602 . . . . 0.0 113.013 174.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.51 16.81 14.89 Favored Glycine 0 N--CA 1.484 1.887 0 CA-C-O 117.167 -1.907 . . . . 0.0 113.501 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -86.76 161.12 18.56 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 116.652 -2.019 . . . . 0.0 108.008 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.45 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -109.71 92.16 3.94 Favored 'General case' 0 C--N 1.294 -1.816 1 N-CA-C 99.813 -4.143 . . . . 0.0 99.813 -179.574 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 31' ' ' GLU . 6.1 p -91.64 176.16 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 C-N-CA 117.308 -1.757 . . . . 0.0 106.368 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.594 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 26.9 t30 -105.72 -21.72 13.12 Favored 'General case' 0 N--CA 1.529 3.498 0 CA-C-O 123.701 1.715 . . . . 0.0 112.243 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.541 ' H ' HG22 ' A' ' 29' ' ' VAL 0.404 3.8 tp10 36.41 67.9 0.29 Allowed 'General case' 0 C--N 1.281 -2.389 5 N-CA-C 135.059 8.911 . . . . 0.0 135.059 179.566 . . . . . . . . 4 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.9 p-10 -137.4 22.66 2.96 Favored 'General case' 0 C--N 1.288 -2.108 4 CA-C-N 95.715 -9.766 . . . . 0.0 96.572 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.548 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 28.5 t70 -115.23 -148.94 0.44 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 127.15 2.18 . . . . 0.0 105.54 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.548 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 1.9 t -120.08 163.32 17.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 126.531 3.062 . . . . 0.0 109.054 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.58 ' CB ' HG21 ' A' ' 47' ' ' ILE . 13.4 tp -123.27 -81.95 0.64 Allowed 'General case' 0 C--N 1.283 -2.319 2 CA-C-N 107.451 -4.432 . . . . 0.0 99.368 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.455 ' SG ' HD13 ' A' ' 47' ' ' ILE . 16.9 p -132.44 172.46 12.45 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.58 ' HA ' ' HA ' ' A' ' 45' ' ' VAL . 3.7 tt0 -130.42 138.51 50.37 Favored 'General case' 0 N--CA 1.5 2.067 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 ' H ' ' A' ' 17' ' ' GLU . 25.2 t -135.26 145.53 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.335 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.499 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 4.7 tt0 -109.12 138.81 44.9 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -164.31 -161.17 0.58 Allowed 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 105.805 -1.924 . . . . 0.0 105.805 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.506 ' C ' ' HG3' ' A' ' 42' ' ' LYS . 5.6 p-10 -29.03 -58.31 0.14 Allowed 'General case' 0 C--N 1.297 -1.713 0 O-C-N 126.562 2.414 . . . . 0.0 114.475 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.506 ' HG3' ' C ' ' A' ' 41' ' ' ASP . 2.9 mttt -137.9 -8.85 1.59 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.678 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -93.73 158.26 15.76 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 114.609 1.337 . . . . 0.0 114.609 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.88 -44.28 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 126.335 2.272 . . . . 0.0 109.451 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 23.4 t -103.53 155.86 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 C-N-CA 125.574 1.55 . . . . 0.0 108.749 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.673 ' HB3' HD12 ' A' ' 47' ' ' ILE . 7.9 mt-10 -114.27 -63.42 1.45 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 126.683 2.489 . . . . 0.0 114.608 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.673 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -92.88 149.64 38.07 Favored Pre-proline 0 C--N 1.281 -2.374 0 CA-C-N 108.821 -3.809 . . . . 0.0 115.094 -178.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.662 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.25 177.59 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.112 0 N-CA-C 107.569 -1.743 . . . . 0.0 107.569 87.582 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 9.7 m -119.13 177.33 1.37 Allowed Pre-proline 0 C--N 1.284 -2.257 0 CA-C-N 112.838 -1.983 . . . . 0.0 113.315 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -95.94 -44.79 0.02 OUTLIER 'Trans proline' 0 CA--C 1.555 1.572 0 N-CA-C 118.57 2.488 . . . . 0.0 118.57 169.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.645 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.8 OUTLIER -130.76 166.24 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 123.191 1.472 . . . . 0.0 114.947 -179.375 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.645 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -121.1 170.57 9.41 Favored 'General case' 0 C--N 1.3 -1.561 1 CA-C-N 107.835 -4.257 . . . . 0.0 112.314 179.971 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.22 -124.64 1.21 Allowed Glycine 0 N--CA 1.49 2.281 1 N-CA-C 96.897 -6.481 . . . . 0.0 96.897 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.542 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 16.8 tttp -107.35 -174.92 2.65 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.415 ' H ' ' HG2' ' A' ' 54' ' ' LYS . 60.3 t -130.93 65.75 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.279 1 N-CA-C 97.292 -5.077 . . . . 0.0 97.292 -179.617 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.458 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 80.1 mt -29.53 -78.09 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 112.242 -2.253 . . . . 0.0 110.956 -179.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -145.68 165.88 27.46 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 33.3 mt -132.78 139.93 48.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 1 N-CA-C 98.258 -4.719 . . . . 0.0 98.258 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -106.97 -31.34 8.36 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 123.819 0.7 . . . . 0.0 111.199 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.452 HG21 HD12 ' A' ' 72' ' ' LEU . 19.8 t -107.39 130.31 23.02 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -49.91 -150.38 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 124.254 3.302 . . . . 0.0 116.487 158.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 39.93 3.57 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 111.86 -2.427 . . . . 0.0 107.847 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -142.82 -6.2 0.71 Allowed Glycine 0 N--CA 1.497 2.734 0 CA-C-N 111.504 -2.589 . . . . 0.0 116.071 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.1 m -121.63 172.67 7.94 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 105.244 -2.132 . . . . 0.0 105.244 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.39 144.31 16.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 102.672 -3.084 . . . . 0.0 102.672 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -118.79 164.97 14.6 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.0 p -109.28 -163.2 0.85 Allowed 'General case' 0 C--N 1.283 -2.307 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.471 HG22 ' CB ' ' A' ' 5' ' ' LYS . 52.2 t -119.39 154.16 21.94 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 1 N-CA-C 92.681 -6.785 . . . . 0.0 92.681 178.748 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 101.06 -38.62 3.06 Favored Glycine 0 N--CA 1.49 2.291 1 N-CA-C 100.416 -5.073 . . . . 0.0 100.416 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.46 ' H ' ' C ' ' A' ' 68' ' ' VAL . 25.4 tt0 -99.94 160.57 14.21 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 101.013 -3.699 . . . . 0.0 101.013 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -105.89 -175.6 2.84 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 101.687 -3.449 . . . . 0.0 101.687 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.68 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . 0.9 OUTLIER -145.15 -57.46 0.33 Allowed 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 16.0 tt -137.13 163.48 32.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 t -135.86 159.21 42.36 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 103.114 -2.921 . . . . 0.0 103.114 179.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.531 ' HB3' ' HB2' ' A' ' 2' ' ' PHE . 1.0 OUTLIER -138.58 147.16 42.68 Favored 'General case' 0 C--N 1.289 -2.062 0 O-C-N 125.392 1.682 . . . . 0.0 107.734 -179.502 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.542 ' CG ' ' H ' ' A' ' 54' ' ' LYS . 2.1 p30 -115.64 158.19 23.09 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 104.154 -2.536 . . . . 0.0 104.154 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.567 ' CB ' ' HB2' ' A' ' 80' ' ' TYR . . . -139.38 139.02 21.46 Favored Pre-proline 0 C--N 1.29 -1.994 0 N-CA-C 102.627 -3.101 . . . . 0.0 102.627 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -70.53 -37.35 7.42 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 121.974 1.783 . . . . 0.0 110.466 173.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.541 ' O ' ' CD1' ' A' ' 80' ' ' TYR . . . -121.97 27.11 6.27 Favored Glycine 0 N--CA 1.493 2.494 0 CA-C-O 115.992 -2.56 . . . . 0.0 113.086 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.567 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 21.7 m-85 . . . . . 0 N--CA 1.503 2.215 0 CA-C-O 115.509 -2.186 . . . . 0.0 108.283 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.047 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -115.34 147.11 40.87 Favored 'General case' 0 N--CA 1.498 1.946 1 N-CA-C 99.897 -4.112 . . . . 0.0 99.897 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -113.65 -168.79 1.39 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 118.878 0.763 . . . . 0.0 112.639 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.439 ' CD2' HD13 ' A' ' 72' ' ' LEU . 41.7 t80 -105.69 -22.94 12.85 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 -179.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.467 ' CG ' HG22 ' A' ' 68' ' ' VAL . 11.0 mmtm -127.55 177.64 6.64 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 102.638 -3.097 . . . . 0.0 102.638 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 83.5 mt -105.62 176.22 1.8 Allowed Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -54.44 82.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.676 1.584 . . . . 0.0 110.111 153.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.509 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.6 t70 -122.06 -82.65 0.65 Allowed 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.485 -2.043 . . . . 0.0 105.485 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.46 HG23 HG12 ' A' ' 68' ' ' VAL . 24.0 pt 39.16 27.71 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 124.055 0.847 . . . . 0.0 111.647 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.18 -70.99 0.05 OUTLIER Glycine 0 N--CA 1.477 1.423 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.825 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.407 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 1.1 mp0 -51.06 153.08 2.01 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 124.415 2.055 . . . . 0.0 116.312 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -22.16 -41.01 0.01 OUTLIER Glycine 0 N--CA 1.498 2.824 0 CA-C-N 110.908 -2.86 . . . . 0.0 118.439 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.466 HD12 ' N ' ' A' ' 13' ' ' ILE . 3.2 mp -115.94 64.0 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.216 1.008 . . . . 0.0 108.81 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.408 ' O ' HG23 ' A' ' 68' ' ' VAL . 2.1 p80 -85.72 7.61 22.92 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-N 114.72 -1.127 . . . . 0.0 112.493 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.1 pt-20 -129.68 -165.89 1.59 Allowed 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.992 0.901 . . . . 0.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.14 112.51 0.55 Allowed Glycine 0 N--CA 1.503 3.106 0 CA-C-O 117.484 -1.731 . . . . 0.0 112.808 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 56.4 tt0 -104.17 85.95 2.47 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 103.223 -2.881 . . . . 0.0 103.223 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.569 HD11 HD11 ' A' ' 72' ' ' LEU . 1.9 mp -87.48 124.63 40.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.9 t -101.8 -46.85 11.32 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 O-C-N 124.53 1.144 . . . . 0.0 109.252 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.433 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 12.1 ttmt -131.69 145.18 51.5 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 124.564 1.165 . . . . 0.0 112.123 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -115.98 -178.64 3.45 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 178.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -126.56 -27.15 3.17 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 111.248 -2.706 . . . . 0.0 111.169 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.575 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 7.4 m -101.49 -177.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.172 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.433 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.2 mptp? -100.19 -41.23 0.22 Allowed Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.502 ' C ' ' H ' ' A' ' 27' ' ' ASP . 43.1 Cg_endo -49.56 170.84 1.38 Allowed 'Cis proline' 0 N--CA 1.498 1.762 1 N-CA-C 124.991 4.958 . . . . 0.0 124.991 29.714 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.575 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -94.22 37.39 3.42 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 105.846 -2.902 . . . . 0.0 105.846 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.544 ' OD1' ' HE3' ' A' ' 54' ' ' LYS . 14.9 t70 3.1 -90.46 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.175 0 O-C-N 127.796 2.703 . . . . 0.0 110.131 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.579 ' HG2' ' CE ' ' A' ' 54' ' ' LYS . 6.7 mt-10 -99.53 111.58 23.91 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 101.972 -3.344 . . . . 0.0 101.972 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 163.98 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 CA-C-O 124.49 2.091 . . . . 0.0 114.704 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.653 HD22 ' CG ' ' A' ' 32' ' ' ASP . 10.2 p-10 -98.22 -171.27 2.11 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 110.075 -3.239 . . . . 0.0 112.17 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 4.7 tt0 -121.88 68.11 0.92 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.653 ' CG ' HD22 ' A' ' 30' ' ' ASN . 3.5 p30 -179.7 -27.61 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 112.965 -1.925 . . . . 0.0 110.808 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.475 ' HB3' ' HB2' ' A' ' 49' ' ' SER . 4.2 t0 -28.77 154.04 0.0 OUTLIER 'General case' 0 N--CA 1.514 2.768 0 CA-C-O 122.992 1.377 . . . . 0.0 114.279 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.677 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -56.17 -176.73 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 124.188 4.885 . . . . 0.0 124.188 -179.251 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.677 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.1 mm? -86.69 174.25 8.97 Favored 'General case' 0 N--CA 1.411 -2.393 2 CA-C-N 101.792 -7.004 . . . . 0.0 101.488 -179.38 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.0 m -127.97 155.08 44.83 Favored 'General case' 0 C--N 1.265 -3.082 2 N-CA-C 97.587 -4.968 . . . . 0.0 97.587 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.433 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 12.9 mt-10 -118.26 103.53 9.91 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 38.4 t -116.59 155.68 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 CA-C-N 113.429 -1.714 . . . . 0.0 107.158 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -118.37 162.07 18.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -155.23 -172.31 4.13 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -17.57 -62.44 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 126.409 2.318 . . . . 0.0 115.2 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.3 mttp -140.45 -13.91 0.99 Allowed 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.185 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -109.71 175.21 5.53 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 116.598 2.073 . . . . 0.0 116.598 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.4 t -122.59 136.48 59.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 1 N-CA-C 99.611 -4.218 . . . . 0.0 99.611 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.7 t -117.47 161.27 16.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.448 1.118 . . . . 0.0 109.589 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 47' ' ' ILE . 11.9 pt-20 -123.67 129.13 50.64 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 110.227 -3.17 . . . . 0.0 106.758 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.522 HD12 ' N ' ' A' ' 47' ' ' ILE . 3.7 mp -125.07 96.71 39.3 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 115.806 -2.045 . . . . 0.0 106.266 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 35' ' ' LEU . 60.7 Cg_endo -68.62 -164.85 0.12 Allowed 'Trans proline' 0 N--CA 1.515 2.742 0 C-N-CA 124.446 3.431 . . . . 0.0 106.917 -174.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.475 ' HB2' ' HB3' ' A' ' 33' ' ' ASP . 14.4 t -104.02 103.25 36.74 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 111.875 -2.42 . . . . 0.0 108.962 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 85.3 Cg_exo -49.31 -55.24 4.33 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.659 2.906 . . . . 0.0 119.01 161.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.402 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.59 168.43 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-O 121.933 0.873 . . . . 0.0 112.748 -179.613 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 4.1 pttt -96.33 167.89 10.9 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 111.409 -2.632 . . . . 0.0 106.719 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.08 -135.87 5.87 Favored Glycine 0 C--N 1.289 -2.071 0 N-CA-C 105.955 -2.858 . . . . 0.0 105.955 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.579 ' CE ' ' HG2' ' A' ' 28' ' ' GLU . 4.3 tptt -116.82 164.92 13.93 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 104.966 -2.235 . . . . 0.0 104.966 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.453 HG11 ' H ' ' A' ' 26' ' ' GLY . 22.1 t -126.43 58.11 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.809 1 N-CA-C 100.164 -4.013 . . . . 0.0 100.164 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 18.0 mt -29.51 -73.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 CA-C-N 110.29 -3.141 . . . . 0.0 115.084 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -137.03 163.9 29.66 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.973 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.5 mt -138.61 144.56 29.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 1 N-CA-C 98.87 -4.493 . . . . 0.0 98.87 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -111.33 -54.79 2.57 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.5 t -113.42 78.77 3.67 Favored Pre-proline 0 C--N 1.3 -1.571 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -55.18 -85.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 121.708 1.605 . . . . 0.0 113.455 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -139.7 170.63 15.54 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 78.41 -35.71 1.78 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.11 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.7 m -99.63 171.98 7.57 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 67.1 t -115.06 142.97 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.66 160.18 31.5 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.8 t -105.41 -156.91 0.59 Allowed 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.509 HG11 ' HB3' ' A' ' 8' ' ' ASP . 61.5 t -121.69 158.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 1 N-CA-C 94.886 -5.968 . . . . 0.0 94.886 178.408 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.43 -29.36 9.73 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 104.675 -3.37 . . . . 0.0 104.675 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.449 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -109.41 156.71 19.72 Favored 'General case' 0 C--N 1.302 -1.483 1 N-CA-C 99.119 -4.4 . . . . 0.0 99.119 179.793 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -87.2 -174.15 4.74 Favored 'General case' 0 C--N 1.288 -2.089 0 N-CA-C 100.93 -3.73 . . . . 0.0 100.93 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.569 HD11 HD11 ' A' ' 18' ' ' ILE . 3.9 tt -145.99 -62.97 0.32 Allowed 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 104.554 -2.387 . . . . 0.0 104.554 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 tt -138.42 162.17 30.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 102.092 -3.299 . . . . 0.0 102.092 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 t -136.92 159.73 41.0 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 103.96 -2.608 . . . . 0.0 103.96 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.4 146.05 36.1 Favored 'General case' 0 C--N 1.284 -2.255 0 CA-C-N 111.806 -2.452 . . . . 0.0 105.113 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.07 159.31 16.68 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 98.895 -4.483 . . . . 0.0 98.895 179.318 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.514 ' H ' ' CA ' ' A' ' 78' ' ' PRO . . . -138.13 -36.79 0.02 OUTLIER Pre-proline 0 C--N 1.289 -2.03 0 CA-C-N 114.274 -1.33 . . . . 0.0 111.093 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.514 ' CA ' ' H ' ' A' ' 77' ' ' ALA . 18.6 Cg_endo -104.18 138.39 1.03 Allowed 'Cis proline' 0 C--N 1.316 -1.139 0 C-N-CA 129.235 0.931 . . . . 0.0 111.334 -24.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.85 41.79 0.76 Allowed Glycine 0 N--CA 1.498 2.825 0 N-CA-C 105.974 -2.851 . . . . 0.0 105.974 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.9 m-30 . . . . . 0 C--N 1.299 -1.591 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.133 0 N-CA-C 104.184 -2.524 . . . . 0.0 104.184 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.442 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -125.17 160.69 28.55 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 103.026 -2.953 . . . . 0.0 103.026 -179.608 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.8 -158.53 0.87 Allowed 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -112.22 -45.14 3.31 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 125.582 1.801 . . . . 0.0 111.819 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HG3' HG22 ' A' ' 68' ' ' VAL . 0.3 OUTLIER -124.24 -175.07 3.15 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 100.815 -3.772 . . . . 0.0 100.815 179.36 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -115.45 -176.39 0.37 Allowed Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 104.288 -2.486 . . . . 0.0 104.288 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.83 88.07 0.05 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 N-CA-C 103.094 -3.464 . . . . 0.0 103.094 145.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.584 ' HB3' HG11 ' A' ' 68' ' ' VAL 0.313 0.8 OUTLIER -121.6 -91.43 0.56 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 111.874 -2.421 . . . . 0.0 104.803 -179.616 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.66 ' H ' HG11 ' A' ' 68' ' ' VAL . 38.8 pt 45.66 37.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -88.65 -171.31 46.03 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.712 -1.755 . . . . 0.0 108.712 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -89.46 163.62 15.18 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-O 122.983 1.373 . . . . 0.0 110.595 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -74.44 0.21 Allowed Glycine 0 C--N 1.293 -1.845 0 CA-C-N 112.346 -2.206 . . . . 0.0 108.824 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.7 mt -131.93 114.66 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 101.612 -3.477 . . . . 0.0 101.612 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -125.26 18.0 8.32 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 121.827 2.103 . . . . 0.0 107.712 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.537 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.5 OUTLIER -127.34 -177.93 4.26 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 123.116 1.436 . . . . 0.0 113.146 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.25 101.03 0.33 Allowed Glycine 0 N--CA 1.503 3.103 0 CA-C-N 112.664 -2.062 . . . . 0.0 110.827 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -101.92 102.25 12.78 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 105.166 -2.161 . . . . 0.0 105.166 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 mt -89.24 131.92 35.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 105.639 -1.986 . . . . 0.0 105.639 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.78 -57.91 4.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -129.37 169.74 14.52 Favored 'General case' 0 N--CA 1.508 2.447 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.789 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 23.8 m95 -130.49 171.64 12.78 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 126.017 2.073 . . . . 0.0 106.763 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.485 ' CD2' HG21 ' A' ' 34' ' ' VAL . 21.8 m-85 -124.94 -52.12 1.67 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 124.937 1.398 . . . . 0.0 109.102 -179.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.5 m -99.32 179.1 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.473 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -119.9 168.26 10.67 Favored Pre-proline 0 C--N 1.292 -1.904 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.439 ' HD3' HD12 ' A' ' 58' ' ' ILE . 83.9 Cg_endo -74.19 144.45 33.42 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 121.453 1.435 . . . . 0.0 108.888 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.401 ' O ' ' NZ ' ' A' ' 54' ' ' LYS . . . 97.95 -14.97 62.28 Favored Glycine 0 CA--C 1.476 -2.383 0 CA-C-O 116.654 -2.192 . . . . 0.0 110.166 179.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 4.3 m-20 -82.61 -173.07 4.41 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.493 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS 0.25 6.5 mt-10 -122.42 158.35 29.91 Favored 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 101.593 -3.484 . . . . 0.0 101.593 179.92 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.4 p -121.93 157.57 26.0 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 CA-C-O 122.228 1.013 . . . . 0.0 110.261 -179.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.459 ' HA ' ' HB2' ' A' ' 52' ' ' LYS . 5.3 m-20 -98.58 -167.65 1.53 Allowed 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 111.066 -2.788 . . . . 0.0 113.283 -178.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 19.9 tt0 -122.98 52.5 1.35 Allowed 'General case' 0 C--N 1.298 -1.641 1 N-CA-C 96.789 -5.263 . . . . 0.0 96.789 -179.818 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.452 ' CG ' ' HB3' ' A' ' 30' ' ' ASN . 0.6 OUTLIER -164.1 -59.21 0.04 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.902 -179.42 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.655 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 14.3 t70 -52.17 -168.91 0.0 OUTLIER 'General case' 0 N--CA 1.513 2.692 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.655 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -97.42 -168.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 129.135 2.974 . . . . 0.0 109.837 -179.357 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.644 ' H ' HG12 ' A' ' 34' ' ' VAL . 24.0 tp -141.23 -95.59 0.14 Allowed 'General case' 0 C--N 1.294 -1.836 1 CA-C-N 107.74 -4.3 . . . . 0.0 100.861 178.704 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -122.47 -179.08 4.08 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-N 118.634 0.652 . . . . 0.0 111.364 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -119.75 111.89 18.57 Favored 'General case' 0 N--CA 1.499 1.979 1 N-CA-C 97.524 -4.991 . . . . 0.0 97.524 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 46.3 t -120.13 151.67 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 119.501 1.046 . . . . 0.0 112.315 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 20.7 tt0 -117.81 151.72 36.77 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.728 -1.124 . . . . 0.0 108.302 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -146.24 -179.88 7.04 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 104.597 -2.371 . . . . 0.0 104.597 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -6.1 -69.67 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.031 0 N-CA-C 116.069 1.877 . . . . 0.0 116.069 -179.381 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.513 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 40.2 mttp -136.73 -20.25 1.33 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 123.319 0.647 . . . . 0.0 110.318 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -100.36 165.56 11.4 Favored 'General case' 0 N--CA 1.492 1.673 0 C-N-CA 118.453 -1.299 . . . . 0.0 111.399 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 10.5 t -132.45 130.57 60.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 N-CA-C 102.896 -3.002 . . . . 0.0 102.896 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 46' ' ' GLU . 1.5 t -127.79 173.56 12.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 CA-C-O 124.755 2.217 . . . . 0.0 105.406 179.277 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.561 ' H ' HG12 ' A' ' 45' ' ' VAL . 10.6 pt-20 -121.32 164.15 17.49 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 108.479 -3.964 . . . . 0.0 105.047 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 46' ' ' GLU . 2.7 mp -125.69 130.54 24.03 Favored Pre-proline 0 C--N 1.295 -1.773 0 N-CA-C 101.548 -3.501 . . . . 0.0 101.548 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.44 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -93.02 -171.98 0.33 Allowed 'Trans proline' 0 N--CA 1.497 1.725 1 C-N-CA 126.087 4.525 . . . . 0.0 108.796 173.457 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.33 98.53 12.42 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 72.2 Cg_exo -48.45 -44.67 29.27 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.549 1.5 . . . . 0.0 110.671 157.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -133.15 166.11 30.35 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 122.463 1.125 . . . . 0.0 109.253 179.436 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.568 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -110.89 146.04 37.22 Favored 'General case' 0 C--N 1.297 -1.688 2 O-C-N 130.118 4.636 . . . . 0.0 104.483 179.784 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.86 -151.06 13.22 Favored Glycine 0 N--CA 1.504 3.199 0 N-CA-C 105.206 -3.158 . . . . 0.0 105.206 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.493 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 53.6 tptt -96.27 171.99 8.24 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 119.993 1.897 . . . . 0.0 106.835 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -125.47 84.09 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 1 N-CA-C 94.46 -6.126 . . . . 0.0 94.46 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.41 -82.03 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 113.516 -1.675 . . . . 0.0 109.438 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -137.94 165.66 25.98 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.504 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.439 HD12 ' HD3' ' A' ' 25' ' ' PRO . 60.0 mt -130.09 137.94 55.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 1 N-CA-C 97.61 -4.959 . . . . 0.0 97.61 179.705 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.408 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.2 mp -97.17 -56.16 2.63 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 124.251 0.97 . . . . 0.0 108.592 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.4 t -112.68 126.44 28.31 Favored Pre-proline 0 C--N 1.295 -1.793 1 N-CA-C 96.939 -5.208 . . . . 0.0 96.939 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.404 ' HB2' ' OE2' ' A' ' 62' ' ' GLU . 2.7 Cg_exo -79.81 -84.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 CA-C-N 121.461 1.557 . . . . 0.0 108.19 174.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.404 ' OE2' ' HB2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -132.24 -151.8 0.47 Allowed 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 100.614 -3.846 . . . . 0.0 100.614 -179.202 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.93 -42.97 0.16 Allowed Glycine 0 C--N 1.283 -2.377 0 CA-C-N 111.029 -2.805 . . . . 0.0 115.116 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.8 m -109.37 -176.43 3.02 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.6 t -111.16 156.07 12.42 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.32 171.25 11.11 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 3.8 t -128.12 -159.79 0.97 Allowed 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 102.846 -3.02 . . . . 0.0 102.846 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.66 HG11 ' H ' ' A' ' 9' ' ' ILE 0.256 57.8 t -117.68 155.38 19.46 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.268 1 N-CA-C 94.431 -6.137 . . . . 0.0 94.431 179.025 . . . . . . . . 4 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . 0.515 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 98.27 -27.61 18.59 Favored Glycine 0 N--CA 1.485 1.932 1 N-CA-C 102.398 -4.281 . . . . 0.0 102.398 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLN . . . . . 0.459 ' H ' ' C ' ' A' ' 68' ' ' VAL . 38.9 tt0 -105.01 154.65 19.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 102.042 -3.318 . . . . 0.0 102.042 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -94.9 179.55 5.19 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 102.201 -3.259 . . . . 0.0 102.201 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 35.8 tp -138.26 -69.9 0.44 Allowed 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.6 tt -141.99 162.22 19.98 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 102.937 -2.986 . . . . 0.0 102.937 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.3 t -137.39 160.04 40.22 Favored 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.457 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.2 tt -133.39 149.87 51.82 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 112.669 -2.06 . . . . 0.0 107.862 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.457 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -109.2 150.68 27.55 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 101.97 -3.345 . . . . 0.0 101.97 179.562 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -141.83 94.72 7.18 Favored Pre-proline 0 C--N 1.289 -2.026 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.418 ' HD3' ' OD1' ' A' ' 76' ' ' ASP . 21.1 Cg_endo -45.0 70.51 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 123.803 3.002 . . . . 0.0 116.486 174.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 126.89 9.63 4.2 Favored Glycine 0 N--CA 1.485 1.929 0 CA-C-O 116.495 -2.281 . . . . 0.0 113.157 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.43 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 14.3 m-30 . . . . . 0 N--CA 1.501 2.087 0 N-CA-C 105.524 -2.028 . . . . 0.0 105.524 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -120.53 159.47 25.13 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 100.893 -3.743 . . . . 0.0 100.893 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 -160.97 0.8 Allowed 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.03 -21.95 3.88 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-N 113.531 -1.668 . . . . 0.0 110.297 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.542 ' HB3' HG22 ' A' ' 68' ' ' VAL . 48.2 mmtt -132.5 145.18 50.96 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 105.479 -2.045 . . . . 0.0 105.479 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.43 173.33 6.08 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 104.071 -2.566 . . . . 0.0 104.071 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -42.48 80.93 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.379 2.053 . . . . 0.0 115.013 158.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.408 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.3 t70 -121.7 -72.64 0.68 Allowed 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 103.584 -2.747 . . . . 0.0 103.584 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.494 ' H ' HG11 ' A' ' 68' ' ' VAL . 35.5 pt 37.41 40.58 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 124.302 1.001 . . . . 0.0 112.863 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.68 -14.34 0.07 OUTLIER Glycine 0 C--N 1.305 -1.188 0 CA-C-O 117.194 -1.892 . . . . 0.0 115.614 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -101.21 -177.93 3.59 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 120.439 2.119 . . . . 0.0 114.733 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -4.47 -66.74 0.0 OUTLIER Glycine 0 N--CA 1.494 2.509 0 CA-C-N 110.178 -3.192 . . . . 0.0 116.182 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.0 mm -127.28 76.42 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -81.97 4.34 23.06 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 112.725 -2.034 . . . . 0.0 111.787 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.519 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 4.5 pt-20 -132.4 -176.7 4.17 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.252 0.549 . . . . 0.0 110.864 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.81 116.29 0.84 Allowed Glycine 0 N--CA 1.494 2.517 0 CA-C-O 118.079 -1.401 . . . . 0.0 111.679 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -102.97 109.87 21.57 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 99.966 -4.087 . . . . 0.0 99.966 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.419 ' HB ' ' HA ' ' A' ' 62' ' ' GLU . 2.7 mt -99.17 126.66 52.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.8 t -93.85 -61.76 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 124.666 1.229 . . . . 0.0 109.971 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.58 ' NZ ' ' CE1' ' A' ' 22' ' ' PHE . 25.1 tttm -130.43 151.04 51.35 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.832 -0.747 . . . . 0.0 111.574 -179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.6 m95 -119.63 173.47 6.99 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 179.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.711 ' CG ' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -133.34 -1.25 3.21 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 -179.783 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.598 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 4.2 m -98.62 170.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 115.318 1.599 . . . . 0.0 115.318 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.424 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.1 mptp? -139.2 48.03 1.56 Allowed Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 125.574 1.796 . . . . 0.0 111.829 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 27' ' ' ASP . 67.2 Cg_exo -8.61 174.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 N-CA-C 118.865 2.602 . . . . 0.0 118.865 -70.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.598 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.11 28.41 8.83 Favored Glycine 0 N--CA 1.505 3.275 0 N-CA-C 107.84 -2.104 . . . . 0.0 107.84 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 25' ' ' PRO . 19.2 t70 8.79 -85.24 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 110.985 -2.608 . . . . 0.0 111.474 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.63 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS . 2.6 mt-10 -104.22 115.53 30.56 Favored 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 105.606 -1.998 . . . . 0.0 105.606 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 p -108.65 161.57 7.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-O 124.819 2.247 . . . . 0.0 110.562 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 29.3 p30 -98.15 -164.16 1.11 Allowed 'General case' 0 C--N 1.284 -2.248 0 CA-C-N 109.965 -3.288 . . . . 0.0 108.883 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.675 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.274 0.3 OUTLIER -122.35 69.71 0.97 Allowed 'General case' 0 C--N 1.292 -1.896 1 N-CA-C 99.497 -4.26 . . . . 0.0 99.497 -179.323 . . . . . . . . 5 4 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.493 ' C ' ' OG ' ' A' ' 49' ' ' SER . 3.5 p30 -177.34 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.489 0 C-N-CA 125.705 1.602 . . . . 0.0 111.735 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.404 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 8.9 t70 18.13 -137.74 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.264 0 N-CA-C 119.661 3.208 . . . . 0.0 119.661 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.711 HG11 ' CG ' ' A' ' 22' ' ' PHE . 1.2 t -114.87 167.4 7.53 Favored 'Isoleucine or valine' 0 CA--C 1.445 -3.095 0 CA-C-O 124.3 2.0 . . . . 0.0 114.29 -179.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.615 ' HA ' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -108.57 120.23 41.85 Favored 'General case' 0 N--CA 1.412 -2.363 3 CA-C-N 106.151 -5.022 . . . . 0.0 99.251 179.877 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 27.7 m -73.57 151.8 40.8 Favored 'General case' 0 C--N 1.263 -3.193 2 N-CA-C 97.986 -4.82 . . . . 0.0 97.986 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -104.52 102.89 12.51 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-N 112.371 -2.195 . . . . 0.0 107.806 -179.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.6 146.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 N-CA-C 104.682 -2.34 . . . . 0.0 104.682 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 19.9 tt0 -115.15 152.43 32.61 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.521 HD21 ' HB3' ' A' ' 43' ' ' ALA . 6.7 p-10 -141.13 -178.13 5.44 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.438 ' CG ' HD22 ' A' ' 40' ' ' ASN . 0.3 OUTLIER -7.58 -72.43 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 116.952 2.205 . . . . 0.0 116.952 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -136.82 -11.61 1.76 Allowed 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 114.318 -1.31 . . . . 0.0 109.255 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.521 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -111.58 178.7 4.24 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 120.91 0.386 . . . . 0.0 111.886 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.5 t -130.86 147.55 33.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.465 -2.42 . . . . 0.0 104.465 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -120.37 161.78 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 122.655 1.217 . . . . 0.0 111.242 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.508 ' C ' HD12 ' A' ' 47' ' ' ILE . 12.1 pt-20 -122.24 122.75 39.87 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 110.489 -3.05 . . . . 0.0 108.186 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.615 ' C ' ' HA ' ' A' ' 35' ' ' LEU . 1.9 mp -115.02 83.16 9.31 Favored Pre-proline 0 CA--C 1.572 1.798 0 CA-C-O 115.946 -1.978 . . . . 0.0 108.729 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 34' ' ' VAL . 75.9 Cg_endo -62.93 -167.09 0.06 OUTLIER 'Trans proline' 0 N--CA 1.52 3.036 0 C-N-CA 123.952 3.102 . . . . 0.0 105.716 176.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.493 ' OG ' ' C ' ' A' ' 32' ' ' ASP . 19.2 p -108.73 86.48 3.71 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -32.22 -49.21 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 121.887 1.725 . . . . 0.0 115.308 163.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.675 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -132.49 164.84 33.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-O 121.817 0.817 . . . . 0.0 110.328 179.646 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.647 ' HD2' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.54 173.32 6.4 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 128.827 3.829 . . . . 0.0 110.11 179.724 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.24 -136.87 5.98 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 104.995 -3.242 . . . . 0.0 104.995 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.63 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 41.0 tptt -112.73 173.26 6.46 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 -179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.499 ' HB ' ' C ' ' A' ' 26' ' ' GLY . 50.5 t -127.35 70.05 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.975 1 N-CA-C 97.342 -5.058 . . . . 0.0 97.342 179.665 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 75.4 mt -38.06 -79.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 111.623 -2.535 . . . . 0.0 114.227 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -143.04 167.48 21.97 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.759 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.1 mp -131.11 141.21 46.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 1 N-CA-C 98.004 -4.813 . . . . 0.0 98.004 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -103.7 -58.85 1.81 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 123.772 0.67 . . . . 0.0 110.555 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.414 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 24.1 t -113.62 75.92 2.77 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -49.76 -83.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.851 2.367 . . . . 0.0 115.2 -167.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.419 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -134.86 -179.91 5.9 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 76.81 -38.57 1.51 Allowed Glycine 0 N--CA 1.49 2.266 0 CA-C-N 114.14 -1.391 . . . . 0.0 114.335 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 2.0 m -103.25 177.14 4.92 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 43.9 t -117.74 148.99 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.8 166.67 14.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.519 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 8.8 t -117.87 -155.45 0.6 Allowed 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 104.783 -2.303 . . . . 0.0 104.783 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.542 HG22 ' HB3' ' A' ' 5' ' ' LYS . 84.4 t -120.44 151.51 23.24 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 1 N-CA-C 97.25 -5.093 . . . . 0.0 97.25 179.106 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 104.58 -38.74 3.12 Favored Glycine 0 N--CA 1.494 2.565 1 N-CA-C 99.768 -5.333 . . . . 0.0 99.768 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 68' ' ' VAL . 35.2 tt0 -100.09 164.49 11.96 Favored 'General case' 0 C--N 1.304 -1.373 1 N-CA-C 99.929 -4.101 . . . . 0.0 99.929 179.501 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.98 -175.52 2.8 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 33.1 tp -135.23 -67.19 0.55 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 103.652 -2.721 . . . . 0.0 103.652 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.2 tt -135.03 165.04 32.13 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 102.988 -2.967 . . . . 0.0 102.988 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.8 t -137.25 161.38 36.37 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 103.45 -2.796 . . . . 0.0 103.45 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.83 152.33 48.99 Favored 'General case' 0 C--N 1.287 -2.138 0 CA-C-N 112.456 -2.156 . . . . 0.0 106.385 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.86 131.57 56.92 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 100.48 -3.896 . . . . 0.0 100.48 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.46 60.19 13.54 Favored Pre-proline 0 C--N 1.295 -1.78 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -53.09 68.34 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.618 0 C-N-CA 124.777 3.651 . . . . 0.0 115.855 -176.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 132.7 68.75 0.08 OUTLIER Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.505 1 N-CA-C 100.096 -4.039 . . . . 0.0 100.096 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 101.771 -3.418 . . . . 0.0 101.771 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.421 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.8 OUTLIER -100.67 85.94 3.02 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 105.622 -1.992 . . . . 0.0 105.622 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -77.96 -178.33 5.45 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -99.91 -29.57 12.5 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 117.903 2.557 . . . . 0.0 117.903 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB3' HG22 ' A' ' 68' ' ' VAL . 30.5 mmtp -127.57 173.64 9.7 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 102.411 -3.181 . . . . 0.0 102.411 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 88.6 mt -101.14 176.18 2.01 Favored Pre-proline 0 C--N 1.299 -1.618 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -66.12 82.04 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 N-CA-C 104.098 -3.078 . . . . 0.0 104.098 158.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -123.87 -80.68 0.63 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 124.583 1.177 . . . . 0.0 109.628 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.417 ' CG2' ' HB ' ' A' ' 68' ' ' VAL . 45.9 pt 41.96 26.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.509 2.515 0 O-C-N 123.38 0.425 . . . . 0.0 110.454 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.24 -69.67 0.18 Allowed Glycine 0 N--CA 1.483 1.776 0 C-N-CA 120.683 -0.77 . . . . 0.0 114.064 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -61.27 171.17 1.44 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 124.537 2.113 . . . . 0.0 116.358 -179.435 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -6.84 -53.1 0.0 OUTLIER Glycine 0 N--CA 1.493 2.469 0 CA-C-N 109.956 -3.293 . . . . 0.0 119.953 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.2 mm -118.96 116.99 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.495 ' O ' HG23 ' A' ' 68' ' ' VAL . 9.5 p80 -96.26 -45.62 6.76 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 114.68 -1.145 . . . . 0.0 112.232 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.563 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 33.8 mt-10 -107.83 -173.2 2.22 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 123.043 1.401 . . . . 0.0 113.059 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.05 122.33 1.98 Allowed Glycine 0 C--N 1.286 -2.205 0 CA-C-N 111.722 -2.49 . . . . 0.0 106.881 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 78.7 tt0 -102.23 96.15 6.79 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 103.399 -2.815 . . . . 0.0 103.399 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.8 mt -86.17 120.62 36.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 -56.09 5.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.969 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.052 -179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.46 ' NZ ' ' OE1' ' A' ' 37' ' ' GLU . 0.1 OUTLIER -136.15 150.68 49.17 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 124.206 0.941 . . . . 0.0 112.12 -179.432 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.757 ' CH2' ' SG ' ' A' ' 36' ' ' CYS . 10.1 m95 -114.38 174.62 5.86 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 124.821 1.325 . . . . 0.0 108.112 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CD2' HG21 ' A' ' 34' ' ' VAL . 6.6 m-85 -128.03 -13.76 5.07 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 112.382 -2.19 . . . . 0.0 112.885 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.625 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 14.7 m -98.89 -172.96 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.653 -0.654 . . . . 0.0 111.761 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.734 ' H ' ' C ' ' A' ' 25' ' ' PRO . 1.3 mptp? -123.08 -30.11 0.05 OUTLIER Pre-proline 0 N--CA 1.503 2.208 0 N-CA-C 119.266 3.061 . . . . 0.0 119.266 179.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.734 ' C ' ' H ' ' A' ' 24' ' ' LYS . 11.3 Cg_endo -39.17 162.82 0.23 Allowed 'Cis proline' 0 N--CA 1.498 1.764 1 N-CA-C 122.747 4.095 . . . . 0.0 122.747 13.208 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.625 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -95.5 32.42 6.27 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 107.824 -2.11 . . . . 0.0 107.824 -179.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.482 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.9 t70 11.79 -100.94 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.248 0 O-C-N 129.749 3.852 . . . . 0.0 109.606 179.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.437 ' OE2' ' HE2' ' A' ' 54' ' ' LYS . 3.6 mt-10 -103.33 130.38 50.59 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 30' ' ' ASN . 7.6 p -120.48 177.91 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 122.348 1.07 . . . . 0.0 112.918 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.488 ' OD1' ' C ' ' A' ' 30' ' ' ASN . 45.0 p30 -95.42 -166.47 1.46 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.961 -1.927 . . . . 0.0 107.422 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.561 ' HB2' ' HB3' ' A' ' 52' ' ' LYS 0.25 2.4 tt0 -124.86 50.75 1.71 Allowed 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 100.467 -3.901 . . . . 0.0 100.467 -179.498 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -175.93 28.32 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.043 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 30' ' ' ASN . 0.5 OUTLIER -96.32 -176.25 3.59 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.945 0.878 . . . . 0.0 111.335 -179.308 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.525 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -74.77 -172.53 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.482 -1.648 0 CA-C-O 127.654 3.597 . . . . 0.0 117.582 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.567 ' HB2' ' H ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.13 -160.21 0.74 Allowed 'General case' 0 C--N 1.276 -2.624 2 CA-C-N 102.377 -6.738 . . . . 0.0 106.959 -179.214 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.757 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 9.2 m -120.09 156.51 30.86 Favored 'General case' 0 C--N 1.273 -2.748 2 N-CA-C 94.215 -6.217 . . . . 0.0 94.215 179.212 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.46 ' OE1' ' NZ ' ' A' ' 20' ' ' LYS . 5.3 tt0 -107.94 109.83 21.42 Favored 'General case' 0 C--N 1.285 -2.236 1 N-CA-C 98.676 -4.564 . . . . 0.0 98.676 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.473 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 56.1 t -121.43 154.9 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 tt0 -114.82 147.2 40.15 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 16.4 p-10 -136.43 -176.0 4.19 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -6.73 -67.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.176 0 O-C-N 126.175 2.172 . . . . 0.0 115.838 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 40.0 mtmt -138.19 -22.18 1.05 Allowed 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 123.011 0.525 . . . . 0.0 109.957 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.75 -168.57 1.54 Allowed 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 29.8 t -123.69 133.7 68.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 N-CA-C 103.309 -2.849 . . . . 0.0 103.309 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.94 153.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 122.515 1.15 . . . . 0.0 109.012 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.505 ' C ' HD12 ' A' ' 47' ' ' ILE . 10.0 pt-20 -119.58 127.79 53.3 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-N 110.86 -2.882 . . . . 0.0 108.526 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.57 HD12 ' N ' ' A' ' 47' ' ' ILE . 1.7 mp -117.2 79.54 11.19 Favored Pre-proline 0 C--N 1.299 -1.588 0 N-CA-C 101.573 -3.491 . . . . 0.0 101.573 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.441 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 86.3 Cg_endo -62.29 -166.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.513 2.639 0 C-N-CA 123.569 2.846 . . . . 0.0 107.854 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 45.9 p -98.78 106.66 38.67 Favored Pre-proline 0 C--N 1.286 -2.153 0 CA-C-N 113.483 -1.69 . . . . 0.0 111.879 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 89.2 Cg_exo -55.32 -44.46 48.66 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.012 1.808 . . . . 0.0 114.979 166.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.509 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -132.13 171.58 17.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 123.837 0.711 . . . . 0.0 109.858 -179.959 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.561 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -105.01 167.85 9.44 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 127.347 2.905 . . . . 0.0 107.614 179.489 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 76' ' ' ASP . . . 144.1 -121.77 1.69 Allowed Glycine 0 C--N 1.285 -2.282 0 N-CA-C 107.891 -2.084 . . . . 0.0 107.891 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.669 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -117.41 166.41 12.35 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.452 ' CG1' ' H ' ' A' ' 26' ' ' GLY . 23.9 t -129.91 59.29 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.751 1 N-CA-C 99.459 -4.274 . . . . 0.0 99.459 179.527 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 21.9 mt -29.1 -76.88 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 111.143 -2.753 . . . . 0.0 115.02 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -143.79 167.16 22.95 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.284 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 58' ' ' ILE . 4.1 mp -135.55 139.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 1 N-CA-C 98.527 -4.619 . . . . 0.0 98.527 179.601 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.7 mp -101.56 -56.91 2.18 Favored 'General case' 0 C--N 1.296 -1.756 0 O-C-N 124.003 0.814 . . . . 0.0 110.604 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 t -117.93 67.96 6.34 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -41.93 -78.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 122.709 2.273 . . . . 0.0 117.989 -167.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -142.97 174.58 10.55 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.66 -52.97 0.91 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.868 -1.158 . . . . 0.0 111.462 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.5 m -102.42 -177.5 3.42 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.2 t -109.95 145.49 16.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 103.733 -2.692 . . . . 0.0 103.733 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -120.55 147.83 44.66 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.287 14.7 t -99.84 -151.7 0.4 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.478 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.529 ' C ' ' H ' ' A' ' 70' ' ' GLN . 61.8 t -118.62 160.75 18.18 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 178.877 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 97.61 -47.28 1.57 Allowed Glycine 0 N--CA 1.499 2.852 1 N-CA-C 98.408 -5.877 . . . . 0.0 98.408 -179.386 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.529 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -89.58 153.61 20.63 Favored 'General case' 0 C--N 1.304 -1.393 1 N-CA-C 99.953 -4.091 . . . . 0.0 99.953 179.325 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.56 -175.94 3.0 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 103.104 -2.924 . . . . 0.0 103.104 179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.7 tp -139.9 -70.44 0.4 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.404 HD11 ' CG1' ' A' ' 55' ' ' VAL . 12.9 tt -139.05 166.33 22.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 104.203 -2.517 . . . . 0.0 104.203 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.2 t -138.92 160.08 40.59 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 102.439 -3.171 . . . . 0.0 102.439 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.421 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -129.98 148.53 51.85 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.022 -179.721 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.432 ' OD2' ' NZ ' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -113.09 150.26 32.35 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 102.227 -3.249 . . . . 0.0 102.227 179.135 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.601 ' H ' ' HA ' ' A' ' 78' ' ' PRO . . . -114.36 -40.94 0.08 OUTLIER Pre-proline 0 C--N 1.295 -1.774 0 O-C-N 124.883 1.365 . . . . 0.0 107.696 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.601 ' HA ' ' H ' ' A' ' 77' ' ' ALA . 10.2 Cg_endo -94.72 176.84 11.42 Favored 'Cis proline' 0 C--N 1.312 -1.375 0 CA-C-N 121.628 1.617 . . . . 0.0 111.328 -22.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.81 -36.72 4.19 Favored Glycine 0 N--CA 1.498 2.8 1 N-CA-C 99.058 -5.617 . . . . 0.0 99.058 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.494 ' H ' ' C ' ' A' ' 78' ' ' PRO . 52.1 t80 . . . . . 0 CA--C 1.573 1.831 1 N-CA-C 98.597 -4.594 . . . . 0.0 98.597 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.474 1 N-CA-C 98.138 -4.764 . . . . 0.0 98.138 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -137.13 90.76 2.56 Favored 'General case' 0 C--N 1.288 -2.078 1 N-CA-C 88.977 -8.157 . . . . 0.0 88.977 178.473 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 3' ' ' GLU . 1.3 pm0 -87.57 -168.1 2.11 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 122.638 1.208 . . . . 0.0 113.843 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.484 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 22.5 t80 -88.22 -46.99 8.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 117.853 2.538 . . . . 0.0 117.853 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.484 ' HE2' ' CZ ' ' A' ' 4' ' ' PHE . 0.3 OUTLIER -131.57 174.68 9.86 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 179.63 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.13 172.96 3.69 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 104.187 -2.523 . . . . 0.0 104.187 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -56.31 89.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 121.43 1.42 . . . . 0.0 111.374 164.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.503 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.5 t0 -122.45 -82.05 0.65 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 102.968 -2.975 . . . . 0.0 102.968 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.5 pt 36.8 37.0 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 CA-C-O 121.601 0.715 . . . . 0.0 109.821 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.7 -154.58 11.94 Favored Glycine 0 N--CA 1.48 1.575 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.32 138.53 37.75 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.44 -74.1 0.33 Allowed Glycine 0 N--CA 1.486 1.968 0 N-CA-C 106.907 -2.477 . . . . 0.0 106.907 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.2 mm -133.46 141.4 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-N 118.363 1.081 . . . . 0.0 108.297 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -131.9 -51.88 0.98 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.635 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -116.59 172.11 7.43 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.463 -1.244 . . . . 0.0 111.995 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.82 155.51 26.17 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 106.542 -2.623 . . . . 0.0 106.542 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.412 ' O ' HG13 ' A' ' 38' ' ' VAL . 0.7 OUTLIER -122.54 136.74 54.96 Favored 'General case' 0 C--N 1.303 -1.445 1 N-CA-C 98.968 -4.456 . . . . 0.0 98.968 179.87 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.437 ' HB ' ' HA ' ' A' ' 62' ' ' GLU 0.285 2.6 mt -103.95 113.67 41.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.278 0 N-CA-C 102.734 -3.062 . . . . 0.0 102.734 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.9 t -76.5 -55.07 12.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HE3' ' CE2' ' A' ' 22' ' ' PHE . 22.4 tttp -141.41 158.32 44.02 Favored 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 118.981 -1.088 . . . . 0.0 113.579 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.509 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 36.9 m95 -113.86 170.89 7.93 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 178.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.494 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.5 m-85 -128.28 -46.43 1.35 Allowed 'General case' 0 C--N 1.3 -1.584 0 CA-C-N 114.126 -1.397 . . . . 0.0 109.735 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 m -97.39 175.68 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -128.04 165.98 26.91 Favored Pre-proline 0 C--N 1.295 -1.797 0 N-CA-C 105.593 -2.003 . . . . 0.0 105.593 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -76.52 122.71 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 121.915 1.744 . . . . 0.0 110.776 -172.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.13 -7.27 19.02 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.226 -2.349 . . . . 0.0 107.226 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.405 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -79.52 173.23 12.79 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 124.177 1.941 . . . . 0.0 111.041 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.667 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.2 OUTLIER -118.55 146.26 44.72 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 100.584 -3.858 . . . . 0.0 100.584 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.542 HG22 ' HB2' ' A' ' 31' ' ' GLU 0.25 0.9 OUTLIER -122.19 171.2 11.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 -179.776 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.461 ' O ' ' HE2' ' A' ' 52' ' ' LYS . 53.7 t30 -119.42 -29.51 5.11 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 125.03 2.348 . . . . 0.0 115.135 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.542 ' HB2' HG22 ' A' ' 29' ' ' VAL 0.366 11.9 tp10 47.26 78.74 0.07 Allowed 'General case' 0 C--N 1.267 -2.995 5 N-CA-C 131.644 7.646 . . . . 0.0 131.644 -179.213 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -155.43 31.5 0.38 Allowed 'General case' 0 C--N 1.28 -2.434 4 CA-C-N 94.066 -10.515 . . . . 0.0 93.984 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.482 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 10.0 m-20 -117.22 -168.7 1.52 Allowed 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 126.927 2.091 . . . . 0.0 107.82 -178.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.494 ' HB ' ' CG ' ' A' ' 22' ' ' PHE . 3.6 t -134.47 161.85 39.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 N-CA-C 100.597 -3.853 . . . . 0.0 100.597 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.551 ' HB2' HG21 ' A' ' 47' ' ' ILE . 3.4 mm? -125.54 -84.85 0.63 Allowed 'General case' 0 C--N 1.272 -2.77 0 CA-C-N 109.874 -3.33 . . . . 0.0 102.389 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.403 ' SG ' ' OE1' ' A' ' 46' ' ' GLU . 11.2 p -123.97 172.77 8.69 Favored 'General case' 0 N--CA 1.495 1.777 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.582 -178.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.367 18.5 tt0 -134.34 138.25 44.77 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 -179.287 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.497 ' HB ' ' CG ' ' A' ' 46' ' ' GLU . 25.5 t -139.77 145.57 26.48 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.427 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 35.6 tt0 -107.29 107.65 18.68 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 6.4 p-10 -136.77 174.57 10.47 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 2.8 p-10 -3.78 -59.49 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 118.234 2.679 . . . . 0.0 118.234 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 28.3 mttm -131.15 -4.05 3.91 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 123.687 0.617 . . . . 0.0 110.029 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -106.09 164.43 11.99 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.75 -43.11 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 111.392 -2.64 . . . . 0.0 109.178 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 18.3 t -111.83 167.35 5.48 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 -179.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.579 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.0 mt-10 -120.5 -73.32 0.65 Allowed 'General case' 0 C--N 1.294 -1.846 0 O-C-N 128.016 3.323 . . . . 0.0 116.556 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.579 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -84.37 142.54 40.65 Favored Pre-proline 0 C--N 1.274 -2.68 0 CA-C-N 108.487 -3.961 . . . . 0.0 110.225 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.536 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -96.64 177.59 0.59 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 N-CA-C 105.248 -2.635 . . . . 0.0 105.248 82.646 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.491 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 1.6 m -124.36 -177.61 0.57 Allowed Pre-proline 0 C--N 1.278 -2.512 0 CA-C-N 114.462 -1.244 . . . . 0.0 109.243 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -87.51 -31.43 0.22 Allowed 'Trans proline' 0 C--N 1.314 -1.285 0 N-CA-C 117.236 1.975 . . . . 0.0 117.236 164.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.525 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.6 p -138.34 167.97 20.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 120.246 3.425 . . . . 0.0 120.246 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.525 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 2.2 ptmm? -97.06 177.26 5.66 Favored 'General case' 0 C--N 1.292 -1.9 1 CA-C-N 106.212 -4.995 . . . . 0.0 110.266 -179.395 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 149.02 -141.71 9.21 Favored Glycine 0 C--N 1.286 -2.237 0 N-CA-C 103.331 -3.908 . . . . 0.0 103.331 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.667 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 12.3 tppt? -110.97 173.23 6.43 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 103.915 -2.624 . . . . 0.0 103.915 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 39.3 t -125.72 68.84 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.166 1 N-CA-C 97.963 -4.829 . . . . 0.0 97.963 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 38.3 mt -30.48 -76.02 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 126.135 2.147 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -142.04 161.58 37.64 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 77.8 mt -132.99 114.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 1 N-CA-C 93.882 -6.34 . . . . 0.0 93.882 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.5 mt -90.9 -40.4 11.75 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 114.759 1.392 . . . . 0.0 114.759 -179.456 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.71 79.97 23.61 Favored Pre-proline 0 N--CA 1.496 1.864 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.817 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_exo -34.8 -107.66 0.0 OUTLIER 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 124.426 3.417 . . . . 0.0 120.532 -175.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.437 ' HA ' ' HB ' ' A' ' 18' ' ' ILE . 3.6 pt-20 -132.73 173.8 10.98 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 56.92 30.94 60.73 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.7 m -138.24 160.28 39.87 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 102.014 -3.328 . . . . 0.0 102.014 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -97.56 135.6 31.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -127.06 144.98 50.89 Favored 'General case' 0 C--N 1.294 -1.834 1 N-CA-C 99.764 -4.162 . . . . 0.0 99.764 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.635 ' HA ' ' HA ' ' A' ' 15' ' ' GLU 0.259 66.8 p -116.87 -144.78 0.38 Allowed 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 124.296 1.998 . . . . 0.0 107.413 -179.855 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.503 HG11 ' HB3' ' A' ' 8' ' ' ASP . 74.8 t -121.65 155.07 25.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 1 N-CA-C 93.247 -6.575 . . . . 0.0 93.247 179.056 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 93.27 -47.04 2.39 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 103.148 -3.981 . . . . 0.0 103.148 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.424 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.2 tt0 -94.0 155.0 17.36 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 102.426 -3.176 . . . . 0.0 102.426 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -102.55 -174.61 2.6 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 102.769 -3.048 . . . . 0.0 102.769 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.6 tp -145.99 -66.84 0.29 Allowed 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 113.349 -1.751 . . . . 0.0 106.874 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 11.8 tt -133.21 166.58 28.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 110.852 -2.886 . . . . 0.0 105.609 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 t -140.19 159.8 41.38 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 102.152 -3.277 . . . . 0.0 102.152 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.403 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.0 OUTLIER -136.62 154.92 50.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.403 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -123.36 145.89 48.39 Favored 'General case' 0 C--N 1.295 -1.798 1 N-CA-C 99.536 -4.246 . . . . 0.0 99.536 179.282 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.401 ' HB3' ' CA ' ' A' ' 78' ' ' PRO . . . -140.79 -49.95 0.02 OUTLIER Pre-proline 0 C--N 1.295 -1.765 0 O-C-N 123.746 0.653 . . . . 0.0 111.581 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.401 ' CA ' ' HB3' ' A' ' 77' ' ' ALA . 51.2 Cg_endo -84.4 -45.85 0.3 Allowed 'Cis proline' 0 C--N 1.315 -1.224 0 CA-C-N 119.722 0.936 . . . . 0.0 109.98 -22.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -141.89 124.84 2.55 Favored Glycine 0 C--N 1.293 -1.818 1 N-CA-C 98.749 -5.74 . . . . 0.0 98.749 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 36.6 p90 . . . . . 0 C--N 1.283 -2.317 0 O-C-N 127.109 2.299 . . . . 0.0 106.007 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.51 2.531 0 N-CA-C 102.668 -3.086 . . . . 0.0 102.668 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.1 t80 16.37 102.96 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 127.051 2.72 . . . . 0.0 112.813 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.722 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 2.6 pm0 -82.53 -171.0 3.24 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-N 110.482 -3.054 . . . . 0.0 112.917 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.469 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.2 t80 -93.86 -49.94 5.58 Favored 'General case' 0 N--CA 1.494 1.725 0 CA-C-N 113.684 -1.598 . . . . 0.0 114.063 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HD3' ' CE2' ' A' ' 4' ' ' PHE . 11.8 mmmm -126.1 165.93 17.95 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 101.633 -3.469 . . . . 0.0 101.633 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 61.0 mt -105.48 -178.03 0.57 Allowed Pre-proline 0 C--N 1.3 -1.564 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.45 96.43 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.356 0 C-N-CA 121.685 1.59 . . . . 0.0 110.855 170.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.779 ' HB3' HG11 ' A' ' 68' ' ' VAL . 24.2 t0 -122.34 -99.3 0.43 Allowed 'General case' 0 C--N 1.302 -1.478 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 179.795 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.501 HG23 ' CG1' ' A' ' 68' ' ' VAL . 32.4 pt 34.74 42.05 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.556 0 O-C-N 124.572 1.17 . . . . 0.0 108.239 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.79 -137.27 4.77 Favored Glycine 0 N--CA 1.482 1.725 0 CA-C-N 114.45 -1.25 . . . . 0.0 113.895 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.63 146.64 28.64 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 104.695 -2.335 . . . . 0.0 104.695 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.31 -76.24 0.22 Allowed Glycine 0 N--CA 1.486 1.969 0 N-CA-C 103.249 -3.94 . . . . 0.0 103.249 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 14' ' ' HIS . 42.1 mm -131.21 173.5 14.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 N-CA-C 103.427 -2.805 . . . . 0.0 103.427 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.429 ' N ' HG22 ' A' ' 13' ' ' ILE . 57.3 t-80 -155.0 -33.09 0.1 Allowed 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.159 1.457 . . . . 0.0 107.701 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.07 -165.54 1.08 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 113.975 -1.466 . . . . 0.0 113.355 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.89 128.18 2.81 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 103.735 -3.746 . . . . 0.0 103.735 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.449 ' HG3' HG22 ' A' ' 65' ' ' VAL . 30.4 tt0 -104.64 91.49 3.88 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 101.146 -3.65 . . . . 0.0 101.146 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.405 HG23 ' HB2' ' A' ' 36' ' ' CYS . 2.5 mt -81.86 110.62 17.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 103.969 -2.604 . . . . 0.0 103.969 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -88.81 -45.28 15.58 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 113.563 -1.653 . . . . 0.0 106.62 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HZ2' ' HB3' ' A' ' 20' ' ' LYS . 2.4 ttmp? -130.9 161.46 31.82 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.117 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.489 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 11.3 m95 -124.28 168.74 12.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 101.457 -3.534 . . . . 0.0 101.457 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 22' ' ' PHE . 6.9 m-85 -123.0 -47.41 2.04 Favored 'General case' 0 C--N 1.295 -1.782 0 O-C-N 124.542 1.151 . . . . 0.0 108.245 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -99.58 178.13 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.331 1.062 . . . . 0.0 110.775 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 ptmt -115.17 172.63 3.48 Favored Pre-proline 0 C--N 1.295 -1.79 0 CA-C-N 112.104 -2.316 . . . . 0.0 105.025 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HB3' HG13 ' A' ' 58' ' ' ILE . 34.3 Cg_endo -93.78 143.45 1.86 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.228 1.952 . . . . 0.0 110.384 166.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.64 -10.33 38.37 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.231 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -108.53 -175.9 2.9 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.773 ' CD ' ' NZ ' ' A' ' 54' ' ' LYS . 0.6 OUTLIER -118.82 163.99 16.07 Favored 'General case' 0 C--N 1.288 -2.066 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.226 -179.724 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.591 HG22 ' HB2' ' A' ' 31' ' ' GLU . 3.1 p -133.01 174.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.525 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 19.8 t-20 -116.21 -35.85 4.23 Favored 'General case' 0 N--CA 1.523 3.203 0 CA-C-O 126.903 3.24 . . . . 0.0 115.649 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.622 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.395 33.0 tt0 20.18 123.08 0.0 OUTLIER 'General case' 0 C--N 1.273 -2.759 5 N-CA-C 151.831 15.123 . . . . 0.0 151.831 -179.537 . . . . . . . . 4 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' CG ' ' N ' ' A' ' 33' ' ' ASP . 11.2 p-10 -123.01 -48.23 2.01 Favored 'General case' 0 C--N 1.287 -2.117 4 CA-C-N 93.237 -10.892 . . . . 0.0 97.625 178.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' CG ' ' A' ' 32' ' ' ASP . 3.7 t0 -22.55 176.6 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.617 0 C-N-CA 131.427 3.891 . . . . 0.0 116.186 179.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -107.39 167.52 3.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 127.366 3.46 . . . . 0.0 114.292 -179.597 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.55 ' H ' HG12 ' A' ' 34' ' ' VAL . 10.1 mp -130.9 -87.34 0.49 Allowed 'General case' 0 C--N 1.283 -2.289 1 CA-C-N 106.562 -4.836 . . . . 0.0 103.688 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.405 ' HB2' HG23 ' A' ' 18' ' ' ILE . 0.5 OUTLIER -127.89 169.63 13.73 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.794 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.679 ' HG3' HG22 ' A' ' 45' ' ' VAL . 1.2 tm-20 -135.09 156.88 48.26 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 126.341 2.276 . . . . 0.0 104.946 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.503 HG23 ' HG3' ' A' ' 46' ' ' GLU . 54.0 t -139.5 179.58 2.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 125.481 1.738 . . . . 0.0 111.439 -179.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.483 ' N ' HG12 ' A' ' 38' ' ' VAL . 25.0 tt0 -137.8 102.72 4.8 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 113.313 -1.767 . . . . 0.0 108.234 178.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.433 HD22 ' CG ' ' A' ' 41' ' ' ASP . 9.9 p-10 -147.41 175.8 10.53 Favored 'General case' 0 N--CA 1.502 2.153 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.916 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.433 ' CG ' HD22 ' A' ' 40' ' ' ASN . 1.0 OUTLIER -15.7 -68.66 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 119.139 3.014 . . . . 0.0 119.139 -179.601 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.14 -8.85 6.49 Favored 'General case' 0 C--N 1.289 -2.023 0 CA-C-N 114.794 -1.093 . . . . 0.0 110.958 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.413 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -111.39 156.03 22.23 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.874 -1.13 . . . . 0.0 109.734 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.47 -88.98 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-N 114.135 -1.393 . . . . 0.0 108.742 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.679 HG22 ' HG3' ' A' ' 37' ' ' GLU . 61.5 t -68.27 162.86 3.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 N-CA-C 104.566 -2.383 . . . . 0.0 104.566 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.511 ' HB3' HD12 ' A' ' 47' ' ' ILE . 2.4 mt-10 -108.3 -60.65 1.7 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 126.806 2.566 . . . . 0.0 115.479 -179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 34' ' ' VAL . 1.6 mp -96.1 143.21 25.73 Favored Pre-proline 0 C--N 1.273 -2.745 1 CA-C-N 108.033 -4.167 . . . . 0.0 108.904 -179.507 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.567 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.03 177.11 0.46 Allowed 'Trans proline' 0 C--N 1.305 -1.731 1 C-N-CA 126.281 4.654 . . . . 0.0 106.509 90.036 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.622 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 16.1 m -128.45 171.15 9.04 Favored Pre-proline 0 C--N 1.28 -2.434 0 O-C-N 125.144 1.528 . . . . 0.0 114.285 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -105.35 -17.13 0.05 OUTLIER 'Trans proline' 0 CA--C 1.555 1.549 0 C-N-CA 124.575 3.517 . . . . 0.0 119.653 173.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.577 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 1.2 p -135.24 170.35 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.705 0 CA-C-O 122.896 1.331 . . . . 0.0 111.789 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.702 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -125.07 178.3 5.61 Favored 'General case' 0 C--N 1.286 -2.195 1 CA-C-N 108.239 -4.073 . . . . 0.0 111.266 -179.555 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.61 -134.93 4.35 Favored Glycine 0 C--N 1.287 -2.177 1 N-CA-C 100.3 -5.12 . . . . 0.0 100.3 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.773 ' NZ ' ' CD ' ' A' ' 28' ' ' GLU . 15.1 tppt? -112.93 176.55 4.97 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 104.497 -2.409 . . . . 0.0 104.497 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 24.0 t -123.75 100.84 8.25 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 1 N-CA-C 93.148 -6.612 . . . . 0.0 93.148 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.5 mt -74.61 -83.08 0.06 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 117.582 -1.647 . . . . 0.0 106.946 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.2 160.99 30.37 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.001 . . . . 0.0 112.668 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.405 HG13 ' HB3' ' A' ' 25' ' ' PRO . 96.7 mt -132.75 118.36 33.79 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 1 N-CA-C 92.761 -6.755 . . . . 0.0 92.761 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.446 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -92.69 -41.18 10.3 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 123.727 0.642 . . . . 0.0 111.787 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.42 ' HB ' ' CD2' ' A' ' 72' ' ' LEU . 3.4 t -111.32 124.59 32.33 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 101.632 -3.47 . . . . 0.0 101.632 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_exo -57.07 -124.16 0.0 OUTLIER 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 123.921 3.081 . . . . 0.0 116.453 176.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.494 ' C ' ' H ' ' A' ' 64' ' ' THR . 0.0 OUTLIER -127.49 -170.34 2.21 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 100.885 -3.746 . . . . 0.0 100.885 179.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.07 -19.95 0.12 Allowed Glycine 0 N--CA 1.491 2.347 0 CA-C-N 113.277 -1.783 . . . . 0.0 113.711 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.494 ' H ' ' C ' ' A' ' 62' ' ' GLU . 2.2 m -101.97 170.03 8.39 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 104.394 -2.447 . . . . 0.0 104.394 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.449 HG22 ' HG3' ' A' ' 17' ' ' GLU . 45.0 t -105.77 148.8 9.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 103.816 -2.661 . . . . 0.0 103.816 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -119.5 156.66 29.82 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.6 p -101.06 -160.86 0.82 Allowed 'General case' 0 C--N 1.283 -2.289 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.779 HG11 ' HB3' ' A' ' 8' ' ' ASP . 52.2 t -126.69 153.17 35.23 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.39 1 N-CA-C 94.353 -6.166 . . . . 0.0 94.353 178.386 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 94.44 -36.16 3.89 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 103.588 -3.805 . . . . 0.0 103.588 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.472 ' H ' ' C ' ' A' ' 68' ' ' VAL . 31.6 tt0 -92.93 163.75 13.57 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 101.817 -3.401 . . . . 0.0 101.817 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.3 m -108.84 -179.02 3.74 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 101.724 -3.435 . . . . 0.0 101.724 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.42 ' CD2' ' HB ' ' A' ' 60' ' ' VAL . 0.4 OUTLIER -149.06 -65.64 0.23 Allowed 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 -179.371 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 7.8 tt -130.19 163.56 35.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.2 t -140.42 158.32 44.18 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 103.142 -2.91 . . . . 0.0 103.142 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -132.39 149.54 52.33 Favored 'General case' 0 C--N 1.287 -2.11 0 CA-C-N 111.83 -2.441 . . . . 0.0 104.855 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.26 123.17 48.12 Favored 'General case' 0 C--N 1.292 -1.913 1 N-CA-C 96.511 -5.366 . . . . 0.0 96.511 179.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -139.77 58.72 12.09 Favored Pre-proline 0 N--CA 1.491 1.607 1 N-CA-C 99.786 -4.153 . . . . 0.0 99.786 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -78.1 67.77 8.03 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 121.778 1.652 . . . . 0.0 112.066 -153.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.3 59.06 0.05 OUTLIER Glycine 0 N--CA 1.501 2.972 0 C-N-CA 119.72 -1.228 . . . . 0.0 112.806 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 116.338 -1.791 . . . . 0.0 107.554 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 2.097 0 N-CA-C 103.73 -2.692 . . . . 0.0 103.73 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.47 ' HB3' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -121.78 128.27 51.54 Favored 'General case' 0 C--N 1.29 -2.015 1 N-CA-C 99.962 -4.088 . . . . 0.0 99.962 -179.635 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -102.23 -173.29 2.3 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.414 ' CE2' ' HD3' ' A' ' 5' ' ' LYS . 12.7 t80 -101.14 -43.16 6.09 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.609 0.719 . . . . 0.0 112.509 -179.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HB2' HG13 ' A' ' 68' ' ' VAL . 0.1 OUTLIER -128.49 160.27 32.84 Favored 'General case' 0 C--N 1.297 -1.685 1 N-CA-C 99.338 -4.319 . . . . 0.0 99.338 179.79 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.43 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 25.5 mt -103.31 -169.37 0.18 Allowed Pre-proline 0 C--N 1.296 -1.745 0 N-CA-C 105.319 -2.104 . . . . 0.0 105.319 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB3' ' A' ' 6' ' ' LEU . 77.0 Cg_exo -55.48 85.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.12 1.88 . . . . 0.0 107.577 148.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.58 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.2 t0 -123.15 -88.65 0.61 Allowed 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.565 ' H ' HG11 ' A' ' 68' ' ' VAL . 1.3 pt 37.77 43.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.321 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.33 -176.1 50.51 Favored Glycine 0 N--CA 1.493 2.453 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.551 -179.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -80.72 144.73 31.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.86 -77.89 0.26 Allowed Glycine 0 C--N 1.294 -1.786 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.2 mt -137.93 103.79 2.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 102.736 -3.061 . . . . 0.0 102.736 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.67 20.71 18.61 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-N 122.178 2.263 . . . . 0.0 108.35 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 1.4 pm0 -121.95 -174.26 2.84 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 123.725 1.726 . . . . 0.0 114.09 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.4 101.65 0.27 Allowed Glycine 0 N--CA 1.492 2.43 0 CA-C-N 112.483 -2.144 . . . . 0.0 109.7 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.614 ' CD ' HE21 ' A' ' 39' ' ' GLN . 54.3 tt0 -92.94 89.2 6.45 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 66' ' ' ALA . 3.9 mt -84.18 103.89 11.9 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 100.851 -3.759 . . . . 0.0 100.851 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.7 t -84.33 -46.17 17.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 113.904 -1.498 . . . . 0.0 107.331 -179.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.455 ' HG2' ' N ' ' A' ' 21' ' ' TRP . 25.8 tttt -142.24 159.77 41.57 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 114.983 -1.008 . . . . 0.0 111.1 -179.543 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.53 ' CE3' HG22 ' A' ' 23' ' ' VAL . 17.7 m95 -122.16 162.52 21.18 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 179.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -120.68 -20.74 6.94 Favored 'General case' 0 C--N 1.292 -1.895 0 O-C-N 124.984 1.428 . . . . 0.0 108.76 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.53 HG22 ' CE3' ' A' ' 21' ' ' TRP . 5.1 m -99.89 179.31 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-O 123.753 1.74 . . . . 0.0 112.147 -179.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.647 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -130.42 140.13 37.73 Favored Pre-proline 0 C--N 1.288 -2.095 1 N-CA-C 97.743 -4.91 . . . . 0.0 97.743 -179.71 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -54.69 162.56 4.73 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.42 1.413 . . . . 0.0 114.945 -175.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.52 26.55 0.08 OUTLIER Glycine 0 C--N 1.294 -1.764 0 CA-C-N 110.785 -2.916 . . . . 0.0 117.662 179.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.508 ' C ' ' HZ2' ' A' ' 54' ' ' LYS . 23.0 t0 -87.0 -168.48 2.26 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 113.498 -3.281 . . . . 0.0 107.115 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.479 ' H ' ' CG ' ' A' ' 27' ' ' ASP . 5.5 mm-40 -102.92 127.55 50.08 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 100.391 -3.929 . . . . 0.0 100.391 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.465 HG23 ' HB3' ' A' ' 33' ' ' ASP . 2.9 p -109.55 160.74 8.33 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 52' ' ' LYS . 3.0 t30 -96.72 -164.17 1.12 Allowed 'General case' 0 C--N 1.292 -1.901 0 CA-C-N 113.472 -1.695 . . . . 0.0 109.137 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.619 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.284 9.9 tt0 -117.87 56.21 0.86 Allowed 'General case' 0 C--N 1.289 -2.048 1 N-CA-C 98.332 -4.692 . . . . 0.0 98.332 -178.88 . . . . . . . . 4 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -178.04 1.39 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.84 0 CA-C-N 112.049 -2.341 . . . . 0.0 116.442 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.485 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 42.3 t0 -90.31 -172.14 3.35 Favored 'General case' 0 N--CA 1.508 2.463 0 CA-C-N 118.789 0.722 . . . . 0.0 111.371 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.545 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -112.51 176.34 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 126.375 2.988 . . . . 0.0 102.956 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.545 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.0 OUTLIER -140.08 -83.29 0.25 Allowed 'General case' 0 C--N 1.274 -2.697 1 CA-C-N 107.485 -4.416 . . . . 0.0 100.504 179.317 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.431 ' SG ' ' CH2' ' A' ' 21' ' ' TRP . 0.0 OUTLIER -126.08 172.34 10.07 Favored 'General case' 0 N--CA 1.51 2.568 0 CA-C-N 122.179 2.263 . . . . 0.0 115.153 -179.287 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.452 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 2.1 tt0 -119.77 101.33 7.82 Favored 'General case' 0 N--CA 1.493 1.707 1 N-CA-C 92.966 -6.679 . . . . 0.0 92.966 179.443 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 t -108.18 150.43 10.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.614 HE21 ' CD ' ' A' ' 17' ' ' GLU . 26.7 tt0 -121.23 164.53 16.81 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 104.116 -2.55 . . . . 0.0 104.116 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.4 HD21 ' HB3' ' A' ' 43' ' ' ALA . 5.2 p-10 -152.98 -178.75 7.11 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 102.623 -3.102 . . . . 0.0 102.623 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -5.79 -57.62 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 118.231 2.678 . . . . 0.0 118.231 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -146.36 -34.3 0.29 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.4 ' HB3' HD21 ' A' ' 40' ' ' ASN . . . -75.31 149.88 38.63 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.86 -1.064 . . . . 0.0 113.2 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 21.9 t -122.6 110.99 28.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 1 N-CA-C 95.696 -5.668 . . . . 0.0 95.696 179.582 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t -114.71 162.61 12.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 CA-C-O 124.709 2.195 . . . . 0.0 108.455 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.431 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -118.35 153.12 34.55 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 109.044 -3.707 . . . . 0.0 106.766 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.431 HD12 ' C ' ' A' ' 46' ' ' GLU . 1.7 mp -121.43 126.25 26.57 Favored Pre-proline 0 C--N 1.302 -1.47 1 N-CA-C 94.132 -6.247 . . . . 0.0 94.132 179.208 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.401 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -90.77 -176.69 1.02 Allowed 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.537 2.158 . . . . 0.0 107.934 167.106 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -91.85 112.8 56.51 Favored Pre-proline 0 C--N 1.288 -2.079 0 CA-C-N 113.207 -1.815 . . . . 0.0 108.228 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 25.3 Cg_exo -69.7 -34.59 14.49 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 121.497 1.465 . . . . 0.0 108.363 168.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.619 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.2 OUTLIER -136.52 168.79 21.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 125.458 1.723 . . . . 0.0 111.94 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.82 162.18 13.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 127.32 2.888 . . . . 0.0 105.307 179.19 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 163.12 -141.84 7.44 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.508 ' HZ2' ' C ' ' A' ' 27' ' ' ASP . 0.5 OUTLIER -117.96 175.28 5.75 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 104.405 -2.442 . . . . 0.0 104.405 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' LEU . 21.7 t -128.52 57.19 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.048 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.414 ' HB2' HG23 ' A' ' 74' ' ' THR . 85.0 mt -26.9 -76.77 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 CA-C-N 112.729 -2.032 . . . . 0.0 113.632 -179.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -130.59 153.5 48.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 124.77 1.294 . . . . 0.0 110.161 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -131.25 119.62 44.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 1 N-CA-C 93.425 -6.509 . . . . 0.0 93.425 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.471 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.0 mp -90.9 -44.86 9.12 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.9 t -119.42 140.65 29.47 Favored Pre-proline 0 C--N 1.296 -1.757 1 N-CA-C 97.802 -4.888 . . . . 0.0 97.802 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.401 ' HG2' ' H ' ' A' ' 62' ' ' GLU . 13.3 Cg_endo -91.51 -101.34 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.033 1.155 . . . . 0.0 110.214 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.401 ' H ' ' HG2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -129.18 -168.71 1.97 Allowed 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 102.071 -3.307 . . . . 0.0 102.071 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 79.67 -45.87 2.98 Favored Glycine 0 C--N 1.287 -2.186 0 CA-C-N 113.404 -1.725 . . . . 0.0 112.101 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.6 m -98.83 172.51 7.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.4 t -108.03 150.63 10.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 104.614 -2.365 . . . . 0.0 104.614 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.485 ' HB3' HD11 ' A' ' 18' ' ' ILE . . . -123.97 168.11 13.25 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 103.661 -2.718 . . . . 0.0 103.661 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.564 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 12.2 t -129.02 -151.32 0.47 Allowed 'General case' 0 C--N 1.285 -2.204 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.58 HG11 ' HB3' ' A' ' 8' ' ' ASP . 97.4 t -121.98 159.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.322 0 N-CA-C 101.028 -3.693 . . . . 0.0 101.028 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.32 -43.86 1.7 Allowed Glycine 0 CA--C 1.549 2.211 1 N-CA-C 97.142 -6.383 . . . . 0.0 97.142 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.511 ' H ' ' C ' ' A' ' 68' ' ' VAL . 34.1 tt0 -88.81 162.56 16.13 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 102.289 -3.226 . . . . 0.0 102.289 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.7 m -109.6 -176.93 3.14 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 101.965 -3.346 . . . . 0.0 101.965 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 53.3 tp -146.91 -65.49 0.28 Allowed 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 1.4 tt -133.25 166.13 30.23 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-N 112.125 -2.307 . . . . 0.0 105.174 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 56' ' ' LEU . 0.8 OUTLIER -138.49 156.71 47.29 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 101.42 -3.548 . . . . 0.0 101.42 179.07 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.47 ' HB3' ' HB3' ' A' ' 2' ' ' PHE . 0.7 OUTLIER -136.11 147.57 47.85 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.742 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.51 142.34 42.43 Favored 'General case' 0 C--N 1.299 -1.63 1 N-CA-C 97.946 -4.835 . . . . 0.0 97.946 179.784 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -140.13 36.6 0.25 Allowed Pre-proline 0 C--N 1.293 -1.853 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.386 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -37.21 61.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 124.921 3.747 . . . . 0.0 119.406 -143.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 153.5 42.3 0.02 OUTLIER Glycine 0 N--CA 1.495 2.59 0 N-CA-C 106.472 -2.651 . . . . 0.0 106.472 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.304 -1.398 0 N-CA-C 100.634 -3.839 . . . . 0.0 100.634 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.069 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -126.07 127.84 46.46 Favored 'General case' 0 N--CA 1.503 2.224 0 N-CA-C 102.569 -3.123 . . . . 0.0 102.569 -179.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.12 -151.25 0.47 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 125.319 1.637 . . . . 0.0 111.818 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.56 ' CE2' ' HE2' ' A' ' 5' ' ' LYS . 8.2 t80 -113.3 -49.68 2.9 Favored 'General case' 0 N--CA 1.502 2.162 0 CA-C-N 113.375 -1.738 . . . . 0.0 114.655 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.56 ' HE2' ' CE2' ' A' ' 4' ' ' PHE . 28.4 mmtt -131.45 155.11 47.92 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 66.0 mt -84.05 173.66 7.0 Favored Pre-proline 0 C--N 1.296 -1.724 0 CA-C-N 113.205 -1.816 . . . . 0.0 107.818 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -54.18 85.91 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.585 2.19 . . . . 0.0 109.791 162.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.496 ' HB3' HG11 ' A' ' 68' ' ' VAL . 10.4 t0 -122.9 -80.22 0.62 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.3 pt 37.07 39.03 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.575 0 CA-C-O 121.896 0.855 . . . . 0.0 109.447 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.12 -150.56 11.33 Favored Glycine 0 N--CA 1.48 1.629 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.594 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -95.01 139.19 31.71 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 103.309 -2.848 . . . . 0.0 103.309 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 120.97 -79.27 0.33 Allowed Glycine 0 N--CA 1.487 2.081 0 N-CA-C 103.774 -3.731 . . . . 0.0 103.774 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.3 mm -130.73 133.25 63.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 22.1 t-80 -130.34 -19.23 3.14 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.503 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 0.5 OUTLIER -131.32 178.1 6.97 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 122.975 1.369 . . . . 0.0 110.55 -179.524 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.83 125.44 4.12 Favored Glycine 0 C--N 1.29 -2.019 0 N-CA-C 104.8 -3.32 . . . . 0.0 104.8 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 37.5 tt0 -100.31 96.31 7.36 Favored 'General case' 0 C--N 1.307 -1.272 1 N-CA-C 97.28 -5.081 . . . . 0.0 97.28 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mt -81.96 125.12 39.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 N-CA-C 103.573 -2.751 . . . . 0.0 103.573 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.6 t -86.38 -64.0 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 103.26 -2.867 . . . . 0.0 103.26 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.454 ' HE3' ' O ' ' A' ' 21' ' ' TRP . 1.3 tmtp? -142.99 167.75 21.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 124.018 0.824 . . . . 0.0 113.22 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.512 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 30.3 m95 -113.73 173.06 6.61 Favored 'General case' 0 N--CA 1.502 2.131 0 C-N-CA 123.92 0.888 . . . . 0.0 109.004 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.419 ' CG ' ' HB ' ' A' ' 34' ' ' VAL . 9.3 m-85 -126.92 -48.51 1.49 Allowed 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.541 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 m -100.23 178.69 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.172 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.02 161.77 26.34 Favored Pre-proline 0 C--N 1.295 -1.785 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.814 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -78.16 122.56 5.76 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.249 1.966 . . . . 0.0 110.857 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.16 -15.99 22.78 Favored Glycine 0 N--CA 1.483 1.816 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.23 174.37 7.32 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 123.018 1.389 . . . . 0.0 111.74 -178.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.93 117.41 28.01 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 111.166 -2.743 . . . . 0.0 104.242 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.498 HG13 ' HB2' ' A' ' 31' ' ' GLU . 9.7 p -108.58 176.59 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.719 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.422 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -104.65 -26.3 12.37 Favored 'General case' 0 N--CA 1.522 3.166 0 CA-C-O 126.698 3.142 . . . . 0.0 112.94 -179.697 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.498 ' HB2' HG13 ' A' ' 29' ' ' VAL 0.377 10.8 tp10 35.46 78.71 0.03 OUTLIER 'General case' 0 C--N 1.272 -2.796 5 N-CA-C 138.398 10.147 . . . . 0.0 138.398 -179.389 . . . . . . . . 4 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -141.67 27.21 1.87 Allowed 'General case' 0 C--N 1.287 -2.127 4 CA-C-N 94.721 -10.218 . . . . 0.0 96.273 179.251 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -108.94 -165.59 1.04 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 126.105 1.762 . . . . 0.0 107.343 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.476 HG12 ' H ' ' A' ' 35' ' ' LEU . 1.6 t -120.3 163.02 18.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 CA-C-O 125.554 2.597 . . . . 0.0 108.893 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.512 ' O ' ' CE3' ' A' ' 21' ' ' TRP . 10.6 mp -126.45 -84.0 0.62 Allowed 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 108.726 -3.852 . . . . 0.0 103.033 179.15 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.573 ' SG ' HG23 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -123.66 172.69 8.62 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 -178.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 45' ' ' VAL 0.369 18.5 tt0 -134.04 140.31 46.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 127.064 2.728 . . . . 0.0 103.646 -179.244 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.573 HG23 ' SG ' ' A' ' 36' ' ' CYS . 25.0 t -139.39 151.34 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 CA-C-N 119.145 0.884 . . . . 0.0 109.7 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 43.4 tp60 -106.5 128.25 53.95 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 8.6 p-10 -156.01 -173.09 4.36 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -11.69 -73.63 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.608 0 O-C-N 126.479 2.362 . . . . 0.0 116.608 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -128.38 -7.27 5.27 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.408 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -97.81 159.2 15.08 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.276 -0.97 . . . . 0.0 113.15 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.9 t -124.65 -35.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 126.678 2.486 . . . . 0.0 112.942 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 10.9 t -113.1 169.51 4.78 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 125.239 1.415 . . . . 0.0 108.282 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.484 ' N ' HG12 ' A' ' 45' ' ' VAL . 3.6 mt-10 -120.45 -67.8 0.95 Allowed 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 121.422 3.86 . . . . 0.0 121.422 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.6 mp -92.85 149.49 37.84 Favored Pre-proline 0 C--N 1.273 -2.73 0 CA-C-N 108.746 -3.843 . . . . 0.0 108.672 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.463 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -103.18 -178.31 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.708 1.373 . . . . 0.0 109.152 83.395 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.432 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 0.7 OUTLIER -130.96 179.53 1.32 Allowed Pre-proline 0 C--N 1.286 -2.164 0 CA-C-N 113.481 -1.69 . . . . 0.0 108.428 -179.798 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -102.32 -26.53 0.03 OUTLIER 'Trans proline' 0 CA--C 1.548 1.179 0 N-CA-C 120.016 3.045 . . . . 0.0 120.016 171.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.517 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.9 OUTLIER -127.89 160.6 37.32 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.454 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.655 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -106.75 167.61 9.75 Favored 'General case' 0 C--N 1.294 -1.825 1 CA-C-N 107.451 -4.431 . . . . 0.0 111.148 -179.625 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.28 -141.37 6.75 Favored Glycine 0 C--N 1.292 -1.909 1 N-CA-C 100.024 -5.23 . . . . 0.0 100.024 -179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.445 ' HG3' ' H ' ' A' ' 55' ' ' VAL . 14.4 tppt? -105.79 175.1 5.61 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 102.151 -3.277 . . . . 0.0 102.151 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.445 ' H ' ' HG3' ' A' ' 54' ' ' LYS . 47.4 t -126.1 60.69 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.216 1 N-CA-C 96.549 -5.352 . . . . 0.0 96.549 179.39 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.406 ' C ' ' O ' ' A' ' 55' ' ' VAL . 91.2 mt -22.55 -80.34 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.163 0 CA-C-N 112.816 -1.993 . . . . 0.0 112.999 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -139.76 164.18 30.64 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 125.049 1.468 . . . . 0.0 107.817 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.9 mt -132.47 130.99 60.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 1 N-CA-C 95.67 -5.678 . . . . 0.0 95.67 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.45 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.9 mp -87.74 -52.61 5.21 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 123.8 0.688 . . . . 0.0 109.689 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 19.5 t -116.67 140.54 26.89 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 101.135 -3.654 . . . . 0.0 101.135 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -87.5 -106.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.694 1.596 . . . . 0.0 111.004 178.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -129.56 159.57 35.95 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 102.567 -3.123 . . . . 0.0 102.567 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 107.17 -33.09 6.63 Favored Glycine 0 N--CA 1.498 2.782 0 C-N-CA 119.278 -1.439 . . . . 0.0 114.61 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.2 m -109.28 -175.9 2.88 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.2 t -112.43 150.93 14.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -121.88 163.73 18.73 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 2.6 p -107.57 -160.77 0.75 Allowed 'General case' 0 C--N 1.285 -2.224 0 N-CA-C 104.234 -2.506 . . . . 0.0 104.234 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.496 HG11 ' HB3' ' A' ' 8' ' ' ASP 0.265 44.6 t -124.0 153.86 30.38 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 1 N-CA-C 92.643 -6.799 . . . . 0.0 92.643 178.226 . . . . . . . . 4 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 95.6 -45.8 1.99 Allowed Glycine 0 N--CA 1.498 2.77 0 N-CA-C 103.294 -3.922 . . . . 0.0 103.294 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.42 ' H ' ' C ' ' A' ' 68' ' ' VAL . 37.3 tt0 -85.84 160.21 19.51 Favored 'General case' 0 C--N 1.303 -1.452 1 N-CA-C 99.777 -4.157 . . . . 0.0 99.777 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.4 m -106.54 -178.43 3.65 Favored 'General case' 0 C--N 1.288 -2.074 0 N-CA-C 102.122 -3.288 . . . . 0.0 102.122 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.508 HD22 ' CE2' ' A' ' 4' ' ' PHE . 47.9 tp -143.33 -60.07 0.42 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.419 HD11 HG13 ' A' ' 55' ' ' VAL . 14.2 tt -132.96 161.97 40.76 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 104.573 -2.38 . . . . 0.0 104.573 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 t -140.09 164.73 29.25 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -134.01 144.21 48.58 Favored 'General case' 0 N--CA 1.505 2.275 0 CA-C-N 113.873 -1.512 . . . . 0.0 109.587 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -110.07 55.19 0.65 Allowed 'General case' 0 N--CA 1.504 2.249 0 CA-C-O 125.05 2.357 . . . . 0.0 112.32 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -91.37 132.26 34.23 Favored Pre-proline 0 C--N 1.293 -1.848 0 CA-C-N 112.456 -2.156 . . . . 0.0 107.652 -179.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -91.43 171.61 2.94 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 124.012 3.141 . . . . 0.0 106.949 150.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.95 -34.04 4.91 Favored Glycine 0 N--CA 1.493 2.487 1 N-CA-C 102.037 -4.425 . . . . 0.0 102.037 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 7.1 m-85 . . . . . 0 C--N 1.302 -1.482 0 N-CA-C 103.078 -2.934 . . . . 0.0 103.078 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -119.22 139.39 51.95 Favored 'General case' 0 N--CA 1.512 2.668 0 N-CA-C 100.732 -3.803 . . . . 0.0 100.732 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.449 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 0.0 OUTLIER -114.99 -161.03 0.76 Allowed 'General case' 0 N--CA 1.502 2.17 0 CA-C-N 120.798 1.635 . . . . 0.0 109.401 -179.67 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.421 ' CD2' ' HD3' ' A' ' 5' ' ' LYS . 8.8 t80 -126.99 -29.1 2.83 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 116.828 2.158 . . . . 0.0 116.828 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.465 ' HB2' HG13 ' A' ' 68' ' ' VAL . 17.9 mmmt -128.26 169.38 14.25 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-N 122.21 2.277 . . . . 0.0 105.279 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 64.6 mt -91.45 177.34 2.26 Favored Pre-proline 0 N--CA 1.493 1.705 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.741 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -61.14 80.05 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.649 0 N-CA-C 106.954 -1.979 . . . . 0.0 106.954 148.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.48 ' HB3' HG11 ' A' ' 68' ' ' VAL . 9.9 t70 -123.09 -80.05 0.62 Allowed 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.495 ' H ' HG11 ' A' ' 68' ' ' VAL . 45.5 pt 38.4 34.78 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.51 0 CA-C-N 119.794 1.179 . . . . 0.0 110.168 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.08 -115.03 2.89 Favored Glycine 0 N--CA 1.48 1.587 0 C-N-CA 120.84 -0.695 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -103.46 133.45 48.49 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.278 0.561 . . . . 0.0 110.873 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 116.92 -78.43 0.29 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 106.613 -2.595 . . . . 0.0 106.613 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.5 mm -133.45 134.1 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.089 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -119.22 -41.96 2.71 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 102.013 -3.328 . . . . 0.0 102.013 179.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.64 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.7 OUTLIER -130.65 167.47 18.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 124.005 0.816 . . . . 0.0 110.098 179.601 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.95 149.27 19.12 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -99.05 97.62 8.74 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 104.11 -2.552 . . . . 0.0 104.11 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.433 HG21 ' O ' ' A' ' 61' ' ' PRO . 17.7 mm -83.85 115.04 25.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 t -97.02 -48.32 12.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 O-C-N 125.061 1.475 . . . . 0.0 111.12 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.589 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -137.79 144.66 41.67 Favored 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.488 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 24.1 m95 -114.25 170.14 8.51 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CZ ' ' HE2' ' A' ' 20' ' ' LYS . 2.6 m-85 -121.47 -51.17 2.08 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 113.87 -1.514 . . . . 0.0 111.161 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 m -100.49 175.01 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 C-N-CA 119.145 -1.022 . . . . 0.0 110.311 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.737 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -116.0 156.87 46.21 Favored Pre-proline 0 C--N 1.299 -1.63 0 N-CA-C 104.323 -2.473 . . . . 0.0 104.323 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -64.67 145.16 86.29 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 120.865 1.044 . . . . 0.0 111.22 171.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.56 19.73 28.94 Favored Glycine 0 N--CA 1.488 2.149 0 CA-C-O 118.733 -1.037 . . . . 0.0 111.864 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -106.33 170.05 8.15 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.63 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.466 ' HG2' ' HE3' ' A' ' 54' ' ' LYS . 21.0 mt-10 -129.25 88.4 2.7 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.454 ' O ' ' HB2' ' A' ' 52' ' ' LYS . 10.3 p -74.36 178.38 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-N 110.718 -2.946 . . . . 0.0 108.892 -179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.468 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 42.6 t30 -107.39 -29.71 9.1 Favored 'General case' 0 N--CA 1.517 2.892 0 CA-C-O 124.693 2.187 . . . . 0.0 112.097 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.483 ' CG ' ' HB2' ' A' ' 49' ' ' SER 0.387 11.1 tp10 44.63 75.22 0.11 Allowed 'General case' 0 C--N 1.279 -2.474 5 N-CA-C 135.413 9.042 . . . . 0.0 135.413 -179.742 . . . . . . . . 4 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 32' ' ' ASP . 11.8 p-10 -144.31 27.36 1.41 Allowed 'General case' 0 C--N 1.284 -2.248 4 CA-C-N 94.649 -10.251 . . . . 0.0 94.709 178.69 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.466 ' H ' ' HA ' ' A' ' 31' ' ' GLU . 4.2 m-20 -112.19 -169.56 1.49 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 127.652 2.381 . . . . 0.0 110.833 -178.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.55 ' HA ' HG22 ' A' ' 47' ' ' ILE . 1.5 t -119.94 162.17 18.64 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 CA-C-O 124.302 2.001 . . . . 0.0 107.994 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.573 ' HB2' HG21 ' A' ' 47' ' ' ILE . 7.1 mp -126.22 -85.35 0.62 Allowed 'General case' 0 C--N 1.282 -2.356 1 CA-C-N 108.162 -4.108 . . . . 0.0 102.485 179.075 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.459 ' SG ' HD13 ' A' ' 47' ' ' ILE . 14.6 p -123.81 174.99 7.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -178.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.655 ' HG2' ' HA ' ' A' ' 45' ' ' VAL . 1.9 tt0 -133.27 140.07 47.27 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 126.925 2.641 . . . . 0.0 105.887 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.431 ' CG2' HD13 ' A' ' 18' ' ' ILE . 29.1 t -137.73 153.56 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-N 119.705 1.139 . . . . 0.0 108.32 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -112.15 122.65 48.33 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.418 ' OD1' ' HB3' ' A' ' 43' ' ' ALA . 4.6 p-10 -159.63 170.78 20.87 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.424 ' CG ' ' H ' ' A' ' 42' ' ' LYS . 6.0 p-10 -3.88 -67.57 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 117.537 2.421 . . . . 0.0 117.537 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.424 ' H ' ' CG ' ' A' ' 41' ' ' ASP . 84.9 mttt -126.19 -0.88 7.07 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 124.42 1.075 . . . . 0.0 111.459 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 40' ' ' ASN . . . -104.01 154.45 19.66 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 114.41 1.263 . . . . 0.0 114.41 -179.506 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.7 t -129.95 -47.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 CA-C-N 111.109 -2.769 . . . . 0.0 109.0 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.655 ' HA ' ' HG2' ' A' ' 37' ' ' GLU . 21.8 t -105.8 160.98 5.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 CA-C-N 112.68 -2.054 . . . . 0.0 106.878 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.537 ' HB3' HD12 ' A' ' 47' ' ' ILE . 4.8 mt-10 -119.36 -67.14 1.01 Allowed 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 120.619 3.563 . . . . 0.0 120.619 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.573 HG21 ' HB2' ' A' ' 35' ' ' LEU . 1.1 mp -90.81 147.38 35.91 Favored Pre-proline 0 C--N 1.272 -2.768 0 CA-C-N 109.781 -3.372 . . . . 0.0 109.587 -179.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.561 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -100.71 178.57 0.23 Allowed 'Trans proline' 0 C--N 1.314 -1.283 0 N-CA-C 107.378 -1.816 . . . . 0.0 107.378 84.303 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.483 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 14.5 m -128.78 -176.55 0.54 Allowed Pre-proline 0 C--N 1.285 -2.232 0 CA-C-N 113.609 -1.632 . . . . 0.0 107.41 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.451 ' CD ' ' HB3' ' A' ' 49' ' ' SER . 87.7 Cg_endo -100.64 -30.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 123.121 2.547 . . . . 0.0 118.093 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -138.18 162.41 30.68 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.33 0 CA-C-O 123.559 1.647 . . . . 0.0 114.381 -179.348 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.532 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -112.52 169.81 8.62 Favored 'General case' 0 C--N 1.296 -1.723 1 CA-C-N 107.796 -4.275 . . . . 0.0 110.213 -179.645 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 167.23 -141.25 6.76 Favored Glycine 0 C--N 1.288 -2.113 1 N-CA-C 96.799 -6.52 . . . . 0.0 96.799 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.466 ' HE3' ' HG2' ' A' ' 28' ' ' GLU . 0.6 OUTLIER -93.6 -179.31 4.98 Favored 'General case' 0 C--N 1.288 -2.066 1 N-CA-C 99.785 -4.154 . . . . 0.0 99.785 179.99 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 48.1 t -127.9 98.39 4.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.451 1 N-CA-C 91.689 -7.152 . . . . 0.0 91.689 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 55.1 mt -58.81 -88.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 124.787 1.304 . . . . 0.0 109.874 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -139.43 166.16 25.31 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -126.57 134.7 65.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 1 N-CA-C 94.43 -6.137 . . . . 0.0 94.43 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.439 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.8 mp -94.6 -57.25 2.53 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.276 -0.97 . . . . 0.0 112.238 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 22.8 t -113.05 94.22 29.02 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 101.061 -3.681 . . . . 0.0 101.061 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.433 ' O ' HG21 ' A' ' 18' ' ' ILE . 13.2 Cg_exo -71.93 -81.31 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 CA-C-N 120.09 1.068 . . . . 0.0 109.558 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -137.11 164.2 28.99 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.53 -49.46 1.2 Allowed Glycine 0 N--CA 1.499 2.881 0 C-N-CA 119.962 -1.113 . . . . 0.0 113.133 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.78 -172.27 2.56 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 105.511 -2.033 . . . . 0.0 105.511 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.1 t -114.92 144.82 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.39 147.84 49.7 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.64 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 7.8 p -106.54 -160.04 0.72 Allowed 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.658 1.694 . . . . 0.0 108.367 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.495 HG11 ' H ' ' A' ' 9' ' ' ILE . 44.8 t -115.07 155.85 16.16 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.309 1 N-CA-C 91.751 -7.129 . . . . 0.0 91.751 178.477 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.19 -36.79 3.77 Favored Glycine 0 N--CA 1.49 2.264 1 N-CA-C 102.464 -4.254 . . . . 0.0 102.464 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.451 ' H ' ' C ' ' A' ' 68' ' ' VAL . 33.0 tt0 -104.2 164.19 11.89 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 102.316 -3.216 . . . . 0.0 102.316 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -98.69 -178.15 3.89 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 103.658 -2.719 . . . . 0.0 103.658 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 36.4 tp -138.66 -72.03 0.41 Allowed 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.001 -2.222 . . . . 0.0 105.001 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 10.9 tt -132.7 159.79 42.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.6 t -137.99 163.92 30.33 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 125.869 1.98 . . . . 0.0 106.496 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.9 155.58 49.58 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 125.636 1.835 . . . . 0.0 110.984 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -120.06 144.8 47.38 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 104.265 -2.494 . . . . 0.0 104.265 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 80' ' ' TYR . . . -143.68 84.07 10.16 Favored Pre-proline 0 N--CA 1.492 1.636 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -61.73 53.68 0.11 Allowed 'Trans proline' 0 N--CA 1.507 2.292 0 C-N-CA 124.792 3.662 . . . . 0.0 118.723 -168.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.21 63.5 0.19 Allowed Glycine 0 N--CA 1.489 2.169 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 1.8 t80 . . . . . 0 N--CA 1.497 1.883 0 N-CA-C 102.821 -3.029 . . . . 0.0 102.821 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.4 ' N ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.494 1.731 1 N-CA-C 97.812 -4.884 . . . . 0.0 97.812 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.468 ' HB3' ' CB ' ' A' ' 75' ' ' LEU . 18.8 t80 -117.2 93.15 4.07 Favored 'General case' 0 C--N 1.297 -1.689 1 N-CA-C 95.009 -5.923 . . . . 0.0 95.009 178.849 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.4 ' OE2' ' N ' ' A' ' 1' ' ' ALA . 7.1 mp0 -68.41 -177.45 0.92 Allowed 'General case' 0 C--N 1.302 -1.493 0 O-C-N 125.6 1.813 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -110.31 -30.15 7.83 Favored 'General case' 0 N--CA 1.51 2.553 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -179.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.572 ' CG ' HG22 ' A' ' 68' ' ' VAL . 36.5 mmtt -127.06 166.59 17.32 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 103.074 -2.935 . . . . 0.0 103.074 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 74.2 mt -108.79 -173.65 0.27 Allowed Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -54.29 85.36 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.856 1.704 . . . . 0.0 109.031 158.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.505 ' HB3' HG11 ' A' ' 68' ' ' VAL . 3.7 t70 -121.88 -74.73 0.61 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 101.761 -3.422 . . . . 0.0 101.761 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.618 ' H ' HG11 ' A' ' 68' ' ' VAL . 40.2 pt 30.47 38.62 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.975 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.53 -46.83 1.01 Allowed Glycine 0 N--CA 1.484 1.847 0 C-N-CA 119.439 -1.362 . . . . 0.0 112.706 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.02 80.9 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 CA-C-O 124.355 2.026 . . . . 0.0 113.987 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.68 -68.18 0.26 Allowed Glycine 0 C--N 1.277 -2.746 0 CA-C-N 111.877 -2.42 . . . . 0.0 107.637 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 14' ' ' HIS . 40.4 mm -127.2 -172.96 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.444 ' N ' HG22 ' A' ' 13' ' ' ILE . 2.1 p80 -144.02 -50.97 0.31 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.583 0.706 . . . . 0.0 111.276 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.7 pt-20 -103.24 -168.81 1.56 Allowed 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 116.381 1.993 . . . . 0.0 116.381 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.09 112.15 0.59 Allowed Glycine 0 C--N 1.286 -2.227 0 CA-C-N 112.795 -2.002 . . . . 0.0 108.202 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -98.95 92.02 5.32 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 101.567 -3.494 . . . . 0.0 101.567 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.7 mt -85.01 104.2 12.89 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.9 t -86.82 -47.49 16.05 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.476 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.423 ' HE2' ' CZ ' ' A' ' 22' ' ' PHE . 41.1 tttt -126.22 146.31 50.04 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-N 114.431 -1.258 . . . . 0.0 113.394 -179.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.463 ' CZ2' ' SG ' ' A' ' 36' ' ' CYS . 4.8 m95 -121.6 176.76 5.54 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 103.846 -2.65 . . . . 0.0 103.846 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.504 ' CD2' HG21 ' A' ' 34' ' ' VAL . 13.8 m-85 -123.76 -34.91 2.96 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 126.257 2.223 . . . . 0.0 112.189 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.531 ' HB ' ' CA ' ' A' ' 26' ' ' GLY . 10.3 m -103.74 176.54 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.977 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -140.9 61.31 14.58 Favored Pre-proline 0 N--CA 1.492 1.627 0 N-CA-C 117.933 2.568 . . . . 0.0 117.933 -179.438 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 23' ' ' VAL . 5.8 Cg_exo -21.54 -179.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 N-CA-C 119.699 2.923 . . . . 0.0 119.699 -60.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.531 ' CA ' ' HB ' ' A' ' 23' ' ' VAL . . . -92.33 28.61 8.69 Favored Glycine 0 N--CA 1.497 2.713 0 CA-C-N 111.597 -2.547 . . . . 0.0 108.198 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 54' ' ' LYS . 5.2 t0 7.86 -95.6 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.16 0 O-C-N 128.527 3.133 . . . . 0.0 110.905 179.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.428 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 3.1 mm-40 -98.44 119.7 37.59 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 100.818 -3.771 . . . . 0.0 100.818 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -120.23 168.03 13.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 122.296 1.046 . . . . 0.0 109.208 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.7 m-20 -99.85 -168.13 1.56 Allowed 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 112.535 -2.12 . . . . 0.0 107.729 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.731 ' HG3' ' HA ' ' A' ' 51' ' ' VAL 0.263 4.6 tt0 -120.62 52.36 1.17 Allowed 'General case' 0 N--CA 1.494 1.753 1 N-CA-C 97.838 -4.875 . . . . 0.0 97.838 -179.727 . . . . . . . . 4 3 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -171.37 36.89 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 111.403 -2.635 . . . . 0.0 111.711 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.46 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 19.1 t70 -112.96 -178.38 3.37 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.455 -0.778 . . . . 0.0 109.116 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.504 HG21 ' CD2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -84.77 -166.06 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 127.314 3.435 . . . . 0.0 117.664 179.75 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.685 ' HB3' ' C ' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -115.27 -150.68 0.47 Allowed 'General case' 0 C--N 1.281 -2.404 2 CA-C-N 103.319 -6.31 . . . . 0.0 108.645 -179.553 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.463 ' SG ' ' CZ2' ' A' ' 21' ' ' TRP . 1.8 m -127.19 159.38 34.47 Favored 'General case' 0 C--N 1.284 -2.282 2 N-CA-C 97.025 -5.176 . . . . 0.0 97.025 179.193 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -114.64 108.6 17.02 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 100.492 -3.892 . . . . 0.0 100.492 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 49.1 t -112.96 147.61 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 37.4 tt0 -113.09 155.53 24.76 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.088 -1.045 . . . . 0.0 108.886 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -140.49 -168.97 2.68 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 104.683 -2.339 . . . . 0.0 104.683 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.457 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.9 OUTLIER -11.13 -64.0 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 126.427 2.33 . . . . 0.0 115.301 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.457 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 17.2 mttp -144.82 -21.87 0.51 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 124.065 0.853 . . . . 0.0 110.439 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -102.44 -176.33 3.08 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.628 1.204 . . . . 0.0 112.431 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 38.3 t -125.94 137.58 57.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 103.398 -2.816 . . . . 0.0 103.398 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.5 t -112.05 157.8 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.569 ' C ' HD12 ' A' ' 47' ' ' ILE . 5.7 pt-20 -119.8 141.26 49.66 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 111.572 -2.558 . . . . 0.0 109.952 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.685 ' C ' ' HB3' ' A' ' 35' ' ' LEU . 1.9 mp -125.92 75.22 71.47 Favored Pre-proline 0 CA--C 1.574 1.87 0 N-CA-C 101.556 -3.498 . . . . 0.0 101.556 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.462 ' N ' ' HB3' ' A' ' 35' ' ' LEU . 78.3 Cg_endo -62.07 -172.42 0.11 Allowed 'Trans proline' 0 N--CA 1.512 2.574 0 C-N-CA 122.894 2.396 . . . . 0.0 108.173 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.7 p -105.07 85.22 1.2 Allowed Pre-proline 0 C--N 1.286 -2.19 0 CA-C-N 112.934 -1.939 . . . . 0.0 111.567 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -46.31 -31.98 10.08 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.588 1.525 . . . . 0.0 112.926 176.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.731 ' HA ' ' HG3' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -131.09 167.61 25.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.547 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -102.76 165.15 11.22 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 127.141 2.776 . . . . 0.0 108.097 179.408 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 148.23 -139.85 7.95 Favored Glycine 0 C--N 1.293 -1.808 0 N-CA-C 106.237 -2.745 . . . . 0.0 106.237 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.601 ' HB2' ' NZ ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -111.91 169.03 9.12 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 -179.503 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.406 HG11 ' H ' ' A' ' 26' ' ' GLY . 33.4 t -128.38 61.55 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 100.856 -3.757 . . . . 0.0 100.856 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.439 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 40.8 mt -31.37 -74.11 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 110.845 -2.889 . . . . 0.0 114.227 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -138.75 163.76 31.34 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 114.127 1.158 . . . . 0.0 114.127 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.4 HD12 ' HD3' ' A' ' 25' ' ' PRO . 56.1 mt -136.36 136.94 48.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 1 N-CA-C 100.062 -4.051 . . . . 0.0 100.062 179.762 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 8.3 mt -94.25 -63.56 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.727 0.775 . . . . 0.0 110.453 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.473 ' CG1' ' HB ' ' A' ' 64' ' ' THR . 15.8 t -115.94 73.8 4.91 Favored Pre-proline 0 N--CA 1.491 1.622 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 -179.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -45.88 -77.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.067 1.845 . . . . 0.0 113.335 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.2 -177.14 4.7 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.45 -49.96 4.32 Favored Glycine 0 N--CA 1.492 2.4 0 CA-C-N 113.929 -1.487 . . . . 0.0 113.007 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.473 ' HB ' ' CG1' ' A' ' 60' ' ' VAL . 5.3 m -103.51 -176.22 3.02 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.4 150.05 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -123.87 160.8 26.66 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 9.5 t -115.25 -161.29 0.77 Allowed 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.618 HG11 ' H ' ' A' ' 9' ' ' ILE . 73.3 t -120.25 153.78 23.28 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 95.036 -5.913 . . . . 0.0 95.036 178.618 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.58 -37.99 3.42 Favored Glycine 0 N--CA 1.492 2.427 1 N-CA-C 101.513 -4.635 . . . . 0.0 101.513 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -97.53 159.43 14.93 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 100.71 -3.811 . . . . 0.0 100.71 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.5 179.25 5.07 Favored 'General case' 0 C--N 1.288 -2.082 0 N-CA-C 100.222 -3.992 . . . . 0.0 100.222 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 52.4 tp -138.81 -67.22 0.46 Allowed 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.78 161.94 37.65 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 103.107 -2.924 . . . . 0.0 103.107 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.8 t -137.42 157.45 46.55 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 126.327 2.267 . . . . 0.0 105.714 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.468 ' CB ' ' HB3' ' A' ' 2' ' ' PHE . 0.6 OUTLIER -137.43 150.92 47.99 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -114.26 151.35 32.98 Favored 'General case' 0 C--N 1.296 -1.72 1 N-CA-C 98.865 -4.494 . . . . 0.0 98.865 179.388 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.433 ' HB3' ' HA ' ' A' ' 78' ' ' PRO . . . -117.76 -36.68 0.07 OUTLIER Pre-proline 0 N--CA 1.501 2.078 0 C-N-CA 119.465 -0.894 . . . . 0.0 112.747 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 77' ' ' ALA . 38.2 Cg_exo -64.02 -178.87 0.65 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 125.701 2.421 . . . . 0.0 107.647 -62.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.44 -39.23 2.1 Favored Glycine 0 N--CA 1.5 2.926 1 N-CA-C 101.933 -4.467 . . . . 0.0 101.933 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.581 0 N-CA-C 101.476 -3.527 . . . . 0.0 101.476 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.476 ' N ' ' O ' ' A' ' 80' ' ' TYR . . . . . . . . 0 N--CA 1.508 2.462 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.531 ' HB2' ' HB3' ' A' ' 75' ' ' LEU . 0.3 OUTLIER -141.38 159.21 42.69 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.869 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.59 -142.42 0.27 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 106.065 -1.828 . . . . 0.0 106.065 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.755 ' CZ ' ' HD3' ' A' ' 5' ' ' LYS . 14.1 t80 -126.37 -60.75 1.24 Allowed 'General case' 0 N--CA 1.504 2.228 0 O-C-N 124.422 1.076 . . . . 0.0 113.34 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.755 ' HD3' ' CZ ' ' A' ' 4' ' ' PHE . 20.9 mmmt -132.1 143.61 50.14 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 67.9 mt -90.27 173.46 5.69 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 125.053 1.471 . . . . 0.0 107.963 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -40.88 81.59 0.01 OUTLIER 'Trans proline' 0 C--N 1.313 -1.294 0 N-CA-C 118.414 2.429 . . . . 0.0 118.414 168.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.466 ' HB3' HG11 ' A' ' 68' ' ' VAL . 12.2 t70 -122.68 -76.82 0.59 Allowed 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 103.604 -2.739 . . . . 0.0 103.604 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 27.4 pt 37.4 44.45 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.251 0 CA-C-O 122.683 1.23 . . . . 0.0 108.865 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 14' ' ' HIS . . . -90.62 -161.95 37.84 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -109.59 160.83 15.93 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 118.551 1.176 . . . . 0.0 108.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.28 -72.49 0.38 Allowed Glycine 0 N--CA 1.485 1.934 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.5 mm -132.4 82.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 124.933 1.02 . . . . 0.0 110.248 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -105.57 16.13 25.92 Favored 'General case' 0 N--CA 1.507 2.38 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.092 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 7.8 pt-20 -140.09 166.92 23.35 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 113.923 -1.49 . . . . 0.0 108.01 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.03 125.3 4.65 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 107.417 -2.273 . . . . 0.0 107.417 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.464 ' H ' HG13 ' A' ' 38' ' ' VAL . 33.8 tt0 -96.9 100.45 11.97 Favored 'General case' 0 C--N 1.302 -1.471 1 N-CA-C 99.04 -4.43 . . . . 0.0 99.04 179.77 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG22 ' A' ' 38' ' ' VAL . 16.0 mm -82.4 124.57 39.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 1 N-CA-C 99.599 -4.223 . . . . 0.0 99.599 -179.766 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.447 HG21 ' HB2' ' A' ' 39' ' ' GLN . 2.0 t -105.24 -39.79 5.4 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.821 ' HE3' ' CZ ' ' A' ' 22' ' ' PHE . 20.5 tttp -136.7 155.25 50.12 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.169 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.423 ' CE3' ' O ' ' A' ' 35' ' ' LEU . 14.8 m95 -122.77 178.81 4.86 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 125.495 1.747 . . . . 0.0 106.489 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.821 ' CZ ' ' HE3' ' A' ' 20' ' ' LYS . 28.3 m-85 -132.94 -52.58 0.91 Allowed 'General case' 0 N--CA 1.504 2.259 0 O-C-N 124.373 1.045 . . . . 0.0 112.638 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 m -99.16 175.86 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 124.062 0.851 . . . . 0.0 109.596 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.486 ' HD3' ' H ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -117.35 161.99 30.5 Favored Pre-proline 0 C--N 1.295 -1.788 0 O-C-N 125.724 1.89 . . . . 0.0 108.443 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -56.07 112.77 1.17 Allowed 'Trans proline' 0 C--N 1.316 -1.153 0 C-N-CA 121.703 1.602 . . . . 0.0 113.013 174.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.51 16.81 14.89 Favored Glycine 0 N--CA 1.484 1.887 0 CA-C-O 117.167 -1.907 . . . . 0.0 113.501 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -86.76 161.12 18.56 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 116.652 -2.019 . . . . 0.0 108.008 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.45 ' OE2' ' NZ ' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -109.71 92.16 3.94 Favored 'General case' 0 C--N 1.294 -1.816 1 N-CA-C 99.813 -4.143 . . . . 0.0 99.813 -179.574 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 31' ' ' GLU . 6.1 p -91.64 176.16 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 C-N-CA 117.308 -1.757 . . . . 0.0 106.368 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.594 ' C ' ' HB3' ' A' ' 52' ' ' LYS . 26.9 t30 -105.72 -21.72 13.12 Favored 'General case' 0 N--CA 1.529 3.498 0 CA-C-O 123.701 1.715 . . . . 0.0 112.243 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.541 ' H ' HG22 ' A' ' 29' ' ' VAL 0.404 3.8 tp10 36.41 67.9 0.29 Allowed 'General case' 0 C--N 1.281 -2.389 5 N-CA-C 135.059 8.911 . . . . 0.0 135.059 179.566 . . . . . . . . 4 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.9 p-10 -137.4 22.66 2.96 Favored 'General case' 0 C--N 1.288 -2.108 4 CA-C-N 95.715 -9.766 . . . . 0.0 96.572 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.548 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 28.5 t70 -115.23 -148.94 0.44 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 127.15 2.18 . . . . 0.0 105.54 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.548 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 1.9 t -120.08 163.32 17.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 126.531 3.062 . . . . 0.0 109.054 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.58 ' CB ' HG21 ' A' ' 47' ' ' ILE . 13.4 tp -123.27 -81.95 0.64 Allowed 'General case' 0 C--N 1.283 -2.319 2 CA-C-N 107.451 -4.432 . . . . 0.0 99.368 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.455 ' SG ' HD13 ' A' ' 47' ' ' ILE . 16.9 p -132.44 172.46 12.45 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.58 ' HA ' ' HA ' ' A' ' 45' ' ' VAL . 3.7 tt0 -130.42 138.51 50.37 Favored 'General case' 0 N--CA 1.5 2.067 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 ' H ' ' A' ' 17' ' ' GLU . 25.2 t -135.26 145.53 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.335 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.499 ' HA ' ' O ' ' A' ' 43' ' ' ALA . 4.7 tt0 -109.12 138.81 44.9 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -164.31 -161.17 0.58 Allowed 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 105.805 -1.924 . . . . 0.0 105.805 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.506 ' C ' ' HG3' ' A' ' 42' ' ' LYS . 5.6 p-10 -29.03 -58.31 0.14 Allowed 'General case' 0 C--N 1.297 -1.713 0 O-C-N 126.562 2.414 . . . . 0.0 114.475 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.506 ' HG3' ' C ' ' A' ' 41' ' ' ASP . 2.9 mttt -137.9 -8.85 1.59 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.678 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 39' ' ' GLN . . . -93.73 158.26 15.76 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 114.609 1.337 . . . . 0.0 114.609 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.88 -44.28 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 126.335 2.272 . . . . 0.0 109.451 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 37' ' ' GLU . 23.4 t -103.53 155.86 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 C-N-CA 125.574 1.55 . . . . 0.0 108.749 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.673 ' HB3' HD12 ' A' ' 47' ' ' ILE . 7.9 mt-10 -114.27 -63.42 1.45 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 126.683 2.489 . . . . 0.0 114.608 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.673 HD12 ' HB3' ' A' ' 46' ' ' GLU . 1.2 mp -92.88 149.64 38.07 Favored Pre-proline 0 C--N 1.281 -2.374 0 CA-C-N 108.821 -3.809 . . . . 0.0 115.094 -178.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.662 ' C ' HG23 ' A' ' 47' ' ' ILE . 0.1 OUTLIER -98.25 177.59 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.112 0 N-CA-C 107.569 -1.743 . . . . 0.0 107.569 87.582 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 31' ' ' GLU . 9.7 m -119.13 177.33 1.37 Allowed Pre-proline 0 C--N 1.284 -2.257 0 CA-C-N 112.838 -1.983 . . . . 0.0 113.315 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -95.94 -44.79 0.02 OUTLIER 'Trans proline' 0 CA--C 1.555 1.572 0 N-CA-C 118.57 2.488 . . . . 0.0 118.57 169.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.645 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.8 OUTLIER -130.76 166.24 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 123.191 1.472 . . . . 0.0 114.947 -179.375 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.645 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -121.1 170.57 9.41 Favored 'General case' 0 C--N 1.3 -1.561 1 CA-C-N 107.835 -4.257 . . . . 0.0 112.314 179.971 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 168.22 -124.64 1.21 Allowed Glycine 0 N--CA 1.49 2.281 1 N-CA-C 96.897 -6.481 . . . . 0.0 96.897 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.542 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 16.8 tttp -107.35 -174.92 2.65 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.415 ' H ' ' HG2' ' A' ' 54' ' ' LYS . 60.3 t -130.93 65.75 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.279 1 N-CA-C 97.292 -5.077 . . . . 0.0 97.292 -179.617 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.458 ' H ' ' HG ' ' A' ' 56' ' ' LEU . 80.1 mt -29.53 -78.09 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 112.242 -2.253 . . . . 0.0 110.956 -179.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -145.68 165.88 27.46 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 33.3 mt -132.78 139.93 48.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 1 N-CA-C 98.258 -4.719 . . . . 0.0 98.258 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 5.6 mp -106.97 -31.34 8.36 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 123.819 0.7 . . . . 0.0 111.199 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.452 HG21 HD12 ' A' ' 72' ' ' LEU . 19.8 t -107.39 130.31 23.02 Favored Pre-proline 0 C--N 1.301 -1.524 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -49.91 -150.38 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 124.254 3.302 . . . . 0.0 116.487 158.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 39.93 3.57 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 111.86 -2.427 . . . . 0.0 107.847 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -142.82 -6.2 0.71 Allowed Glycine 0 N--CA 1.497 2.734 0 CA-C-N 111.504 -2.589 . . . . 0.0 116.071 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.1 m -121.63 172.67 7.94 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 105.244 -2.132 . . . . 0.0 105.244 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.39 144.31 16.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 102.672 -3.084 . . . . 0.0 102.672 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -118.79 164.97 14.6 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.0 p -109.28 -163.2 0.85 Allowed 'General case' 0 C--N 1.283 -2.307 0 N-CA-C 106.32 -1.733 . . . . 0.0 106.32 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.471 HG22 ' CB ' ' A' ' 5' ' ' LYS . 52.2 t -119.39 154.16 21.94 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 1 N-CA-C 92.681 -6.785 . . . . 0.0 92.681 178.748 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 101.06 -38.62 3.06 Favored Glycine 0 N--CA 1.49 2.291 1 N-CA-C 100.416 -5.073 . . . . 0.0 100.416 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.46 ' H ' ' C ' ' A' ' 68' ' ' VAL . 25.4 tt0 -99.94 160.57 14.21 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 101.013 -3.699 . . . . 0.0 101.013 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -105.89 -175.6 2.84 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 101.687 -3.449 . . . . 0.0 101.687 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.68 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . 0.9 OUTLIER -145.15 -57.46 0.33 Allowed 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 16.0 tt -137.13 163.48 32.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 t -135.86 159.21 42.36 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 103.114 -2.921 . . . . 0.0 103.114 179.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.531 ' HB3' ' HB2' ' A' ' 2' ' ' PHE . 1.0 OUTLIER -138.58 147.16 42.68 Favored 'General case' 0 C--N 1.289 -2.062 0 O-C-N 125.392 1.682 . . . . 0.0 107.734 -179.502 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.542 ' CG ' ' H ' ' A' ' 54' ' ' LYS . 2.1 p30 -115.64 158.19 23.09 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 104.154 -2.536 . . . . 0.0 104.154 179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.567 ' CB ' ' HB2' ' A' ' 80' ' ' TYR . . . -139.38 139.02 21.46 Favored Pre-proline 0 C--N 1.29 -1.994 0 N-CA-C 102.627 -3.101 . . . . 0.0 102.627 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -70.53 -37.35 7.42 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 121.974 1.783 . . . . 0.0 110.466 173.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.541 ' O ' ' CD1' ' A' ' 80' ' ' TYR . . . -121.97 27.11 6.27 Favored Glycine 0 N--CA 1.493 2.494 0 CA-C-O 115.992 -2.56 . . . . 0.0 113.086 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.567 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 21.7 m-85 . . . . . 0 N--CA 1.503 2.215 0 CA-C-O 115.509 -2.186 . . . . 0.0 108.283 -179.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.047 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -115.34 147.11 40.87 Favored 'General case' 0 N--CA 1.498 1.946 1 N-CA-C 99.897 -4.112 . . . . 0.0 99.897 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -113.65 -168.79 1.39 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 118.878 0.763 . . . . 0.0 112.639 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.439 ' CD2' HD13 ' A' ' 72' ' ' LEU . 41.7 t80 -105.69 -22.94 12.85 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 -179.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' CG ' HG22 ' A' ' 68' ' ' VAL . 11.0 mmtm -127.55 177.64 6.64 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 102.638 -3.097 . . . . 0.0 102.638 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 83.5 mt -105.62 176.22 1.8 Allowed Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -54.44 82.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.676 1.584 . . . . 0.0 110.111 153.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.509 ' HB3' HG11 ' A' ' 68' ' ' VAL . 7.6 t70 -122.06 -82.65 0.65 Allowed 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.485 -2.043 . . . . 0.0 105.485 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.46 HG23 HG12 ' A' ' 68' ' ' VAL . 24.0 pt 39.16 27.71 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 124.055 0.847 . . . . 0.0 111.647 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.18 -70.99 0.05 OUTLIER Glycine 0 N--CA 1.477 1.423 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.825 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.407 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 1.1 mp0 -51.06 153.08 2.01 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 124.415 2.055 . . . . 0.0 116.312 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -22.16 -41.01 0.01 OUTLIER Glycine 0 N--CA 1.498 2.824 0 CA-C-N 110.908 -2.86 . . . . 0.0 118.439 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.466 HD12 ' N ' ' A' ' 13' ' ' ILE . 3.2 mp -115.94 64.0 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.216 1.008 . . . . 0.0 108.81 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.408 ' O ' HG23 ' A' ' 68' ' ' VAL . 2.1 p80 -85.72 7.61 22.92 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-N 114.72 -1.127 . . . . 0.0 112.493 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 5.1 pt-20 -129.68 -165.89 1.59 Allowed 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.992 0.901 . . . . 0.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.14 112.51 0.55 Allowed Glycine 0 N--CA 1.503 3.106 0 CA-C-O 117.484 -1.731 . . . . 0.0 112.808 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 38' ' ' VAL . 56.4 tt0 -104.17 85.95 2.47 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 103.223 -2.881 . . . . 0.0 103.223 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.569 HD11 HD11 ' A' ' 72' ' ' LEU . 1.9 mp -87.48 124.63 40.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.9 t -101.8 -46.85 11.32 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 O-C-N 124.53 1.144 . . . . 0.0 109.252 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.433 ' NZ ' ' OE2' ' A' ' 37' ' ' GLU . 12.1 ttmt -131.69 145.18 51.5 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 124.564 1.165 . . . . 0.0 112.123 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -115.98 -178.64 3.45 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 178.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -126.56 -27.15 3.17 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 111.248 -2.706 . . . . 0.0 111.169 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.575 ' HB ' ' N ' ' A' ' 26' ' ' GLY . 7.4 m -101.49 -177.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.172 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.433 ' H ' ' C ' ' A' ' 25' ' ' PRO . 4.2 mptp? -100.19 -41.23 0.22 Allowed Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.502 ' C ' ' H ' ' A' ' 27' ' ' ASP . 43.1 Cg_endo -49.56 170.84 1.38 Allowed 'Cis proline' 0 N--CA 1.498 1.762 1 N-CA-C 124.991 4.958 . . . . 0.0 124.991 29.714 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.575 ' N ' ' HB ' ' A' ' 23' ' ' VAL . . . -94.22 37.39 3.42 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 105.846 -2.902 . . . . 0.0 105.846 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.544 ' OD1' ' HE3' ' A' ' 54' ' ' LYS . 14.9 t70 3.1 -90.46 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.175 0 O-C-N 127.796 2.703 . . . . 0.0 110.131 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.579 ' HG2' ' CE ' ' A' ' 54' ' ' LYS . 6.7 mt-10 -99.53 111.58 23.91 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 101.972 -3.344 . . . . 0.0 101.972 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 163.98 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 CA-C-O 124.49 2.091 . . . . 0.0 114.704 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.653 HD22 ' CG ' ' A' ' 32' ' ' ASP . 10.2 p-10 -98.22 -171.27 2.11 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 110.075 -3.239 . . . . 0.0 112.17 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 4.7 tt0 -121.88 68.11 0.92 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.653 ' CG ' HD22 ' A' ' 30' ' ' ASN . 3.5 p30 -179.7 -27.61 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 112.965 -1.925 . . . . 0.0 110.808 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.475 ' HB3' ' HB2' ' A' ' 49' ' ' SER . 4.2 t0 -28.77 154.04 0.0 OUTLIER 'General case' 0 N--CA 1.514 2.768 0 CA-C-O 122.992 1.377 . . . . 0.0 114.279 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.677 HG12 ' H ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -56.17 -176.73 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.291 -1.977 1 N-CA-C 124.188 4.885 . . . . 0.0 124.188 -179.251 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.677 ' H ' HG12 ' A' ' 34' ' ' VAL . 1.1 mm? -86.69 174.25 8.97 Favored 'General case' 0 N--CA 1.411 -2.393 2 CA-C-N 101.792 -7.004 . . . . 0.0 101.488 -179.38 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.0 m -127.97 155.08 44.83 Favored 'General case' 0 C--N 1.265 -3.082 2 N-CA-C 97.587 -4.968 . . . . 0.0 97.587 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.433 ' OE2' ' NZ ' ' A' ' 20' ' ' LYS . 12.9 mt-10 -118.26 103.53 9.91 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 17' ' ' GLU . 38.4 t -116.59 155.68 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 CA-C-N 113.429 -1.714 . . . . 0.0 107.158 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -118.37 162.07 18.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -155.23 -172.31 4.13 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -17.57 -62.44 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 126.409 2.318 . . . . 0.0 115.2 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.3 mttp -140.45 -13.91 0.99 Allowed 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.185 179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -109.71 175.21 5.53 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 116.598 2.073 . . . . 0.0 116.598 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.4 t -122.59 136.48 59.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 1 N-CA-C 99.611 -4.218 . . . . 0.0 99.611 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.7 t -117.47 161.27 16.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 122.448 1.118 . . . . 0.0 109.589 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 47' ' ' ILE . 11.9 pt-20 -123.67 129.13 50.64 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 110.227 -3.17 . . . . 0.0 106.758 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.522 HD12 ' N ' ' A' ' 47' ' ' ILE . 3.7 mp -125.07 96.71 39.3 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 115.806 -2.045 . . . . 0.0 106.266 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 35' ' ' LEU . 60.7 Cg_endo -68.62 -164.85 0.12 Allowed 'Trans proline' 0 N--CA 1.515 2.742 0 C-N-CA 124.446 3.431 . . . . 0.0 106.917 -174.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.475 ' HB2' ' HB3' ' A' ' 33' ' ' ASP . 14.4 t -104.02 103.25 36.74 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 111.875 -2.42 . . . . 0.0 108.962 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 85.3 Cg_exo -49.31 -55.24 4.33 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.659 2.906 . . . . 0.0 119.01 161.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.402 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -136.59 168.43 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-O 121.933 0.873 . . . . 0.0 112.748 -179.613 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 4.1 pttt -96.33 167.89 10.9 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 111.409 -2.632 . . . . 0.0 106.719 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.08 -135.87 5.87 Favored Glycine 0 C--N 1.289 -2.071 0 N-CA-C 105.955 -2.858 . . . . 0.0 105.955 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.579 ' CE ' ' HG2' ' A' ' 28' ' ' GLU . 4.3 tptt -116.82 164.92 13.93 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 104.966 -2.235 . . . . 0.0 104.966 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.453 HG11 ' H ' ' A' ' 26' ' ' GLY . 22.1 t -126.43 58.11 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.809 1 N-CA-C 100.164 -4.013 . . . . 0.0 100.164 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 18.0 mt -29.51 -73.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 CA-C-N 110.29 -3.141 . . . . 0.0 115.084 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -137.03 163.9 29.66 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.973 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.5 mt -138.61 144.56 29.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 1 N-CA-C 98.87 -4.493 . . . . 0.0 98.87 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 59' ' ' LEU . 5.6 mp -111.33 -54.79 2.57 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 3.5 t -113.42 78.77 3.67 Favored Pre-proline 0 C--N 1.3 -1.571 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -55.18 -85.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 121.708 1.605 . . . . 0.0 113.455 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -139.7 170.63 15.54 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 78.41 -35.71 1.78 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.824 -1.179 . . . . 0.0 112.11 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.7 m -99.63 171.98 7.57 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 67.1 t -115.06 142.97 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.66 160.18 31.5 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 4.8 t -105.41 -156.91 0.59 Allowed 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.509 HG11 ' HB3' ' A' ' 8' ' ' ASP . 61.5 t -121.69 158.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 1 N-CA-C 94.886 -5.968 . . . . 0.0 94.886 178.408 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.43 -29.36 9.73 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 104.675 -3.37 . . . . 0.0 104.675 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.449 ' H ' ' C ' ' A' ' 68' ' ' VAL . 26.3 tt0 -109.41 156.71 19.72 Favored 'General case' 0 C--N 1.302 -1.483 1 N-CA-C 99.119 -4.4 . . . . 0.0 99.119 179.793 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -87.2 -174.15 4.74 Favored 'General case' 0 C--N 1.288 -2.089 0 N-CA-C 100.93 -3.73 . . . . 0.0 100.93 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.569 HD11 HD11 ' A' ' 18' ' ' ILE . 3.9 tt -145.99 -62.97 0.32 Allowed 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 104.554 -2.387 . . . . 0.0 104.554 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 tt -138.42 162.17 30.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 102.092 -3.299 . . . . 0.0 102.092 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 t -136.92 159.73 41.0 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 103.96 -2.608 . . . . 0.0 103.96 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.4 146.05 36.1 Favored 'General case' 0 C--N 1.284 -2.255 0 CA-C-N 111.806 -2.452 . . . . 0.0 105.113 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.07 159.31 16.68 Favored 'General case' 0 N--CA 1.491 1.605 1 N-CA-C 98.895 -4.483 . . . . 0.0 98.895 179.318 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.514 ' H ' ' CA ' ' A' ' 78' ' ' PRO . . . -138.13 -36.79 0.02 OUTLIER Pre-proline 0 C--N 1.289 -2.03 0 CA-C-N 114.274 -1.33 . . . . 0.0 111.093 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.514 ' CA ' ' H ' ' A' ' 77' ' ' ALA . 18.6 Cg_endo -104.18 138.39 1.03 Allowed 'Cis proline' 0 C--N 1.316 -1.139 0 C-N-CA 129.235 0.931 . . . . 0.0 111.334 -24.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.85 41.79 0.76 Allowed Glycine 0 N--CA 1.498 2.825 0 N-CA-C 105.974 -2.851 . . . . 0.0 105.974 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.9 m-30 . . . . . 0 C--N 1.299 -1.591 1 N-CA-C 98.912 -4.477 . . . . 0.0 98.912 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.133 0 N-CA-C 104.184 -2.524 . . . . 0.0 104.184 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.442 ' O ' ' HA ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -125.17 160.69 28.55 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 103.026 -2.953 . . . . 0.0 103.026 -179.608 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.8 -158.53 0.87 Allowed 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -112.22 -45.14 3.31 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 125.582 1.801 . . . . 0.0 111.819 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HG3' HG22 ' A' ' 68' ' ' VAL . 0.3 OUTLIER -124.24 -175.07 3.15 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 100.815 -3.772 . . . . 0.0 100.815 179.36 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -115.45 -176.39 0.37 Allowed Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 104.288 -2.486 . . . . 0.0 104.288 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.83 88.07 0.05 OUTLIER 'Trans proline' 0 C--N 1.304 -1.777 0 N-CA-C 103.094 -3.464 . . . . 0.0 103.094 145.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.584 ' HB3' HG11 ' A' ' 68' ' ' VAL 0.313 0.8 OUTLIER -121.6 -91.43 0.56 Allowed 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 111.874 -2.421 . . . . 0.0 104.803 -179.616 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.66 ' H ' HG11 ' A' ' 68' ' ' VAL . 38.8 pt 45.66 37.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -88.65 -171.31 46.03 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.712 -1.755 . . . . 0.0 108.712 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -89.46 163.62 15.18 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-O 122.983 1.373 . . . . 0.0 110.595 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -74.44 0.21 Allowed Glycine 0 C--N 1.293 -1.845 0 CA-C-N 112.346 -2.206 . . . . 0.0 108.824 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.7 mt -131.93 114.66 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 101.612 -3.477 . . . . 0.0 101.612 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -125.26 18.0 8.32 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 121.827 2.103 . . . . 0.0 107.712 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.537 ' HA ' ' HA ' ' A' ' 67' ' ' THR . 0.5 OUTLIER -127.34 -177.93 4.26 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 123.116 1.436 . . . . 0.0 113.146 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.25 101.03 0.33 Allowed Glycine 0 N--CA 1.503 3.103 0 CA-C-N 112.664 -2.062 . . . . 0.0 110.827 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -101.92 102.25 12.78 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 105.166 -2.161 . . . . 0.0 105.166 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 mt -89.24 131.92 35.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 105.639 -1.986 . . . . 0.0 105.639 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.78 -57.91 4.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -129.37 169.74 14.52 Favored 'General case' 0 N--CA 1.508 2.447 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.789 -179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 23.8 m95 -130.49 171.64 12.78 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 126.017 2.073 . . . . 0.0 106.763 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.485 ' CD2' HG21 ' A' ' 34' ' ' VAL . 21.8 m-85 -124.94 -52.12 1.67 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 124.937 1.398 . . . . 0.0 109.102 -179.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.5 m -99.32 179.1 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.473 ' NZ ' ' OD2' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -119.9 168.26 10.67 Favored Pre-proline 0 C--N 1.292 -1.904 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.439 ' HD3' HD12 ' A' ' 58' ' ' ILE . 83.9 Cg_endo -74.19 144.45 33.42 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 121.453 1.435 . . . . 0.0 108.888 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.401 ' O ' ' NZ ' ' A' ' 54' ' ' LYS . . . 97.95 -14.97 62.28 Favored Glycine 0 CA--C 1.476 -2.383 0 CA-C-O 116.654 -2.192 . . . . 0.0 110.166 179.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' NZ ' ' A' ' 24' ' ' LYS . 4.3 m-20 -82.61 -173.07 4.41 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.493 ' HG2' ' NZ ' ' A' ' 54' ' ' LYS 0.25 6.5 mt-10 -122.42 158.35 29.91 Favored 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 101.593 -3.484 . . . . 0.0 101.593 179.92 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.4 p -121.93 157.57 26.0 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 CA-C-O 122.228 1.013 . . . . 0.0 110.261 -179.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.459 ' HA ' ' HB2' ' A' ' 52' ' ' LYS . 5.3 m-20 -98.58 -167.65 1.53 Allowed 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 111.066 -2.788 . . . . 0.0 113.283 -178.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 52' ' ' LYS . 19.9 tt0 -122.98 52.5 1.35 Allowed 'General case' 0 C--N 1.298 -1.641 1 N-CA-C 96.789 -5.263 . . . . 0.0 96.789 -179.818 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.452 ' CG ' ' HB3' ' A' ' 30' ' ' ASN . 0.6 OUTLIER -164.1 -59.21 0.04 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.902 -179.42 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.655 ' CG ' ' H ' ' A' ' 34' ' ' VAL . 14.3 t70 -52.17 -168.91 0.0 OUTLIER 'General case' 0 N--CA 1.513 2.692 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.655 ' H ' ' CG ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -97.42 -168.34 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 129.135 2.974 . . . . 0.0 109.837 -179.357 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.644 ' H ' HG12 ' A' ' 34' ' ' VAL . 24.0 tp -141.23 -95.59 0.14 Allowed 'General case' 0 C--N 1.294 -1.836 1 CA-C-N 107.74 -4.3 . . . . 0.0 100.861 178.704 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -122.47 -179.08 4.08 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-N 118.634 0.652 . . . . 0.0 111.364 -179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -119.75 111.89 18.57 Favored 'General case' 0 N--CA 1.499 1.979 1 N-CA-C 97.524 -4.991 . . . . 0.0 97.524 179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 46.3 t -120.13 151.67 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 119.501 1.046 . . . . 0.0 112.315 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 20.7 tt0 -117.81 151.72 36.77 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.728 -1.124 . . . . 0.0 108.302 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -146.24 -179.88 7.04 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 104.597 -2.371 . . . . 0.0 104.597 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -6.1 -69.67 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.031 0 N-CA-C 116.069 1.877 . . . . 0.0 116.069 -179.381 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.513 ' N ' ' CG ' ' A' ' 41' ' ' ASP . 40.2 mttp -136.73 -20.25 1.33 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 123.319 0.647 . . . . 0.0 110.318 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -100.36 165.56 11.4 Favored 'General case' 0 N--CA 1.492 1.673 0 C-N-CA 118.453 -1.299 . . . . 0.0 111.399 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 39' ' ' GLN . 10.5 t -132.45 130.57 60.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 N-CA-C 102.896 -3.002 . . . . 0.0 102.896 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 46' ' ' GLU . 1.5 t -127.79 173.56 12.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 CA-C-O 124.755 2.217 . . . . 0.0 105.406 179.277 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.561 ' H ' HG12 ' A' ' 45' ' ' VAL . 10.6 pt-20 -121.32 164.15 17.49 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 108.479 -3.964 . . . . 0.0 105.047 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 46' ' ' GLU . 2.7 mp -125.69 130.54 24.03 Favored Pre-proline 0 C--N 1.295 -1.773 0 N-CA-C 101.548 -3.501 . . . . 0.0 101.548 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.44 ' O ' ' HD3' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -93.02 -171.98 0.33 Allowed 'Trans proline' 0 N--CA 1.497 1.725 1 C-N-CA 126.087 4.525 . . . . 0.0 108.796 173.457 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.33 98.53 12.42 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 48' ' ' PRO . 72.2 Cg_exo -48.45 -44.67 29.27 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.549 1.5 . . . . 0.0 110.671 157.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG2' ' N ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER -133.15 166.11 30.35 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-O 122.463 1.125 . . . . 0.0 109.253 179.436 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.568 ' HD3' ' H ' ' A' ' 52' ' ' LYS . 0.0 OUTLIER -110.89 146.04 37.22 Favored 'General case' 0 C--N 1.297 -1.688 2 O-C-N 130.118 4.636 . . . . 0.0 104.483 179.784 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.86 -151.06 13.22 Favored Glycine 0 N--CA 1.504 3.199 0 N-CA-C 105.206 -3.158 . . . . 0.0 105.206 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.493 ' NZ ' ' HG2' ' A' ' 28' ' ' GLU . 53.6 tptt -96.27 171.99 8.24 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 119.993 1.897 . . . . 0.0 106.835 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -125.47 84.09 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 1 N-CA-C 94.46 -6.126 . . . . 0.0 94.46 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.41 -82.03 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.802 0 CA-C-N 113.516 -1.675 . . . . 0.0 109.438 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -137.94 165.66 25.98 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.504 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.439 HD12 ' HD3' ' A' ' 25' ' ' PRO . 60.0 mt -130.09 137.94 55.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 1 N-CA-C 97.61 -4.959 . . . . 0.0 97.61 179.705 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.408 ' N ' HD12 ' A' ' 59' ' ' LEU . 6.2 mp -97.17 -56.16 2.63 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 124.251 0.97 . . . . 0.0 108.592 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.4 t -112.68 126.44 28.31 Favored Pre-proline 0 C--N 1.295 -1.793 1 N-CA-C 96.939 -5.208 . . . . 0.0 96.939 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.404 ' HB2' ' OE2' ' A' ' 62' ' ' GLU . 2.7 Cg_exo -79.81 -84.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 CA-C-N 121.461 1.557 . . . . 0.0 108.19 174.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.404 ' OE2' ' HB2' ' A' ' 61' ' ' PRO . 0.0 OUTLIER -132.24 -151.8 0.47 Allowed 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 100.614 -3.846 . . . . 0.0 100.614 -179.202 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.93 -42.97 0.16 Allowed Glycine 0 C--N 1.283 -2.377 0 CA-C-N 111.029 -2.805 . . . . 0.0 115.116 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.8 m -109.37 -176.43 3.02 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.6 t -111.16 156.07 12.42 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -126.32 171.25 11.11 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 3.8 t -128.12 -159.79 0.97 Allowed 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 102.846 -3.02 . . . . 0.0 102.846 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.66 HG11 ' H ' ' A' ' 9' ' ' ILE 0.256 57.8 t -117.68 155.38 19.46 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.268 1 N-CA-C 94.431 -6.137 . . . . 0.0 94.431 179.025 . . . . . . . . 4 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . 0.515 ' N ' HG12 ' A' ' 68' ' ' VAL . . . 98.27 -27.61 18.59 Favored Glycine 0 N--CA 1.485 1.932 1 N-CA-C 102.398 -4.281 . . . . 0.0 102.398 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.459 ' H ' ' C ' ' A' ' 68' ' ' VAL . 38.9 tt0 -105.01 154.65 19.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 102.042 -3.318 . . . . 0.0 102.042 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 1.6 m -94.9 179.55 5.19 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 102.201 -3.259 . . . . 0.0 102.201 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 35.8 tp -138.26 -69.9 0.44 Allowed 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 12.6 tt -141.99 162.22 19.98 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 102.937 -2.986 . . . . 0.0 102.937 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 2' ' ' PHE . 2.3 t -137.39 160.04 40.22 Favored 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 102.806 -3.035 . . . . 0.0 102.806 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.457 HD23 ' H ' ' A' ' 76' ' ' ASP . 1.2 tt -133.39 149.87 51.82 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 112.669 -2.06 . . . . 0.0 107.862 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.457 ' H ' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -109.2 150.68 27.55 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 101.97 -3.345 . . . . 0.0 101.97 179.562 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 79' ' ' GLY . . . -141.83 94.72 7.18 Favored Pre-proline 0 C--N 1.289 -2.026 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.418 ' HD3' ' OD1' ' A' ' 76' ' ' ASP . 21.1 Cg_endo -45.0 70.51 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 123.803 3.002 . . . . 0.0 116.486 174.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 77' ' ' ALA . . . 126.89 9.63 4.2 Favored Glycine 0 N--CA 1.485 1.929 0 CA-C-O 116.495 -2.281 . . . . 0.0 113.157 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.43 ' HB2' ' CB ' ' A' ' 77' ' ' ALA . 14.3 m-30 . . . . . 0 N--CA 1.501 2.087 0 N-CA-C 105.524 -2.028 . . . . 0.0 105.524 179.51 . . . . . . . . 1 1 . 1 stop_ save_